Note: Descriptions are shown in the official language in which they were submitted.
CA 02703356 2010-04-22
1
DESCRIPTION
Method for Detection of Cancer
TECHNICAL FIELD
[0001]
The present invention relates to a novel method for detecting a cancer(s).
BACKGROUND ART
[0002]
Cancers are the commonest cause for death among all of the causes for death,
and the main therapies therefor are palliative treatment in which surgical
treatment is
combined with radiotherapy and chemotherapy. By virtue of the advance in
medical
technology, cancers have become such diseases that can be highly possibly
cured if
they can be found in the early stage. Therefore, a detection method of cancer
which
can be easily carried out by testing serum, urine or the like without physical
and
economical burden to patients is demanded.
[0003]
Recently, methods wherein tumor products such as tumor markers are
measured have been widely used as diagnostic methods using blood or urine.
Examples of the tumor product include tumor-related antigens, enzymes,
specific
proteins, metabolites, tumor genes, products of tumor genes, and tumor-
suppressor
genes. In some cancers, a carcinoembryonic antigen CEA, glycoproteins CA19-9
and CA125, a prostate-specific antigen PSA, calcitonin which is a peptide
hormone
produced in thyroid and the like are utilized as tumor markers in cancer
diagnosis.
However, in most types of cancers, there are no tumor markers useful for
cancer
diagnosis. Further, since most of the tumor markers currently known exist only
in
very small amounts (e.g., in the order of pg/mL) in body fluid, their
detection
requires a highly sensitive measurement method or a special technique. Under
such
circumstances, if a novel cancer test method by which various cancers can be
CA 02703356 2010-04-22
2
detected by simple operations is provided, its use for diagnosis of various
cancers are
expected to be developed.
[0004]
The method would be very useful if it further enables diagnosis of cancers
developed in invisible parts, assessment of the stage of cancer progression,
assessment of the grade of cancer malignancy, follow-up of postoperative
patients,
diagnosis of recurrence, diagnosis of metastasis, monitoring of therapy and
the like,
in addition to detection of cancers.
[0005]
More particularly, if a method which enables diagnosis of cancers developed
in invisible parts is provided, it would be useful for early detection of
cancers in parts
where cancers are hardly realized, for example, the inside of the abdominal
cavity.
Further, even in cases where the tumor is too small to be found visually,
detection of
such cancers that cannot be found by ultrasonography, CT (computed tomography)
or
MRI (magnetic resonance imaging) is also made possible.
[0006]
The stage of cancer progression is classified based on the extent of expansion
of the tumor at the primary site and whether or not metastasis has occurred to
a
regional lymph node or a distant organ. In general, the disease stage is
classified
into 5 stages, wherein a larger number indicates a more advanced state.
Although,
strictly speaking, the definition varies depending on organs, the disease
stage 0
indicates a cancer staying within epithelium and the stage IV indicates a
cancer with
distant metastasis. If the stage of cancer progression as described above can
be
determined, determination of an appropriate therapeutic strategy and, in
addition,
assessment of therapeutic effects of anticancer drugs are made possible. In
regard to
the determination of the therapeutic strategy, for example, some of prostate
cancers
are low malignant and hardly progress, hence do not require treatment; and
others are
CA 02703356 2010-04-22
3
progressive and metastasize to bones and/or the like, causing pain and death
of
patients. Since hormonotherapy and extirpative surgery are accompanied by side
effects, it is necessary to appropriately judge and determine the therapeutic
approach.
Further, if whether the selected anticancer drug is appropriate or not, when
to end the
administration of the anticancer drug and the like can be appropriately
judged, the
physical and economical burden on the patient can also be reduced. Therefore,
it is
important that the stage of progression can be assessed.
[0007]
One of the characteristics of cancer cells is blastogenesis, that is,
dedifferentiation. Except for a part of cancers, lower-differentiated cancer
cells
such as those poorly differentiated or undifferentiated grow more rapidly
after the
metastasis, and the prognosis is poor. Such cancers are said to be highly
malignant.
Conversely, highly-differentiated cancer cells, that is, those showing a high
degree of
cell differentiation maintain the structural and functional traits of the
organ from
which they were originated, and can be said to be less malignant. If such
cancer
malignancy can be determined, it is made possible to secure a larger margin of
excision of the tumor in cases where its malignancy is high even if the size
of the
tumor is small, as well as to follow up the patient, paying attention to
larger areas in
the surrounding tissues.
[0008]
In cases where diagnosis of the postoperative course including recurrence and
metastasis is possible, diagnosis of whether the tumor has been completely
excised
by the operation is made possible. Since recurrence is likely to occur in
cases where
the excision was incomplete, this can be used as a basis for judging whether a
more
careful follow up of the patient at short intervals is necessary and, in some
cases, for
deciding whether an early reoperation should be carried out. Furthermore,
recurrent
cancer can be found at its early stage with a high possibility. In the case of
distant
CA 02703356 2010-04-22
4
metastasis, its detection is likely to be late, but if a method which enables
diagnosis
of metastasis is provided, a basis for deciding whether the region to be
checked
should be extended in addition to the site where the tumor was excised and the
vicinity thereof can be obtained.
[0009]
If monitoring of therapy is possible, an appropriate therapeutic method or
combination of therapeutic methods can be selected among various therapeutic
methods to optimize the therapy. If one can see the therapeutic effects of
anticancer
agents, selection of the dosing periods and the types and doses of anticancer
agents
may be made easier. Further, after excision of the tumor, one can know
presence/absence of remaining tumor, and during follow up of the patient, one
can
have a clue to find metastasis or recurrence as early as possible, so that
initiation of
early treatment is possible. If monitoring of a therapeutic effect is
possible, whether
the therapeutic approach was appropriate and whether the therapeutic approach
should be changed to another can be judged.
[0010]
It is known that dogs age 7 times faster than human. Recently, a companion
animal is kept as a member of a family and often has a lifestyle similar to
that of its
owner. Therefore, if the companion animal is suffering from cancer, it is
possible to
predict that the owner has a high risk of development of cancer in the future.
If
accurate diagnosis of cancer in companion animals is possible, it is expected
to be
useful as a clue for prophylaxis of cancer in the owners.
[00111
It is said that about 6,390,000 and about 17,640,000 dogs are currently kept
in
Japan and the U.S., respectively. Since, in addition to rabies vaccination,
combination vaccines such as pentavalent, heptavalent and octavalent vaccines
have
become popular, occurrence of highly lethal infectious diseases such as canine
CA 02703356 2010-04-22
parvovirus infection, canine distemper virus infection, canine parainfluenza
(kennel
cough), canine adenovirus type IT infection (kennel cough), canine infectious
hepatitis, canine coronavirus infection and leptospirosis decreased.
Therefore, the
average life expectancy of dogs increased, and aged dogs of 7 years old or
older
5 occupy 35.5% of the total number of the kept dogs. As the causes of
death, cancer,
hypertension, cardiac diseases and the like are consistently increasing like
in human.
In the U.S., about 4,000,000 dogs/year are diagnosed as cancer, and it is also
said that
about 1,600,000 dogs in Japan potentially have a certain tumor.
[0012]
However, there exist no simple diagnostic agents for animal cancers so far,
and in the field of animal healthcare, test methods such as photography by X-
ray, CT
and MRI are not commonly used. Their diagnosis is carried out by palpation,
simple blood test and a test by radiography, which largely depend on
experience of a
veterinarian. Although some veterinarians have begun to employ a test method
using serum, human tumor markers are used in the method since canine tumor
markers have not been found yet.
[0013]
Accurate diagnosis of cancer requires an abdominal operation, and there are
large problems of the physical burden to a dog and the economical burden to
its
owner. If diagnosis of cancers can be conveniently carried out in companion
animals such as dogs and cats, early detection and accurate diagnosis of the
cancers
are made possible, which is useful for treatment of the cancers in the
companion
animals. Further, if a method which enables such simple diagnosis of cancers
using
serum is provided, it is expected that the method not only makes it possible
to
diagnose cancers but also contributes a great deal to periodic health
examination,
preoperative diagnosis and determination of the therapeutic strategy.
[0014]
CA 02703356 2010-04-22
6
Unlike in human, medical examination is not popular in companion animals.
Therefore, in many cases, tumor in a companion animal is found at its late
stage, and
the owner realizes the tumor and takes his animal only after the tumor has
grown
bigger. In cases where the grown tumor is malignant, surgical therapy such as
operation and administration of an anticancer agent or the like are very often
too late.
Therefore, in cases where the cancer was judged as malignant by a
veterinarian,
anticancer drug therapy is generally carried out without operation. Even in
cases
where an operation is carried out, the operation must be strictly controlled
to secure
the margin and prevent dispersion of blood and cells during the operation. It
is
desirable to start anticancer drug therapy immediately after the operation and
to
follow up the patient at short intervals. It is expected that early detection
of cancers
is made easier if the above-described diagnosis is adopted into the medical
examination of dogs, so-called "dog dock", which is recently being
popularized.
[0015]
On the other hand, in the case of a benign tumor, an operation can be decided
to be carried out even if the tumor is large. All that is required is to care
the excised
area, and there is no need for treatment with neither expensive anticancer
drugs nor
being nervous about the follow up.
[0016]
In view of the above-described circumstances, if a simple means for detecting
cancers with a high sensitivity which can be applied to cancer diagnosis in
animals is
provided, accurate and efficient therapy is made possible, which is highly
advantageous to both owners and veterinarians.
[0017]
Non-patent Literature 1: Investigation by Ministry of Health, Labour and
Welfare,
2004
Non-patent Literature 2: Nikkei Science, 2007, March, pp. 80-88
CA 02703356 2010-04-22
7
Non-patent Literature 3: Clinical Tests, 2003, December, vol. 47, No. 13, p.
1641-
1654
Non-patent Literature 4: Statistics of Diseases of Dogs and Cats, 2005,
January
Non-patent Literature 5: Companion Animal Health Products: 2006 Edition By Tim
Wesley, ANIMAL PHARM REPORTS
Non-patent Literature 6: Expansion of Cancer and Stage of Progression. Hideaki
Tsukuma, Department of Cancer Control and Statistics, Osaka Medical Center for
Cancer and Cardiovascular Diseases
Non-patent Literature 7: Proteins, Nucleic Acids and Enzymes, vol. 50, No. 11,
p.
1405-1412
Non-patent Literature 8: J Cell Sci. 115: 1825-35
Non-patent Literature 9: Blood. 95: 1788-96
Non-patent Literature 10: Mol Endocrinol. 9: 243-54 (1995)
Non-patent Literature 11: J Cell Biol. 145: 83-98 (1999)
DISCLOSURE OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
[0018]
An object of the present invention is to provide means for detecting a
cancer(s) which is useful in diagnosing a cancer(s).
MEANS FOR SOLVING THE PROBLEM
[0019]
The present inventors intensively studied to obtain a cDNA encoding a
protein which binds to an antibody existing in serum derived from a tumor-
bearing
living body by the SEREX method using a cDNA library derived from canine
testis
and serum of a tumor-bearing dog, which cDNA was used to prepare a polypeptide
having the amino acid sequence shown in SEQ ID NO:2, a canine calmegin protein
having the amino acid sequence shown in SEQ ID NO:16, a canine centrosomal
CA 02703356 2010-04-22
8
protein (which may be hereinafter abbreviated as CEP) having the amino acid
sequence shown in SEQ ID NO:26, and the canine thyroid hormone receptor
interactor 11 (which may be hereinafter described as "TRIP11") having the
amino
acid sequence shown in SEQ ID NO:45. Further, based on a human gene
homologous to the obtained gene, a polypeptide having the amino acid sequence
shown in SEQ ID NO:4, a human calmegin protein having the amino acid sequence
shown in SEQ ID NO:18, a human CEP having the amino acid sequence shown in
SEQ ID NO:28, and a human TRIP11 having the amino acid sequence shown in SEQ
ID NO:47 were prepared. The inventors found that genes encoding these proteins
are specifically expressed in canine and human testis and malignant cancer
cells (see,
Examples A-1, B-1, C-1 and D-1), and that recombinant proteins prepared based
on
the amino acid sequences of these proteins specifically react with the serum
in
cancer-bearing living body, as well as that each of the above-mentioned
polypeptides
and homologous factors thereof can be specifically detected in a cancer-
bearing
living body by an antibody prepared by using the respective recombinant
proteins,
thereby completing the present invention.
[0020]
That is, the present invention provides a method for detecting a cancer(s),
which is applied to a sample separated from a living body and comprises
measuring
an expression of at least one of the polypeptides (a) to (d) below:
(a) a polypeptide produced in said living body and having a reactivity to
bind to an antibody against a polypeptide having the amino acid sequence shown
in
SEQ ID NO:2 or 4 by antigen-antibody reaction;
(b) calmegin;
(c) a polypeptide having a reactivity to bind to an antibody against a
centrosomal protein having the amino acid sequence shown in SEQ ID NO:26, 28
or
42 by antigen-antibody reaction;
CA 02703356 2010-04-22
9
(d) thyroid hormone receptor interactor 11.
[0021]
The present invention also provides a reagent for detecting a cancer(s),
comprising a polypeptide which immunologically reacts with an antibody induced
in
a living body against any one of the polypeptides (i) to (1) below:
(i) a polypeptide having the amino acid sequence shown in SEQ ID
NO:2
or 4;
calmegin;
(k) a centrosomal protein having the amino acid sequence shown in
SEQ
ID NO:26, 28 or 42;
(1) thyroid hormone receptor interactor 11.
[0022]
The present invention further provides a reagent for detecting a cancer(s),
comprising an antibody which immunologically reacts with any one of the
polypeptides (m) to (p) below or antigen-binding fragment thereof:
(m) a polypeptide produced in a living body and having a reactivity to bind
to an antibody against a polypeptide having the amino acid sequence shown in
SEQ
ID NO:2 or 4 by antigen-antibody reaction;
(n) calmegin;
(o) a polypeptide produced in a living body and having a reactivity to bind
to an antibody against a centrosomal protein having the amino acid sequence
shown
in SEQ ID NO:26, 28 or 42 by antigen-antibody reaction;
(p) thyroid hormone receptor interactor 11.
[0023]
The present invention still further provides a reagent for detecting a
cancer(s),
comprising a polynucleotide which specifically hybridizes with a partial
region of the
base sequence shown in any one of SEQ ID NOs:1, 3, 15, 17, 25, 27, 41, 44 and
46 in
81594498
SEQUENCE LISTING.
[0023a]
The present invention as claimed relates to:
- a method for detecting a cancer(s), which is applied to a sample separated
from
5 a living body and comprises measuring an expression of a polypeptide
having a reactivity to
bind to an antibody against a centrosomal protein by antigen-antibody
reaction, wherein the
centrosomal protein has the amino acid sequence shown in SEQ ID NO:26, 28 or
42;
- a reagent for detecting a cancer(s), comprising a polypeptide which
immunologically reacts with an antibody induced in a living body against a
centrosomal
10 protein having the amino acid sequence shown in SEQ ID NO:26, 28 or 42;
- a reagent for detecting a cancer(s), comprising an antibody which
immunologically reacts with a polypeptide produced in a living body and having
a reactivity
to bind to an antibody against a centrosomal protein having the amino acid
sequence shown in
SEQ ID NO:26, 28 or 42 by antigen-antibody reaction, or antigen-binding
fragment thereof;
and
- a reagent for detecting a cancer(s), comprising a polynucleotide which
specifically hybridizes with a partial region of the base sequence shown in
any one of SEQ ID
NOs:25, 27 and 41.
EFFECTS OF TIIE INVENTION
[0024]
By the present invention, a novel method for detecting a cancer(s) was
provided. As will be concretely described in Examples below, recombinant
polypeptides
prepared based on the amino acid sequence shown in SEQ ID NO:2 or 4, the amino
acid
sequence of calmegin, the amino acid sequence of CEP shown in SEQ ID NO:26, 28
or 42
and the amino acid sequence of TRIP 11 react with antibodies which
specifically exist in
CA 2703356 2019-03-11
CA 02703356 2016-05-12
55225-16
10a
serum of cancer patients. Therefore, cancers in a living body can be detected
by measuring the
antibody in a sample according to the method of the present invention. Cancers
in a living
body can also be detected by measuring the antigen protein per se which the
antibody
recognizes. Because the method of the present invention makes it possible to
detect invisible
small cancers and cancers which exist in a deep part of a body, it is also
useful for early
detection of cancers in medical examinations and the like. If the method of
the present
invention is used in following-up of the patients after cancer therapy,
recurrence of the cancer
can be detected in its early stage. Moreover, the method of the present
invention makes it
possible to assess the stage of cancer progression such as growth of the
tumor, invasion of the
tumor to the surrounding tissues, and metastasis of the cancer to lymph nodes
and distant
organs. Furthermore, the method of the present invention makes it possible to
assess the grade
of cancer malignancy, because patients suffering from more malignant cancer
have more
amount of the antibody mentioned above in serum compared to those suffering
from less
malignant cancer. Furthermore, based on the increase or decrease of the above-
mentioned
antibody in serum, how much the administered anticancer drug is effective, or
whether a
portion of the tumor is left in the patient after extirpation of the tumor can
be assessed, as well
as a clue to find metastasis and/or recurrence as early as possible can be
CA 02703356 2010-04-22
11
obtained during the follow-up. Thus, by the method of the present invention,
monitoring of the therapy, which provides a basis for adoption of the
therapeutic
approach, such as whether the therapeutic approach applied to a patient is
appropriate
or not, whether the approach should be changed to another or not, or whether
any
therapy should be started or not, can be attained. Furthermore, as shown in
the
Examples below, mRNAs encoding a polypeptide having the amino acid sequence
shown in SEQ ID NO:2 or 4, calmegin, CEP having the amino acid sequence shown
in SEQ ID NO:26, 28 or 42, and encoding TRIP11 are highly expressed
specifically
in the testis and cancer cells. Therefore, cancers can be detected by
measuring the
mRNAs.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025]
Fig. 1 shows the expression pattern of the gene identified in Example A-1 in
normal tissues and tumor cell lines. Reference numeral 1: the expression
pattern of
the identified gene; Reference numeral 2: the expression pattern of the GAPDH
gene.
Fig. 2 shows the detection by Coomassie staining of the recombinant canine
protein, which is an example of the polypeptide used in the present invention,
produced in E. coli and purified in Example A. Reference numeral 3: the band
for
the recombinant canine protein.
Fig. 3 shows some of the results of cancer diagnosis in cancer-bearing dogs
carried out using the recombinant canine protein prepared in Example A.
Fig. 4 shows some of the results of detailed cancer diagnosis in cancer-
bearing dogs carried out using the recombinant canine protein prepared in
Example A.
Fig. 5 shows the expression pattern of the gene encoding calmegin protein in
normal tissues and tumor cell lines. Reference numeral 1: the expression
pattern of
the gene encoding calmegin protein; Reference numeral 2: the expression
pattern of
the GAPDH gene.
CA 02703356 2010-04-22
12
Fig. 6 shows the detection by Coomassie staining of canine calmegin, which
is an example of the polypeptide used in the present invention, produced in E.
coli
and purified in Example B. Reference numeral 3: the band for the canine
calmegin
protein.
Fig. 7 shows some of the results of cancer diagnosis in cancer-bearing dogs
carried out using the canine calmegin protein prepared in Example B.
Fig. 8 shows some of the results of detailed cancer diagnosis in cancer-
bearing dogs carried out using the canine calmegin protein prepared in Example
B.
Fig. 9 shows the expression pattern of the gene encoding CEP in normal
tissues and tumor cell lines. Reference numeral 1: the expression pattern of
the
gene encoding CEP; Reference numeral 2: the expression pattern of the GAPDH
gene.
Fig. 10 shows the detection by Coomassie staining of the polypeptide derived
from canine CEP, which is an example of the polypeptide used in the present
invention, produced in E. coli and purified in Example C. Reference numeral 3:
the
band for the polypeptide derived from canine CEP.
Fig. 11 shows some of the results of cancer diagnosis in cancer-bearing dogs
carried out using the polypeptide derived from canine CEP prepared in Example
C.
Fig. 12 shows some of the results of detailed cancer diagnosis in cancer-
bearing dogs carried out using the polypeptide derived from canine CEP
prepared in
Example C.
Fig. 13 shows the expression pattern of the gene encoding the TRIP11 protein
in normal tissues and tumor cell lines. Reference numeral 1: the expression
pattern
of the gene encoding the TRIP11 protein; Reference numeral 2: the expression
pattern of the GAPDH gene.
Fig. 14 shows the detection by Coomassie staining of the polypeptide derived
from canine TRIP11, which is an example of the polypeptide used in the present
CA 02703356 2010-04-22
13
invention, produced in E. coli and purified in Example D. Reference numeral 3:
the
band for the polypeptide derived from canine TRIP11.
Fig. 15 shows some of the results of cancer diagnosis in cancer-bearing dogs
carried out using the polypeptide derived from canine TRIP11 prepared in
Example
D.
Fig. 16 shows some of the results of detailed cancer diagnosis in cancer-
bearing dogs carried out using the polypeptide derived from canine TRIP11
prepared
in Example D.
BEST MODE FOR CARRYING OUT THE INVENTION
[0026]
In the method of the present invention, the expression of a prescribed
polypeptide is measured using a sample separated from a living body. The
method
for measuring the expression of a polypeptide using the sample includes a
method in
which an antibody against the polypeptide, which antibody is contained in the
sample,
is measured by immunoassay (Method 1); a method in which the polypeptide per
se
contained in the sample is measured by immunoassay (Method 2); and a method in
which mRNA contained in the sample which encodes the polypeptide is measured
(Method 3). In the method of the present invention, the expression of the
polypeptide may be measured by any of these three methods. In the present
invention, the term "measurement" includes detection, quantification and semi-
quantification.
[0027]
The above-mentioned prescribed polypeptide whose expression is measured
in the method of the present invention is at least one of the polypeptides (a)
to (d)
below:
(a) a polypeptide produced in the living body and having a
reactivity to
bind to an antibody against a polypeptide having the amino acid sequence shown
in
CA 02703356 2010-04-22
14
SEQ ID NO:2 or 4 by antigen-antibody reaction;
(b) calmegin;
(c) a polypeptide having a reactivity to bind to an antibody against a
centrosomal protein having the amino acid sequence shown in SEQ ID NO:26, 28
or
42 by antigen-antibody reaction;
(d) thyroid hormone receptor interactor 11.
[0028]
As shown in the following Examples, cancers are successfully detected even
by measuring the expression of just one of these polypeptides. Therefore, in
the
present invention, the expression of just one of the polypeptides (a) to (d)
may be
measured, as well as two or more of the polypeptides (a) to (d) may be
measured in
combination. When two or more polypeptides are measured, cancers can be
detected with higher accuracy (see, Example E below).
[0029]
The polypeptide (a) is a polypeptide which is produced in a living body and
has a reactivity to bind to an antibody against a polypeptide having the amino
acid
sequence shown in SEQ ID NO:2 or 4 by antigen-antibody reaction. In other
words,
the prescribed polypeptide whose expression should be measured is a
polypeptide
which has the same antigenicity as a canine-derived polypeptide of SEQ ID NO:2
or
as a human-derived polypeptide of SEQ ID NO:4.
[0030]
Specific examples of such a polypeptide include a canine-derived polypeptide
of SEQ ID NO:2 and a human-derived polypeptide of SEQ ID NO:4. These
polypeptides are the very corresponding antigen of "an antibody against a
polypeptide
having the amino acid sequence shown in SEQ ID NO:2 or 4", and thus included
in
the above-mentioned prescribed polypeptide. Specific examples of the
polypeptide
also include a polypeptide which is derived from other mammals and has the
same
CA 02703356 2010-04-22
antigenicity as the above-mentioned canine- or human-derived polypeptide (such
a
polypeptide is hereinafter referred to as "homologous factor", and the human-
derived
polypeptide as described above may also be referred to as "human homologous
factor" of the canine-derived polypeptide).
5 [0031]
SEQ ID NO:2 shows the amino acid sequence of the polypeptide with
unknown function identified in the Examples below as a polypeptide which binds
to
an antibody existing specifically in serum derived from a cancer-bearing dog
(the
antibody may also be hereinafter referred to as "cancer-specific antibody" of
dogs),
10 which identification was carried out by the SEREX method using a canine
testis-
derived cDNA library and serum of cancer-bearing dogs (see, Example A-1).
Therefore, cancers in dogs can be detected by measuring this cancer-specific
antibody against a polypeptide of SEQ ID NO:2 in accordance with Method 1
above
(see, Examples A-3 and A-4). Cancers in dogs can also be detected by measuring
15 the polypeptide of SEQ ID NO:2 per se, which is the antigen, in
accordance with
Method 2 above (see, Examples A-5 and A-6). Moreover, since the expression of
mRNA encoding the antigen polypeptide is significantly high in the testis and
cancer
cells as shown in the following Examples (see, Example A-1), cancers in dogs
can
also be detected by measuring the mRNA. It is noted that, although the amino
acid
sequence of the canine polypeptide shown in SEQ ID NO:2 is registered in the
NCBI
database under the Accession No. XP 535343 (protein) and Accession No.
XM 535343 (coding gene), its function has not been reported yet.
[0032]
SEQ ID NO:4 shows the amino acid sequence of the human homologous
factor of the canine-derived polypeptide described above, which was found by
BLAST homology search. The base sequence encoding the human homologous
factor and the amino acid sequence thereof are shown in SEQ ID NOs:3 and 4,
CA 02703356 2010-04-22
16
respectively, and also registered in the NCBI database under Accession No.
NP 689873 (protein) and Accession No. NM 152660 (coding gene). Similarly to
the canine-derived polypeptide described above, any functions of the human
homologous factor have not been reported. As concretely shown in the following
Examples, similarly to the canine-derived polypeptide of SEQ ID NO:2, the
expression level of mRNA encoding the human homologous factor is significantly
high in human testis and cancer cells, and an antibody against the human
homologous
factor is not detected in healthy humans. Therefore, cancers in humans can be
detected by determining the expression of a polypeptide of SEQ ID NO:4 in the
humans.
[0033]
Specific examples of the homologous factor in other mammals which has the
same antigenicity as the above-mentioned canine-derived polypeptide or the
human
homologous factor thereof include, for example, the polypeptide which
specifically
exists in cancer-bearing cats as shown in the following Examples. This feline
polypeptide immunologically reacts with not only an antibody prepared by using
as
an inununogen the canine-derived polypeptide of SEQ ID NO:2, but also an
antibody
prepared by using as an immunogen the human homologous factor of SEQ ID NO:4
(see, Examples A-5 and A-6). Therefore, this feline polypeptide is the feline
homologous factor which has the same antigenicity as the above-described
canine-
and human-derived polypeptides, and included in the scope of a polypeptide
"which
has a reactivity to bind to an antibody against a polypeptide having the amino
acid
sequence shown in SEQ ID NO:2 or 4 by antigen-antibody reaction", whose
expression is to be measured in the present invention. As concretely described
in
the Examples below, an antibody induced in cats against the feline homologous
factor is detected only in cancer-bearing cats and not detected in healthy
cats. The
feline homologous factor per se, which is the antigen, is also detected only
in cancer-
CA 02703356 2010-04-22
17
bearing cats and not detected in healthy cats. Therefore, by measuring the
expression of the homologous factor in mammals other than dogs and humans,
cancers in the mammals can be detected.
[0034]
The polypeptide (a) described above is preferably a polypeptide having the
amino acid sequence shown in SEQ ID NO:2 in SEQUENCE LISTING, or a
polypeptide which has a homology of not less than 95% thereto and is produced
in a
living body. The homology between the canine-derived polypeptide (SEQ ID
NO:2) and the human homologous factor thereof (SEQ ID NO:4) is 93% in terms of
base sequence and 99% in terms of amino acid sequence. Although dogs and
humans are genetically distant, the homologous factor in such a genetically
distant
species shares a very high homology of 99% at amino acid level. Therefore, it
is
believed that the homologous factor in mammals other than human also shares as
high homology as not less than 95% with the canine-derived polypeptide of SEQ
ID
NO:2.
[0035]
The above-described polypeptide (b), Calmegin, was identified as a protein
which is expressed specifically at the time of differentiation of a spermatid,
and has a
chaperone activity in vitro. Since it is expressed only in testis and
disappears in a
mature sperm, calmegin is considered to have a function to fold proteins
involved in
differentiation of spermatid (Non-patent Literature 7: Naokazu Inoue, Ryo
Yamaguchi and Masahito Ikawa, Protein, Nucleic Acid and Enzyme, vol. 50, No.
11,
1405-1412). However, there has been no report showing that the protein is
expressed in a cancer and useful for cancer diagnosis and the like.
[0036]
SEQ ID NO:16 shows the amino acid sequence of canine calmegin. The
canine calmegin having this amino acid sequence was identified as a
polypeptide
CA 02703356 2010-04-22
18
which binds to an antibody existing specifically in serum derived from a
cancer-
bearing dog, which identification was carried out by the SEREX method using a
canine testis-derived cDNA library and serum of cancer-bearing dogs (see,
Example
= B-1). That is, in cancer-bearing dogs, an antibody against calmegin
having the
amino acid sequence shown in SEQ ID NO:16 is specifically induced. Therefore,
cancers in dogs can be detected by measuring the above-mentioned antibody
against
calmegin having the amino acid sequence shown in SEQ ID NO:16 in accordance
with Method 1 above (see, Examples B-3 and B-4). Cancers in dogs can also be
detected by measuring calmegin of SEQ ID NO:16 per se, which is the antigen,
in
accordance with Method 2 above (see, Examples B-5 and B-6). Moreover, since
the
expression of mRNA encoding calmegin is significantly high in the testis and
cancer
cells as shown in the following Examples (see, Example B-1), cancers in dogs
can
also be detected by measuring the mRNA.
[0037]
In the method of the present invention, not only the canine calmegin of SEQ
ID NO:16 but also calmegin in other mammals (hereinafter also referred to as
"homologous factor" of canine calmegin; in cases where the simple term
"calmegin"
is used, not only canine calmegin but also other mammalian calmegin are
referred to
by the term) may be measured. As concretely described in the Example below,
similarly to canine calmegin of SEQ ID NO:16, the expression level of mRNA
encoding human calmegin is also significantly high in human testis and cancer
cells,
and an antibody against human calmegin is not detected in healthy humans. An
antibody against feline calmegin is detected only in cancer-bearing cats and
not
detected in healthy cats. Therefore, by measuring the expression of calmegin
in
mammals other than dogs, cancers in the mammals can also be detected. Besides
canine calmegin, examples of the calmegin to be measured in the method of the
present invention include, but not limited to, human calmegin, feline calmegin
and
CA 02703356 2010-04-22
19
the like. The base sequence encoding human calmegin and the amino acid
sequence
thereof are shown in SEQ ID NOs:17 and 18 in SEQUENCE LISTING, respectively,
and the homology between human calmegin and canine calmegin is 90% in terms of
base sequence and 89% in terms of amino acid sequence. Although dogs and
humans are genetically distant, the calmegin in such genetically distant
species share
a very high homology of 89% at amino acid level. Therefore, it is believed
that
calmegin in mammals other than human also shares as high homology as not less
than about 80% with canine calmegin. That is, calmegin to be measured in the
method of the present invention preferably has a homology of not less than
80%,
more preferably not less than 85% to canine calmegin shown in SEQ ID NO:16,
although not restricted thereto.
[0038]
The polypeptide (c) described above is a polypeptide which has a reactivity to
bind to an antibody against centrosomal protein (CEP) having the amino acid
sequence shown in SEQ ID NO:26, 28 or 42 by antigen-antibody reaction. In
other
words, the polypeptide (c) described above is a polypeptide which has the same
antigenicity as canine-derived CEP of SEQ ID NO:26 or 42 or human-derived CEP
of SEQ ID NO:28.
[0039]
Specific examples of such a prescribed CEP include canine-derived CEP of
SEQ ID NO:26 or 42, and human-derived CEP of SEQ ID NO:28. These CEPs are
the very corresponding antigen of "an antibody against CEP having the amino
acid
sequence shown in SEQ ID NO:26, 28 or 42", and thus included in a prescribed
CEP
as mentioned above. Specific examples of the CEP also include CEP derived from
other mammals which has the same antigenicity as the above-mentioned canine-
or
human-derived CEP (such CEP is hereinafter referred to as "homologous factor",
and
human-derived CEP mentioned above may also be referred to as "human
CA 02703356 2010-04-22
homologous factor" of canine-derived CEP).
[0040]
SEQ ID NO:26 shows the amino acid sequence of canine CEP identified as a
= polypeptide which binds to an antibody existing specifically in serum
derived from a
5 cancer-bearing dog (hereinafter also referred to as a canine "cancer-
specific
antibody"), which identification was carried out by the SEREX method using a
canine testis-derived cDNA library and serum of cancer-bearing dogs (see,
Example
C-1). Therefore, cancers in dogs can be detected by measuring the above-
mentioned antibody against canine CEP having the amino acid sequence shown in
10 SEQ ID NO:26 in accordance with Method 1 above (see, Examples C-3 and C-
4).
Cancers in dogs can also be detected by measuring CEP of SEQ ID NO:26 per se,
which is the antigen, in accordance with Method 2 above (see, Examples C-5 and
C-
6). Moreover, since the expression of mRNA encoding CEP of SEQ ID
NO:26 is
significantly high in the testis and cancer cells as shown in the following
Examples
15 (see, Example C-1), cancers in dogs can also be detected by measuring
the mRNA.
CEP is a protein which is required by the centrosome to control microtubules,
and
also involved in maturation of the centrosome. Frequent occurrence of
chromosomal translocation is known in a part of myeloproliferative disorders,
and
since the CEP gene exists at the point where the translocation occurs, it is
considered
20 to have a certain relationship with the disorders. However, there has
been no report
showing that the protein is expressed in a cancer and useful for cancer
diagnosis
(Non-patent Literature 8: J Cell Sci. 115:1825-35; Non-patent Literature 9:
Blood.
95:1788-96).
[0041]
SEQ ID NO:42 shows the amino acid sequence of a known canine CEP
registered in a database, which was found as a protein sharing very high
homology
with the obtained canine CEP mentioned above by BLAST search (see, Example C-
CA 02703356 2010-04-22
21
1). The base sequence of this known canine CEP is shown in SEQ ID NO:41.
Similarly to canine CEP of SEQ ID NO:26, canine CEP of SEQ ID NO:42 is also
considered to be highly expressed in cancer-bearing dogs, and cancers in dogs
can be
detected by determining the expression of this known canine CEP as concretely
described in the following Examples.
[0042]
SEQ ID NO:28 shows the amino acid sequence of a human homologous
factor of the canine-derived CEP mentioned above, which amino acid sequence
was
found by BLAST homology search. The base sequence encoding the human
homologous factor and the amino acid sequence thereof are shown in SEQ ID
NOs:27 and 28 in SEQUENCE LISTING, respectively. As concretely described in
the Examples below, similarly to canine-derived CEP of SEQ ID NO:26, the
expression level of mRNA encoding the human homologous factor is significantly
high in human testis and cancer cells, and an antibody against the human
homologous
factor is not detected in healthy humans. Therefore, cancers in humans can be
detected by determining the expression of CEP of SEQ ID NO:28 in the humans.
[0043]
Specific examples of the homologous factor in other mammals which has the
same antigenicity as the above-described canine-derived CEP or as the human
homologous factor thereof include, for example, CEP which specifically exists
in
cancer-bearing cats as shown in the following Examples. The feline CEP
immunologically reacts with not only an antibody prepared by using as an
immunogen canine-derived CEP of SEQ ID NO:26 or 42, but also an antibody
prepared by using as an immunogen the human homologous factor of SEQ ID NO:28
(see, Examples C-5 and C-6). Therefore, this feline CEP is a feline homologous
factor which has the same antigenicity as the above-mentioned canine- and
human-
derived CEPs, and thus included in the scope of a CEP "which has a reactivity
to
CA 02703356 2010-04-22
22
bind to an antibody against CEP having the amino acid sequence shown in SEQ ID
NO:26, 28 or 42 by antigen-antibody reaction", whose expression is to be
measured
in the present invention. As concretely described in the Examples below, an
antibody induced in cats against the feline homologous factor is detected only
in
cancer-bearing cats and not detected in healthy cats. The feline homologous
factor
per se, which is the antigen, is also detected only in cancer-bearing cats and
not
detected in healthy cats. Therefore, by measuring the homologous factor in
mammals other than dogs and humans, cancers in the mammals can also be
detected.
[0044]
Preferably, the CEP whose expression should be measured in the detection
method of the present invention is CEP having the amino acid sequence shown in
SEQ ID NO:26 or 42 in SEQUENCE LISTING, or a polypeptide which has a
homology of not less than 80% thereto and is produced in a living body. The
homology between canine-derived CEP and human homologous factor thereof is
87% in terms of base sequence and 84% in terms of amino acid sequence.
Although dogs and humans are genetically distant, the homologous factor in
such a
genetically distant species shares very high homology of 84% at amino acid
level.
Therefore, it is believed that the homologous factor in mammals other than
human
also shares as high homology as not less than 80% with the canine CEP.
[0045]
The above-described polypeptide (d), TRIP11 (thyroid hormone receptor
interactor 11), was first identified as a factor which interacts with the
thyroid
hormone receptor 0, and its binding to Golgi bodies and microtubules also
became
evident, so that it is considered to play a role in maintaining the shapes of
these
organelles by making links between Golgi bodies, microtubules and the like.
However, there has been no report showing that the protein is expressed in a
cancer
and useful for cancer diagnosis and the like (Non-patent Literature 10: Mol
CA 02703356 2010-04-22
23
Endocrinol. 9:243-54 (1995); Non-patent Literature 11: J Cell Biol. 145: 83-98
(1999)).
[0046]
SEQ ID NO:45 shows the amino acid sequence of canine TRIP11. The
canine TRIP11 having this amino acid sequence was identified as a polypeptide
which binds to an antibody existing specifically in serum derived from a
cancer-
bearing dog, which identification was carried out by the SEREX method using a
canine testis-derived cDNA library and serum of cancer-bearing dogs (see,
Example
D-1). That is, in cancer-bearing dogs, an antibody against TRIP11 having the
amino
acid sequence shown in SEQ ID NO:45 is specifically induced. Therefore,
cancers
in dogs can be detected by measuring the above-mentioned antibody against
TRIP11
having the amino acid sequence shown in SEQ ID NO:45 in accordance with Method
1 above (see, Examples D-3 and D-4). Cancers in dogs can also be detected by
measuring TRIP11 of SEQ ID NO:45 per se, which is the antigen, in accordance
with
Method 2 above (see, Examples D-5 and D-6). Moreover, since the expression of
mRNA encoding TRIP11 is significantly high in the testis and cancer cells as
shown
in the following Examples (see, Example D-1), cancers in dogs can also be
detected
by measuring the mRNA.
[0047]
In the method of the present invention, not only canine TRIP11 of SEQ ID
NO:45 but also TRIP11 in other mammals (hereinafter also referred to as
"homologous factor" of canine TRIP11; in cases where the simple term "TRIP11"
is
used, not only canine TRIP11 but also other mammalian TRIP11 are referred to
by
the term) may be measured. As concretely described in the Example below,
similarly to canine TRIP11 of SEQ ID NO:45, the expression level of mRNA
encoding human TRIP11 is also significantly high in human testis and cancer
cells,
and an antibody against human TRIP11 is not detected in healthy humans. An
CA 02703356 2010-04-22
24
antibody against feline TRIP11 is detected only in cancer-bearing cats and not
detected in healthy cats. Therefore, by measuring the expression of TRIP11 in
mammals other than dog, cancers in the mammals can also be detected. Besides
canine TRIP11, examples of the TRIP11 to be measured in the method of the
present
invention include, but not limited to, human TRIP11, feline TRIP11 and the
like.
The base sequence encoding human TRIP11 and the amino acid sequence thereof
are
shown in SEQ ID NOs:46 and 47 in SEQUENCE LISTING, respectively, and the
homology between canine TRIP11 and human TRIP11 is 88% in terms of base
sequence and 86% in terms of amino acid sequence. Although dogs and humans are
genetically distant, the TRIP1ls in such genetically distant species share
very high
homology of 86% at amino acid level with each other. Therefore, it is believed
that
TRIP11 in mammals other than human also shares as high homology as not less
than
about 75% with canine TRIP11. That is, the TRIP11 whose expression should be
measured in the method of the present invention preferably has a homology of
not
less than 75%, more preferably not less than 80% to the amino acid sequence of
canine TRIP11 shown in SEQ ID NO :45, although not restricted thereto.
[0048]
It should be noted that the term "having the amino acid sequence" in the
present invention means that amino acid residues are aligned in that order.
Accordingly, for example, "a polypeptide having the amino acid sequence shown
in
SEQ ID NO:2" means a polypeptide having a size of 306 amino acid residues,
whose
amino acid sequence is Met Ala Ala Leu ... (snip) ... Ile Thr Ser Pro as shown
in SEQ
ID NO:2. Further, ''a polypeptide having the amino acid sequence shown in SEQ
ID NO:2" may be abbreviated as "a polypeptide of SEQ ID NO:2". This also
applies to the term "having the base sequence". It should be noted that the
term
"polypeptide" in the present invention means a molecule formed by peptide
bonding
of a plurality of amino acids, and includes not only polypeptide molecules
having a
CA 02703356 2010-04-22
large number of amino acids constituting them, but also low molecular weight
molecules having a small number of amino acids (oligopeptides) and full-length
proteins. Thus, in the present invention, proteins consisting of the full
length of
SEQ ID NO:2, 4, 16, 18, 26, 28, 42,45 or 47 are also included in
"polypeptide".
5 [0049]
In Method 1 above, measurement of the cancer-specific antibody which may
exist in the sample can be easily carried out by immunoassay using an
antigenic
substance which immunologically reacts with the antibody. The immunoassay per
se is a conventional well-known method as explained in detail below. Examples
of
10 the antigenic substance which may be used in the immunoassay include a
polypeptide
of SEQ ID NO:2, 16, 26, 42 or 45, which induces the antibody in cancer-bearing
dogs. As antibodies have the cross-reactivity, a molecule may be bound to an
antibody which is induced against another immunogen, as long as the molecule
has
any structure thereon which is similar to the epitope of the immunogen. For
15 example, polypeptides having high amino acid sequence homology to each
other
often have epitopes with similar structures, and in such cases both
polypeptides may
have the same antigenicity. As concretely described in the Examples below,
canine-
derived polypeptide of SEQ ID NO:2, 16, 26, 42 or 45 immunologically reacts
with
not only an antibody induced in cancer-bearing dogs against the polypeptide
but also
20 an antibody induced in cancer-bearing cats against a feline homologous
factor. The
human homologous factor immunologically reacts with the above-described
antibodies induced in cancer-bearing dogs and cats. Therefore, in Method 1 of
the
present invention, any mammalian homologous factors may be used as an antigen
in
the immunoassay.
25 [0050]
Antigenic substances having a large molecular weight and a complex
structure, such as proteins, usually have a plurality of sites with different
structures
CA 02703356 2010-04-22
26
on their surface. Therefore, such a large, complex antigenic substance induces
a
plurality of kinds of antibodies which respectively recognize each of the
sites in a
living body. That is, an antibody induced in a living body against an
antigenic
substance such as a protein is a polyclonal antibody, which is a mixture of a
plurality
of kinds of antibodies. The cancer-specific antibodies found by the present
inventors, which specifically exist in the serum from cancer-bearing living
bodies
and specifically bind to a polypeptide of SEQ ID NO:2, 16, 26, 42 or 45 or
homologous factors thereof by antigen-antibody reaction, are also a polyclonal
antibody. It should be noted that, in the present invention, the term
"polyclonal
antibody" means an antibody which exists in serum from a living body having an
antigenic substance therein and is induced in the living body against the
antigenic
substance.
[0051]
In the Example A below, a polypeptide consisting of the entire region of SEQ
ID NO:2 and a polypeptide consisting of the entire region of SEQ ID NO:4,
which is
the human homologous factor, were prepared as an antigen for immunoassay of
the
cancer-specific antibody, and the reactivity of these polypeptides with the
antibody in
the serum derived from a cancer-bearing living body was confirmed. In the
Example B below, a polypeptide consisting of the entire region of SEQ ID NO:16
(canine calmegin) and a polypeptide consisting of the entire region of SEQ ID
NO:18
(human calmegin), which is the human homologous factor thereof, were prepared,
and the reactivity of these polypeptides with the antibody in the serum
derived from a
cancer-bearing living body was confirmed. In the Example C below, a
polypeptide
consisting of a region of 1514th to 2339th amino acids of SEQ ID NO:26 (canine
CEP) and a polypeptide consisting of a region of 1513rd to 2325th amino acids
of
SEQ ID NO:28 (human CEP) were prepared, and the reactivity of these
polypeptides
with the antibody in the serum derived from a cancer-bearing living body was
CA 02703356 2010-04-22
27
confirmed. In the Example D below, a polypeptide consisting of a region of
237th
to 1023rd amino acids of SEQ ID NO:45 (canine TRIP11) and a polypeptide
consisting of a region of 236th to 1023rd amino acids of SEQ ID NO :47 (human
TRIP11) were prepared, and the reactivity of these polypeptides with the
antibody in
the serum derived from a cancer-bearing living body was confirmed. However,
since the antibodies mentioned above are polyclonal, a polypeptide consisting
of the
full length of SEQ ID NO:2, 16, 26, 42 or 45 or a homologous factor thereof of
course binds to the antibody. A fragment of the polypeptide can also bind to
the
antibody contained in the serum from a cancer-bearing living body, since the
polyclonal antibody may include antibodies which recognize the structure of
the
fragment. That is, not only a polypeptide consisting of the full length of SEQ
ID
NO:2, 16, 26, 42 or 45 or a homologous factor thereof but also a fragment
thereof
may be used in measurement of the polyclonal antibody specifically contained
in the
serum of a cancer-bearing living body, and is useful for detection of a
cancer(s).
[0052]
Thus, a polypeptide used as an antigen for immunoassay in Method 1 of the
present invention is not restricted to a polypeptide consisting of the full
length of
SEQ ID NO:2, 16, 26, 42 or 45 or a homologous factor thereof (e.g. SEQ ID
NO:4,
18, 28, 47, etc.), and includes a polypeptide fragment which consists of not
less than
7 consecutive, preferably not less than 10 consecutive amino acids of the
amino acid
sequence shown in SEQ ID NO:2, 16, 26, 42 or 45 or of a homologous factor
thereof,
and immunologically reacts with a polyclonal antibody against a canine-derived
polypeptide of SEQ ID NO:2, 16, 26, 42 or 45 or a homologous factor thereof
(the
polypeptide fragment may also be hereinafter referred to as "specifically-
reactive
partial polypeptide" for convenience). It should be noted that, as known in
the art, a
polypeptide having not less than about 7 amino acid residues can exert its
antigenicity.
CA 02703356 2010-04-22
28
[0053]
However, in cases where the number of the amino acid residues are too small,
the possibility that the antigen polypeptide may cross-react with antibodies
against
proteins which exist in the sample and are different from the canine-derived
polypeptide of SEQ ID NO:2, 16, 26, 42 or 45 or the homologous factor thereof
is
increased. Therefore, in view of attaining a high accuracy in the immunoassay,
a
polypeptide fragment consisting of a large number of the amino acid residues
is
preferred as an antigen used in the immunoassay. For example, in the case of a
polypeptide of SEQ ID NO:2 or a homologous factor thereof, it is desired that
the
number of the amino acid residues of the used polypeptide fragment should be
preferably not less than 30, more preferably not less than 100, still more
preferably
not less than 200, still more preferably not less than 250. In the case of
canine
calmegin of SEQ ID NO:16 or a homologous factor thereof, it is desired that
the
number of the amino acid residues should be preferably not less than 30, more
preferably not less than 100, still more preferably not less than 200, still
more
preferably not less than 400, still more preferably not less than 550. In the
case of
canine CEP of SEQ ID NO:26 or 42 or a homologous factor thereof, it is desired
that
the number of the amino acid residues should be preferably not less than 30,
more
preferably not less than 100, still more preferably not less than 300, still
more
preferably not less than 600, and the number of the amino acid residues may be
not
less than 1000, not less than 1500, or not less than 2000. In the case of
canine
TRIP11 of SEQ ID NO:45 or a homologous factor thereof, it is desired that the
number of the amino acid residues should be preferably not less than 30, more
preferably not less than 100, still more preferably not less than 300, still
more
preferably not less than 600, and the number of the residues may be not less
than
1000, or not less than 1500.
[0054]
CA 02703356 2010-04-22
29
Specific examples of the polypeptide used as an antigen include the following
polypeptides:
(e) a polypeptide having the amino acid sequence shown in SEQ ID
NO:2
or 4;
(0 a polypeptide having the amino acid sequence shown in SEQ ID
NO:16 or 18;
(g) a polypeptide consisting of not less than 500 consecutive amino acids
of the amino acid sequence shown in SEQ ID NO:26 and comprising not less than
500 consecutive amino acids located in the region of 1514th to 2339th amino
acids of
SEQ ID NO:26, or a polypeptide consisting of not less than 500 consecutive
amino
acids of the amino acid sequence shown in SEQ ID NO:28 and comprising not less
than 500 consecutive amino acids located in the region of 1513rd to 2325th
amino
acids of SEQ ID NO:28;
(h) a polypeptide consisting of not less than 500 consecutive amino acids
of the amino acid sequence shown in SEQ ID NO:45 and comprising not less than
500 consecutive amino acids located in the region of 237th to 1023rd amino
acids of
SEQ ID NO:45, or a polypeptide consisting of not less than 500 consecutive
amino
acids of the amino acid sequence shown in SEQ ID NO:47 and comprising not less
than 500 consecutive amino acids located in the region of 236th to 1023rd
amino
acids of SEQ ID NO:47.
[0055]
Preferred examples of the polypeptide (g) above (a polypeptide of SEQ ID
NO:26 or a fragment thereof, or a polypeptide of SEQ ID NO:28 or a fragment
thereof) include a fragment which comprises a region of 1514th to 2339th amino
acids of the amino acid sequence shown in SEQ ID NO:26 and consists of not
more
than 1000 amino acids, and a fragment which comprises a region of 1513rd to
2325th
amino acids of the amino acid sequence shown in SEQ ID NO:28 and consists of
not
CA 02703356 2010-04-22
more than 1000 amino acids. More preferred examples thereof include a fragment
consisting of a region of 1514th to 2339th amino acids (SEQ ID NO:35) of the
amino
acid sequence shown in SEQ ID NO:26, and a fragment consisting of a region of
1513rd to 2325th amino acids (SEQ ID NO:36) of the amino acid sequence shown
in
5 SEQ ID NO:28.
[0056]
Preferred examples of the polypeptide (h) above (a polypeptide of SEQ ID
NO:45 or a fragment thereof, or a polypeptide of SEQ ID NO:47 or a fragment
thereof) include a fragment which comprises a region of 237th to 1023rd amino
acids
10 of the amino acid sequence shown in SEQ ID NO:45 and consists of not
more than
1000 amino acids, and a fragment which comprises a region of 236th to 1023rd
amino acids of the amino acid sequence shown in SEQ ID NO:47 and consists of
not
more than 1000 amino acids. More preferred examples thereof include a fragment
consisting of a region of 237th to 1023rd amino acids (SEQ ID NO:54) of the
amino
15 acid sequence shown in SEQ ID NO:45, and a fragment consisting of a
region of
236th to 1023rd amino acid (SEQ ID NO:55) of the amino acid sequence shown in
SEQ ID NO:47.
[0057]
It is well-known in the art that, in general, there are cases where a protein
20 antigen retains substantially the same antigenicity as the original even
if the amino
acid sequence of the protein is modified such that a small number of amino
acids are
substituted, deleted and/or inserted. Therefore, the polypeptides each of
which has
the same amino acid sequence as the polypeptide of SEQ ID NO:2, 16, 26, 42 or
45
or the homologous factor thereof except that a small number of amino acid
residues
25 are substituted, deleted and/or inserted, whose sequence has a homology
of not less
than 80%, preferably not less than 90%, more preferably not less than 95%,
still more
preferably not less than 98% to the sequence of the original polypeptide, and
which
CA 02703356 2010-04-22
31
polypeptide specifically binds to a polyclonal antibody against a polypeptide
having
the amino acid sequence shown in SEQ ID NO:2, 16, 26, 42 or 45 or a homologous
factor thereof by antigen-antibody reaction (the polypeptides may also be
hereinafter
referred to as "specifically-reactive modified polypeptide" for convenience),
may also
be used for detection of cancers. Preferably, the specifically-reactive
modified
polypeptide has the same amino acid sequence as the polypeptide of SEQ ID
NO:2,
16, 26, 42 or 45 or a homologous factor thereof (preferably having the
sequence
shown in SEQ ID NO:4, 18, 28 or 47) except that one or several amino acid
residues
are substituted, deleted and/or inserted.
[0058]
As used herein, the term "homology" of amino acid sequences means a value
expressed in percentage which is calculated by aligning two amino acid
sequences to
be compared such that the number of matched amino acid residues is the
maximum,
and dividing the number of the matched amino acid residues by the number of
the
total amino acid residues. When the above-described alignment is carried out,
a
gap(s) is/are inserted into one or both of the two sequences to be compared as
required. Such alignment of sequences can be carried out using a well-known
program such as BLAST, FASTA and CLUSTAL W. When a gap(s) is/are inserted,
the above-described number of the total amino acid residues is calculated by
counting
one gap as one amino acid residue. When the thus counted numbers of the total
amino acid residues are different between the two sequences to be compared,
homology (%) is calculated by dividing the number of matched amino acid
residues
by the number of total amino acid residues in the longer sequence. The 20
types of
amino acids constituting the naturally occurring proteins may be classified
into
groups each of which has similar properties, for example, into neutral amino
acids
with side chains having low polarity (Gly, Ile, Val, Leu, Ala, Met, Pro),
neutral
amino acids having hydrophilic side chains (Asn, Gin, Thr, Ser, Tyr, Cys),
acidic
CA 02703356 2010-04-22
32
amino acids (Asp, Glu), basic amino acids (Arg, Lys, His) and aromatic amino
acids
(Phe, Tyr, Trp). It is known that, in most cases, substitutions of amino acids
within
the same group do not change the properties of the polypeptides. Therefore, in
cases where the amino acid residue(s) of the polypeptide of SEQ ID NO:2, 16,
26, 42
or 45 or a homologous factor thereof is/are substituted, the probability that
the ability
to bind to the corresponding antibody can be maintained may be made high by
conducting the substitution(s) within the same group.
[0059]
The polypeptides which contain the above-described polypeptide used in the
present invention as a partial sequence (i.e., the polypeptides used in the
present
invention which have other (poly)peptide(s) added at one or both ends thereof)
and
which specifically bind to a polyclonal antibody against a polypeptide of SEQ
ID
NO:2, 16, 26, 42 or 45 or a homologous factor thereof (the polypeptides may
also be
hereinafter referred to as "specifically-reactive added polypeptide" for
convenience)
may also be used for detection of cancers.
[0060]
The above-described polypeptides used in the present invention may be
prepared by chemical synthesis such as the Fmoc method
(fluorenylmethyloxycarbonyl method), the tBoc method (t-butyloxycarbonyl
method)
or the like, or prepared by a conventional method using a commercially
available
peptide synthesizer. The polypeptides may also be easily prepared by a known
genetic engineering method. For example, the desired polypeptides may be
obtained by extracting RNAs from a tissue expressing a gene encoding a
polypeptide
of SEQ ID NO:2, 16, 26, 42 or 45 or a homologous factor thereof, preparing
cDNA
of the gene by RT-PCR, inserting the full length or a desired part of the cDNA
into
an expression vector, and then introducing the vector into a host cell. The
base
sequences of cDNAs encoding the canine polypeptide of SEQ ID NO:2, canine
CA 02703356 2010-04-22
33
calmegin of SEQ ID NO:16, canine CEPs of SEQ ID NOs:26 and 42, and canine
TRIP11 of SEQ ID NO:45 are shown in SEQ ID NO:1, SEQ ID NO:15, SEQ ID
NOs:25 and 41, and SEQ ID NO:44, respectively, and the base sequences of cDNAs
encoding human homologous factors of the above polypeptides are shown in SEQ
ID
NO:3, SEQ ID NO:17 (human calmegin), SEQ ID NO:27 (human CEP), and SEQ ID
NO:47 (human TRIP11), respectively. Therefore, referring to these base
sequences,
primers used in RT-PCR may easily be designed. Further, as explained below,
genes encoding a homologous factor in mammals other than human may be
amplified
by using primers designed in reference to the base sequences of canine
polypeptides
and human homologous factors. Therefore, cDNAs encoding e.g. a feline
homologous factor may easily be prepared in the same manner as described
above.
Extraction of RNAs, RT-PCR, insertion of cDNA into a vector, and introduction
of a
vector into a host cell may be performed by a well-known method as described
below.
Vectors and host cells which may be used are well-known, and various vectors
and
host cells are commercially available.
[0061]
The above-described host cells are not restricted as long as they can express
the above-described polypeptide, and examples thereof include prokaryotic
cells such
as E. coil; and eukaryotic cells such as mammalian cultured cells including
monkey
kidney cells COS 1 and Chinese hamster ovary cells CHO, budding yeast, fission
yeast, silkworm cells, and Xenopus laevis egg cells.
[0062]
In cases where prokaryotic cells are used as the host cells, an expression
vector having the origin that enables its replication in a prokaryotic cell, a
promoter,
a ribosome binding site, a DNA cloning site, a terminator and the like is used
as the
expression vector. Examples of the expression vector for E. coil include the
pUC
system, pBluescriptII, pET expression system and pGEX expression system. By
CA 02703356 2010-04-22
34
incorporating DNA encoding the above-described polypeptide into such an
expression vector and transforming prokaryotic host cells with the vector,
followed
by culturing the obtained transformant, the polypeptide encoded by the above-
described DNA can be expressed in the prokaryotic host cells. In this case,
the
polypeptide can also be expressed as a fusion protein with another protein.
The
DNA encoding the above-described polypeptide may be obtained by preparing cDNA
by RT-PCR as described above, or may be synthesized by a conventional method
using a commercially available nucleic acid synthesizer as explained below. It
should be noted that the base sequences of cDNAs encoding polypeptides of SEQ
ID
NOs:2, 4, 16, 18, 26, 28, 42, 45 and 47 are shown in SEQ ID NOs:1, 3, 15, 17,
25, 27,
41, 44 and 46 in SEQUENCE LISTING, respectively.
[0063]
In cases where eukaryotic cells are used as the host cells, an expression
vector
for eukaryotic cells having a promoter, splicing site, poly(A) addition site
and the like
is used as the expression vector. Examples of such an expression vector
include
pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, the EBV vector,
pRS, pcDNA3, pMSG and pYES2. In the same manner as described above, by
incorporating DNA encoding the polypeptide used in the present invention into
such
an expression vector and transforming eukaryotic host cells with the vector,
followed
by culturing the obtained transformant, the polypeptide encoded by the above-
described DNA can be expressed in the eukaryotic host cells. In cases where
pIND/V5-His, pFLAG-CMV-2, pEGFP-N1 or pEGFP-C1 was used as the expression
vector, the above-described polypeptide can be expressed as a fusion protein
having
various added tags such as His tag, FLAG tag, myc tag, HA tag or GFP.
[0064]
Introduction of the expression vector to the host cells can be carried out
using
a well-known method such as electroporation, the calcium phosphate method, the
CA 02703356 2010-04-22
liposome method or the DEAE dextran method.
[0065]
Isolation and purification of a polypeptide of interest from the host cells
can
= be carried out by a combination of known separation operations. Examples
of the
5 operations include treatment by a denaturant such as urea or by a
surfactant;
ultrasonication treatment; enzyme digestion; salting-out and solvent
fractional
precipitation; dialysis; centrifugation; ultrafiltration; gel filtration; SDS-
PAGE;
isoelectric focusing; ion-exchange chromatography; hydrophobic chromatography;
affinity chromatography; and reversed-phase chromatography.
10 [0066]
The polypeptides obtained by the above method include those in the form of a
fusion protein with another arbitrary protein. Examples thereof include fusion
proteins with glutathione S-transferase (GST) and with a His tag. Such a
polypeptide in the form of a fusion protein is also included in the
specifically-reactive
15 added polypeptide described above, and may be used in Method 1 of the
present
invention. Further, in some cases, a polypeptide expressed in a transformed
cell is
modified in various ways in the cell after translation thereof. Such a
polypeptide
having a post-translational modification may also be used in Method 1 of the
present
invention, as long as it has an ability to bind to a polyclonal antibody
against a
20 polypeptide of SEQ ID NO:2 or 4. Examples of such a post-translational
modification include elimination of N-terminus methionine, N-terminus
acetylation,
glycosylation, limited degradation by an intracellular protease,
myristoylation,
isoprenylation and phosphorylation.
[0067]
25 Measurement of the antibody in a sample may easily be carried out by
immunoassay using the above-described polypeptide as an antigen. Immunoassays
per se are well-known in the art, and includes, when classified based on the
reaction
CA 02703356 2010-04-22
36
mode, sandwich method, competition method, agglutination method, Western blot
method and the like. When classified based on the label, immunoassays include
radioimmunoassay, fluorescence immunoassay, enzyme immunoassay, biotin
immunoassay and the like, and the immunoassay of the above-described antibody
may be carried out by any of these immunoassays. Although not restricted, the
sandwich ELISA and competition method may be preferably used as an
immunoassay of the above antibody in the present invention, as these methods
are
simple and do not require a large-scale apparatus. In cases where enzymes are
used
as a label of antibodies, the used enzyme is not particularly restricted as
long as it
satisfies such conditions that the turnover number is large, that the enzyme
is stable
even when it is bound to an antibody, that it specifically colors its
substrate and the
like. For example, enzymes used in an ordinary enzyme immunoassay such as
peroxidase, 13-ga1actosidase, alkaline phosphatase, glucose oxidase,
acetylcholinesterase, glucose-6-phosphate dehydrogenase, and malate
dehydrogenase
may be used. Enzyme inhibitors, coenzymes and the like may also be used.
Binding of these enzymes with an antibody may be carried out by a known method
using a cross-linking agent such as a maleimide compound. As a substrate,
known
substances may be used depending on the kind of the used enzyme. For example,
in
cases where peroxidase is used as an enzyme, 3,3',5,5'-tetramethylbenzidine
may be
used; and in cases where alkaline phosphatase is used as an enzyme, para-
nitrophenol
or the like may be used. As a radioisotope, those used in an ordinary
radioimmunoassay such as 1251 and 3H may be used. As a fluorescent dye, one
used
in an ordinary fluorescent antibody technique such as fluorescein
isothiocyanate
(FITC), tetramethylrhodamine isothiocyanate (TRITC) or the like may be used.
[0068]
These immunoassays per se are well-known in the art, and so it is not
necessary to explain these immunoassays in the present specification. Briefly,
in
CA 02703356 2010-04-22
37
sandwich immunoassays, for example, the above-mentioned polypeptide used as an
antigen is immobilized on a solid phase, and then reacted with a sample such
as a
serum. After washing the solid phase, the resultant is reacted with an
appropriate
secondary antibody. After washing the solid phase, the secondary antibody
bound
to the solid phase is measured. In the method for detecting a cancer(s)
according to
the present invention, it is preferred to immobilize an antigen polypeptide on
a solid
phase, because immobilization on a solid phase makes it possible to easily
remove
the unbound secondary antibody. As the secondary antibody, for example, anti-
dog
IgG antibody may be used in cases where the sample is obtained from dogs. The
secondary antibody bound to a solid phase may be measured by labeling the
secondary antibody with a labeling substance exemplified above. The thus
measured amount of the secondary antibody corresponds to the amount of the
above-
mentioned antibody in a serum sample. In cases where an enzyme is used as a
labeling substance, the amount of the antibody may be measured by adding a
substrate which is decomposed by the enzymatic activity to develop a color,
and then
optically measuring the amount of decomposed substrate. In cases where a
radioisotope is used as a labeling substance, the amount of radiation from the
radioisotope may be measured with a scintillation counter or the like.
[0069]
In Method 2 of the present invention, at least one polypeptide selected from
the group consisting of the polypeptide of SEQ ID NO:2 or a homologous factor
thereof, calmegin, CEP of SEQ ID NO:26 or 42 or a homologous factor thereof
and
TRIP11, which may be contained in a sample obtained from a living body, is
measured. As explained above, the abundance of the cancer-specific antibody
which immunologically reacts with the polypeptide of SEQ ID NO:2 or a
homologous factor thereof, calmegin in dogs, humans or the like, CEP of SEQ ID
NO:26 or 42 or a homologous factor thereof, or TRIP11 in dogs, humans or the
like
CA 02703356 2010-04-22
38
is significantly high in cancer patients, which indicates that the production
of these
polypeptides or homologous factors thereof, which are the antigen of the
cancer-
specific antibody, is significantly high in cancer patients. As concretely
described
in the Examples below, cancers can also be detected by measuring the antigen
per se.
Therefore, similarly to Method 1 above, cancers in a living body can be
detected by
measuring the polypeptide of SEQ ID NO:2 or a homologous factor thereof,
calmegin, CEP of SEQ ID NO:26 of 42 or a homologous factor thereof, or TRIP11
per se.
[0070]
Measurement of the polypeptide in a sample may easily be carried out by a
well-known immunoassay. Specifically, for example, the polypeptide of SEQ ID
NO:2, 16, 26, 42 or 45 or a homologous factor thereof which may exist in a
sample
may be measured by preparing an antibody or antigen-binding fragment thereof
which immunologically reacts with the polypeptide of SEQ ID NO:2, 16, 26, 42
or
45 or a homologous factor thereof, and then carrying out an immunoassay using
the
prepared antibody or fragment thereof. Because antibodies have a cross-
reactivity
as explained above, not only a canine-derived polypeptide of SEQ ID NO:2, 16,
26,
42 or 45 but also a homologous factor in other mammals, for example, a human
homologous factor of SEQ ID NO:4, 18, 28 or 47 or a feline homologous factor,
may
be measured by using the antibody or antigen-binding fragment thereof which
immunologically reacts with the canine-derived polypeptide of SEQ ID NO:2, 16,
26,
42 or 45. Immunoassays per se are a well-known, conventional method as
described above.
[0071]
The term "antigen-binding fragment" herein means fragment such as Fab
fragment or F(ab)2 fragment of the antibody, which exhibits antigen-binding
property
of the antibody. Although the antibody may be either a polyclonal antibody or
CA 02703356 2010-04-22
39
monoclonal antibody, a monoclonal antibody is preferred for immunoassays and
the
like, because the reproducibility is high. Methods for preparing a polyclonal
or
monoclonal antibody using a polypeptide as an immunogen are well-known, and
may
be easily carried out by a conventional method. For example, antibodies
against the
polypeptide may be induced by immunizing an animal with an immunogen, the
polypeptide conjugated to a carrier protein such as keyhole limpet hemocyanin
(KLH) or casein, together with an adjuvant. Then antibody-producing cells such
as
spleen cells or lymphocytes are collected from the immunized animal and fused
with
myeloma cells to prepare hybridomas. Among the hybridomas, one producing the
antibody which binds to the protein of SEQ ID NO:2, 16, 26, 42 or 45 or a
homologous factor thereof is selected and proliferated, and then the antibody
whose
corresponding antigen is the above-mentioned protein may be collected from the
culture supernatant. The above-described method is a conventional well-known
method.
[0072]
In Method 3 of the present invention, mRNA encoding any one of the
polypeptides selected from the group consisting of the polypeptide of SEQ ID
NO:2
or a homologous factor thereof, calmegin, CEP of SEQ ID NO:26 or 42 or a
homologous factor thereof and TRIP11, which may be contained in a sample
obtained from a living body, is measured. As concretely described in the
Examples
below, the expression level of mRNA encoding the canine-derived polypeptide of
SEQ ID NO:2 or the human homologous factor thereof shown in SEQ ID NO:4;
mRNA encoding canine calmegin of SEQ ID NO:16 or human calmegin of SEQ ID
NO:18; mRNA encoding canine CEP of SEQ ID NO:26 or 42 or the human
homologous factor thereof shown in SEQ ID NO:28; and mRNA encoding canine
TRIP11 of SEQ ID NO:45 or human TRIP11 of SEQ ID NO:47 is significantly high
in cancer cells. Therefore, cancers in a living body can be detected by
measuring
CA 02703356 2010-04-22
the mRNA in a sample.
[0073]
For example, mRNA in a sample may be quantified by a conventional method
such as real-time detection RT-PCR using the mRNA as a template, and may also
be
5 roughly quantified based on the staining intensity in a conventional
Northern blotting.
The sequence of cDNAs encoding the polypeptides of SEQ ID NOs:2, 4, 16, 18,
26,
28, 42, 45 and 47 are shown in SEQ ID NOs:1, 3, 15, 17, 25, 27, 41,44 and 46,
respectively. Referring to these sequences, a polynucleotide which
specifically
hybridizes with a partial region of the base sequence shown in SEQ ID NO:1, 3,
15,
10 17, 25, 27, 41, 44 or 46 (hereinafter referred to as "polynucleotide for
cancer
detection") may be prepared, and using the polynucleotide as a probe or a
primer for
nucleic acid amplification, the amount of the mRNA in a sample may be
measured.
As explained below, mRNA encoding homologous factors in mammals other than
dogs and humans may also be measured by using a polynucleotide which
specifically
15 hybridizes with a partial region of the base sequence shown in SEQ ID
NO:1 or 3.
Similarly, mRNA encoding calmegin in mammals other than dogs and humans may
also be measured by using a polynucleotide which specifically hybridizes with
a
partial region of the base sequence shown in SEQ ID NO:15 or 17; mRNA encoding
homologous factors in mammals other than dogs and humans may also be measured
20 by using a polynucleotide which specifically hybridizes with a partial
region of the
base sequence shown in SEQ ID NO:25, 27 or 41; and mRNA encoding TRIP11 in
mammals other than dogs and humans may also be measured by using a
polynucleotide which specifically hybridizes with a partial region of the base
sequence shown in SEQ ID NO:44 or 46. In the present invention, polynucleotide
25 may be RNA or DNA.
[0074]
The term "specifically hybridize" used herein means that a certain sequence
CA 02703356 2010-04-22
41
hybridizes only with the subject partial region and does not substantially
hybridize
with the other regions under ordinary hybridization conditions.
[0075]
The term "ordinary hybridization condition" refers to a condition used for
annealing in the ordinary PCR or the ordinary detection with probes. For
example,
in the case of PCR with Taq polymerase, the term refers to a reaction
condition at an
appropriate annealing temperature of about 54 C to 60 C using a common buffer
such as one containing 50 mM KC1, 10 mM Tris-HC1 (pH 8.3 to 9.0) and 1.5 mM
MgC12. In the case of Northern hybridization, the term refers to a reaction
condition
at an appropriate hybridization temperature of 42 C to 65 C using a common
hybridization solution such as one containing 5 x SSPE, 50% formamide, 5 x
Denhardt's solution and 0.1 to 0.5% SDS. It should be noted, however, that the
appropriate annealing temperature and hybridization temperature are not
restricted to
those exemplified above, and may be determined based on Tm of the primer or
the
probe and on the empirical rules. Those skilled in the art can easily
determine the
appropriate temperature.
[0076]
The term "does not substantially hybridize" means that a hybridization does
not occur at all or, even if it occurs, the degree of the hybridization with
regions other
than the subject partial region is considerably lower than that of the
hybridization
with the subject region so that the hybridization with other regions can be
relatively
ignored. Examples of the polynucleotide which specifically hybridizes under
such
conditions include those having a certain homology to the subject partial
region, for
example, those having a homology of not less than 70%, preferably not less
than 80%,
more preferably not less than 90%, still more preferably not less than 93%,
still more
preferably not less than 95%, still more preferably not less than 98% to the
subject
partial region. Most preferably, the polynucleotide has the same base sequence
as
CA 02703356 2010-04-22
42
the subject partial region. The same definition as for the homology of amino
acid
sequences applies to the homology of base sequences. Even if a polynucleotide
for
cancer detection comprises any region which does not hybridizes with the
subject
region at its end, a probe consisting of such a polynucleotide may be used for
detecting cancers as long as a region which hybridizes with the subject region
occupies about half or more of the whole probe. Similarly, a primer consisting
of
such a polynucleotide can normally anneal to the subject region to allow the
extension reaction to occur and thus may be used for detecting cancers, as
long as a
region which hybridizes with the subject region occupies about half or more of
the
whole primer and is located at the 3'-end of the primer. It should be noted
that, in
cases where polynucleotides for cancer detection comprise any region which
does not
hybridizes with the subject region at its end, the homology to the subject
base
sequence is calculated based only on the region which hybridizes with the
subject
region, ignoring the non-hybridizing region.
[0077]
In the present invention, the term "partial region" refers to a region
consisting
of a part of the base sequence shown in SEQ ID NO:1, 3, 15, 17, 25, 27, 41, 44
or 46.
A "partial region'' preferably consists of not less than 18 consecutive bases.
It is
understood that "base sequence shown in SEQ ID NO:1" as used herein includes
not
only the base sequence expressly written in the SEQ ID NO:1, but also the
sequence
complementary thereto. Thus, for example, the phrase "a polynucleotide having
the
base sequence shown in SEQ ID NO:1" includes a single strand polynucleotide
having the base sequence expressly written in the SEQ ID NO:1, a single strand
polynucleotide having the sequence complementary thereto, and a double strand
polynucleotide composed of these single strand polynucleotides. When the
polynucleotides used in the present invention or polynucleotides encoding the
polypeptides used in the present invention are prepared, any one of these base
CA 02703356 2010-04-22
43
sequences should be appropriately selected, and those skilled in the art can
easily
carry out the selection.
[0078]
In view of assuring specificity, the number of bases of the polynucleotide for
cancer detection is preferably not less than 18 bases. In cases where the
polynucleotide is used as a probe, the size is preferably not less than 18
bases, more
preferably not less than 20 bases, and not more than the full length of the
coding
region. In cases where the polynucleotide is used as a primer, the size is
preferably
not less than 18 bases, and preferably not more than 50 bases. Preferred
examples
of the polynucleotide for cancer detection include those consisting of not
less than 18
consecutive bases of the base sequence shown in SEQ ID NO:1, 3, 15, 17, 25,
27, 41,
44 or 46.
[0079]
It is apparent for those skilled in the art who refer to the present
specification
that a polynucleotide which specifically hybridizes with a partial region of
SEQ ID
NO:1, 15, 25 or 44 is used for measurement of mRNA encoding a canine
polypeptide
of SEQ ID NO:2, 16, 26 or 45, respectively; and that a polynucleotide which
specifically hybridizes with a partial region of SEQ ID NO:3, 17, 27 or 46 is
used for
a measurement of mRNA encoding a human homologous factor of SEQ ID NO:4, 18,
28 or 47, respectively. It should be noted that homologous factors usually
share
high homology with each other even at a base sequence level. For example, SEQ
ID NOs:1 and 3 share 93% homology, SEQ ID NOs:15 and 17 share 90% homology,
SEQ ID NOs:25 and 27 share 87% homology, and SEQ ID NOs:44 and 46 share
88% homology, which are very high homology. Thus, a polynucleotide
specifically
hybridizing with a partial region of SEQ ID NO:1, 15, 25 or 44 may also
specifically
hybridize with the corresponding partial region of SEQ ID NO:3, 17, 27 or 46,
respectively. As practically demonstrated in the Examples below, for example,
by
CA 02703356 2010-04-22
44
using a set of primers having the base sequences shown in SEQ ID NOs:7 and 8,
respectively, mRNA encoding the canine-derived polypeptide of SEQ ID NO:2 and
mRNA encoding the human homologous factor of SEQ ID NO:4 both may be
measured, because the respective primers specifically hybridize with not only
a
partial region of SEQ ID NO:1 but also a partial region of SEQ ID NO:3
(Example
A). By using a set of primers having the base sequences shown in SEQ ID
NOs:19
and 20, respectively, mRNA encoding the canine calmegin of SEQ ID NO:16 and
mRNA encoding the human homologous factor, the human calmegin of SEQ ID
NO:18, both may be measured, because the respective primers specifically
hybridize
with not only a partial region of SEQ ID NO:15 but also a partial region of
SEQ ID
NO:17 (Example B). By using a set of primers having the base sequences shown
in
SEQ ID NOs:29 and 30, respectively, mRNA encoding the canine CEP of SEQ ID
NO:26 or 42 and mRNA encoding the human homologous factor, the human CEP of
SEQ ID NO:28, both may be measured, because the respective primers
specifically
hybridize with a partial region of SEQ ID NO:25, a partial region of SEQ ID
NO:27,
and also a partial region of SEQ ID NO:41 (Example C). By using a set of
primers
having the base sequences shown in SEQ ID NOs:48 and 49, respectively, mRNA
encoding the canine TRIP11 of SEQ ID NO:45 and mRNA encoding the human
homologous factor, the human TRIP11 of SEQ ID NO:47, both may be measured,
because the respective primers specifically hybridize with not only a partial
region of
SEQ ID NO:44 but also a partial region of SEQ ID NO:46 (Example D). Thus, for
example, by using the polynucleotide specifically hybridizing with a partial
region of
the canine base sequence shown in SEQ ID NO:1; SEQ ID NO:15; SEQ ID NO:25;
or SEQ ID NO:44, not only mRNA encoding the canine polypeptide of SEQ ID
NO:2; SEQ ID NO:16; SEQ ID NOs:26 and 42; or SEQ ID NO:45 but also mRNA
encoding the human homologous factor thereof, the polypeptide of SEQ ID NO:4;
SEQ ID NO:18; SEQ ID NO:28; or SEQ ID NO:47, may be measured, respectively.
CA 02703356 2010-04-22
Furthermore, mRNA encoding the homologous factor in other mammals such as cats
may also be measured by using the same polynucleotides.
[0080]
In designing a polynucleotide for cancer detection, it is more desirable to
5 select a partial region in which homology between SEQ ID NOs:1 and 3; SEQ
ID
NOs:15 and 17; SEQ ID NOs:25 and 27; or SEQ ID NOs:44 and 46 is especially
high (preferably a partial region having the same sequence). It is expected
that a
region especially highly homologous between dog and human also shares very
high
homology with a certain partial region of the homologous genes in other animal
10 species. Therefore, by selecting a partial region in such a manner, the
accuracy of
measurement of mRNA which encodes homologous factors in animal species other
than dog and human can be more improved.
[0081]
The methods per se for measuring a test nucleic acid using a polynucleotide
15 which specifically hybridizes with a partial region of the test nucleic
acid as a primer
for a gene-amplification method such as PCR or as a probe are well-known, and
include Northern blotting, in situ hybridization and the like, as well as RT-
PCR as
described in detail in the following Examples. Any of these well-known
measurement methods may be used for measuring mRNA level in the present
20 invention.
[0082]
The nucleic acid-amplification methods per se such as PCR are well-known
in the art, and the reagent kits and apparatuses are also commercially
available, so
that they may be easily carried out. That is, for example, a test nucleic acid
serving
25 as a template (e.g., cDNA of the gene encoding the protein having the
amino acid
sequence shown in SEQ ID NO:2, 4, 16, 18, 26, 28, 45 or 47) and a pair of
polynucleotides for cancer detection (primers) are mixed in a known buffer in
the
CA 02703356 2010-04-22
46
presence of Taq polymerase and dNTP, and the steps of denaturation, annealing
and
extension are carried out by changing the temperature of the reaction mixture.
Usually, the denaturation step is carried out at 90 to 95 C, the annealing
step is
carried out at Tm between the template and the primers or a vicinity thereof
(preferably within 4 C), and the extension step is carried out at 72 C which
is the
optimum temperature of Taq polymerase. The reaction time of each step is
selected
from about 30 seconds to 2 minutes. By repeating this thermal cycle for about
25 to
40 times, the region between a pair of the primers is amplified. The nucleic
acid-
amplification method is not restricted to PCR, and other nucleic acid-
amplification
methods well-known in the art may also be employed. By carrying out the
nucleic
acid-amplification method using a pair of the above-described polynucleotides
for
cancer detection as primers and using the test nucleic acid as a template, the
test
nucleic acid is amplified. In contrast, in cases where the test nucleic acid
is not
contained in the sample, the amplification does not occur. Therefore, by
detecting
the amplification product, whether the test nucleic acid exists in the sample
or not
may be determined. Detection of the amplification product may be carried out
by a
method in which the reaction solution after the amplification is subjected to
electrophoresis and then the bands are stained with ethidium bromide or the
like, or
by a method in which the amplification product after electrophoresis is
immobilized
on a solid phase such as a nylon membrane; a labeled probe which specifically
hybridizes with the test nucleic acid is hybridized with the test nucleic
acid; and then
the label is detected after washing. Alternatively, the test nucleic acid in
the sample
may be quantified by the so-called realtime detection PCR using a quencher
fluorescent dye and a reporter fluorescent dye. ' Since the kits for realtime
detection
PCR are also commercially available, realtime detection PCR may also be
carried out
easily. The test nucleic acid may also be semi-quantified based on the
intensity of
the electrophoretic band. The test nucleic acid may be mRNA or cDNA reverse-
CA 02703356 2010-04-22
47
transcribed from mRNA. In cases where mRNA is amplified as the test nucleic
acid,
NASBA method (3SR method, TMA method) using the above-described pair of
primers may also be employed. NASBA method per se is well-known, and kits
therefor are commercially available, so that NASBA method may easily be
carried
out using the above-described pair of primers.
[0083]
As the probe, a labeled probe obtained by labeling the above-described
polynucleotide for cancer detection with a fluorescent label, radioactive
label, biotin
label or the like may be used. The methods per se for labeling a
polynucleotide are
well-known. Whether the test nucleic acid exists in the sample or not may be
determined by immobilizing the test nucleic acid or amplification product
thereof on
a solid phase, hybridizing the labeled probe therewith, and measuring the
label bound
to the solid phase after washing. Alternatively, the polynucleotide for cancer
detection may be immobilized on a solid phase to hybridize the test nucleic
acid
therewith and detect the test nucleic acid bound to the solid phase by a
labeled probe
or the like. In such a case, the polynucleotide for cancer detection
immobilized on
the solid phase is also called a probe. The methods for measuring a test
nucleic acid
using a polynucleotide probe are also well-known in the art, and may be
attained by
bringing a polynucleotide probe into contact with the test nucleic acid in a
buffer at
Tm or a vicinity thereof (preferably within 4 C) so as to hybridize them, and
then
measuring the hybridized labeled probe or the test nucleic acid bound to the
immobilized probe. Such a method includes well-known methods such as Northern
blot and in situ hybridization, and Southern blot. Any of such known methods
may
be used in the present invention.
[0084]
In the detection method of the present invention, whether the subject living
body suffers from cancer or not or the like is determined based on the
expression
CA 02703356 2010-04-22
48
level of the polypeptide measured as described above. Although the cancer
detection may be attained simply by measuring the expression of the
polypeptide in
the subject living body, it is preferred to obtain the normal reference value
by
determining the expression level of the polypeptide (the amount of the
antibody,
polypeptide or mRNA) in one or more samples from healthy individuals to
compare
the measured value in the subject living body with the normal reference value,
in
view of increasing the measurement accuracy. In order to further increase the
measurement accuracy, the cancer reference value may be obtained by
determining
the expression level of the polypeptide in samples obtained from many patients
who
have been revealed to suffer from cancer to compare the measured value of the
subject living body with both of the normal and cancer reference values. The
above
mentioned reference values may be determined by expressing the expression
level of
the polypeptide in each sample in values and calculating the average value
thereof.
The normal and cancer reference values may be determined beforehand by
measuring
the expression level of the polypeptide in many healthy and cancer subjects.
Thus,
the predetermined reference values may also be used when comparing the
measured
value with the reference values in the present invention.
[0085]
In cases where cancer detection is carried out based on the expression levels
of two or more of the above-described four polypeptides, the subject living
body may
be judged to suffer from cancer when the expression level of any one
polypeptide
indicates cancer (see, Example E below).
[0086]
The detection method of the present invention may be carried out in
combination with diagnosis using other cancer antigens and/or cancer markers
so that
the detection accuracy of cancers can be more improved. For example, in
measuring the above-mentioned cancer-specific antibody according to the
present
CA 02703356 2010-04-22
49
invention, other polypeptide(s) highly expressed in cancer tissues may be used
as an
antigen in the same manner as the above-described polypeptides. The method of
the
present invention may also be carried out in combination with diagnosis using
known
cancer markers.
[0087]
By the detection method of the present invention, cancers in a living body can
be detected. Especially, as described in the following Examples, the method of
the
present invention can detect even an invisible small cancer or a cancer which
exists
in a deep part of a body, and thus the method is useful for early detection of
cancers.
Further, by applying the detection method of the present invention to patients
in the
follow-up period after cancer therapy, the recurrent cancer, if any, can be
detect in its
early stage.
[0088]
If the more cancer cells expressing the prescribed polypeptide to be measured
in the present invention proliferate in a cancer-bearing living body, the more
the
polypeptides and mRNAs encoding them accumulate in the body, which causes the
increased amount of the antibodies against the above-mentioned polypeptides in
the
serum. On the other hand, the more cancer cells decrease, the more the
accumulated polypeptides and mRNAs encoding them decrease in the body, which
causes the decreased amount of the antibodies against the above-mentioned
polypeptides in the serum. Thus, if the expression level of the prescribed
polypeptide is high, it can be determined that tumor growth and/or metastasis
of
cancer occurs, i.e., the stage of progression of cancer is advanced. Indeed,
as
concretely described in the Examples below, it was observed that the amount of
the
above-mentioned antibody increases in the serum of cancer-bearing body along
with
the cancer progression such as tumor growth or metastasis. Hence, the stage of
cancer progression can be detected by the method of the present invention.
CA 02703356 2010-04-22
[0089]
Further, as shown in the Example below, when compared between the same
kind of tumors, a malignant one produces significantly more amount of the
antibodies than a benign one. Therefore, if the expression level of the
prescribed
5 polypeptides is high, it can be determined that the grade of cancer
malignancy is
higher. That is, the grade of cancer malignancy can also be detected by the
method
of the present invention.
[0090]
Furthermore, the effect of the cancer therapy can be monitored based on the
10 increase or decrease of the expression level of the prescribed
polypeptides. As
described in the Example below, compared to the cancer-bearing state,
individuals
receiving an anticancer drug for prevention of recurrence after tumor
extirpation
show decreased expression of the polypeptides. This applies to benign tumors.
That is, in cases where the expression of the polypeptides can be observed,
the
15 decreased expression of the polypeptides is observed when complete
extirpation of
the benign tumor is attained. Therefore, by observing the expression level of
the
above-mentioned polypeptides on individuals during or after cancer therapy,
a clue to assess how much the administered anticancer drug was effective, or
whether
a portion of the tumor is left in the patient after extirpation of the tumor
can be
20 obtained, as well as a clue to find metastasis and/or recurrence as
early as possible
can be obtained during the follow-up. If cancer is appropriately treated in a
patient,
the expression level of the polypeptides becomes lower in the patient after
therapy
than before therapy. In such a case, it can be judged that the effect of the
therapy
which was (is being) performed on the patient is good. In cases where the
25 expression level of the polypeptides increases or is sustained, or once
decreases and
then increases, it can be judged that the effect of the therapy is not good
enough.
Thus, a useful basis for adoption of the therapeutic approach can be obtained.
For
CA 02703356 2010-04-22
51
example, it can be judged, based on the above-described change of the
expression
level, whether the therapeutic approach should be changed to another, whether
or
how the dose of the anticancer drug should be changed, and so on.
[0091]
Cancers to be detected by the method of the present invention are those
expressing at least one polypeptide selected from the group consisting of the
polypeptide of SEQ ID NO:2 or a homologous factor thereof, calmegin, CEP of
SEQ
ID NO:26 or 42 or a homologous factor thereof, and TRIP11. Examples of the
cancer to be detected include, but not limited to, brain tumor; squamous cell
carcinomas of head, neck, lung, uterus and esophagus; melanoma;
adenocarcinomas
of lung and uterus; renal cancer; malignant mixed tumor; hepato cellular
carcinoma;
basal cell carcinoma; acanthomatous epulis; intraoral tumor; perianal
adenocarcinoma; anal sac tumor; anal sac apocrine carcinoma; Sertoli cell
tumor;
vulva cancer; sebaceous adenocarcinoma; sebaceous epithelioma; sebaceous
adenoma; sweat gland carcinoma; intranasal adenocarcinoma; nasal
adenocarcinoma;
thyroid cancer; colon cancer; bronchial adenocarcinoma; adenocarcinoma; ductal
carcinoma; mammary adenocarcinoma; combined mammary adenocarcinoma;
mammary gland malignant mixed tumor; intraductal papillary adenocarcinoma;
fibrosarcoma; hemangiopericytoma; osteosarcoma; chondrosarcoma; soft tissue
sarcoma; histiocytic sarcoma; myxosarcoma; undifferentiated sarcoma; lung
cancer;
mastocytoma; cutaneous leiomyoma; intra-abdominal leiomyoma; leiomyoma;
chronic lymphocytic leukemia; lymphoma; gastrointestinal lymphoma; digestive
organ lymphoma; small cell or medium cell lymphoma; adrenomedullary tumor;
granulosa cell tumor; pheochromocytoma; bladder cancer (transitional cell
carcinoma); suppurative inflammation; intra-abdominal liver tumor; liver
cancer;
plasmacytoma; malignant hemangiopericytoma; angiosarcoma; anal sac
adenocarcinoma; oral cancer; metastatic malignant melanoma; amelanotic
malignant
CA 02703356 2010-04-22
52
melanoma; cutaneous malignant melanoma; malignant myoepithelioma; malignant
seminoma; seminoma; adenocarcinoma of the large intestine; gastric
adenocarcinoma; low-grade sebaceous carcinoma; ceruminous adenocarcinoma;
apocrine carcinoma; poorly differentiated apocrine sweat gland carcinoma;
malignant
fibrous histiocytoma; multiple myeloma; mesenchymal malignant tumor;
liposarcoma; osteosarcoma; sarcoma of unknown origin; soft part sarcoma
(spindle
cell tumor); poorly differentiated sarcoma; synovial sarcoma; angiosarcoma;
metastatic malignant epithelioma; tubular mammary adenocarcinoma; mammary
ductal carcinoma; inflammatory breast cancer; germinoma; leukemia; invasive
trichoepithelioma; medium cell lymphoma; multicentric lymphoma; osteosarcoma
(mammary gland); mastocytoma (Patnaik II type); mastocytoma (Grade II); and
leiomyosarcoma. The living bodies to which the method of the present invention
applies are mammals, preferably humans, dogs and cats.
[0092]
The sample subjected to the method of the present invention include body
fluids such as blood, serum, plasma, ascites and pleural effusion, and tissues
and
cells. Particularly, serum, plasma, ascites and pleural effusion may be
preferably
used in Method 1 and Method 2 above. A tissue sample and cell sample are
preferred in the case of Method 3 above in which mRNA is measured.
[0093]
The polypeptides used as an antigen for immunoassay in Method 1 (i.e., a
canine-derived polypeptide of SEQ ID NO:2, SEQ ID NO:16, SEQ ID NO:26 or 42
or SEQ ID NO:45 and homologous factors thereof, specifically-reactive partial
polypeptides, specifically-reactive modified polypeptides, and specifically-
reactive
added polypeptides) may be provided as a reagent for detecting a cancer(s).
The
reagent may consist only of the above-mentioned polypeptide, or may contain
various
additives useful for stabilizing the polypeptide and the like. The reagent may
also
CA 02703356 2010-04-22
53
be provided in the form of being immobilized on a solid phase such as a plate
or
membrane.
[0094]
The antibodies or antigen-binding fragments thereof which immunologically
react with the canine polypeptide of SEQ ID NO:2, SEQ ID NO:16, SEQ ID NO:26
or 42 or SEQ ID NO:45 or a homologous factor thereof, which are used for
measuring the canine polypeptide or the homologous factor thereof by
immunoassay,
may also be provided as a reagent for detecting a cancer(s). The reagent may
also
consist only of the above-mentioned antibody or antigen-binding fragment
thereof, or
may contain various additives useful for stabilizing the antibody or antigen-
binding
fragment thereof and the like. The antibody or antigen-binding fragment
thereof
may also be in the form of being conjugated with a metal such as manganese or
iron.
Since such a metal-conjugated antibody or antigen-binding fragment thereof
accumulates in a site in which a large amount of antigen protein exists when
administered to a body, the existence of cancer cells which produce the
antigen
protein can be detected by measuring the metal by MRI or the like.
[0095]
Furthermore, the above-described polynucleotides for cancer detection used
for measuring mRNA in Method 3 may also be provided as a reagent for detecting
a
cancer(s). The reagent may also consist only of the polynucleotide, or may
contain
various additives useful for stabilizing the polynucleotide and the like. The
= polynucleotide for cancer detection contained in the reagent is
preferably a primer or
a probe. The conditions and preferred examples of the polynucleotide for
cancer
detection are as already described above.
EXAMPLES
[0096]
The present invention will now be described more concretely by way of
CA 02703356 2010-04-22
54
Examples.
[0097]
Example A-1: Acquisition of Novel Cancer Antigen Protein by SEREX Method
(1) Preparation of cDNA Library
Total RNA was prepared from testis tissue of a healthy dog by the Acid
guanidium-Phenol-Chloroform method, and poly(A) RNA was purified using
Oligotex-dT30 mRNA purification Kit (manufactured by Takara Shuzo Co., Ltd.)
in
accordance with the protocol attached to the kit.
[0098]
Using the obtained mRNA (5 fig), a dog testis cDNA phage library was
synthesized. Preparation of the cDNA phage library was carried out using cDNA
Synthesis Kit, ZAP-cDNA Synthesis Kit, and ZAP-cDNA Gigapack III Gold Cloning
Kit (manufactured by STRATAGENE) in accordance with the protocols attached to
the kits. The size of the prepared cDNA phage library was 1.3 x 106 pfu/ml.
[0099]
(2) Screening of cDNA Library with Serum
Using the dog testis-derived cDNA phage library prepared as described above,
inununoscreening was carried out. More particularly, host E. coli cells (XL 1-
Blue
MRP) were infected with the library such that 2,340 clones should appear on an
NZY agarose plate having the size of (1)90 x 15 mm, and cultured at 42 C for 3
to 4
hours to allow the phage to form plaques. The plate was covered with
nitrocellulose
membrane (Hybond C Extra: manufactured by GE Healthcare Bio-Science)
impregnated with IPTG (isopropyl-P-D-thiogalactoside) at 37 C for 4 hours to
induce
and express proteins, which were thus transferred to the membrane.
Subsequently,
the membrane was recovered and soaked in TBS (10 mM Tris-HC1, 150 mM NaCl;
pH 7.5) containing 0.5% non-fat dry milk, followed by shaking it at 4 C
overnight to
suppress non-specific reactions. This filter was allowed to react with 500-
fold
CA 02703356 2010-04-22
diluted canine patient serum at room temperature for 2 to 3 hours.
[0100]
As the above-described canine patient serum, serum collected from canine
patients suffering from squamous cell carcinoma was used. The serum was stored
5 at -80 C and pretreated immediately before use. The method of the
pretreatment of
the serum was as follows. That is, host E. coli cells (XL1-Blue MRF) were
infected
with X ZAP Express phage to which no foreign gene was inserted, and then
cultured
on NZY plate medium at 37 C overnight. Subsequently, the buffer of 0.2 M
NaHCO3, pH 8.3 containing 0.5 M NaC1 was added to the plate, and the plate was
10 left to stand at 4 C for 15 hours, followed by collecting the
supernatant as an E.
co/i/phage extract. Thereafter, the collected E. co/i/phage extract was
allowed to
flow through an NHS column (manufactured by GE Healthcare Bio-Science) to
immobilize proteins derived from the E. co/i/phage thereon. The serum from the
canine patients was allowed to flow through and react with this protein-
immobilized
15 column to remove antibodies adsorbed on E. coil and/or the phage. The
serum
fraction that passed through the column was 500-fold diluted with TBS
containing
0.5% non-fat dry milk, and the resulting diluent was used as the material for
the
immunoscreening.
[0101]
20 The membrane on which the thus treated serum and the above-described
fusion protein were blotted was washed 4 times with TBS-T (0.05% Tween
20/TBS),
and allowed to react with goat anti-dog IgG (Goat anti Dog IgG-h+I HRP
conjugated:
manufactured by BETHYL Laboratories) 5,000-fold diluted with TBS containing
0.5% non-fat dry milk as a secondary antibody at room temperature for 1 hour,
25 followed by detection by the enzyme coloring reaction using the NBT/BCIP
reaction
solution (manufactured by Roche). Colonies at positions where a positive
coloring
reaction was observed were recovered from the NZY agarose plate having the
size of
CA 02703356 2010-04-22
56
4090 x 15 mm, and dissolved in 500 of SM buffer (100 mM NaC1, 10 rnM
MgC1SO4, 50 mM Tris-HC1, 0.01% gelatin; pH 7.5). The screening was repeated as
a second and third screening in the same manner as described above until a
single
coloring reaction-positive colony was obtained, thereby isolating one positive
clone
after screening of 30,940 phage clones reactive with IgG in the serum.
[0102]
(3) Homology Search of Isolated Antigen Gene
To subject the single positive clone isolated by the above-described method to
a base sequence analysis, an operation of conversion of the phage vector to a
plasmid
vector was carried out. More particularly, 200 I of a solution prepared to
contain a
host E. coil (XL1-Blue MRF") such that the absorbance 0D600 should be 1.0 was
mixed with 100 I of a purified phage solution and further with I [11 of
ExAssist
helper phage (manufactured by STRATAGENE), and the reaction was allowed to
proceed at 37 C for 15 minutes. To the reaction mixture, 3 ml of LB medium was
added, and the mixture was cultured at 37 C for 2.5 to 3 hours, followed by
immediate incubation in a water bath at 70 C for 20 minutes. The mixture was
then
centrifuged at 4 C at 1,000 xg for 15 minutes, and the supernatant was
recovered as a
phagemid solution. Subsequently, 200 I of a solution prepared to contain a
phagemid host E. coil (SOLR) such that the absorbance 0D600 should be 1.0 was
mixed with 10 Id of a purified phage solution, and the reaction was allowed to
proceed at 37 C for 15 minutes. Thereafter, 50 1 of the reaction mixture was
plated on ampicillin (final concentration: 50 g/m1)-containing LB agar
medium, and
cultured at 37 C overnight. A single colony of transformed SOLR was recovered
and cultured in ampicillin (final concentration: 50 g/m1)-containing LB
medium at
37 C, followed by purification of plasmid DNA having an insert of interest
using
QIAGEN plasmid Miniprep Kit (manufactured by Qiagen).
[0103]
CA 02703356 2010-04-22
57
The purified plasmid was subjected to an analysis of the entire sequence of
the insert by the primer walking method using the T3 primer described in SEQ
ID
NO:5 and the T7 primer described in SEQ ID NO:6. By this sequence analysis,
the
gene sequence described in SEQ ID NO:1 was obtained. Using the base sequence
and the amino acid sequence of this gene, homology search against known genes
was
carried out using a homology search program BLAST
(http://vvvvw.ncbi.nlm.nih.gov/BLAST/). As a result, it was revealed that the
obtained gene is the gene (Accession No. XM_535343) encoding a protein
(Accession No.XP 535343) whose function is unknown. The human homologous
factor of this gene was the gene (Accession No.NM 152660) encoding a protein
(Accession No.NP 689873) whose function is also unknown (homology: base
sequence, 93%; amino acid sequence, 99%). The base sequence of the human
homologous factor is shown in SEQ ID NO:3, and the amino acid sequence thereof
is
shown in SEQ ID NO:4.
[0104]
(4) Analysis of Expression in Each Tissue
The expression of the gene, which was obtained by the above-described
method, in normal tissues and various cell lines of dog and human were
investigated
by the RT-PCR (Reverse Transcription-PCR) method. The reverse transcription
reaction was carried out as follows. That is, total RNA was extracted from 50
to
100 mg of each tissue or 5 to 10 x 106 cells of each cell line using TRIZOL
reagent
(manufactured by Invitrogen) in accordance with the protocol attached to the
kit.
Using this total RNA, cDNA was synthesized by Superscript First-Strand
Synthesis
System for RT-PCR (manufactured by Invitrogen) in accordance with the protocol
attached to the kit. As the cDNAs from human normal tissues (brain,
hippocampus,
testis, colon and placenta), Gene Pool cDNA (manufactured by Invitrogen),
QUICK-
Clone cDNA (manufactured by CLONTECH) and Large-Insert cDNA Library
CA 02703356 2010-04-22
58
(manufactured by CLONTECH) were used. The PCR reactions were carried out as
follows using primers (described in SEQ ID NOs:7 and 8) specific to the
obtained
canine gene and its human homologous gene. That is, respective reagents and
the
attached buffer were mixed such that the mixture should contain 0.25 III of
the
sample prepared by the reverse transcription reaction, 2 uM each of the above
primers, 0.2 mM each of dNTP and 0.65 U of ExTaq polymerase (manufactured by
Takara Shuzo Co., Ltd.) in a total volume of 25 I, and the reaction was
carried out
with 30 cycles of 94 C for 30 seconds, 55 C for 30 seconds and 72 C for 1
minute
using Thermal Cycler (manufactured by BIO RAD). The gene-specific primers
having the base sequences shown in the above-described SEQ ID NOs:7 and 8 were
those which amplify the regions of the 87th to 606th bases of the base
sequence of
SEQ ID NO:1 and the 173rd to 695th bases of the base sequence of SEQ ID NO:3,
and can be used for investigation of the expression of both the canine gene
and its
human homologous gene. As a control for comparison, primers (described in SEQ
ID NOs:9 and 10) specific to GAPDH were used simultaneously. As a result, as
shown in Fig. 1, strong expression of the obtained canine gene was observed in
testis
among the normal dog tissues, and on the other hand, strong expression was
observed
in the canine breast cancer cell line. Expression of the human homologous gene
was confirmed, as is the case with the canine gene, only in testis among the
human
normal tissues, but the expression was detected in brain tumor, leukemia,
breast
cancer and lung cancer cells among human cancer cell lines. Thus, the human
homologous gene was also confirmed to be specifically expressed in testis and
cancer
cells.
[0105]
In Fig. 1, reference numeral 1 in the ordinate indicates the expression
pattern
of the above identified gene, and reference numeral 2 indicates the expression
pattern
of the GAPDH gene as a control for comparison.
CA 02703356 2010-04-22
59
[0106]
Example A-2: Preparation of Novel Cancer Antigen Proteins
(1) Preparation of Recombinant Protein
Based on the gene of SEQ ID NO:1 obtained in Example A-1, a recombinant
protein was prepared by the following method. Respective reagents and the
attached buffer were mixed such that the mixture should contain 1 ul of the
vector
which was prepared from the phagemid solution obtained in Example A-1 and was
subjected to the sequence analysis, 0.4 uM each of two kinds of primers having
Ndel
and Xhol restriction sites (described in SEQ ID NOs:11 and 12), 0.2 mM dNTP
and
1.25 U of PrimeSTAR HS polymerase (manufactured by Takara Shuzo Co., Ltd.) in
a
total volume of 50 ptl, and PCR was carried out with 30 cycles of 98 C for 10
seconds, 55 C for 15 seconds and 72 C for 1 minute using Thermal Cycler
(manufactured by BIO RAD). Using the above-described two kinds of primers, the
region encoding the entire amino acid sequence of SEQ ID NO:2 is obtained.
After
the PCR, the amplified DNA was subjected to electrophoresis using 1% agarose
gel,
and a DNA fragment of about 930 bp was purified using QIAquick Gel Extraction
Kit (manufactured by QIAGEN).
[0107]
The purified DNA fragment was ligated into a cloning vector pCR-Blunt
(manufactured by Invitrogen). E. coli was transformed with the resulting
ligation
product, and plasmids were recovered thereafter, followed by confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
Ndel and XhoI and purified using QIAquick Gel Extraction Kit, followed by
inserting
the gene sequence of interest into an expression vector for E. coli, pET16b
(manufactured by Novagen) that had been treated with Ndel and Xhol. Usage of
this vector enables production of a His-tag fusion recombinant protein. E.
coli for
CA 02703356 2010-04-22
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E. coli with 1 mM IPTG.
[0108]
On the other hand, based on the gene of SEQ ID NO:3, a recombinant protein
5 of the human homologous gene was prepared by the following method.
Respective
reagents and the attached buffer were mixed such that the mixture should
contain 1
1 of the cDNA prepared in Example A-1 whose expression could be confirmed by
the RT-PCR method in various tissues/cells, 0.4 M each of two kinds of
primers
having EcoRV and EcoRI restriction sites (described in SEQ ID NOs:13 and 14),
0.2
10 mM dNTP and 1.25 U of PrimeS TAR HS polyrnerase (manufactured by Takara
Shuzo Co., Ltd.) in a total volume of 50 I, and PCR was carried out with 30
cycles
of 98 C for 10 seconds, 55 C for 15 seconds and 72 C for 1 minute using
Thermal
Cycler (manufactured by BIO RAD). Using the above-described two kinds of
primers, the region encoding the entire amino acid sequence of SEQ ID NO:4 is
15 obtained. After the PCR, the amplified DNA was subjected to
electrophoresis using
1% agarose gel, and a DNA fragment of about 930 bp was purified using QIAquick
Gel Extraction Kit (manufactured by QIAGEN).
[0109]
The purified DNA fragment was ligated into a cloning vector pCR-Blunt
20 (manufactured by Invitrogen). E. coil was transformed with the resulting
ligation
product, and plasmids were recovered thereafter, followed by confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
EcoRV and EcoRI and purified using QIAquick Gel Extraction Kit, followed by
25 inserting the gene sequence of interest into an expression vector for E.
coil, pET30a
(manufactured by Novagen) that had been treated with EcoRV and EcoRl. Usage of
this vector enables production of a His-tag fusion recombinant protein. E.
coli for
CA 02703356 2010-04-22
61
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E. coil with 1 mM IPTG.
[0110]
(2) Purification of Recombinant Protein
The above-obtained recombinant E. coil cells that expressed SEQ ID NO:1
and SEQ ID NO:3, respectively, were cultured in ampicillin (final
concentration: 100
pg/m1)-containing LB medium at 37 C until the absorbance at 600 nm reached
about
0.7, and then IPTG was added thereto such that its final concentration should
be 1
mM, followed by culturing them at 37 C for 4 hours. Subsequently, the cells
were
collected by centrifugation at 4,800 rpm for 10 minutes. The pellet of the
cells was
suspended in phosphate-buffered saline and further subjected to centrifugation
at
4,800 rpm for 10 minutes to wash the cells.
[0111]
The cells were suspended in 50 mM Tris-HC1 buffer (pH 8.0) and subjected
to sonication on ice. The sonicated solution of E. coil was centrifuged at
6,000 rpm
for 20 minutes to obtain the supernatant as the soluble fraction and the
precipitate as
the insoluble fraction.
[0112]
The insoluble fraction was suspended in 50 mM Tris-HC1 buffer (pH 8.0) and
centrifuged at 6,000 rpm for 15 minutes. This operation was repeated twice and
an
operation of removal of proteases was carried out.
[0113]
The residue was suspended in 6M guanidine hydrochloride (manufactured by
Sigma Aldrich Japan), 0.15 M sodium chloride-containing 50 mM Tris-HC1 buffer
(pH 8.0), and the resulting suspension was left to stand at 4 C for 15 hours
to
denature proteins. Thereafter, the suspension was centrifuged at 6,000 rpm for
30
minutes, and the obtained soluble fraction was placed in a nickel chelate
column
CA 02703356 2010-04-22
62
prepared by a conventional method (carrier: Chelating Sepharose (trademark)
Fast
Flow (GE Health Care); column volume: 5mL; equilibration buffer: 6M guanidine
hydrochloride, 0.15 M sodium chloride-containing 50 mM Tris-HC1 buffer (pH
8.0)),
followed by leaving it to stand at 4 C overnight to allow adsorption to the
nickel-
chelated carrier. The supernatant was recovered by centrifugation of this
column
carrier at 1,500 rpm for 5 minutes, and the column carrier was suspended in
phosphate-buffered saline, followed by refilling the column with the resulting
suspension.
[0114]
The fraction that was not adsorbed to the column was washed away with 10
column volumes of 0.5 M sodium chloride-containing 0.1 M acetate buffer (pH
4.0),
and elution was immediately carried out with 0.5 M sodium chloride-containing
0.1
M acetate buffer (pH 3.0). Six column volumes of the eluted fraction was
collected
in each elution step. Elution of the proteins of interest was confirmed by
Coomassie
staining carried out according to a conventional method. Based on the result,
the
eluted fractions were desalted and concentrated to obtain the material to be
solid-
phased for diagnosis.
[0115]
Example A-3: Cancer Diagnosis Using Recombinant Canine Protein
(1) Cancer Diagnosis in Dogs
Blood samples were collected from 486 canine patients in which malignant or
benign tumors were found and 6 healthy dogs, and sera were separated
therefrom.
Using the recombinant canine protein prepared in Example A-2 and anti-dog IgG
antibody, the IgG antibody titer of the sera which specifically react with the
recombinant protein was measured by ELISA.
[0116]
As for immobilization of the prepared protein on a solid phase, 100 tL/well
CA 02703356 2010-04-22
63
of a solution of the recombinant protein diluted to 50 ng/mL with phosphate
buffered
saline was added to a 96-well Immobilizer Amino plate (manufactured by Nunc),
and
the plate was left to stand at 4 C overnight. As for blocking, 100 nL/well of
50 mM
= sodium bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum
albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour.
Serum was 500-fold diluted with the blocking solution, and 100 4/well of the
diluted serum was added to the plate, followed by shaking the plate at room
temperature for 3 hours to allow the reaction to proceed. After washing the
wells 3
times with phosphate buffered saline containing 0.05% Tween20 (manufactured by
Wako Pure Chemicals) (hereinafter referred to as PBS-T), 100 4/well of HRP-
conjugated dog IgG antibody (Goat anti Dog IgG-h+I HRP conjugated:
manufactured
by BETHYL Laboratories) 3,000-fold diluted with the blocking solution was
added
thereto, and the plate was shaken at room temperature for 1 hour to allow the
reaction
to proceed.. After washing the wells 3 times with PBS-T, 100 1..t1/wel1 of a
HRP
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 l/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the prepared recombinant protein was
not
immobilized and a plate with which the serum from a cancer-bearing dog was not
reacted were measured in the same manner as above.
[0117]
Among the total 486 samples used in the above-described cancer diagnosis,
311 samples were definitely diagnosed as malignant by pathological diagnosis
using
the extirpated tumor tissue.
CA 02703356 2010-04-22
64
[0118]
Specifically, the samples were diagnosed as cancer such as malignant
melanoma; malignant mixed tumor; hepatocellular carcinoma; basal cell
carcinoma;
*tr.
acanthomatous epulis; intraoral tumor; perianal adenocarcinoma; anal sac
tumor; anal
sac apocrine carcinoma; Sertoli cell tumor; vulva cancer; sebaceous
adenocarcinoma;
sebaceous epithelioma; sebaceous adenoma; sweat gland carcinoma; intranasal
adenocarcinoma; nasal adenocarcinoma; thyroid cancer; colon cancer; bronchial
adenocarcinoma; adenocarcinoma; ductal carcinoma; mammary adenocarcinoma;
combined mammary adenocarcinoma; mammary gland malignant mixed tumor;
intraductal papillary adenocarcinoma; fibrosarcoma; hemangiopericytoma;
osteosarcoma; chondrosarcoma; soft tissue sarcoma; histiocytic sarcoma;
myxosarcoma; undifferentiated sarcoma; lung cancer; mastocytoma; cutaneous
leiomyoma; intra-abdominal leiomyoma; leiomyoma; squamous cell carcinoma;
chronic lymphocytic leukemia; lymphoma; gastrointestinal lymphoma; digestive
organ lymphoma; small cell or medium cell lymphoma; adrenomedullary tumor;
granulosa cell tumor; pheochromocytoma; bladder cancer (transitional cell
carcinoma); suppurative inflammation; intra-abdominal liver tumor; liver
cancer;
plasmacytoma; malignant hemangiopericytoma; angiosarcoma; anal sac
adenocarcinoma; oral cancer; metastatic malignant melanoma; amelanotic
malignant
melanoma; cutaneous malignant melanoma; malignant myoepithelioma; malignant
seminoma; seminoma; adenocarcinoma of the large intestine; gastric
adenocarcinoma; low-grade sebaceous carcinoma; ceruminous adenocarcinoma;
apocrine carcinoma; poorly differentiated apocrine sweat gland carcinoma;
malignant
fibrous histiocytoma; multiple myeloma; mesenchymal malignant tumor;
liposarcoma; osteosarcoma; sarcoma of unknown origin; soft part sarcoma
(spindle
cell tumor); poorly differentiated sarcoma; synovial sarcoma; angiosarcoma;
metastatic malignant epithelioma; tubular mammary adenocarcinoma; mammary
CA 02703356 2010-04-22
ductal carcinoma; inflammatory breast cancer; germinoma; leukemia; invasive
trichoepithelioma; medium cell lymphoma; multicentric lymphoma; osteosarcoma
(mammary gland); mastocytoma (Patnaik II type); mastocytoma (Grade II);
imb
leiomyosarcoma or the like.
5 [0119]
As shown in Fig. 3, sera from these cancer-bearing dogs showed a
significantly high antibody titer against the recombinant protein. It was
revealed
that, by diagnosing a sample showing twice the average value of healthy canine
samples as malignant, 192 samples i.e. 61.7% of the malignant cases could be
10 successfully diagnosed as malignant. The details of these 192 cancer
samples are as
follows. It is noted that the following number of each cancer case is a
cumulative
total, as some samples contained multiple primaries.
Malignant melanoma, 10 cases; lymphoma, 9 cases; pheochromocytoma, 1 case;
granulosa cell tumor, 1 case; hepatocellular carcinoma, 3 cases; angioma, 1
case;
15 malignant testicular tumor, 9 cases; intraoral tumor, 4 cases; perianal
adenocarcinoma, 7 cases; osteosarcoma, 3 cases; fibrosarcoma, 8 cases; ductal
carcinoma, 19 cases; chondrosarcoma, 1 case; mammary adenocarcinoma, 35 cases;
combined mammary adenocarcinoma, 24 cases; lung cancer, 1 case; sebaceous
adenocarcinoma, 2 cases; nasal adenocarcinoma, 2 cases; mastocytoma, 26 cases;
20 adrenomedullary tumor, 1 case; leiomyosarcoma, 2 cases; squamous cell
carcinoma,
7 cases; chronic lymphocytic leukemia, 1 case; undifferentiated sarcoma, 1
case;
malignant mixed tumor, 2 cases; hemangiopericytoma, 1 case; tumor in the left
knee
joint, 1 case; tumor in the posterior segment of the left lobe of the lung, 1
case;
bladder cancer (transitional cell carcinoma), 1 case; soft part sarcoma
(spindle cell
25 tumor), 1 case; ceruminous adenocarcinoma, 1 case; multicentric
lymphoma, 2 cases;
liposarcoma, 1 case; synovial sarcoma, 1 case; invasive trichoepithelioma, 1
case;
anal sac adenocarcinoma, 1 case.
CA 02703356 2010-04-22
66
[0120]
The above-described diagnostic method was also carried out using pleural
effusion samples and ascites samples collected from terminal cancer dogs. As a
result, values similar to those detected in serum samples could be detected,
and hence
cancer diagnosis could be successfully attained.
[0121]
Furthermore, it was confirmed that diagnostic approaches such as diagnosis of
cancers existing in an invisible part of the body, assessment of cancer stage
and grade,
follow-up of postoperative patients, diagnosis of recurrence and metastasis
and the
like can also be attained by applying the above-described diagnostic method.
The
followings are several of the practical examples of the detailed diagnosis
shown in
Fig. 4.
[0122]
(2)-1 Diagnosis of Invisible Tumors
In Canine Patient 1 (Flat-Coated Retriever), any tumors were not found on
June 7, 2007. But about 20 days later, on June 24, 2007, a pedunculated tumor
with
a diameter of 2 mm was found on the gum at the root of the canine tooth. The
tumor was ligated at its pedunculated part and excised on the day it found.
The
absorbance at 450 nm observed before the tumor became visible with the naked
eye
was 0.32, which was significantly high and not so different from the
absorbance at
the time of finding tumor, 0.37. The result indicates that it is possible to
diagnose
= cancers even in an invisible part such as an intraperitoneal part by the
method of the
present invention.
[0123]
Rise of the value was observed before the tumor became visible with the
naked eye, which is considered to have been a sign of tumor development. Thus,
the method of the present invention is useful in medical examinations such as
CA 02703356 2010-04-22
67
periodic health examination.
[0124]
Canine Patient 1 was again checked by the serodiagnosis 2 weeks after the
tumor excision. As a result, the absorbance at 450 nm greatly decreased to
0.07.
Thus, it was also confirmed that the cancer antigen-expressing tumor which had
caused the increased antibody titer was completely removed (see, (2)-4, Follow-
Up
of Postoperative Patients).
[0125]
(2)-2 Assessment of Stage of Cancer Progression
The stage of cancer progression is determined based on the size or depth of
the tumor, how much the tumor exerts influence on the surrounding tissues,
whether
the tumor metastasizes or not, and the like. It was revealed herein that the
detected
value is higher than before if the metastasis occurs, i.e., the cancer has
advanced.
The following is another example of assessment of stage of a certain cancer
case,
which received anticancer drug therapy.
[0126]
Canine Patient 2 (Mixed Breed) underwent tumor extirpation by amputating
the right hind leg on October 13, 2006. According to the pathological
diagnosis
using the extirpated tumor, it was a highly-malignant mastocytoma at Grade II
rather
close to Grade III. On March 12, 2007, metastasis and recurrence were found in
the
right groin and liver, and anticancer drug therapy (vinblastine and
prednisolone) was
started without any surgical operations. Administration of anticancer drugs
was
started at the time of finding the metastasis and recurrence, and drugs were
administered 1, 2, 4 and 8 weeks thereafter again. The serodiagnosis was
carried
out each time drugs were administered to find that the absorbance at 450 nrn
was
0.36, 0.37, 0.26, 0.20 and 0.29, respectively. The value gradually decreased
with
anticancer drugs administered with short intervals from the start to the 4th
week,
CA 02703356 2010-04-22
68
which indicates that the progression of cancer could be suppressed. However,
the
value increased again in the 8th week, when 1 month had passed since the
previous
administration, which indicates that the cancer began to advance again. It was
also
confirmed clinically that the tumor grew larger at that time. The result
obtained in
Canine Patient 2 revealed that the stage of cancer progression can also be
assessed by
this method, and that the effect of anticancer drug therapy can also be
assessed as
shown above.
[0127]
(2)-3 Assessment of Grade of Cancer Malignancy
Basaliomas include malignant type and benign type. Recently, according to
the new WHO classification, malignant basaliomas are called basal cell
carcinoma,
and benign basaliomas are called trichoblastoma.
[0128]
Canine Patient 3 (Beagle) was diagnosed as basal cell carcinoma (malignant).
The serodiagnosis was carried out at the time of the surgery to find that the
absorbance at 450 nm was 0.35. On the other hand, in Canine Patient 4 (Mixed
Breed) diagnosed as trichoblastoma (benign), the serodiagnosis carried out at
the
time of the surgery revealed that the absorbance at 450 nm was 0, not detected
at all.
Thus, even in the case of the same basaliomas, malignant basal cell carcinoma
and
benign trichoblastoma can be distinctively diagnosed.
[0129]
Next example is mammary gland tumors. Mammary gland tumors include
malignant tumors such as mammary adenocarcinoma and mammary gland malignant
mixed tumor, and benign mammary tumors which do not show malignant symptoms.
Canine Patient 5 (Yorkie) underwent extirpation of mammary gland malignant
mixed
tumor and mammary adenocarcinoma on May 17, 2006. In general, the complete
excision of mixed tumors in mammary gland is easy because they are poorly
invasive
CA 02703356 2010-04-22
69
to the surrounding tissues even if they are malignant, and thus the
postoperative
course of the patients is usually uneventful. However, Canine Patient 5 had
been
diagnosed as highly malignant tumor, because the pathological diagnosis using
the
extirpated tissue revealed that some components of the specimen from Canine
Patient
5 showed an invasive nature. On the other hand, mammary adenocarcinoma is a
highly invasive tumor which often recurs and metastasizes. Although invasion
of
the tumor cells was not observed in the specimen from Canine Patient 5, it had
been
pointed out that highly malignant components possibly proliferated in other
region
out of the specimen. Thus, the findings in the pathological diagnosis clearly
taught
that Canine Patient 5 was suffering from highly malignant mammary cancer. A
blood sample was collected during the surgery and the serodiagnosis was
carried out
to find that the absorbance at 450 nm was 0.39. Canine Patient 6 (Yorkshire
Terrier) underwent extirpation of mammary tumor on January 28, 2007. According
to the pathological diagnosis using the extirpated tissue, atypism of cells
was low,
and thus Canine Patient 6 was diagnoses as benign mastadenoma without
malignant
findings. A blood sample was collected during the surgery and the
serodiagnosis
was carried out to find that the absorbance at 450 nm was 0.05. The results in
the
two cases above revealed that highly malignant tumors show a higher value than
low
malignant, benign tumors.
[0130]
(2)-4 Follow-Up of Postoperative Patients
Canine Patient 7 (Shih Tzu) visited the hospital due to an intraoral tumor and
underwent the extirpation on March 22, 2007. The serodiagnosis was carried out
at
that time to find that the absorbance at 450 nm was 0.40. In addition, based
on the
pathological diagnosis using the extirpated tissue, Canine Patient 7 was
diagnosed as
malignant acanthomatous epulis. This kind of tumor often recurs if excision is
insufficient, though distant metastasis seldom happens. Thus, it is important
CA 02703356 2010-04-22
whether the tumor can be completely excised by surgery or not. According to
the
follow up on May 18, 2007, the absorbance at 450 nm was 0.25, and hence the
antibody titer was decreased. The recurrence has not been found till August of
2007.
Thus, it is considered that the value obtained in the serodiagnosis became
lower than
5 that obtained at the time of surgery because the tumor could be
completely excised
from Canine Patient 7.
[0131]
(2)-5 Diagnosis of Recurrence
Canine Patient 8 (Husky) underwent an extirpation of mammary
10 adenocarcinoma on May 8, 2007. The serodiagnosis was carried out at the
time of
the surgery to find that the absorbance at 450 nm was 0.08. The pathological
diagnosis using the extirpated tissue revealed that highly atypical epithelial
cells
proliferated and mainly formed ductal structures, and thus this patient was
diagnosed
as primary breast adenocarcinoma. It was said that the patient was at a high
risk of
15 recurrence or metastasis to lymph nodes or distant organs, as many
cancer cells had
already entered the lymph vessels at that time. On June 28, 2007, about 1-and-
a-
half month after the surgery, metastasis was found at the same site. The value
detected by the serodiagnosis carried out then was 0.08, which did not
decrease at all.
Thus, it is considered that the value of the serodiagnosis stayed unchanged
from the
20 beginning of May to the end of June because the tumor could not have
been
completely excised or recurrence would have occurred in Canine Patient 8.
= [0132]
(2)-6 Diagnosis of Metastasis
Canine Patient 9 (Scottish Terrier), repeatedly undergoing metastasis and
25 recurrence, was diagnosed as mammary tumor in February of 2003;
intraoral
malignant melanoma in August of 2003; malignant melanoma of the lip in January
of
2005; and as intraoral melanoma on April 13, 2005, all of which were excised
by
CA 02703356 2010-04-22
71
surgery. This patient visited the hospital again on December 17, 2006 for
follow-up
after the recurrence of intraoral melanoma in April of 2005, and the
serodiagnosis
.;
was carried out at that time to find that the absorbance at 450 nm was 0.3.
Half a
year later, on June 20, 2007, the patient again visited the hospital because
of the
hypertrophy of cervical and malar lymph nodes. In the case of lymphomas,
hypertrophy of lymph nodes is systemically observed. Because Canine Patient 9
had only two swollen lymph nodes, this patient was clinically diagnosed as
probable
metastatic lymphoma. The diagnosis according to the present invention also
revealed that it was a tumor which had metastasized from the tumor previously
existed in this patient as the absorbance at 450 nm greatly increased to 0.75.
[0133]
(2)-7 Therapy Monitoring
Canine Patient 11 (Miniature Dachshund) underwent tumor extirpation on
April 19, 2007. According to the pathological diagnosis using the extirpated
tumor,
the patient was suffering from moderately-malignant combined mammary
adenocarcinoma with a high probability of invasive and metastatic development.
The serodiagnosis was carried out at that time to reveal that the absorbance
at 450 nm
was 0.26. On June 3, 2008, about 1 year after the extirpation, the
serodiagnosis was
carried out to find that the absorbance at 450 nm greatly decreased to 0.13.
Although any recurrent tumors were not found with the naked eye, an anticancer
drug
(INTERCAT) was administered once-weekly for 2 months to prevent recurrence.
The serodiagnosis was carried out 2, 4, and 6 weeks after the administration
of the
anticancer drug started to reveal that the absorbance at 450 nm was 0.09, 0.07
and
0.08, respectively. These results obtained in Canine Patient 11 confirmed that
the
value becomes lower than that detected in a cancer-bearing state if tumors can
be
completely removed, as well as that the value does not increase if anticancer
drug
treatment successfully prevents cancer metastasis, and thus change in treated
patients
CA 02703356 2010-04-22
72
can be followed. In addition, the diagnosis of recurrence can also be carried
out as
shown in Canine Patient 8, which confirms that the therapy monitoring can also
be
made possible.
[0134]
(2)-8 Diagnosis of Malignancy of Recurrent Tumor
Canine Patient 12 (Chihuahua) underwent tumor extirpation on April 27,
2007. According to the pathological diagnosis using the extirpated tumor, this
patient was suffering from ductal carcinoma originated from mammary ductal
epithelium, i.e., malignant breast cancer. On June 29, 2008, about 1 year
thereafter,
tumor was found again and extirpated. According to the pathological diagnosis
using the extirpated tumor, although tumor cells which were originated from
mammary ductal epithelium formed irregular glandular cavities and developed to
reduplicate toward the lumens, the constituting cells had an almost uniformly
egg-
shaped nucleus and atypism of the cells was low, and therefore the tumor was
diagnosed as benign mammary adenocarcinoma. The serodiagnosis was carried out
but the absorbance at 450 nm was 0.02, hardly detected. The results observed
in
Canine Patients 8 and 12 confirmed that the value of the serodiagnosis does
not
decrease or is sustained in cases where the recurrent tumor is malignant, and
is hardly
detected in cases where the tumor is benign.
[0135]
(2)-9 Prognosis of Canine Patient Bearing Benign Tumor
Canine Patient 13 (Toy Poodle) underwent tumor extirpation on October 9,
=
2007. The pathological diagnosis using the extirpated tumor revealed that
mammary epithelial cells and myoepithelial cells were both proliferated to
form the
tumor, but that both of them did not show any malignant findings, and
therefore this
patient was diagnosed as benign mixed tumor. According to the serodiagnosis
carried out at that time, the absorbance at 450 nm was 0.07, slightly
detected. On
CA 02703356 2010-04-22
73
June 5, 2008, 8 months thereafter, a blood sample was collected again and the
serodiagnosis was carried out to find that the absorbance at 450 nm was 0, not
'
detected at all. Recurrence was not found clinically at that time. These
results
indicated that, even in the case where tumor is benign, complete removal of
the
tumor results in the decreased value of the serodiagnosis if a detectable
value can be
observed in cancer-bearing state, and hence prognosis can be attained.
[0136]
(3) Diagnosis in Cats
Next, cancer-bearing cats and healthy cats were diagnosed. Using the
above-described recombinant canine protein and anti-cat IgG antibody, the IgG
antibody titer of feline serum which specifically reacts with the polypeptide
was
measured in the same manner as described above. As a secondary antibody, HRP-
conjugated anti-cat IgG antibody (PEROXIDASE-CONJUGATED GOAT IgG
FRACTION TO CAT IgG (WHOLE MOLECULE): manufactured by CAPPEL
RESERCH REAGENTS) 8,000-fold diluted with the blocking solution was used.
[0137]
Feline Patient 1 (Chinchilla) underwent tumor extirpation of mammary
adenocarcinoma on August 17, 2005. The absorbance at 450 nm was 0.32. In
Feline Patient 2 (Himalayan), which underwent extirpation of ductal carcinoma
on
October 17, 2006, the absorbance at 450 nm was 0.18. On the other hand, the
absorbance was not detected in healthy cats at all.
[0138]
Thus, similarly to dogs, the absorbance value was detected in samples from
cats suffering from cancer, while the absorbance value was not detected at all
in
samples from healthy cats. Hence, similarly to dogs, cancers in cats can also
be
detected by this method using a recombinant canine protein.
[0139]
CA 02703356 2010-04-22
74
(4) Diagnosis in Healthy Human
Using the above-described recombinant canine protein and anti-human IgG
antibody above, the IgG antibody titer of healthy human serum which
specifically
reacts with the polypeptide was measured in the same manner as described
above.
As a secondary antibody, HRP-conjugated anti-human IgG antibody (HRP-Goat
Anti-Human IgG(H+L) Conjugate: manufactured by Zymed Laboratories) 10,000-
fold diluted with the blocking solution was used. As a positive control, an
immobilized ovalbumin antigen prepared by immobilizing 50 i.tg/m1 ovalbumin in
phosphate buffered saline on a solid phase was used. As a result, in Healthy
Human
1, the absorbance at 450 nm observed on an ovalbumin antigen was 0.25, while
the
absorbance at 450 nm observed on the recombinant protein was 0, not detected
at all.
Similarly, in Healthy Human 2, the absorbance at 450 tun observed on an
ovalbumin
antigen was 0.18, while the absorbance at 450 nm observed on the recombinant
protein was 0, not detected at all.
[0140]
Example A-4: Cancer Diagnosis Using Recombinant Human Protein
Using the recombinant human protein prepared in Example A-2, the IgG
antibody titer of human, canine and feline sera which react with the protein
was
measured in the same manner as in Example A-3.
[0141]
The diagnosis was carried out using healthy human serum. In the same
manner as in Example A-3 (4), ovalbumin antigen was used as a positive
control.
As a result, the absorbance value was detected in the case where ovalbumin was
immobilized on a solid phase, while the absorbance value was hardly detected
in the
case where a human calmegin protein was immobilized on a solid phase.
[0142]
Similarly, in healthy dogs and cats, the absorbance at 450 mil was hardly
CA 02703356 2010-04-22
detected in the case where the protein was immobilized on a solid phase.
[0143]
On the other hand, Canine Patient 10 (Shih Tzu) underwent extirpation of
mammary adenocarcinoma on June 21, 2007. According to the pathological
5 diagnosis using the extirpated tissue, the mammary gland tissue contained
highly
atypical, invasive cells, and grew to form adenomatous hyperplasia showing
large
and small massive structures. Hence, this patient was diagnosed as malignant
tumor.
In this Canine Patient 10, the absorbance at 450 nm was 0.29. The malignancy
diagnosis was carried out using additional 310 serum samples which had been
10 diagnosed as malignant based on the pathological diagnosis. As a result,
by
diagnosing a sample showing twice the average value of healthy canine samples
as
malignant, 189 samples i.e. 60.8% of the malignant cases could be successfully
diagnosed as malignant. Moreover, in Feline Patient 3 (Mixed Breed), which
underwent extirpation of mammary adenocarcinoma on April 3, 2007, the
absorbance
15 at 450 nm was 0.14.
[0144]
The above-described results indicate that the diagnosis can be similarly
attained in humans, dogs and cats even by using the recombinant human protein.
[0145]
20 Furthermore, pleural effusion and ascites samples collected from
terminal
cancer dogs were subjected to the diagnosis using the recombinant human
protein in
the same manner as the recombinant canine protein. As a result, values similar
to
those detected in serum samples could be detected, and hence cancer diagnosis
could
be successfully attained.
25 [0146]
Example A-5: Cancer Diagnosis by Measuring Antigen Polypeptide (1)
Mice and rabbits were immunized with the recombinant canine polypeptide
CA 02703356 2010-04-22
76
prepared in Example A-2 to obtain an antibody specific to this antigen. Using
this
polyclonal antibody, detection of the antigen polypeptide per se contained in
the
serum from cancer bearing living body was carried out by sandwich ELISA. Using
anti-mouse IgG antibody, the amount of the protein in the serum which
specifically
reacts with the prepared polyclonal antibody specific to the protein was
measured by
sandwich ELISA.
[0147]
As for immobilization of a primary antibody on a solid phase, 100 4/well of
the rabbit antiserum 20-fold diluted with phosphate buffered saline was added
to a
96-well Immobilizer Amino plate (manufactured by Nunc), and the plate was
shaken
at room temperature for 2 hours. As for blocking, 100 4/well of 50 mM sodium
bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour. To
the plate, 100 [IL/well of the serum from cancer-bearing body diluted with the
blocking solution was added, and the plate was shaken at room temperature for
3
hours to allow the reaction to proceed. As for the diluted serum, a 10-fold
serial
dilution ranging 10 to 1,000-fold was prepared. After washing the wells 3
times
with phosphate buffered saline containing 0.05% Tween20 (manufactured by Wako
Pure Chemicals) (hereinafter referred to as PBS-T), 100 4/well of mouse
antiserum
200-fold diluted with the blocking solution was added thereto, and the plate
was
shaken at room temperature for 1 hour to allow the reaction to proceed. After
washing the wells 3 times with PBS-T, 100 4/well of HRP-conjugated mouse IgG
antibody (Stabilized Goat Anti Mouse HRP conjugated : manufactured by PIERCE)
2,000-fold diluted with the blocking solution was added thereto as a tertiary
antibody,
and the plate was shaken at room temperature for 1 hour to allow the reaction
to
proceed. After washing the wells 3 times with PBS-T, 100 [11/well of a HRP
CA 02703356 2010-04-22
77
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
= PIERCE), was added thereto, and the enzyme-substrate reaction was allowed
to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 [11/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the rabbit antiserum was not
immobilized
and a plate with which serum from a cancer-bearing body was not reacted were
measured in the same manner as described above.
[0148]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody prepared by using the
recombinant
canine polypeptide as an immunogen.
[0149]
Example A-6: Cancer Diagnosis by Measuring Antigen Polypeptide (2)
Mice and rabbits were immunized with the recombinant human protein
prepared in Example A-2 to obtain an antibody specific to this antigen. In the
same
manner as in Example 5, detection of the antigen polypeptide per se contained
in the
serum from cancer-bearing body was carried out by sandwich ELISA using this
= polyclonal antibody.
[0150]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
CA 02703356 2010-04-22
78
antigen polypeptide was detected with an antibody prepared by using the
recombinant
human polypeptide as an immunogen.
[0151]
Example B-1: Acquisition of Novel Cancer Antigen Protein by SEREX Method
(1) Preparation of cDNA Library
Total RNA was prepared from testis tissue of a healthy dog by the Acid
guanidium-Phenol-Chloroform method, and poly(A) RNA was purified using
Oligotex-dT30 mRNA purification Kit (manufactured by Takara Shuzo Co., Ltd.)
in
accordance with the protocol attached to the kit.
[0152]
Using the obtained mRNA (5 jig), a dog testis cDNA phage library was
synthesized. Preparation of the cDNA phage library was carried out using cDNA
Synthesis Kit, ZAP-cDNA Synthesis Kit, and ZAP-cDNA Gigapack III Gold Cloning
Kit (manufactured by STRATAGENE) in accordance with the protocols attached to
the kits. The size of the prepared cDNA phage library was 1.3 x 106 pfu/ml.
[0153]
(2) Screening of cDNA Library with Serum
Using the dog testis-derived cDNA phage library prepared as described above,
immunoscreening was carried out. More particularly, host E. coil cells (XL1-
Blue
MRF') were infected with the library such that 2,340 clones should appear on
an
NZY agarose plate having the size of (I)90 x 15 mm, and cultured at 42 C for 3
to 4
hours to allow the phage to form plaques. The plate was covered with
nitrocellulose
membrane (Hybond C Extra: manufactured by GE Healthcare Bio-Science)
impregnated with IPTG (isopropyl-13-D-thiogalactoside) at 37 C for 4 hours to
induce
and express proteins, which were thus transferred to the membrane.
Subsequently,
the membrane was recovered and soaked in TBS (10 mM Tris-HC1, 150 mM NaCl;
pH 7.5) containing 0.5% non-fat dry milk, followed by shaking at 4 C overnight
to
CA 02703356 2010-04-22
79
suppress non-specific reactions. This filter was allowed to react with 500-
fold
diluted canine patient serum at room temperature for 2 to 3 hours.
[0154]
As the above-described canine patient serum, serum collected from canine
patients suffering from tumor proximal to the anus was used. The serum was
stored at -80 C and pretreated immediately before use. The method of the
pretreatment of the serum was as follows. That is, host E. coil cells (XL I-
Blue
MRF') were infected with X ZAP Express phage to which no foreign gene was
inserted, and then cultured on NZY plate medium at 37 C overnight.
Subsequently,
the buffer of 0.2 M NaHCO3, pH 8.3 containing 0.5 M NaCl was added to the
plate,
and the plate was left to stand at 4 C for 15 hours, followed by collecting
the
supernatant as an E. co/i/phage extract. Thereafter, the collected E.
co/i/phage
extract was allowed to flow through an NHS column (manufactured by GE
Healthcare Bio-Science) to immobilize proteins derived from the E. co/i/phage
thereon. The serum from the canine patients was allowed to flow through and
react
with this protein-immobilized column to remove antibodies adsorbed on E. coil
and/or the phage. The serum fraction that passed through the column was 500-
fold
diluted with TBS containing 0.5% non-fat dry milk, and the resulting diluent
was
used as the material for the immunoscreening.
[0155]
The membrane on which the thus treated serum and the above-described
fusion protein were blotted was washed 4 times with TBS-T (0.05% Tween
20/TBS),
and allowed to react with goat anti-dog IgG (Goat anti Dog IgG-h+I HRP
conjugated:
manufactured by BETHYL Laboratories) 5,000-fold diluted with TBS containing
0.5% non-fat dry milk as a secondary antibody at room temperature for 1 hour,
followed by detection by the enzyme coloring reaction using the NBT/BCIP
reaction
solution (manufactured by Roche). Colonies at positions where a positive
coloring
CA 02703356 2010-04-22
reaction was observed were recovered from the NZY agarose plate having the
size of
(D90 x 15 mm, and dissolved in 500 I of SM buffer (100 mM NaCI, 10 mM
MgC1SO4, 50 mM Tris-HCI, 0.01% gelatin; pH 7.5). The screening was repeated as
a second and third screening in the same manner as described above until a
single
5 coloring reaction-positive colony was obtained, thereby isolating one
positive clone
after screening of 30,940 phage clones reactive with IgG in the serum.
[0156]
(3) Homology Search of Isolated Antigen Gene
To subject the single positive clone isolated by the above-described method to
10 a base sequence analysis, an operation of conversion of the phage vector
to a plasmid
vector was carried out. More particularly, 200 pi of a solution prepared to
contain a
host E. coli (XL1-Blue MRF) such that the absorbance 0D600 should be 1.0 was
mixed with 100 1 of a purified phage solution and further with 1 I of
ExAssist
helper phage (manufactured by STRATAGENE), and the reaction was allowed to
15 proceed at 37 C for 15 minutes. To the reaction mixture, 3 ml of LB
medium was
added, and the mixture was cultured at 37 C for 2.5 to 3 hours, followed by
immediate incubation in a water bath at 70 C for 20 minutes. The mixture was
then
centrifuged at 4 C at 1,000 xg for 15 minutes, and the supernatant was
recovered as a
phagemid solution. Subsequently, 200 pi of a solution prepared to contain a
20 phagemid host E. coli (SOLR) such that the absorbance Mom should be 1.0
was
mixed with 10 ill of a purified phage solution, and the reaction was allowed
to
proceed at 37 C for 15 minutes. Thereafter, 50 1 of the reaction mixture was
plated on ampicillin (final concentration: 50 g/m1)-containing LB agar
medium, and
cultured at 37 C overnight. A single colony of transformed SOLR was recovered
25 and cultured in ampicillin (final concentration: 50 ig/m1)-containing LB
medium at
37 C, followed by purification of plasmid DNA having an insert of interest
using
QIAGEN plasmid Miniprep Kit (manufactured by Qiagen).
CA 02703356 2010-04-22
81
[0157]
The purified plasmid was subjected to an analysis of the entire sequence of
the insert by the primer walking method using the T3 primer described in SEQ
ID
NO:5 and the T7 primer described in SEQ ID NO:6. By this sequence analysis,
the
gene sequence described in SEQ ID NO:15 was obtained. Using the base sequence
and the amino acid sequence of this gene, homology search against known genes
was
carried out using a homology search program BLAST
(http://www.ncbi.nlm.nih.gov/BLAST/). As a result, it was revealed that the
obtained gene is the calmegin gene. The human homologous factor of the canine
calmegin gene was human calmegin (homology: base sequence, 90%; amino acid
sequence, 89%). The base sequence of human calmegin is shown in SEQ ID NO:17,
and the amino acid sequence thereof is shown in SEQ ID NO:18.
[0158]
(4) Analysis of Expression in Each Tissue
The expression of the gene, which was obtained by the above-described
method, in normal tissues and various cell lines of dog and human were
investigated
by the RT-PCR (Reverse Transcription-PCR) method. The reverse transcription
reaction was carried out as follows. That is, total RNA was extracted from 50
to
100 mg of each tissue or 5 to 10 x 106 cells of each cell line using TRIZOL
reagent
(manufactured by Invitrogen) in accordance with the protocol attached to the
kit.
Using this total RNA, cDNA was synthesized by Superscript First-Strand
Synthesis
System for RT-PCR (manufactured by Invitrogen) in accordance with the protocol
attached to the kit. As the cDNAs from human normal tissues (brain,
hippocampus,
testis, colon and placenta), Gene Pool cDNA (manufactured by Invitrogen),
QUICK-
Clone cDNA (manufactured by CLONTECH) and Large-Insert cDNA Library
(manufactured by CLONTECH) were used. The PCR reactions were carried out as
follows using primers (described in SEQ ID NOs:19 and 20) specific to the
obtained
CA 02703356 2010-04-22
82
gene. That is, respective reagents and the attached buffer were mixed such
that the
mixture should contain 0.25 1 of the sample prepared by the reverse
transcription
reaction, 2 M each of the above primers, 0.2 mM each of dNTP and 0.65 U of
= ExTaq polymerase (manufactured by Takara Shuzo Co., Ltd.) in a total
volume of 25
I, and the reaction was carried out with 30 cycles of 94 C for 30 seconds, 55
C for
30 seconds and 72 C for 1 minute using Thermal Cycler (manufactured by BIO
RAD). The above-described gene-specific primers were those which amplify the
regions of the 755th to 1318th bases of the base sequence of SEQ ID NO:15
(canine
calmegin gene) and the 795th to 1358th bases of the base sequence of SEQ ID
NO:17,
and can be used for investigation of the expression of both the canine
calmegin gene
and the human calmegin gene. As a control for comparison, primers (described
in
SEQ ID NOs:9 and 10) specific to GAPDH were used simultaneously. As a result,
as shown in Fig. 5, strong expression was observed in testis among the normal
dog
tissues, and on the other hand, strong expression was observed in canine tumor
cell
lines. Expression of the human calmegin gene was confirmed, as is the case
with
the canine calmegin gene, only in testis among the normal tissues, but the
expression
was detected in brain tumor, leukemia and esophagus cancer cells among cancer
cell
lines. Thus, the human calmegin gene was also confirmed to be specifically
expressed in testis and cancer cells.
[0159]
In Fig. 5, reference numeral 1 in the ordinate indicates the expression
pattern
of the calmegin gene, and reference numeral 2 indicates the expression pattern
of the
GAPDH gene as a control for comparison.
[0160]
Example B-2: Preparation of Canine and Human Calmegin Proteins
(1) Preparation of Recombinant Protein
Based on the gene of SEQ ID NO:15 obtained in Example B-1, a recombinant
CA 02703356 2010-04-22
83
protein was prepared by the following method. Respective reagents and the
attached buffer were mixed such that the mixture should contain I 1 of the
vector
that was prepared from the phagemid solution obtained in Example B-1 and was
subjected to the sequence analysis, 0.4 M each of two kinds of primers having
BamHI and EcoRI restriction sites (described in SEQ ID NOs:21 and 22), 0.2 mM
dNTP and 1.25 U of PrimeSTAR HS polymerase (manufactured by Takara Shuzo
Co., Ltd.) in a total volume of 50 1, and PCR was carried out with 30 cycles
of 98 C
for 10 seconds, 55 C for 15 seconds and 72 C for 2 minutes using Thermal
Cycler
(manufactured by BIO RAD). Using the above-described two kinds of primers, the
region encoding the entire amino acid sequence of SEQ ID NO:16 is obtained.
After the PCR, the amplified DNA was subjected to electrophoresis using 1%
agarose gel, and a DNA fragment of about 1.9 kbp was purified using QIAquick
Gel
Extraction Kit (manufactured by QIAGEN).
[0161]
The purified DNA fragment was ligated into a cloning vector pCR-Blunt
(manufactured by Invitrogen). E. coli was transformed with the resulting
ligation
product, and plasmids were recovered thereafter, followed by confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
BamHI and EcoRI and purified using QIAquick Gel Extraction Kit, followed by
inserting the gene sequence of interest into an expression vector for E. coil,
pET30a
(manufactured by Novagen) that had been treated with BamHI and EcoRI . Usage
of this vector enables production of a His-tag fusion recombinant protein. E.
coil
for expression, BL21 (DE3), was transformed with this plasmid, and expression
of
the protein of interest was induced in E. coil with 1 mM IPTG.
[0162]
Based on the gene of SEQ ID NO:17, a recombinant protein of the human
CA 02703356 2010-04-22
84
homologous gene was prepared by the following method. Respective reagents and
the attached buffer were mixed such that the mixture should contain 1 I of
the
cDNA prepared in Example B-1 whose expression could be confirmed by the RT-
PCR method in various tissues/cells, 0.4 M each of two kinds of primers
having
EcoRI and Xhof restriction sites (described in SEQ ID NOs:23 and 24), 0.2 mM
dNTP and 1.25 U of PrimeSTAR HS polymerase (manufactured by Takara Shuzo
Co., Ltd.) in a total volume of 50 p.1, and PCR was carried out with 30 cycles
of 98 C
for 10 seconds, 55 C for 15 seconds and 72 C for 2 minutes using Thermal
Cycler
(manufactured by BIO RAD). Using the above-described two kinds of primers, the
region encoding the entire amino acid sequence of SEQ ID NO:18 is obtained.
After the PCR, the amplified DNA was subjected to electrophoresis using 1%
agarose gel, and a DNA fragment of about 1.9 kbp was purified using QIAquick
Gel
Extraction Kit (manufactured by QIAGEN).
[0163]
The purified DNA fragment was ligated into a cloning vector pCR-Blunt
(manufactured by Invitrogen). E. coli was transformed with the resulting
ligation
product, and plasmids were recovered thereafter, followed by confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
EcoRI and Xhol and purified using QIAquick Gel Extraction Kit, followed by
inserting the gene sequence of interest into an expression vector for E. coli,
pET30a
(manufactured by Novagen) that had been treated with EcoRI and Xhol. Usage of
this vector enables production of a His-tag fusion recombinant protein. E.
coli for
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E. coli with 1 mM IPTG.
[0164]
(2) Purification of Recombinant Protein
CA 02703356 2010-04-22
The above-obtained recombinant E. coli cells that expressed SEQ ID NO:15
and SEQ ID NO:17, respectively, were cultured in kanamycin (final
concentration:
30 g/ml)-containing LB medium at 37 C until the absorbance at 600 nm reached
about 0.7, and then IPTG was added thereto such that its final concentration
should
5 be 1 mM, followed by culturing them at 37 C for 4 hours. Subsequently,
the cells
were collected by centrifugation at 4,800 rpm for 10 minutes. The pellet of
the cells
was suspended in phosphate-buffered saline and further subjected to
centrifugation at
4,800 rpm for 10 minutes to wash the cells.
[0165]
10 The obtained pellet of E. coil cells was suspended in 20 mM phosphate
buffer
(pH 7.0) and subjected to sonication on ice. The sonicated solution of E. coil
was
centrifuged at 6,000 rpm for 20 minutes to obtain the supernatant as the
soluble
fraction and the precipitate as the insoluble fraction.
[0166]
15 The soluble fraction was placed in an cation-exchange column (carrier:
SP
Sepharose (trademark) Fast Flow (GE Health Care); column volume: 5mL;
equilibration buffer: 20 mM phosphate buffer (pH 7.0)). The column was washed
with 10 column volumes of 20 mM phosphate buffer (pH 7.0), and then elution
was
immediately carried out with density gradient of salt by 0.3 M-1.0 M sodium
20 chloride-containing 20 mM phosphate buffer (pH 7.0). Six column volumes
of the
eluted fraction was collected in each elution step.
[0167]
Among these eluted fractions, all the fractions eluted with 0.3 M sodium
chloride-containing 20 mM phosphate buffer (pH 7.0) and the 1st fraction
eluted with
25 1.0 M sodium chloride-containing 20 mM phosphate buffer (pH 7.0) were
combined,
and the resulting solution was subjected to additional purification by a
secondary
column.
CA 02703356 2010-04-22
86
[0168]
For the secondary column, a column carrier Bio gel HT Type II (BioRad) was
used. The column volume was 5 mL. The column was equilibrated with 10
column volumes of 0.3 M sodium chloride-containing 20 mM phosphate buffer (pH
7.0), and the above-described eluted fractions were placed in the column. The
fractions that were not adsorbed to the column was washed away with 10 column
volumes of 0.3 M sodium chloride-containing 20 mM phosphate buffer (pH 7.0)
and
0.1 M phosphate buffer (pH 7.0). Immediately thereafter, elution was carried
out
with 0.2 M phosphate buffer (pH 7.0). Six column volumes of the eluted
fraction
was collected in each elution step. Elution of the proteins of interest was
confirmed
by Coomassie staining carried out according to a conventional method. Based on
the result, the eluted fractions were desalted and concentrated to obtain the
material
to be solid-phased for diagnosis.
[0169]
Example B-3: Cancer Diagnosis Using Canine Calmegin Protein
(1) Cancer Diagnosis in Dogs
Blood samples were collected from 486 canine patients in which malignant or
benign tumors were found and 6 healthy dogs, and sera were separated
therefrom.
Using the canine calmegin protein prepared in Example B-2 and anti-dog IgG
antibody, the IgG antibody titer of the sera which specifically react with the
protein
was measured by ELISA.
[0170]
As for immobilization of the prepared protein on a solid phase, 100 L/well
of a solution of the recombinant protein diluted to 50 ug/mL with phosphate
buffered
saline was added to a 96-well Immobilizer Amino plate (manufactured by Nunc),
and
the plate was left to stand at 4 C overnight. As for blocking, 100 pt/well of
50 mM
sodium bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
CA 02703356 2010-04-22
87
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour.
Serum was 1,000-fold diluted with the blocking solution, and and 100 4/well of
the
diluted serum was added to the plate, followed by shaking the plate at room
temperature for 3 hours to allow the reaction to proceed. After washing the
wells 3
times with phosphate buffered saline containing 0.05% Tween20 (manufactured by
Wako Pure Chemicals) (hereinafter referred to as PBS-T), 100 4/well of HRP-
conjugated dog IgG antibody (Goat anti Dog IgG-h+I HRP conjugated:
manufactured
by BETHYL Laboratories) 3,000-fold diluted with the blocking solution was
added
thereto, and the plate was shaken at room temperature for 1 hour to allow the
reaction
to proceed.. After washing the wells 3 times with PBS-T, 100 pil/well of a HRP
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 p1/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the prepared recombinant protein was
not
immobilized and a plate with which the serum from a cancer-bearing dog was not
reacted were measured in the same manner as above.
[0171]
Among the total 486 samples used in the above-described cancer diagnosis,
311 samples were definitely diagnosed as malignant by pathological diagnosis
using
the extirpated tumor tissue.
[0172]
Specifically, the samples were diagnosed as cancer such as malignant
melanoma; malignant mixed tumor; hepatocellular carcinoma; basal cell
carcinoma;
acanthomatous epulis; intraoral tumor; perianal adenocarcinoma; anal sac
tumor; anal
CA 02703356 2010-04-22
88
sac apocrine carcinoma; Sertoli cell tumor; vulva cancer; sebaceous
adenocarcinoma;
sebaceous epithelioma; sebaceous adenoma; sweat gland carcinoma; intranasal
adenocarcinoma; nasal adenocarcinoma; thyroid cancer; colon cancer; bronchial
adenocarcinoma; adenocarcinoma; ductal carcinoma; mammary adenocarcinoma;
combined mammary adenocarcinoma; mammary gland malignant mixed tumor;
intraductal papillary adenocarcinoma; fibrosarcoma; hemangiopericytoma;
osteosarcoma; chondrosarcoma; soft tissue sarcoma; histiocytic sarcoma;
myxosarcoma; undifferentiated sarcoma; lung cancer; mastocytoma; cutaneous
leiomyoma; intra-abdominal leiomyoma; leiomyoma; squamous cell carcinoma;
chronic lymphocytic leukemia; lymphoma; gastrointestinal lymphoma; digestive
organ lymphoma; small cell or medium cell lymphoma; adrenomedullary tumor;
granulosa cell tumor; pheochromocytoma; bladder cancer (transitional cell
carcinoma); suppurative inflammation; intra-abdominal liver tumor; liver
cancer;
plasmacytoma; malignant hemangiopericytoma; angiosarcoma; anal sac
adenocarcinoma; oral cancer; metastatic malignant melanoma; amelanotic
malignant
melanoma; cutaneous malignant melanoma; malignant myoepithelioma; malignant
seminoma; seminoma; adenocarcinoma of the large intestine; gastric
adenocarcinoma; low-grade sebaceous carcinoma; ceruminous adenocarcinoma;
apocrine carcinoma; poorly differentiated apocrine sweat gland carcinoma;
malignant
fibrous histiocytoma; multiple myeloma; mesenchymal malignant tumor;
liposarcoma; osteosarcoma; sarcoma of unknown origin; soft part sarcoma
(spindle
cell tumor); poorly differentiated sarcoma; synovial sarcoma; angiosarcoma;
metastatic malignant epithelioma; tubular mammary adenocarcinoma; mammary
ductal carcinoma; inflammatory breast cancer; germinoma; leukemia; invasive
trichoepithelioma; medium cell lymphoma; multicentric lymphoma; osteosarcoma
(mammary gland); mastocytoma (Patnaik II type); mastocytoma (Grade II);
leiomyosarcoma or the like.
CA 02703356 2010-04-22
89
[0173]
As shown in Fig. 7, sera from these cancer-bearing dogs showed a
significantly high antibody titer against the recombinant protein. It was
revealed
that, by diagnosing a sample showing twice the average value of healthy canine
samples as malignant, 177 samples i.e. 56.9% of the malignant cases could be
successfully diagnosed as malignant. The details of these 177 cancer samples
are as
follows. It is noted that the following number of each cancer case is a
cumulative
total, as some samples contained multiple primaries.
Malignant melanoma, 10 cases; lymphoma, 10 cases; pheochromocytoma, 1 case;
granulosa cell tumor, 1 case; hepatocellular carcinoma, 4 cases; sweat gland
carcinoma, 5 cases; angioma, 1 case; malignant testicular tumor, 7 cases;
intraoral
tumor, 4 cases; perianal adenocarcinoma, 11 cases; osteosarcoma, 4 cases;
fibrosarcoma, 7 cases; chondrosarcoma, 2 case; mammary adenocarcinoma, 35
cases;
combined mammary adenocarcinoma, 27 cases; lung cancer, 2 cases; sebaceous
adenocarcinoma, 2 cases; nasal adenocarcinoma, 2 cases; mastocytoma, 25 cases;
adrenomedullary tumor, 1 case; leiomyosarcoma, 1 case; squamous cell
carcinoma, 5
cases; chronic lymphocytic leukemia, 1 case; germinoma, 1 case; malignant
fibrous
histiocytoma, 1 case; metastatic malignant epithelioma, I case; mammary ductal
carcinoma, 1 case; angiosarcoma, 1 case; tubular mammary adenocarcinoma, 1
case;
invasive trichoepithelioma, 1 case; prostate cancer, 1 case; bronchial
adenocarcinoma,
1 case.
= [0174]
The above-described diagnostic method was also carried out using pleural
effusion samples and ascites samples collected from terminal cancer dogs. As a
result, values similar to those detected in serum samples could be detected,
and hence
cancer diagnosis could be successfully attained.
[0175]
CA 02703356 2010-04-22
Furthermore, it was confirmed that diagnostic approaches such as diagnosis of
cancers existing in an invisible part of the body, assessment of cancer stage
and grade,
follow-up of postoperative patients, diagnosis of recurrence and metastasis
and the
like can also be attained by applying the above-described diagnostic method.
The
5 followings are several of the practical examples of the detailed
diagnosis shown in
Fig. 8.
[0176]
(2)-1 Diagnosis of Invisible Tumors
In Canine Patient 1 (Flat-Coated Retriever), any tumors were not found on
10 June 7, 2007. But about 20 days later, on June 24, 2007, a pedunculated
tumor with
a diameter of 2 mm was found on the gum at the root of the canine tooth. The
tumor was ligated at its pedunculated part and excised on the day it found.
The
absorbance at 450 nm observed before the tumor became visible with the naked
eye
was 0.31, which was significantly high and not so different from the
absorbance at
15 the time of finding tumor, 0.33. This result indicates that it is
possible to diagnose
cancers even in an invisible part such as an intraperitoneal part by the
method of the
present invention.
[0177]
Rise of the value was observed before the tumor became visible with the
20 naked eye, which is considered to have been a sign of tumor development.
Thus,
the method of the present invention is useful in medical examinations such as
periodic health examination.
[0178]
Canine Patient 1 was again checked by the serodiagnosis 2 weeks after the
25 tumor excision. As a result, the absorbance at 450 nm was greatly
reduced to 0.17.
Thus, it was also confirmed that the cancer antigen-expressing tumor which had
caused the increased antibody titer was completely removed (see, (2)-4, Follow-
Up
CA 02703356 2010-04-22
91
of Postoperative Patients).
[0179]
(2)-2 Assessment of Stage of Cancer Progression
The stage of cancer progression is determined based on the size or depth of
the tumor, how much the tumor exerts influence on the surrounding tissues,
whether
the tumor metastasizes or not, and the like. It was revealed herein that the
detected
value is higher than before if the metastasis occurs, i.e., the cancer has
advanced.
The following is another example of a stage assessment of a certain cancer
case,
which received anticancer drug therapy.
[0180]
Canine Patient 2 (Miniature Dachshund) visited the hospital with chief
complaints of nausea and emaciation on February 21, 2007, and two massive
tumors
were found in the abdominal cavity. This patient underwent tumor extirpation
on
February 23, 2007. The swollen right kidney weighed 433 g. The neighboring
lymph node was well-vascularized and weighed 42 g. Based on the pathological
diagnosis using the extirpated tissue, the patient was diagnosed as
multicentric
malignant lymphoma. It was said that there was a probability that the tumor
cells
would spread into other organs in the abdominal cavity, as a disseminated
spread of
tumor cells was observed in the adipose tissue. The anticancer drug
administration
(Oncovin) was started postoperatively on March 1, 2007, and the serodiagnosis
was
carried out 3 times, i.e., on the day the administration was started, and 2
and 3
months thereafter. As a result, the absorbance at 450 nm was 0.18, 0.16, and
0.14,
respectively. The value had gradually decreased since the start of the
administration,
which confirmed that the anticancer drug took effect. Thus, it was confirmed
that
cancer progression could be inhibited. Hence, the results in Canine Patient 2
confirmed that the stage of cancer progression can also be assessed. In
addition, it
was confirmed that the effect of anticancer drug therapy can also be assessed
as
CA 02703356 2010-04-22
92
described above.
[0181]
(2)-3 Assessment of Grade of Cancer Malignancy
Basaliomas include malignant type and benign type. Recently, according to
the new WHO classification, malignant basaliomas are called basal cell
carcinoma,
and benign basaliomas are called trichoblastoma.
[0182]
Canine Patient 3 (Beagle) was diagnosed as basal cell carcinoma (malignant).
The serodiagnosis was carried out at the time of the surgery to find that the
absorbance at 450 nm was 0.13. On the other hand, in the case of Canine
Patient 4
(Mixed Breed) diagnosed as trichoblastoma (benign), the serodiagnosis carried
out at
the time of the surgery revealed that the absorbance at 450 nm was 0, not
detected at
all. Thus, even in the case of the same basaliomas, malignant basal cell
carcinoma
and benign trichoblastoma can be distinctively diagnosed.
[0183]
Next example is mammary gland tumors. Mammary gland tumors include
malignant tumors such as mammary adenocarcinoma and mammary gland malignant
mixed tumor, and benign mammary tumors which do not show malignant symptoms.
Canine Patient 5 (Yorkie) underwent extirpation of mammary gland malignant
mixed
tumor and mammary adenocarcinoma on May 17, 2006. In general, the complete
excision of mixed tumors in mammary gland is easy because they are poorly
invasive
to the surrounding tissues even if they are malignant, and thus the
postoperative
course of the patients is usually uneventful. However, Canine Patient 5 had
been
diagnosed as highly malignant tumor, because the pathological diagnosis using
the
extirpated tissue revealed that some components of the specimen from Canine
Patient
5 showed an invasive nature. On the other hand, mammary adenocarcinoma is a
highly invasive tumor which often recurs and metastasizes. Although invasion
of
CA 02703356 2010-04-22
93
tumor cells was not observed in the specimen from Canine Patient 5, it had
been
pointed out that highly malignant components possibly proliferated in other
region
out of the specimen. Thus, the findings in the pathological diagnosis clearly
taught
that Canine Patient 5 was suffering from highly malignant mammary cancer. A
blood sample was collected during the surgery and the serodiagnosis was
carried out
to find that the absorbance at 450 nm was 0.57. On the other hand, Canine
Patient 6
(Yorkshire Terrier) underwent extirpation of mammary tumor on January 28,
2007.
According to the pathological diagnosis using the extirpated tissue, atypism
of cells
was low, and thus Canine Patient 6 was diagnoses as benign mastadenoma without
malignant findings. A blood sample was collected during the surgery and the
serodiagnosis was carried out to find that the absorbance at 450 nm was 0. The
results in the two cases above revealed that highly malignant tumors show a
higher
value than low malignant, benign tumors.
[0184]
(2)-4 Follow-Up of Postoperative Patients
Canine Patient 7 (Shih Tzu) visited the hospital due to an intraoral tumor and
underwent the extirpation on March 22, 2007. The serodiagnosis was carried out
then to find that the absorbance at 450 nm was 0.70. In addition, based on the
pathological diagnosis using the extirpated tissue, Canine Patient 7 was
diagnosed as
malignant acanthomatous epulis. This kind of tumor often recurs if excision is
insufficient, though distant metastasis seldom happens. Thus, it is important
whether the tumor can be completely excised by surgery or not. According to
the
follow-up on May 18, 2007, the absorbance at 450 nm decreased to 0.47. The
recurrence has not been found till August of 2007. Thus, it is considered that
the
value obtained by the serodiagnosis became lower than that obtained at the
time of
surgery because the tumor could be completely excised from Canine Patient 7.
[0185]
CA 02703356 2010-04-22
94
(2)-5 Diagnosis of Recurrence
Canine Patient 8 (Husky) underwent extirpation of mammary adenocarcinoma
on May 8, 2007. The serodiagnosis was carried out at the time of the surgery
to find
that the absorbance at 450 nm was 0.11. The pathological diagnosis using the
extirpated tissue revealed that highly atypical epithelial cells proliferated
and mainly
formed ductal structures, and thus this patient was diagnosed as primary
breast
adenocarcinoma. It was said that the patient was at a high risk of recurrence
or
metastasis to lymph nodes or distant organs, as many cancer cells had already
entered
the lymph vessels at that time. On June 28, 2007, about 1-and-a-half-month
after
the surgery, metastasis was found at the same site. The value detected by the
serodiagnosis increased to 0.12. Thus, it was confirmed that the value
detected by
the serodiagnosis was higher in the end of June than in the beginning of May
because
the tumor could not have been completely excised or recurrence would have
occurred
in Canine Patient 8.
[0186]
Canine Patient 9 (Sheltie) underwent extirpation of ductal carcinoma on
October 24, 2006. The serodiagnosis carried out at that time revealed that the
absorbance at 450 nm was approximately 0, hardly detected. About 3 months
later,
on January 31, 2007, this patient visited the hospital because of cancer
recurrence
and underwent extirpation again. According to the pathological diagnosis using
the
extirpated tissue, many cancer cells having egg-shaped atypical nuclei invaded
lymph
vessels and metastasis was observed in the inguinal lymph node, and thus the
patient
was diagnosed as ductal carcinoma (breast cancer) with a probability of
distant
metastasis. The serodiagnosis was carried out at that time to find that the
absorbance at 450 nm increased to 0.10. Thus, similarly to above, it was
revealed
that the value of the serodiagnosis increased 3 months later because the tumor
could
not have been completely excised or recurrence of the tumor would have
occurred in
CA 02703356 2010-04-22
Canine Patient 9.
[0187]
(2)-6 Diagnosis of Metastasis
Canine Patient 10 (Scottish Terrier), repeatedly undergoing metastasis and
5 recurrence, was diagnosed as mammary tumor in February of 2003; intraoral
malignant melanoma in August of 2003; malignant melanoma of the lip in January
of
2005; and as intraoral melanoma on April 13, 2005, all of which were excised
by
surgery. This patient visited the hospital again on December 17, 2006 for
follow-up
after the recurrence of intraoral melanoma in April of 2005, and the
serodiagnosis
10 was carried out at that time to find that the absorbance at 450 rim was
0.39. Half a
year later, on June 20, 2007, the patient again visited the hospital because
of the
hypertrophy of cervical and malar lymph nodes. In the case of lymphomas,
hypertrophy of lymph nodes is systemically observed. Because Canine Patient 10
had only two swollen lymph nodes, this patient was clinically diagnosed as
probable
15 metastatic lymphoma. The diagnosis according to the present invention
also
revealed that it was a tumor which had metastasized from the tumor previously
existed in this patient as the absorbance at 450 nm greatly increased to 0.80.
[0188]
Canine Patient 11 (Shiba mu) underwent extirpation of oral malignant
20 melanoma of the right lip on March 11, 2006. This patient has a history
of
anticancer drug treatment (cyclophosphamide) from June 10 to September 26 in
2006,
and has received BIREMO S, which contains organic germanium as a main
ingredient, since May 23, 2006. On March 20, 2007, this patient underwent
extirpation of a tumor which was considered to be metastasis from the tumor
25 mentioned above, and the serodiagnosis was carried out. As a result, the
absorbance
at 450 nm was 0.06. Based on the pathological diagnosis using the tissue
extirpated
at that time, Canine Patient 11 was diagnosed as metastatic malignant
melanoma.
CA 02703356 2010-04-22
96
On June 27, 2007, three months after the extirpation of metastatic melanoma,
metastasis occurred in this patient again. The tumor which was extirpated on
March
20, 2007 existed in the right cervical part, and this time tumor occurred on
the
opposite side. As for the shape of the tumor, a black mass was formed
similarly to
the previous tumor. The tumor, having the size of 3.1 x 3.2 x 0.8 cm, was also
clinically diagnosed as metastasis. The serodiagnosis was carried out again to
find
that the absorbance at 450 nm increased to 0.19, which indicated that it was
metastatic tumor.
[0189]
(2)-7 Therapy Monitoring
Canine Patient 11 (Miniature Dachshund) underwent tumor extirpation on
April 19, 2007. According to the pathological diagnosis using the extirpated
tumor,
the patient was suffering from moderately-malignant combined mammary
adenocarcinoma with a high probability of invasive and metastatic development.
The serodiagnosis was carried out at that time to find that the absorbance at
450 nm
was 0.30. On June 3, 2008, about 1 year after the extirpation, the
serodiagnosis was
carried out to find that the absorbance at 450 nm decreased to 0.25. Although
any
recurrent tumors were not found with the naked eye, an anticancer drug
(INTERCAT) was administered once-weekly for 2 months to prevent recurrence.
The serodiagnosis was carried out 2, 4, and 6 weeks after the administration
of the
anticancer drug started to reveal that the absorbance at 450 nm was 0.25, 0.19
and
0.19, respectively. These results obtained in Canine Patient 11 confirmed that
the
value becomes lower than that detected in a cancer-bearing state if tumors can
be
completely removed, as well as that the value does not increase if anticancer
drug
treatment successfully prevents cancer metastasis, and thus change in treated
patients
can be followed. In addition, the diagnosis of recurrence can also be carried
out as
shown in Canine Patient 8, which confirms that the therapy monitoring can also
be
CA 02703356 2010-04-22
97
made possible.
[0190]
(2)-8 Diagnosis of Malignancy of Recurrent Tumor
Canine Patient 12 (Chihuahua) underwent tumor extirpation on April 27,
2007. According to the pathological diagnosis using the extirpated tumor, this
patient was suffering from ductal carcinoma originated from mammary ductal
epithelium, i.e., malignant breast cancer. On June 29, 2008, about 1 year
thereafter,
tumor was found again and extirpated. According to the pathological diagnosis
using the extirpated tumor, although tumor cells which were originated from
mammary ductal epithelium formed irregular glandular cavities and developed to
reduplicate toward the lumens, the constituting cells had an almost uniformly
egg-
shaped nucleus and atypism of the cells was low, and therefore the tumor was
diagnosed as benign mammary adenocarcinoma. The serodiagnosis was carried out
but the absorbance at 450 nm was 0, not detected at all. The results observed
in
Canine Patients 8 and 12 revealed that the value of the serodiagnosis does not
decrease or is sustained in cases where the recurrent tumor is malignant, and
is not
detected in cases where the tumor is benign.
[0191]
(2)-9 Prognosis of Canine Patient Bearing Benign Tumor
Canine Patient 13 (Toy Poodle) underwent tumor extirpation on October 9,
2007. According to the pathological diagnosis using the extirpated tumor,
mammary epithelial cells and myoepithelial cells were both proliferated to
form the
=
tumor, but both of them did not show any malignant findings, and therefore it
was
diagnosed as benign mixed tumor. The serodiagnosis showed the result that the
absorbance at 450 nm was 0.13, slightly detected. On June 5, 2008, 8 months
thereafter, a blood sample was collected again and the serodiagnosis was
carried out
to find that the absorbance at 450 urn was 0, not detected at all. Recurrence
was not
CA 02703356 2010-04-22
98
found clinically at that time. These results confirmed that, even in the case
where
tumor is benign, complete removal of the tumor results in the decreased value
in
serodiagnosis if a detectable value can be observed in cancer-bearing state,
and thus
prognosis can be attained.
[0192]
(3) Diagnosis in Cats
Next, cancer-bearing cats and healthy cats were diagnosed. Using the
above-described canine calmegin protein and anti-cat IgG antibody, the IgG
antibody
titer of feline serum which specifically reacts with the polypeptide was
measured in
the same manner as described above. As a secondary antibody, HRP-conjugated
anti-cat IgG antibody (PEROXIDASE-CONJUGATED GOAT IgG FRACTION TO
CAT IgG (WHOLE MOLECULE): manufactured by CAPPEL RESERCH
REAGENTS) 8,000-fold diluted with the blocking solution was used.
[0193]
Feline Patient 1 (Chinchilla) underwent tumor extirpation of mammary
adenocarcinoma on August 17, 2005. The absorbance at 450 nm was 0.22. In
Feline Patient 2 (Himalayan), which underwent extirpation of ductal carcinoma
on
October 17, 2006, the absorbance at 450 nm was 0.21. On the other hand, the
absorbance was not detected in healthy cats at all.
0194]
Thus, similarly to dogs, the absorbance value was detected in samples from
cats suffering from cancer, while the absorbance value was not detected at all
in
samples from healthy cats. Hence, similarly to dogs, cancers in cats can also
be
diagnosed by this method using a canine calmegin protein.
[0195]
(4) Diagnosis in Healthy Human
Using the above-described canine calmegin protein and anti-human IgG
CA 02703356 2010-04-22
99
antibody above, the IgG antibody titer of healthy human serum which
specifically
reacts with the protein was measured in the same manner as described above. As
a
secondary antibody, HRP-conjugated anti-human IgG antibody (HRP-Goat
Anti-
Human IgG(H+L) Conjugate: manufactured by Zymed Laboratories) 10,000-fold
diluted with the blocking solution was used. As a positive control, an
immobilized
ovalbumin antigen prepared by immobilizing 50 pg/m1 ovalbumin in phosphate
buffered saline on a solid phase was used. As a result, in Healthy Human 1,
the
absorbance at 450 nm observed on an ovalbumin antigen was 0.25, while the
absorbance at 450 nm observed on the recombinant protein was 0.03, hardly
detected.
[0196]
Example B-4: Cancer Diagnosis Using Human Calmegin Protein
Using the human calmegin protein prepared in Example B-2, the IgG
antibody titer of human, canine and feline sera which react with the protein
was
measured in the same manner as in Example B-3.
[0197]
The diagnosis was carried out using healthy human serum. In the same
manner as in Example B-3 (4), ovalbumin antigen was used as a positive
control.
As a result, the absorbance value was detected in the case where ovalbumin was
immobilized on a solid phase, while the absorbance value was hardly detected
in the
case where a human calmegin protein was immobilized on a solid phase.
[0198]
Similarly, in healthy dogs and cats, the absorbance at 450 nm was hardly
detected in the case where the protein was immobilized on a solid phase.
[0199]
On the other hand, Canine Patient 12 (Shih Tzu) underwent extirpation of
mammary adenocarcinoma on June 21, 2007. According to the pathological
diagnosis using the extirpated tissue, the mammary gland tissue contained
highly
CA 02703356 2010-04-22
100
atypical, invasive cells, and grew to form adenomatous hyperplasia showing
large
and small massive structures. Hence, this patient was diagnosed as malignant
tumor.
In this Canine Patient 12, the absorbance at 450 nm was 0.70. The malignancy
diagnosis was carried out using additional 310 serum samples which had been
diagnosed as malignant based on the pathological diagnosis. As a result, by
diagnosing a sample showing twice the average value of healthy canine samples
as
malignant, 171 samples i.e. 55.0% of the malignant cases could be successfully
diagnosed as malignant. Moreover, in Feline Patient 3 (Mixed Breed), which
underwent extirpation of mammary adenocarcinoma on April 3, 2007, the
absorbance
at 450 nm was 0.38.
[0200]
The above described results indicates that the diagnosis can be similarly
attained in humans, dogs and cats even by using a human calmegin protein.
[0201]
Furthermore, pleural effusion and ascites samples collected from terminal
cancer dogs were subjected to the diagnosis using the recombinant human
protein in
the same manner as the recombinant canine protein. As a result, values similar
to
those detected in serum samples could be detected, and hence cancer diagnosis
could
be successfully attained.
[0202]
Example B-5: Cancer Diagnosis by Measuring Antigen Polypeptide (1)
Mice and rabbits were immunized with the recombinant canine protein
prepared in Example B-2 to obtain an antibody specific to this antigen. Using
this
polyclonal antibody, detection of the antigen polypeptide per se contained in
the
serum from cancer bearing living body was carried out by sandwich ELISA. Using
anti-mouse IgG antibody, the amount of the protein in the serum which
specifically
reacts with the prepared polyclonal antibody specific to the protein was
measured by
CA 02703356 2010-04-22
101
sandwich ELISA.
[0203]
As for immobilization of a primary antibody on a solid phase, 100 L/well of
the rabbit antiserum 20-fold diluted with phosphate buffered saline was added
to a
96-well Immobilizer Amino plate (manufactured by Nunc), and the plate was
shaken
at room temperature for 2 hours. As for blocking, 100 L/well of 50 mM sodium
bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour. To
the plate, 100 L/well of the serum from cancer-bearing body diluted with the
blocking solution was added, and the plate was shaken at room temperature for
3
hours to allow the reaction to proceed. As for the diluted serum, a 10-fold
serial
dilution ranging 10 to 1,000-fold was prepared. After washing the wells 3
times
with phosphate buffered saline containing 0.05% Tween20 (manufactured by Wako
Pure Chemicals) (hereinafter referred to as PBS-T), 100 L/well of mouse
antiserum
200-fold diluted with the blocking solution was added thereto, and the plate
was
shaken at room temperature for 1 hour to allow the reaction to proceed. After
washing the wells 3 times with PBS-T, 100 L/well of HRP-conjugated mouse IgG
antibody (Stabilized Goat Anti Mouse HRP conjugated : manufactured by PIERCE)
2000-fold diluted with the blocking solution was added thereto as a tertiary
antibody,
and the plate was shaken at room temperature for 1 hour to allow the reaction
to
proceed. After washing the wells 3 times with PBS-T, 100 l/well of a HRP
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 l/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
CA 02703356 2010-04-22
102
reader. As a control, a plate on which the rabbit antiserum was not
immobilized
and a plate with which serum from a cancer-bearing body was not reacted were
measured in the same manner as described above.
[0204]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody prepared by using the
recombinant
canine polypeptide as an immunogen.
[0205]
Example B-6: Cancer Diagnosis by Measuring Antigen Polypeptide (2)
Mice and rabbits were immunized with the recombinant human protein
prepared in Example B-2 to obtain an antibody specific to this antigen. In the
same
manner as in Example B-5, detection of the antigen polypeptide per se
contained in
the serum from cancer-bearing body was carried out by sandwich ELISA using
this
polyclonal antibody.
[0206]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody prepared by using the
recombinant
human polypeptide as an immunogen.
[0207]
Example C-1: Acquisition of Novel Cancer Antigen Protein by SEREX Method
(1) Preparation of cDNA Library
CA 02703356 2010-04-22
103
Total RNA was prepared from testis tissue of a healthy dog by the Acid
guanidium-Phenol-Chloroform method, and poly(A) RNA was purified using
Oligotex-dT30 mRNA purification Kit (manufactured by Takara Shuzo Co., Ltd.)
in
accordance with the protocol attached to the kit.
[0208]
Using the obtained mRNA (5 tg), a dog testis cDNA phage library was
synthesized. Preparation of the cDNA phage library was carried out using cDNA
Synthesis Kit, ZAP-cDNA Synthesis Kit, and ZAP-cDNA Gigapack III Gold Cloning
Kit (manufactured by STRATAGENE) in accordance with the protocols attached to
the kits. The size of the prepared cDNA phage library was 1.3 x 106 pfithnl.
[0209]
(2) Screening of cDNA Library with Serum
Using the dog testis-derived cDNA phage library prepared as described above,
immunoscreening was carried out. More particularly, host E. coil cells (XL1-
Blue
MRF') were infected with the library such that 2,340 clones should appear on
an
NZY agarose plate having the size of 090 x 15 mm, and cultured at 42 C for 3
to 4
hours to allow the phage to form plaques. The plate was covered with
nitrocellulose
membrane (Hybond C Extra: manufactured by GE Healthcare Bio-Science)
impregnated with IPTG (isopropyl-p-D-thiogalactoside) at 37 C for 4 hours to
induce
and express proteins, which were thus transferred to the membrane.
Subsequently,
the membrane was recovered and soaked in TBS (10 mM Tris-HCl, 150 mM NaCl;
pH 7.5) containing 0.5% non-fat dry milk, followed by shaking it at 4 C
overnight to
suppress non-specific reactions. This filter was allowed to react with 500-
fold
diluted canine patient serum at room temperature for 2 to 3 hours.
[0210]
As the above-described canine patient serum, serum collected from canine
patients suffering from squamous cell carcinoma was used. The serum was stored
CA 02703356 2010-04-22
104
at -80 C and pretreated immediately before use. The method of the pretreatment
of
the serum was as follows. That is, host E. coli cells (XL1-Blue MRF') were
infected
with X ZAP Express phage to which no foreign gene was inserted, and then
cultured
on NZY plate medium at 37 C overnight. Subsequently, the buffer of 0.2 M
NaHCO3, pH 8.3 containing 0.5 M NaC1 was added to the plate, and the plate was
left to stand at 4 C for 15 hours, followed by collecting the supernatant as
an E.
coli/phage extract. Thereafter, the collected E. coli/phage extract was
allowed to
flow through an NHS column (manufactured by GE Healthcare Bio-Science) to
immobilize proteins derived from the E. coli/phage thereon. The serum from the
canine patients was allowed to flow through and react with this protein-
immobilized
column to remove antibodies adsorbed on E. coli and/or the phage. The serum
fraction that passed through the column was 500-fold diluted with TBS
containing
0.5% non-fat dry milk, and the resulting diluent was used as the material for
the
immunoscreening.
[0211]
The membrane on which the thus treated serum and the above-described
fusion protein were blotted was washed 4 times with TBS-T (0.05% Tween
20/TBS),
and allowed to react with goat anti-dog IgG (Goat anti Dog IgG-h+I HRP
conjugated:
manufactured by BETHYL Laboratories) 5,000-fold diluted with TBS containing
0.5% non-fat dry milk as a secondary antibody at room temperature for 1 hour,
followed by detection by the enzyme coloring reaction using the NBT/BCIP
reaction
solution (manufactured by Roche). Colonies at positions where a positive
coloring
reaction was observed were recovered from the NZY agarose plate having the
size of
1190 x 15 mm, and dissolved in 500111 of SM buffer (100 mM NaC1, 10 mM
MgC1SO4, 50 mM Tris-HC1, 0.01% gelatin; pH 7.5). The screening was repeated as
a second and third screening in the same manner as described above until a
single
coloring reaction-positive colony was obtained, thereby isolating one positive
clone
CA 02703356 2010-04-22
105
after screening of 30,940 phage clones reactive with IgG in the serum.
[0212]
(3) Homology Search of Isolated Antigen Gene
To subject the single positive clone isolated by the above-described method to
a base sequence analysis, an operation of conversion of the phage vector to a
plasmid
vector was carried out. More particularly, 200 1 of a solution prepared to
contain a
host E. coil (XL1-Blue MRF') such that the absorbance 0D600 should be 1.0 was
mixed with 100 1 of a purified phage solution and further with 1 I of
ExAssist
helper phage (manufactured by STRATAGENE), and the reaction was allowed to
proceed at 37 C for 15 minutes. To the reaction mixture, 3 ml of LB medium was
added, and the mixture was cultured at 37 C for 2.5 to 3 hours, followed by
immediate incubation in a water bath at 70 C for 20 minutes. The mixture was
then
centrifuged at 4 C at 1,000 xg for 15 minutes, and the supernatant was
recovered as a
phagemid solution. Subsequently, 200 1 of a solution prepared to contain a
phagemid host E. coil (SOLR) such that the absorbance 0D600 should be 1.0 was
mixed with 10 I of a purified phage solution, and the reaction was allowed to
proceed at 37 C for 15 minutes. Thereafter, 50 1 of the reaction mixture was
plated on ampicillin (final concentration: 50 g/m1)-containing LB agar
medium, and
cultured at 37 C overnight. A single colony of transformed SOLR was recovered
and cultured in ampicillin (final concentration: 50 g/m1)-containing LB
medium at
37 C, followed by purification of plasmid DNA having an insert of interest
using
QIAGEN plasmid Miniprep Kit (manufactured by Qiagen).
[0213]
The purified plasmid was subjected to an analysis of the entire sequence of
the insert by the primer walking method using the T3 primer described in SEQ
ID
NO:5 and the T7 primer described in SEQ ID NO:6. By this sequence analysis,
the
gene sequence described in SEQ ID NO:25 was obtained. Using the base sequence
CA 02703356 2010-04-22
106
and the amino acid sequence of this gene, homology search against known genes
was
carried out using a homology search program BLAST
(http://www.ncbi.nlm.nih.gov/BLAST/). As a result, it was revealed that the
obtained gene has 99% homology (which was calculated only in the overlapping
region) to the registered CEP gene described in SEQ ID NO :41 in terms of base
sequence and amino acid sequence, so that the gene was judged as the CEP gene.
The obtained human homologous factor of the canine CEP was human CEP
(homology to the CEP gene described in SEQ ID NO:25: base sequence, 87%; amino
acid sequence, 84%). The base sequence of human CEP is shown in SEQ ID
NO:27, and the amino acid sequence thereof is shown in SEQ ID NO:28.
[0214]
(4) Analysis of Expression in Each Tissue
The expression of the gene, which was obtained by the above-described
method, in normal tissues and various cell lines of dog and human were
investigated
by the RT-PCR (Reverse Transcription-PCR) method. The reverse transcription
reaction was carried out as follows. That is, total RNA was extracted from 50
to
100 mg of each tissue or 5 to 10 x 106 cells of each cell line using TRIZOL
reagent
(manufactured by Invitrogen) in accordance with the protocol attached to the
kit.
Using this total RNA, cDNA was synthesized by Superscript First-Strand
Synthesis
System for RT-PCR (manufactured by Invitrogen) in accordance with the protocol
attached to the kit. As the cDNAs from human normal tissues (brain,
hippocampus,
= testis, colon and placenta), Gene Pool cDNA (manufactured by Invitrogen),
QUICK-
Clone cDNA (manufactured by CLONTECH) and Large-Insert cDNA Library
(manufactured by CLONTECH) were used. The PCR reactions were carried out as
follows using primers (described in SEQ ID NOs:29 and 30) specific to the
obtained
gene. That is, respective reagents and the attached buffer were mixed such
that the
mixture should contain 0.25 l of the sample prepared by the reverse
transcription
CA 02703356 2010-04-22
107
reaction, 2 pM each of the above primers, 0.2 mM each of dNTP and 0.65 U of
ExTaq polymerase (manufactured by Takara Shuzo Co., Ltd.) in a total volume of
25
1.11, and the reaction was carried out with 30 cycles of 94 C for 30 seconds,
55 C for
30 seconds and 72 C for 30 seconds using Thermal Cycler (manufactured by BIO
RAD). The above-described gene-specific primers were those which amplify the
regions of the 4582nd to 5124th bases of the base sequences of SEQ ID NOs:25
and
41 (canine CEP gene) and the 4610th to 5152nd bases of the base sequence of
SEQ
ID NO:27 (human CEP gene), and can be used for investigation of the expression
of
both the canine CEP gene and the human CEP gene. As a control for comparison,
primers (described in SEQ ID NOs:9 and 10) specific to GAPDH were used
simultaneously. As a result, as shown in Fig. 9, strong expression of the
canine
CEP gene was observed in testis among the normal dog tissues, and on the other
hand, strong expression was observed in the canine breast cancer cell line.
Expression of the human CEP gene was confirmed, as is the case with the canine
CEP gene, only in testis among the human normal tissues, but the expression
was
detected in brain tumor, leukemia and esophagus cancer cells among human
cancer
cell lines, and especially, strong expression was observed in the leukemia
cell line.
Thus, the human CEP gene was also confirmed to be specifically expressed in
testis
and cancer cells.
[0215]
In Fig. 9, reference numeral 1 in the ordinate indicates the expression
pattern
of the CEP gene, and reference numeral 2 indicates the expression pattern of
the
GAPDH gene as a control for comparison.
[0216]
Example C-2: Preparation of Polypeptides Derived from Canine and Human CEPs
(1) Preparation of Recombinant Protein
Based on the gene of SEQ ID NO:25 obtained in Example C-1, a recombinant
CA 02703356 2010-04-22
108
protein was prepared by the following method. Respective reagents and the
attached buffer were mixed such that the mixture should contain 1 I of the
vector
that was prepared from the phagemid solution obtained in Example C-1 and was
subjected to the sequence analysis, 0.4 ttM each of two kinds of primers
having
BamHI and Sall restriction sites (described in SEQ ID NOs:31 and 32), 0.2 mM
dNTP and 1.25 U of PrimeSTAR HS polymerase (manufactured by Takara Shuzo
Co., Ltd.) in a total volume of 50 1, and PCR was carried out with 30 cycles
of 98 C
for 10 seconds, 55 C for 5 seconds and 72 C for 7 minutes using Thermal Cycler
(manufactured by BIO RAD). Using the above-described two kinds of primers, a
region encoding an amino acid region (SEQ ID NO:35) of 1514th to 2339th amino
acids of SEQ ID NO:26 is obtained. After the PCR, the amplified DNA was
subjected to electrophoresis using 1% agarose gel, and a DNA fragment of about
2.5
kbp was purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0217]
In the same manner, PCR was carried out using two kinds of primers
described in SEQ ID NOs:37 and 38 to obtain the region encoding the entire
amino
acid sequence of SEQ ID NO:26. After the PCR, the amplified DNA was subjected
to electrophoresis using 1% agarose gel, and a DNA fragment of about 7.0 kbp
was
purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0218]
Moreover, PCR was carried out using two kinds of primers described in SEQ
ID NOs:37 and 43 to obtain the region encoding the entire amino acid sequence
of
SEQ ID NO:42. After the PCR, the amplified DNA was subjected to
electrophoresis using 1% agarose gel, and a DNA fragment of about 7.8 kbp was
purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0219]
Each of the purified DNA fragments was ligated into a cloning vector pCR-
CA 02703356 2010-04-22
109
Blunt (manufactured by Invitrogen). E. coli was transformed with the resulting
ligation product, and plasmids were recovered thereafter, followed by
confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
BamHI and Sall and purified using QIAquick Gel Extraction Kit, followed by
inserting the gene sequence of interest into an expression vector for E. coil,
pET30a
(manufactured by Novagen) that had been treated with BamHI and Sall. Usage of
this vector enables production of a His-tag fusion recombinant protein. E.
coli for
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E coli with 1 mM IPTG.
[0220]
Further, based on the gene of SEQ ID NO:27, a recombinant protein of the
human homologous gene was prepared by the following method. Respective
reagents and the attached buffer were mixed such that the mixture should
contain 1
1 of the cDNA prepared in Example C-1 whose expression could be confirmed by
the RT-PCR method in various tissues/cells, 0.4 1.1M each of two kinds of
primers
having BamHI and Sall restriction sites (described in SEQ ID NOs:33 and 34),
0.2
mM dNTP and 1.25 U of PrimeSTAR HS polymerase (manufactured by Takara
Shuzo Co., Ltd.) in a total volume of 50 I, and PCR was carried out with 30
cycles
of 98 C for 10 seconds, 55 C for 5 seconds and 72 C for 7 minutes using
Thermal
Cycler (manufactured by BIO RAD). Using the above-described two kinds of
primers, a region encoding an amino acid region (SEQ ID NO:36) of 1513rd to
2325th amino acids of SEQ ID NO:28 is obtained. After the PCR, the amplified
DNA was subjected to electrophoresis using 1% agarose gel, and a DNA fragment
of
about 2.5 kbp was purified using QIAquick Gel Extraction Kit (manufactured by
QIAGEN).
[0221]
CA 02703356 2010-04-22
110
In the same manner, PCR was carried out using two kinds of primers
described in SEQ ID NOs:39 and 40 to obtain the region encoding the entire
amino
acid sequence of SEQ ID NO:28. After the PCR, the amplified DNA was subjected
to electrophoresis using 1% agarose gel, and a DNA fragment of about 7.0 kbp
was
purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0222]
Each of the purified DNA fragments was ligated into a cloning vector pCR-
Blunt (manufactured by Invitrogen). E, coli was transformed with the resulting
ligation product, and plasmids were recovered thereafter, followed by
confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
BamHI and Sall and purified using QIAquick Gel Extraction Kit, followed by
inserting the gene sequence of interest into an expression vector for E. coil,
pET30a
(manufactured by Novagen) that had been treated with BamHI and Sall. Usage of
this vector enables production of a His-tag fusion recombinant protein. E.
coil for
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E. coil with 1 mM IPTG.
[0223]
(2) Purification of Recombinant Protein
The above-obtained recombinant E. coil cells that expressed a part of SEQ ID
NO:26 and a part of SEQ ID NO:28, respectively, were cultured in kanamycin
(final
concentration: 30 fig/m1)-containing LB medium at 37 C until the absorbance at
600
nm reached about 0.7, and then IPTG was added thereto such that its final
concentration should be 1 mM, followed by culturing them at 30 C for 20 hours.
Subsequently, the cells were collected by centrifugation at 4,800 rpm for 10
minutes.
The pellet of the cells was suspended in phosphate-buffered saline and further
subjected to centrifugation at 4,800 rpm for 10 minutes to wash the cells.
CA 02703356 2010-04-22
111
[0224]
The cells were suspended in phosphate-buffered saline and subjected to
sonication on ice. The sonicated solution of E. coil was centrifuged at 7,000
rpm
for 20 minutes to obtain the supernatant as the soluble fraction and the
precipitate as
the insoluble fraction. The insoluble fraction was suspended in 4% Triton X-
100
solution and the resulting suspension was centrifuged at 7,000 rpm for 20
minutes.
This operation was repeated twice and an operation of removal of proteases was
carried out. The residue was suspended in 8 M urea (manufactured by Sigma
Aldrich Japan)-containing 10 mM Tris-HC1, 100 mM phosphate buffer (hereinafter
referred to as 8 M urea solution) and a protease inhibitor cocktail solution,
and the
resulting suspension was left to stand at 4 C for 15 hours to denature
proteins.
[0225]
Thereafter, the suspension was centrifuged at 7,000 rpm for 20 minutes, and
the obtained soluble fraction was placed in a nickel chelate column prepared
by a
conventional method (carrier: Chelating Sepharose (trademark) Fast Flow (GE
Health Care); column volume: 5mL; equilibration buffer: 8M urea solution),
followed by leaving it to stand at 4 C overnight. The supernatant was
recovered by
centrifugation of this column carrier at 1,500 rpm for 5 minutes, and the
column
carrier was suspended in phosphate-buffered saline followed by refilling the
column
with the resulting suspension. The fraction that was not adsorbed to the
column
was washed away with 5 column volumes of 8 M urea solution, 10 column volumes
of 0.5 M sodium chloride-containing 0.1 M acetate buffer (pH 5.0) and 10 mM
imidazole-containing 20 mM phosphate buffer (pH 8.0), and elution was
immediately carried out with a five-step density gradient of 100 mM-500 mM
imidazole. Five column volumes of the eluted fraction was collected in each
elution
step. Elution of the proteins of interest was confirmed by Coomassie staining
carried out according to a conventional method. Based on the result, the
eluted
CA 02703356 2010-04-22
112
fractions were desalted and concentrated to obtain the material to be solid-
phased for
diagnosis.
[0226]
In the same manner, the recombinant E. coil cells that expressed the full-
length of SEQ ID NOs:26, 28 and 42, respectively, were cultured and the
proteins of
interest were purified to obtain the material to be solid-phased for
diagnosis.
[0227]
Example C-3: Cancer Diagnosis Using Polypeptide Derived from Canine CEP
(1) Cancer Diagnosis in Dogs
Blood samples were collected from 486 canine patients in which malignant or
benign tumors were found and 6 healthy dogs, and sera were separated
therefrom.
Using the partial polypeptide of canine CEP (SEQ ID NO:35; 1514th to 2339th
amino acid region of SEQ ID NO:26) prepared in Example C-2 and anti-dog IgG
antibody, the IgG antibody titer of the sera which specifically react with the
polypeptide was measured by ELISA.
[0228]
As for immobilization of the prepared protein on a solid phase, 100 ptL/well
of a solution of the recombinant protein diluted to 50 ttg/mL with phosphate
buffered
saline was added to a 96-well Immobilizer Amino plate (manufactured by Nunc),
and
the plate was left to stand at 4 C overnight. As for blocking, 100 iL/well of
50 mM
sodium bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour.
Serum sample was 500-fold diluted with the blocking solution, and 100 uL/well
of
the diluted serum was added to the plate, followed by shaking the plate at
room
temperature for 3 hours to allow the reaction to proceed. After washing the
wells 3
times with phosphate buffered saline containing 0.05% Tween20 (manufactured by
CA 02703356 2010-04-22
113
Wako Pure Chemicals) (hereinafter referred to as PBS-T), 100 L/well of HRP-
conjugated dog IgG antibody (Goat anti Dog IgG-h+I HRP conjugated:
manufactured
by BETHYL Laboratories) 3,000-fold diluted with the blocking solution was
added
thereto, and the plate was shaken at room temperature for 1 hour to allow the
reaction
to proceed.. After washing the wells 3 times with PBS-T, 100 I/well of a HRP
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 l/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the prepared recombinant protein was
not
immobilized and a plate with which the serum from a cancer-bearing dog was not
reacted were measured in the same manner as above.
[0229]
Among the total 486 samples used in the above-described cancer diagnosis,
311 samples were definitely diagnosed as malignant by pathological diagnosis
using
the extirpated tumor tissue.
[0230]
Specifically, the samples were diagnosed as cancer such as malignant
melanoma; malignant mixed tumor; hepatocellular carcinoma; basal cell
carcinoma;
acanthomatous epulis; intraoral tumor; perianal adenocarcinoma; anal sac
tumor; anal
sac apocrine carcinoma; Sertoli cell tumor; vulva cancer; sebaceous
adenocarcinoma;
sebaceous epithelioma; sebaceous adenoma; sweat gland carcinoma; intranasal
adenocarcinoma; nasal adenocarcinoma; thyroid cancer; colon cancer; bronchial
adenocarcinoma; adenocarcinoma; ductal carcinoma; mammary adenocarcinoma;
combined mammary adenocarcinoma; mammary gland malignant mixed tumor;
intraductal papillary adenocarcinoma; fibrosarcoma; hemangiopericytoma;
CA 02703356 2010-04-22
114
osteosarcoma; chondrosarcoma; soft tissue sarcoma; histiocytic sarcoma;
myxosarcoma; undifferentiated sarcoma; lung cancer; mastocytoma; cutaneous
leiomyoma; intra-abdominal leiomyoma; leiomyoma; squamous cell carcinoma;
chronic lymphocytic leukemia; lymphoma; gastrointestinal lymphoma; digestive
organ lymphoma; small cell or medium cell lymphoma; adrenomedullary tumor;
granulosa cell tumor; pheoclu.omocytoma; bladder cancer (transitional cell
carcinoma); suppurative inflammation; intra-abdominal liver tumor; liver
cancer;
plasmacytoma; malignant hemangiopericytoma; angiosarcoma; anal sac
adenocarcinoma; oral cancer; metastatic malignant melanoma; amelanotic
malignant
melanoma; cutaneous malignant melanoma; malignant myoepithelioma; malignant
seminoma; seminoma; adenocarcinoma of the large intestine; gastric
adenocarcinoma; low-grade sebaceous carcinoma; ceruminous adenocarcinoma;
apocrine carcinoma; poorly differentiated apocrine sweat gland carcinoma;
malignant
fibrous histiocytoma; multiple myeloma; mesenchymal malignant tumor;
liposarcoma; osteosarcoma; sarcoma of unknown origin; soft part sarcoma
(spindle
cell tumor); poorly differentiated sarcoma; synovial sarcoma; angiosarcoma;
metastatic malignant epithelioma; tubular mammary adenocarcinoma; mammary
ductal carcinoma; inflammatory breast cancer; germinoma; leukemia; invasive
trichoepithelioma; medium cell lymphoma; multicentric lymphoma; osteosarcoma
(mammary gland); mastocytoma (Patnaik II type); mastocytoma (Grade II);
leiomyosarcoma or the like.
[0231]
As shown in Fig. 11, sera from these cancer-bearing dogs showed a
significantly high antibody titer against the recombinant protein. It was
revealed
that, by diagnosing a sample showing twice the average value of healthy canine
samples as malignant, 197 samples i.e. 63.3% of the malignant cases could be
successfully diagnosed as malignant. The details of these 197 cancer samples
are as
CA 02703356 2010-04-22
115
follows. It is noted that the following number of each cancer case is a
cumulative
total, as some samples contained multiple primaries.
Malignant melanoma, 8 cases; lymphoma, 9 cases; pheochromocytoma, 1 case;
=
suppurative inflammation, 1 case; granulosa cell tumor, 1 case; hepatocellular
carcinoma, 5 cases; angioma, 1 case; malignant testicular tumor, 6 cases;
intraoral
tumor, 5 cases; perianal adenocarcinoma, 12 cases; osteosarcoma, 4 cases;
fibrosarcoma, 8 cases; ductal carcinoma, 10 cases; chondrosarcoma, 2 cases;
mammary adenocarcinoma, 35 cases; combined mammary adenocarcinoma, 24
cases; lung cancer, 2 cases; sebaceous adenocarcinoma, 2 cases; nasal
adenocarcinoma, 2 cases; mastocytoma, 24 cases; adrenomedullary tumor, 1 case;
leiomyosarcoma, 1 case; squamous cell carcinoma, 4 cases; chronic lymphocytic
leukemia, 1 case; undifferentiated sarcoma, 1 case; malignant mixed tumor, 1
case;
tumor in the posterior segment of the left lobe of the lung, 1 case; tumor in
the right
infra-axillary region, 1 case; tumor in the elbow of the right forelimb, 1
case; bladder
cancer (transitional cell carcinoma), 1 case; metastatic malignant melanoma, 3
cases;
amelanotic malignant melanoma, 1 case; adenocarcinoma of the large intestine,
1
case; plasmacytoma, 1 case; histiocytic sarcoma, 1 case; liposarcoma, 1 case;
poorly
differentiated sarcoma, 1 case; synovial sarcoma, 1 case; malignant
hemangiopericytoma, 1 case; apocrine sweat gland carcinoma, 3 cases; bronchial
adenocarcinoma, 1 case.
[0232]
The above-described diagnostic method was also carried out using pleural
effusion samples and ascites samples collected from terminal cancer dogs. As a
result, values similar to those detected in serum samples could be detected,
and hence
cancer diagnosis could be successfully attained.
[0233]
Furthermore, it was confirmed that diagnostic approaches such as diagnosis of
CA 02703356 2010-04-22
116
cancers existing in an invisible part of the body, assessment of cancer stage
and grade,
follow-up of postoperative patients, diagnosis of recurrence and metastasis
and the
like can also be attained by applying the above-described diagnostic method.
The
followings are several of the practical examples of the detailed diagnosis
shown in
Fig. 12.
[0234]
(2)-1 Diagnosis of Invisible Tumors
In Canine Patient 1 (Flat-Coated Retriever), any tumors were not found on
June 7, 2007. But about 20 days later, on June 24, 2007, a pedunculated tumor
with
a diameter of 2 mm was found on the gum at the root of the canine tooth. The
tumor was ligated at its pedunculated part and excised on the day it found.
The
absorbance at 450 nm observed before the tumor became visible with the naked
eye
was 0.41, which was significantly high and not so different from the
absorbance at
the time of finding tumor, 0.43. The result indicates that it is possible to
diagnose
cancers even in an invisible part such as an intraperitoneal part by the
method of the
present invention.
[0235]
Rise of the value was observed before the tumor became visible with the
naked eye, which is considered to have been a sign of tumor development. Thus,
the method of the present invention is useful in medical examinations such as
periodic health examination.
[0236]
Canine Patient 1 was again checked by the serodiagnosis 2 weeks after the
tumor excision. As a result, the absorbance at 450 nm was greatly reduced to
0.06.
Thus, it was also confirmed that the cancer antigen-expressing tumor which had
caused the increased antibody titer was completely removed (see, (2)-4, Follow-
Up
of Postoperative Patients).
CA 02703356 2010-04-22
117
[0237]
(2)-2 Assessment of Stage of Cancer Progression
The stage of cancer progression is determined based on the size or depth of
the tumor, how much the tumor exerts influence on the surrounding tissues,
whether
the tumor metastasizes or not, and the like. It was revealed herein that the
detected
value is higher than before if the metastasis occurs, i.e., the cancer has
advanced.
The following is another example of a stage assessment of a certain cancer
case,
which received anticancer drug therapy.
[0238]
Canine Patient 2 (Miniature Dachshund) visited the hospital with chief
complaints of nausea and emaciation on February 21, 2007, and two massive
tumors
were found in the abdominal cavity. This patient underwent tumor extirpation
on
February 23, 2007. The swollen right kidney weighed 433 g. The neighboring
lymph node was well-vascularized and weighed 42 g. Based on the pathological
diagnosis using the extirpated tissue, the patient was diagnosed as
multicentric
malignant lymphoma. It was said that there was a probability that the tumor
cells
would spread into other organs in the abdominal cavity, as a disseminated
spread of
tumor cells was observed in the adipose tissue. The anticancer drug
administration
(Oncovin) was started postoperatively on March 1, 2007, and the serodiagnosis
was
carried out 3 times, i.e., on the day the administration was started, and 2
and 3
months thereafter. As a result, the absorbance at 450 nm was 0.15, 0.15, and
0.07,
respectively. The value had gradually decreased since the start of the
administration,
which confirmed that the anticancer drug took effect. Thus, it was confirmed
that
cancer progression could be inhibited. Hence, the results in Canine Patient 2
confirmed that the stage of cancer progression can also be assessed. In
addition, it
was confirmed that the effect of anticancer drug therapy can also be assessed
as
described above.
CA 02703356 2010-04-22
118
[0239]
(2)-3 Assessment of Grade of Cancer Malignancy
;
Basaliomas include malignant type and benign type. Recently, according to
the new WHO classification, malignant basaliomas are called basal cell
carcinoma,
and benign basaliomas are called trichoblastoma.
[0240]
Canine Patient 3 (Beagle) was diagnosed as basal cell carcinoma (malignant).
The serodiagnosis was carried out at the time of the surgery to find that the
absorbance at 450 nrn was 0.14. On the other hand, in Canine Patient 4 (Mixed
Breed) diagnosed as trichoblastoma (benign), the serodiagnosis carried out at
the
time of the surgery revealed that the absorbance at 450 nm was 0, not detected
at all.
Thus, even in the case of the same basaliomas, malignant basal cell carcinoma
and
benign trichoblastoma can be distinctively diagnosed.
[0241]
Next example is mammary gland tumors. Mammary gland tumors include
malignant tumors such as mammary adenocarcinoma and mammary gland malignant
mixed tumor, and benign mammary tumors which do not show malignant symptoms.
Canine Patient 5 (Yorkie) underwent extirpation of mammary gland malignant
mixed
tumor and mammary adenocarcinoma on May 17, 2006. In general, the complete
excision of mixed tumors in mammary gland is easy because they are poorly
invasive
to the surrounding tissues even if they are malignant, and thus the
postoperative
course of the patients is usually uneventful. However, Canine Patient 5 had
been
diagnosed as highly malignant tumor, because the pathological diagnosis using
the
extirpated tissue revealed that some components of the specimen from Canine
Patient
5 showed an invasive nature. On the other hand, mammary adenocarcinoma is a
highly invasive tumor which often recurs and metastasizes. Although invasion
of
the tumor cells was not observed in the specimen from Canine Patient 5, it had
been
CA 02703356 2010-04-22
119
pointed out that highly malignant components possibly proliferated in other
region
out of the specimen. Thus, the findings in the pathological diagnosis clearly
taught
that Canine Patient 5 was suffering from highly malignant mammary cancer. A
blood sample was collected during the surgery and the serodiagnosis was
carried out
to find that the absorbance at 450 nm was 0.77. On the other hand, Canine
Patient 6
(Yorkshire Terrier) underwent extirpation of mammary tumor on January 28,
2007.
According to the pathological diagnosis using the extirpated tissue, atypism
of cells
was low, and thus Canine Patient 6 was diagnosed as benign mastadenoma without
malignant findings. A blood sample was collected during the surgery and the
serodiagnosis was carried out to find that the absorbance at 450 inn was 0.
The
results in the two cases above revealed that highly malignant tumors show a
higher
value than low malignant, benign tumors.
[0242]
(2)-4 Follow-Up of Postoperative Patients
Canine Patient 7 (Mixed Breed) underwent extirpation of perianal adenoma in
August of 2003 and on August 9, 2006. The tumor extirpated on August 9, 2006
was clinically diagnosed as recurrence, because the similar tumor again
occurred at
the same site. The pathological diagnosis using the tissue extirpated at the
second
time revealed that tumor cells were highly invasive and atypical showing
anisokaryosis and dyskaryosis, and also that a lot of dividing nuclei were
observed.
Thus, the patient was diagnosed as malignant tumor. According to the
diagnostic
pathologist, it is necessary to pay attention to local recurrence or
metastasis which
would occur again. The serodiagnosis was carried out at that time. As a
result, the
absorbance at 450 nm was 0.43. On December 19, 2006, about 4 months after the
surgery, the serodiagnosis was carried out again on the patient in the course
of
follow-up. As a result, the absorbance at 450 nm decreased to 0.32. Neither
recurrence nor metastasis has been found till August of 2007. Thus, it is
considered
CA 02703356 2010-04-22
120
that the value obtained in the serodiagnosis became lower than that obtained
at the
time of surgery because the tumor could be completely extirpated in Canine
Patient 7.
[0243]
(2)-5 Diagnosis of Recurrence
Canine Patient 8 (Husky) underwent an extirpation of mammary
adenocarcinoma on May 8, 2007. According to the serodiagnosis carried out at
the
time of the surgery, the absorbance at 450 nm was 0.09. The pathological
diagnosis
using the extirpated tissue revealed that highly atypical epithelial cells
proliferated
and mainly formed ductal structures, and thus this patient was diagnosed as
primary
breast adenocarcinoma. It was said that the patient was at a high risk of
recurrence
or metastasis to lymph nodes or distant organs, as many cancer cells had
already
entered the lymph vessels at that time. On June 28, 2007, about I-and-a-half
month
after the surgery, metastasis was found at the same site. The serodiagnosis
was
carried out at that time to find that the value increased to 0.10. Thus, it
was
confirmed that the value detected by the serodiagnosis was higher in the end
of June
than in the beginning of May because the tumor could not have been completely
excised or recurrence would have occurred in Canine Patient 8.
[0244]
Canine Patient 9 (Sheltie) underwent extirpation of ductal carcinoma on
October 24, 2006. The serodiagnosis was carried out at that time. As a result,
the
absorbance at 450 nm was 0.02. About 3 months later, on January 31, 2007, this
patient visited the hospital because of cancer recurrence and underwent
extirpation
again. According to the pathological diagnosis using the extirpated tissue,
many
cancer cells having egg-shaped atypical nuclei invaded lymph vessels and
metastasis
was observed in the inguinal lymph node, and thus the patient was diagnosed as
ductal carcinoma (breast cancer) with a probability of distant metastasis. The
serodiagnosis was carried out at that time to find that the absorbance at 450
nm
CA 02703356 2010-04-22
121
increased to 0.09. Thus, similarly to above, it was confirmed that the value
of the
serodiagnosis increased 3 months later because the tumor could not have been
completely excised or recurrence of the tumor would have occurred in Canine
Patient
9.
[0245]
(2)-6 Diagnosis of Metastasis
Canine Patient 10 (Scottish Terrier), repeatedly undergoing metastasis and
recurrence, was diagnosed as mammary tumor in February of 2003; intraoral
malignant melanoma in August of 2003; malignant melanoma of the lip in January
of
2005; and as intraoral melanoma on April 13, 2005, all of which were excised
by
surgery. This patient visited the hospital again on December 17, 2006 for
follow-up
after the recurrence of intraoral melanoma in April of 2005, and the
serodiagnosis
was carried out at that time. As a result, the absorbance at 450 nm was 0.42.
Half
a year later, on June 20, 2007, the patient again visited the hospital because
of the
hypertrophy of cervical and malar lymph nodes. In the case of lymphomas,
hypertrophy of lymph nodes is systemically observed. Because Canine Patient 10
had only two swollen lymph nodes, this patient was clinically diagnosed as
probable
metastatic lymphoma. The diagnosis according to the present invention also
revealed that it was a metastatic tumor from one which had previously existed
in this
patient, as the absorbance at 450 nm greatly increased to 0.91.
[0246]
(2)-7 Therapy Monitoring
Canine Patient 12 (Mixed Breed) underwent tumor extirpation on July 27,
2007. The pathological diagnosis using the extirpated tumor revealed that
breast
cancer grew continuously in the mammary ducts. Thus, this patient was
diagnosed
as ductal carcinoma. According to the serodiagnosis carried out at that time,
the
absorbance at 450 nm was 0.24. Cancer recurrence has not been found up to this
CA 02703356 2010-04-22
122
time, i.e. 13 months after the extirpation. The serodiagnosis was again
carried out
on September 3, 2007, about 1 month after the extirpation; October 12, 2007, 2
months after the extirpation; and on June 1, 2008, 10 month after the
extirpation.
As a result, the absorbance at 450 nm was 0.18, 0.18 and 0.12, respectively.
[0247]
These results obtained in Canine Patient 12 confirmed that the value becomes
lower than that detected in a cancer-bearing state if tumors can be completely
removed, as well as that the value does not increase unless cancer recurs, and
thus
change in treated patients can be followed. In addition, the diagnosis of
recurrence
can also be carried out as shown in Canine Patient 8, which confirms that the
therapy
monitoring can also be made possible.
[0248]
(2)-8 Diagnosis of Malignancy of Recurrent Tumor
Canine Patient 13 (Golden Retriever) underwent tumor extirpation on May 1,
2005. The pathological diagnosis using the extirpated tumor revealed that the
tumor
in this patient was malignant neoplastic lesion originated from mammary ductal
epithelium, i.e., malignant mammary ductal carcinoma and malignant papillary
carcinoma continuously growing through the mammary ducts. On June 28, 2008,
about 3 years thereafter, tumor was found again and thus extirpation was
carried out.
The pathological diagnosis using the extirpated tumor revealed that nothing
but
severe infiltration of inflammatory cells such as neutrophils, macrophages,
plasma
cells and the like could be observed around surgical sutures under the skin
which was
considered to be the previous surgical wound, and thus the patient was
diagnosed as
having no neoplastic lesions. According to the serodiagnosis carried out at
that time,
the absorbance at 450 nm was 0, not detected at all. The results observed in
Canine
Patients 8, 9 and 13 indicated that the value of the serodiagnosis does not
decrease or
is sustained in cases where the recurrent tumor is malignant, and is not
detected in
CA 02703356 2010-04-22
123
cases where the tumor is benign.
[0249]
(2)-9 Prognosis of Canine Patient Bearing Benign Tumor
Canine Patient 14 (Toy Poodle) underwent tumor extirpation on October 9,
2007. The pathological diagnosis using the extirpated tumor revealed that
mammary epithelial cells and myoepithelial cells were both proliferated to
form the
tumor, but that both of them did not show any malignant findings, and
therefore this
patient was diagnosed as benign mixed tumor. According to the serodiagnosis
carried out at that time, the absorbance at 450 nm was 0.05, slightly
detected. On
June 5, 2008, 8 months thereafter, a blood sample was collected again and the
serodiagnosis was carried out to find that the absorbance at 450 nm was 0, not
detected at all. Recurrence was not found clinically at that time. These
results
indicated that, even in the case where tumor is benign, complete removal of
the
tumor results in the decreased value of the serodiagnosis if a detectable
value can be
observed in cancer-bearing state, and hence prognosis can be attained.
[0250]
(3) Diagnosis in Cats
Next, cancer-bearing cats and healthy cats were diagnosed. Using the
above-described partial polypeptide of canine CEP and anti-cat IgG antibody,
the IgG
antibody titer of feline serum which specifically reacts with the polypeptide
was
measured in the same manner as described above. As a secondary antibody, HRP-
conjugated anti-cat IgG antibody (PEROXIDASE-CONJUGATED GOAT IgG
FRACTION TO CAT IgG (WHOLE MOLECULE): manufactured by CAPPEL
RESERCH REAGENTS) 8,000-fold diluted with the blocking solution was used.
[0251]
Feline Patient 1 (Chinchilla) underwent extirpation of mammary
adenocarcinoma on August 17, 2005. The absorbance at 450 nm was 0.48. In
CA 02703356 2010-04-22
124
Feline Patient 2 (Himalayan), which underwent extirpation of ductal carcinoma
on
October 17, 2006, the absorbance at 450 nm was 0.18. On the other hand, the
absorbance was not detected in healthy cats at all.
[0252]
Thus, similarly to dogs, the absorbance value was detected in samples from
cats suffering from cancer, while the absorbance value was not detected at all
in
samples from healthy cats. Hence, similarly to dogs, cancers in cats can also
be
detected by this method using a polypeptide derived from canine CEP.
[0253]
(4) Diagnosis in Healthy Human
Using the above-described partial polypeptide of canine CEP and anti-human
IgG antibody above, the IgG antibody titer of healthy human serum which
specifically reacts with the polypeptide was measured in the same manner as
described above. As a secondary antibody, HRP-conjugated anti-human IgG
antibody (HRP-Goat Anti-Human IgG(H+L) Conjugate: manufactured by Zymed
Laboratories) 10,000-fold diluted with the blocking solution was used. As a
positive control, an immobilized ovalbumin antigen prepared by immobilizing 50
vtg/m1 ovalbumin in phosphate buffered saline on a solid phase was used. As a
result, in Healthy Human 1, the absorbance at 450 nm observed on an ovalbumin
antigen was 0.25, while the absorbance at 450 nm observed on the recombinant
protein was 0.02, hardly detected. Similarly, in Healthy Human 2, the
absorbance at
450 nm observed on an ovalbumin antigen was 0.18, while the absorbance at 450
nm
observed on the recombinant protein was 0.03, hardly detected.
[0254]
Further, the diagnosis was carried out in the same manner as described above
using a full-length canine CEP having the sequence shown in SEQ ID NO:26
prepared in Example C-2. As a result, the diagnosis can be similarly attained
in
CA 02703356 2010-04-22
125
humans, dogs and cats.
[0255]
Furthermore, the diagnosis was carried out in the same manner as described
above using a full-length canine CEP having the sequence shown in SEQ ID NO:42
prepared in Example C-2. As a result, the diagnosis can be similarly attained
in
humans, dogs and cats.
[0256]
Example C-4: Cancer Diagnosis Using Polypeptide Derived from Human CEP
Using the partial polypeptide of human CEP (SEQ ID NO:36; 1513rd to
23251h amino acid region of SEQ ID NO:28) prepared in Example C-2, the IgG
antibody titer of human, canine and feline sera which react with the
polypeptide was
measured in the same manner as in Example C-3.
[0257]
The diagnosis was carried out using healthy human serum. In the same
manner as in Example C-3 (4), ovalbumin antigen was used as a positive
control.
As a result, the absorbance value was detected in the case where ovalbumin was
immobilized on a solid phase, while the absorbance value was hardly detected
in the
case where the partial polypeptide of human CEP was immobilized on a solid
phase.
[0258]
Similarly, in healthy dogs and cats, the absorbance at 450 nm was hardly
detected in the case where the polypeptide was immobilized on a solid phase.
[0259]
On the other hand, Canine Patient 11 (Shih Tzu) underwent extirpation of
mammary adenocarcinoma on June 21, 2007. According to the pathological
diagnosis using the extirpated tissue, the mammary gland tissue contained
highly
atypical, invasive cells, and grew to form adenomatous hyperplasia showing
large
and small massive structures. Hence, this patient was diagnosed as malignant
tumor.
CA 02703356 2010-04-22
126
In Canine Patient 11, the absorbance at 450 nm was 0.33. The malignancy
diagnosis was carried out using additional 310 serum samples which had been
diagnosed as malignant by pathological diagnosis. As a result, by diagnosing a
= sample showing twice the average value of healthy canine samples as
malignant, 185
samples i.e. 59.5% of the malignant cases could be successfully diagnosed as
malignant.
[0260]
Moreover, in Feline Patient 3 (Mixed Breed), which underwent extirpation of
mammary adenocarcinoma on April 3, 2007, the absorbance at 450 nm was 0.15.
[0261]
The above described results indicated that the diagnosis can also be similarly
carried out in humans, dogs and cats by using a polypeptide derived from human
CEP.
[0262]
Furthermore, pleural effusion and ascites samples collected from terminal
cancer dogs were subjected to the diagnosis using the recombinant human
protein in
the same manner as the recombinant canine protein. As a result, values similar
to
those detected in serum samples could be detected, and hence cancer diagnosis
could
be successfully attained.
[0263]
In addition, the diagnosis was carried out in the same manner as described
above using a full-length human CEP having the sequence shown in SEQ ID NO:28
prepared in Example C-2. As a result, the diagnosis could also be similarly
carried
out in humans, dogs and cats.
[0264]
Example C-5: Cancer Diagnosis by Measuring Antigen Polypeptide (1)
Mice and rabbits were immunized with the recombinant canine protein having
CA 02703356 2010-04-22
127
the sequence shown in SEQ ID NO:35 prepared in Example C-2 to obtain an
antibody specific to this antigen. Using this polyclonal antibody, detection
of the
antigen polypeptide per se contained in the serum from cancer bearing living
body
was carried out by sandwich ELISA. Using anti-mouse IgG antibody, the amount
of
the protein in the serum which specifically reacts with the prepared
polyclonal
antibody specific to the protein was measured by sandwich ELISA.
[0265]
As for immobilization of a primary antibody on a solid phase, 100 pL/well of
the rabbit antiserum 20-fold diluted with phosphate buffered saline was added
to a
96-well Immobilizer Amino plate (manufactured by Nunc), and the plate was
shaken
at room temperature for 2 hours, As for blocking, 100 IA L/well of 50 mM
sodium
bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour. To
the plate, 100 L/well of the serum from cancer-bearing body diluted with the
blocking solution was added, and the plate was shaken at room temperature for
3
hours to allow the reaction to proceed. As for the diluted serum, a 10-fold
serial
dilution ranging 10 to 1,000-fold was prepared. After washing the wells 3
times
with phosphate buffered saline containing 0.05% Tween20 (manufactured by Wako
Pure Chemicals) (hereinafter referred to as PBS-T), 100 [tL/well of mouse
antiserum
200-fold diluted with the blocking solution was added thereto, and the plate
was
shaken at room temperature for 1 hour to allow the reaction to proceed. After
washing the wells 3 times with PBS-T, 100 uL/well of HRP-conjugated mouse IgG
antibody (Stabilized Goat Anti Mouse HRP conjugated: manufactured by PIERCE)
2,000-fold diluted with the blocking solution was added thereto as a tertiary
antibody,
and the plate was shaken at room temperature for 1 hour to allow the reaction
to
proceed. After washing the wells 3 times with PBS-T, 100 ul/well of a HRP
CA 02703356 2010-04-22
128
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 111/wel1 of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the rabbit antiserum was not
immobilized
and a plate with which serum from a cancer-bearing body was not reacted were
measured in the same manner as described above.
[0266]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody which was prepared by using
the
recombinant canine polypeptide as an immunogen.
[0267]
In addition, the diagnosis was carried out in the same manner as described
above using an antibody which was prepared by using as an immunogen the full-
length canine CEP having the sequence shown in SEQ ID NO:26 prepared in
Example C-2.
[0268]
As a result, cancers could also be diagnosed in dogs and cats by this method
in which the antigen polypeptide was detected with an antibody which was
prepared
by using a full-length canine CEP as an immunogen.
[0269]
Furthermore, the diagnosis was carried out in the same manner as described
above using an antibody which was prepared by using as an immunogen the full-
CA 02703356 2010-04-22
129
length canine CEP having the sequence shown in SEQ ID NO:42 prepared in
Example C-2.
[0270]
As a result, cancers could also be diagnosed in dogs and cats by this method
in which the antigen polypeptide was detected with an antibody which was
prepared
by using a full-length canine CEP as an immunogen.
[0271]
Example C-6: Cancer Diagnosis by Measuring Antigen Polypeptide (2)
Mice and rabbits were immunized with the recombinant human protein
having the sequence shown in SEQ ID NO:36 prepared in Example C-2 to obtain an
antibody specific to this antigen. In the same manner as in Example C-5,
detection
of the antigen polypeptide per se contained in the serum from cancer-bearing
living
body was carried out by sandwich ELISA using this polyclonal antibody.
[0272]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody prepared by using the
recombinant
human polypeptide as an immunogen.
[0273]
In addition, the diagnosis was carried out in the same manner as described
above using an antibody which was prepared by using as an immunogen the full-
length human CEP having the sequence shown in SEQ ID NO:28 prepared in
Example C-2.
[0274]
As a result, cancers could also be diagnosed in dogs and cats by this method
CA 02703356 2010-04-22
130
in which the antigen polypeptide was detected with an antibody which was
prepared
by using a full-length human CEP as an immunogen.
[0275]
Example D-1: Acquisition of Novel Cancer Antigen Protein by SEREX Method
(1) Preparation of cDNA Library
Total RNA was prepared from testis tissue of a healthy dog by the Acid
guanidiurn-Phenol-Chloroforrn method, and poly(A) RNA was purified using
Oligotex-dT30 mRNA purification Kit (manufactured by Takara Shuzo Co., Ltd.)
in
accordance with the protocol attached to the kit.
[0276]
Using the obtained mRNA (5 tg), a dog testis cDNA phage library was
synthesized. Preparation of the cDNA phage library was carried out using cDNA
Synthesis Kit, ZAP-cDNA Synthesis Kit, and ZAP-cDNA Gigapack III Gold Cloning
Kit (manufactured by STRATAGENE) in accordance with the protocols attached to
the kits. The size of the prepared cDNA phage library was 1.3 x 106 pfu/ml.
[0277]
(2) Screening of cDNA Library with Serum
Using the dog testis-derived cDNA phage library prepared as described above,
immunoscreening was carried out. More particularly, host E. coli cells (XL1-
Blue
MRF') were infected with the library such that 2,340 clones should appear on
an
NZY agarose plate having the size of 090 x 15 mm, and cultured at 42 C for 3
to 4
hours to allow the phage to form plaques. The plate was covered with
nitrocellulose
membrane (Hybond C Extra: manufactured by GE Healthcare Bio-Science)
impregnated with IPTG (isopropyl-P-D-thiogalactoside) at 37 C for 4 hours to
induce
and express proteins, which were thus transferred to the membrane.
Subsequently,
the membrane was recovered and soaked in TBS (10 mM Tris-HC1, 150 mM NaCI;
pH 7.5) containing 0.5% non-fat dry milk, followed by shaking at 4 C overnight
to
CA 02703356 2010-04-22
131
suppress non-specific reactions. This filter was allowed to react with 500-
fold
diluted canine patient serum at room temperature for 2 to 3 hours.
[0278]
As the above-described canine patient serum, serum collected from canine
patients suffering from breast cancer was used. The serum was stored at -80 C
and
pretreated immediately before use. The method of the pretreatment of the serum
was as follows. That is, host E. coli cells (XL1-Blue MRF') were infected with
X
ZAP Express phage to which no foreign gene was inserted, and then cultured on
NZY plate medium at 37 C overnight. Subsequently, the buffer of 0.2 M NaHCO3,
pH 8.3 containing 0.5 M NaC1 was added to the plate, and the plate was left to
stand
at 4 C for 15 hours, followed by collecting the supernatant as an E.
coli/phage extract.
Thereafter, the collected E. coli/phage extract was allowed to flow through an
NHS
column (manufactured by GE Healthcare Bio-Science) to immobilize proteins
derived from the E. coli/phage thereon. The serum from the canine patients was
allowed to flow through and react with this protein-immobilized column to
remove
antibodies adsorbed on E. coli and/or the phage. The serum fraction that
passed
through the column was 500-fold diluted with TBS containing 0.5% non-fat dry
milk,
and the resulting diluent was used as the material for the immunoscreening.
[0279]
The membrane on which the thus treated serum and the above-described
fusion protein were blotted was washed 4 times with TBS-T (0.05% Tween
20/TBS),
and allowed to react with goat anti-dog IgG (Goat anti Dog IgG-h+I HRP
conjugated:
manufactured by BETHYL Laboratories) 5,000-fold diluted with TBS containing
0.5% non-fat dry milk as a secondary antibody at room temperature for 1 hour,
followed by detection by the enzyme coloring reaction using the NBT/BCIP
reaction
solution (manufactured by Roche). Colonies at positions where a positive
coloring
reaction was observed were recovered from the NZY agarose plate having the
size of
CA 02703356 2010-04-22
132
090 X 15 mm, and dissolved in 500 1 of SM buffer (100 mM NaC1, 10 mM
MgC1SO4, 50 mM Tris-HC1, 0.01% gelatin; pH 7.5). The screening was repeated as
a second and third screening in the same manner as described above until a
single
= e coloring reaction-positive colony was obtained, thereby
isolating one positive clone
after screening of 30,940 phage clones reactive with IgG in the serum.
[0280]
(3) Homology Search of Isolated Antigen Gene
To subject the single positive clone isolated by the above-described method to
a base sequence analysis, an operation of conversion of the phage vector to a
plasmid
vector was carried out. More particularly, 200 t1 of a solution prepared to
contain a
host E. coil (XL1-Blue MRF') such that the absorbance 0D600 should be 1.0 was
mixed with 100 IA of a purified phage solution and further with 1 I of
ExAssist
helper phage (manufactured by STRATAGENE), and the reaction was allowed to
proceed at 37 C for 15 minutes. To the reaction mixture, 3 ml of LB medium was
added, and the mixture was cultured at 37 C for 2.5 to 3 hours, followed by
immediate incubation in a water bath at 70 C for 20 minutes. The mixture was
then
centrifuged at 4 C at 1,000 xg for 15 minutes, and the supernatant was
recovered as a
phagemid solution. Subsequently, 200 1 of a solution prepared to contain a
phagemid host E. coil (SOLR) such that the absorbance 0D600 should be 1.0 was
mixed with 10 I of a purified phage solution, and the reaction was allowed to
proceed at 37 C for 15 minutes. Thereafter, 50 I of the reaction mixture was
plated on ampicillin (final concentration: 50 g/m1)-containing LB agar
medium, and
cultured at 37 C overnight. A single colony of transformed SOLR was recovered
and cultured in ampicillin (final concentration: 50 g/m1)-containing LB
medium at
37 C, followed by purification of plasmid DNA having an insert of interest
using
QIAGEN plasmid Miniprep Kit (manufactured by Qiagen).
[0281]
CA 02703356 2010-04-22
133
The purified plasmid was subjected to an analysis of the entire sequence of
the insert by the primer walking method using the T3 primer described in SEQ
ID
NO:5 and the T7 primer described in SEQ ID NO:6. By this sequence analysis,
the
- gene sequence described in SEQ ID NO:44 was obtained. Using the base
sequence
and the amino acid sequence of this gene, homology search against known genes
was
carried out using a homology search program BLAST
(http://www.ncbi.nlm.nih.gov/BLAST/). As a result, it was revealed that the
obtained gene is the TRIP]] gene. The human homologous factor of canine
TRIP11 was human TRIP11 (homology: base sequence, 88%; amino acid sequence,
86%). The base sequence of human TRIP11 is shown in SEQ ID NO:46, and the
amino acid sequence thereof is shown in SEQ ID NO:47.
[0282]
(4) Analysis of Expression in Each Tissue
The expression of the gene, which was obtained by the above-described
method, in normal tissues and various cell lines of dog and human were
investigated
by the RT-PCR (Reverse Transcription-PCR) method. The reverse transcription
reaction was carried out as follows. That is, total RNA was extracted from 50
to
100 mg of each tissue or 5 to 10 x 106 cells of each cell line using TRIZOL
reagent
(manufactured by Invitrogen) in accordance with the protocol attached to the
kit.
Using this total RNA, cDNA was synthesized by Superscript First-Strand
Synthesis
System for RT-PCR (manufactured by Invitrogen) in accordance with the protocol
attached to the kit. As the cDNAs from human normal tissues (brain,
hippocampus,
testis, colon and placenta), Gene Pool cDNA (manufactured by Invitrogen),
QUICK-
Clone cDNA (manufactured by CLONTECH) and Large-Insert cDNA Library
(manufactured by CLONTECH) were used. The PCR reactions were carried out as
follows using primers (described in SEQ ID NOs:48 and 49) specific to the
obtained
gene. That is, respective reagents and the attached buffer were mixed such
that the
CA 02703356 2010-04-22
134
mixture should contain 0.25 p1 of the sample prepared by the reverse
transcription
reaction, 2 1.tM each of the above primers, 0.2 mM each of dNTP and 0.65 U of
ExTaq polymerase (manufactured by Takara Shuzo Co., Ltd.) in a total volume of
25
= pl, and the reaction was carried out with 30 cycles of 94 C for 30
seconds, 55 C for
30 seconds and 72 C for 1.5 minutes using Thermal Cycler (manufactured by BIO
RAD). The above-described gene-specific primers were those which amplify the
regions of the 1519th to 2957th bases of the base sequence of SEQ ID NO:44
(canine
TRIP 1 I gene) and the 1872nd to 3310th bases of the base sequence of SEQ ID
NO:46 (human TRIP 1 I gene), and can be used for investigation of the
expression of
both the canine TRIP]] gene and the human TRIP 11 gene. As a control for
comparison, primers (described in SEQ ID NOs:9 and 10) specific to GAPDH were
used simultaneously. As a result, as shown in Fig. 13, strong expression of
the
canine TRIP 1 1 gene was observed in testis among the normal dog tissues, and
on the
other hand, strong expression was observed in the canine breast cancer cell
line.
Expression of the human TRIP 1 1 gene was confirmed, as is the case with the
canine
TRIP]] gene, only in testis among the human normal tissues, but the expression
was
detected in many types of cancer cell lines such as brain tumor, leukemia,
breast
cancer, lung cancer and esophagus cancer cell lines among human cancer cell
lines.
Thus, the human TRIP]] gene was also confirmed to be specifically expressed in
testis and cancer cells.
[0283]
In Fig. 13, reference numeral 1 in the ordinate indicates the expression
pattern
of the TRIP]] gene, and reference numeral 2 indicates the expression pattern
of the
GAPDH gene as a control for comparison.
[0284]
Example D-2: Preparation of Canine and Human TRIP11 proteins
(1) Preparation of Recombinant Protein
CA 02703356 2010-04-22
135
Based on the gene of SEQ ID NO:44 obtained in Example D-1, a recombinant
protein was prepared by the following method. Respective reagents and the
;OP attached buffer were mixed such that the mixture should contain 1
1..11 of the vector
which was prepared from the phagemid solution obtained in Example D-1 and was
subjected to the sequence analysis, 0.4 tiM each of two kinds of primers
having Sall
and Xhol restriction sites (described in SEQ ID NOs:50 and 51), 0.2 mM dNTP
and
1.25 U of PrimeSTAR HS polymerase (manufactured by Takara Shuzo Co., Ltd.) in
a
total volume of 50 ill, and PCR was carried out with 30 cycles of 98 C for 10
seconds, 55 C for 5 seconds and 72 C for 6 minutes using Thermal Cycler
(manufactured by BIO RAD). Using the above-described two kinds of primers, a
region encoding an amino acid region (SEQ ID NO:54) of 237th to 1023rd amino
acids of SEQ ID NO:45 is obtained. After the PCR, the amplified DNA was
subjected to electrophoresis using 1% agarose gel, and a DNA fragment of about
2.4
kbp was purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0285]
In the same manner, PCR was carried out using two kinds of primers
described in SEQ ID NOs:56 and 57 to obtain a region encoding the entire amino
acid sequence of SEQ ID NO:45. After the PCR, the amplified DNA was subjected
to electrophoresis using 1% agarose gel, and a DNA fragment of about 6.0 kbp
was
purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0286]
Each of the purified DNA fragments was ligated into a cloning vector pCR-
Blunt (manufactured by Invitrogen). E. coli was transformed with the resulting
ligation product, and plasmids were recovered thereafter, followed by
confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
Sall and Xhol and purified using QIAquick Gel Extraction Kit, followed by
inserting
CA 02703356 2010-04-22
136
the gene sequence of interest into an expression vector for E. coil, pET30b
(manufactured by Novagen) that had been treated with Sall and XhoI. Usage of
this
vector enables production of a His-tag fusion recombinant protein. E. coil for
a. a
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E. coli with 1 mM IPTG.
[0287]
Further, based on the gene of SEQ ID NO:46, a recombinant protein of the
human homologous gene was prepared by the following method. Respective
reagents and the attached buffer were mixed such that the mixture should
contain 1
pi of the cDNA prepared in Example D-1 whose expression could be confirmed by
the RT-PCR method in various tissues/cells, 0.4 111\4 each of two kinds of
primers
having Ndel and Kpnl restriction sites (described in SEQ ID NOs:52 and 53),
0.2
mM dNTP and 1.25 U of PrimeSTAR HS polymerase (manufactured by Takara
Shuzo Co., Ltd.) in a total volume of 50 iil, and PCR was carried out with 30
cycles
of 98 C for 10 seconds, 55 C for 5 seconds and 72 C for 6 minutes using
Thermal
Cycler (manufactured by BIO RAD). Using the above-described two kinds of
primers, a region encoding an amino acid region (SEQ ID NO:55) of 236th to
1023rd
amino acids of SEQ ID NO:47 is obtained. After the PCR, the amplified DNA was
subjected to electrophoresis using 1% agarose gel, and a DNA fragment of about
2.4
kbp was purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0288]
In the same manner, PCR was carried out using two kinds of primers
described in SEQ ID NOs:58 and 59 to obtain a region encoding the entire amino
acid sequence of SEQ ID NO:47. After the PCR, the amplified DNA was subjected
to electrophoresis using 1% agarose gel, and a DNA fragment of about 6.0 kbp
was
purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
[0289]
CA 02703356 2010-04-22
137
Each of the purified DNA fragments was ligated into a cloning vector pCR-
Blunt (manufactured by Invitrogen). E. coli was transformed with the resulting
ligation product, and plasmids were recovered thereafter, followed by
confirming, by
sequencing, that the amplified gene fragment matches the sequence of interest.
The
plasmid that matched the sequence of interest was treated with restriction
enzymes
Ndel and Kpnl and purified using QIAquick Gel Extraction Kit, followed by
inserting
the gene sequence of interest into an expression vector for E. coli, pET30b
(manufactured by Novagen) that had been treated with Ndel and Kpnl. Usage of
this vector enables production of a His-tag fusion recombinant protein. E.
coli for
expression, BL21 (DE3), was transformed with this plasmid, and expression of
the
protein of interest was induced in E. coli with 1 mM IPTG.
[0290]
(2) Purification of Recombinant Proteins
The above-obtained recombinant E. coli cells that expressed a part of SEQ ID
NO:44 and a part of SEQ ID NO:46, respectively, were cultured in kanamycin
(final
concentration: 30 g/ml)-containing LB medium at 37 C until the absorbance at
600
nm reached about 0.7, and then IPTG was added thereto such that its final
concentration should be 1 mM, followed by culturing them at 30 C for 20 hours.
Subsequently, the cells were collected by centrifugation at 4,800 rpm for 10
minutes.
The pellet of the cells was suspended in phosphate-buffered saline and further
subjected to centrifugation at 4,800 rpm for 10 minutes to wash the cells.
[0291]
The cells were suspended in phosphate-buffered saline and subjected to
sonication on ice. The sonicated solution of E. coli was centrifuged at 7,000
rpm
for 15 minutes to obtain the supernatant as the soluble fraction and the
precipitate as
the insoluble fraction.
[0292]
CA 02703356 2010-04-22
138
The insoluble fraction was suspended in 4% Triton X-100 solution and the
resulting suspension was centrifuged at 7,000 rpm for 10 minutes. This
operation
was repeated twice and an operation of removal of proteases was carried out.
, =
Thereafter, the residue was suspended in phosphate-buffered saline and an
operation
of removal of the surfactant was carried out.
[0293]
The residue was suspended in 6M guanidine hydrochloride (manufactured by
Sigma Aldrich Japan)-containing 20 mM phosphate buffer (pH 8.0), and the
resulting
suspension was left to stand at 4 C for 15 hours to denature proteins.
Thereafter,
the suspension was centrifuged at 7,000 rpm for 20 minutes, and the obtained
soluble
fraction was placed in a nickel chelate column prepared by a conventional
method
(carrier: Chelating Sepharose (trademark) Fast Flow (GE Health Care); column
volume: 5mL; equilibration buffer: 6M guanidine hydrochloride-containing 20 mM
phosphate buffer (pH 8.0)). The fraction that was not adsorbed to the column
was
washed away with 10 column volumes of 6 M sodium chloride-containing 20 mM
phosphate buffer (pH 8.0) and 10 mM imidazole-containing 20 mM phosphate
buffer
(pH 8.0), and elution was immediately carried out with a four-step density
gradient of
50 mM-500 mM imidazole. Five column volumes of the eluted fractions was
collected in each elution step. Elution of the proteins of interest was
confirmed by
Coomassie staining carried out according to a conventional method. Based on
the
result, the eluted fractions were desalted and concentrated to obtain the
material to be
solid-phased for diagnosis.
[0294]
In the same manner, the recombinant E. coli cells that expressed the full-
length of SEQ ID NOs:45 and 47, respectively, were cultured, and the proteins
of
interest were purified to obtain the material to be solid-phased for
diagnosis.
[0295]
CA 02703356 2010-04-22
139
Example D-3: Cancer Diagnosis Using Polypeptide Derived from Canine TRIP11
(1) Cancer Diagnosis in Dogs
Blood samples were collected from 486 canine patients in which malignant or
benign tumors were found and 6 healthy dogs, and sera were separated
therefrom.
Using the partial polypeptide of canine TRIP11 (SEQ ID NO:54; 237th to 1023rd
amino acid region of SEQ ID NO:45) prepared in Example D-2 and anti-dog IgG
antibody, the IgG antibody titer of the sera which specifically react with the
polypeptide was measured by ELISA.
[0296]
As for immobilization of the prepared protein on a solid phase, 100 A/well
of a solution of the recombinant protein diluted to 50 jag/mL with phosphate
buffered
saline was added to a 96-well Immobilizer Amino plate (manufactured by Nunc),
and
the plate was left to stand at 4 C overnight. As for blocking, 100 4/well of
50 mM
sodium bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour.
Serum sample was 1,000-fold diluted with the blocking solution, and 100
L/well of
the diluted serum was added to the plate, followed by shaking the plate at
room
temperature for 3 hours to allow the reaction to proceed. After washing the
wells 3
times with phosphate buffered saline containing 0.05% Tween20 (manufactured by
Wako Pure Chemicals) (hereinafter referred to as PBS-T), 100 p,L/well of HRP-
conjugated dog IgG antibody (Goat anti Dog IgG-h+I HRP conjugated:
manufactured
by BETHYL Laboratories) 3,000-fold diluted with the blocking solution was
added
thereto, and the plate was shaken at room temperature for 1 hour to allow the
reaction
to proceed. After washing the wells 3 times with PBS-T, 100 p1/well of a HRP
substrate, TMB (1-Step Turbo TMB (tetrarnethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
CA 02703356 2010-04-22
140
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 p1/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the prepared recombinant protein was
not
immobilized and a plate with which the serum from a cancer-bearing dog was not
reacted were measured in the same manner as above.
[0297]
Among the total 486 samples used in the above-described cancer diagnosis,
311 samples were definitely diagnosed as malignant by pathological diagnosis
using
the extirpated tumor tissue.
[0298]
Specifically, the samples were diagnosed as cancer such as malignant
melanoma; malignant mixed tumor; hepatocellular carcinoma; basal cell
carcinoma;
acanthomatous epulis; intraoral tumor; perianal adenocarcinoma; anal sac
tumor; anal
sac apocrine carcinoma; Sertoli cell tumor; vulva cancer; sebaceous
adenocarcinoma;
sebaceous epithelioma; sebaceous adenoma; sweat gland carcinoma; intranasal
adenocarcinoma; nasal adenocarcinoma; thyroid cancer; colon cancer; bronchial
adenocarcinoma; adenocarcinoma; ductal carcinoma; mammary adenocarcinoma;
combined mammary adenocarcinoma; mammary gland malignant mixed tumor;
intraductal papillary adenocarcinoma; fibrosarcoma; hemangiopericytoma;
osteosarcoma; chondrosarcoma; soft tissue sarcoma; histiocytic sarcoma;
myxosarcoma; undifferentiated sarcoma; lung cancer; mastocytoma; cutaneous
leiomyoma; intra-abdominal leiomyoma; leiomyoma; squamous cell carcinoma;
chronic lymphocytic leukemia; lymphoma; gastrointestinal lymphoma; digestive
organ lymphoma; small cell or medium cell lymphoma; adrenomedullary tumor;
granulosa cell tumor; pheochromocytoma; bladder cancer (transitional cell
carcinoma); suppurative inflammation; intra-abdominal liver tumor; liver
cancer;
CA 02703356 2010-04-22
141
plasmacytoma; malignant hemangiopericytoma; angiosarcoma; anal sac
adenocarcinoma; oral cancer; metastatic malignant melanoma; amelanotic
malignant
melanoma; cutaneous malignant melanoma; malignant myoepithelioma; malignant
= seminoma; seminoma; adenocarcinoma of the large intestine; gastric
adenocarcinoma; low-grade sebaceous carcinoma; ceruminous adenocarcinoma;
apocrine carcinoma; poorly differentiated apocrine sweat gland carcinoma;
malignant
fibrous histiocytoma; multiple myeloma; mesenchymal malignant tumor;
liposarcoma; osteosarcoma; sarcoma of unknown origin; soft part sarcoma
(spindle
cell tumor); poorly differentiated sarcoma; synovial sarcoma; angiosarcoma;
metastatic malignant epithelioma; tubular mammary adenocarcinoma; mammary
ductal carcinoma; inflammatory breast cancer; germinoma; leukemia; invasive
trichoepithelioma; medium cell lymphoma; multicentric lymphoma; osteosarcoma
(mammary gland); mastocytoma (Patnaik II type); mastocytoma (Grade II);
leiomyosarcoma or the like.
[0299]
As shown in Fig. 15, sera from these cancer-bearing dogs showed a
significantly high antibody titer against the recombinant protein. It was
revealed
that, by diagnosing a sample showing twice the average value of healthy canine
samples as malignant, 78 samples i.e. 25.1% of the malignant cases could be
successfully diagnosed as malignant. The details of these 78 cancer samples
are as
follows. It is noted that the following number of each cancer case is a
cumulative
total, as some samples contained multiple primaries.
Malignant melanoma, 4 cases; lymphoma, 5 cases; suppurative inflammation, 1
case;
granulosa cell tumor, 1 case; hepatocellular carcinoma, 2 cases; malignant
testicular
tumor, 2 cases; intraoral tumor, 3 cases; perianal adenoma, 5 cases;
osteosarcoma, 2
cases; ductal carcinoma, 6 cases; mammary adenocarcinoma, 16 cases; combined
mammary adenocarcinoma, 8 cases; lung cancer, 1 case; sebaceous
adenocarcinoma,
CA 02703356 2010-04-22
142
2 cases; mastocytoma, 6 cases; leiomyosarcoma, 2 cases; squamous cell
carcinoma, 4
cases; malignant mixed tumor, 1 case; metastatic malignant melanoma, 1 case;
mammary ductal carcinoma, 1 case; apocrine carcinoma, 1 case; gastric
adenocarcinoma, 1 case; multicentric lymphoma, 1 case; seminoma, 1 case;
plasmacytoma, 1 case.
[0300]
The above-described diagnostic method was also carried out using pleural
effusion samples and ascites samples collected from terminal cancer dogs. As a
result, values similar to those detected in serum samples could be detected,
and hence
cancer diagnosis could be successfully attained.
[0301]
Furthermore, it was confirmed that diagnostic approaches such as diagnosis of
cancers existing in an invisible part of the body, assessment of cancer stage
and grade,
follow-up of postoperative patients, diagnosis of recurrence and metastasis
and the
like can also be attained by applying the above-described diagnostic method.
The
followings are several of the practical examples of the detailed diagnosis
shown in
Fig. 4.
[0302]
(2)-1 Diagnosis of Invisible Tumors
In Canine Patient 1 (Flat-Coated Retriever), any tumors were not found on
June 7, 2007. But about 20 days later, on June 24, 2007, a pedunculated tumor
with
a diameter of 2 mm was found on the gum at the root of the canine tooth. The
tumor was ligated at its pedunculated part and excised on the day it found.
The
absorbance at 450 nm observed before the tumor became visible with the naked
eye
was 0.15, which was significantly high and not so different from the
absorbance at
the time of finding tumor, 0.14. The result indicates that it is possible to
diagnose
cancers even in an invisible part such as an intraperitoneal part by the
method of the
CA 02703356 2010-04-22
143
present invention.
[0303]
Rise of the value was observed before the tumor became visible with the
naked eye, which is considered to have been a sign of tumor development. Thus,
the method of the present invention is useful in medical examinations such as
periodic health examination.
[0304]
Canine Patient 1 was again checked by the serodiagnosis 2 weeks after the
tumor excision. As a result, the absorbance at 450 nm was 0, not detected.
Thus,
it was also confirmed that the cancer antigen-expressing tumor which had
caused the
increased antibody titer was completely removed (see, (2)-4, Follow-Up of
Postoperative Patients).
[0305]
(2)-2 Assessment of Stage of Cancer Progression
The stage of cancer progression is determined based on the size or depth of
the tumor, how much the tumor exerts influence on the surrounding tissues,
whether
the tumor metastasizes or not, and the like. It was revealed herein that the
detected
value is higher than before if the metastasis occurs, i.e., the cancer has
advanced.
[0306]
(2)-3 Assessment of Grade of Cancer Malignancy
Basaliomas include malignant type and benign type. Recently, according to
the new WHO classification, malignant basaliomas are called basal cell
carcinoma,
and benign basaliomas are called trichoblastoma.
[0307]
Canine Patient 2 (Beagle) was diagnosed as basal cell carcinoma (malignant).
The serodiagnosis was carried out at the time of the surgery. As a result, the
absorbance at 450 nin was 0.15. On the other hand, in Canine Patient 3 (Mixed
CA 02703356 2010-04-22
144
Breed) diagnosed as trichoblastoma (benign), the serodiagnosis carried out at
the
time of the surgery revealed that the absorbance at 450 nm was 0, not detected
at all.
Thus, even in the case of the same basaliomas, malignant basal cell carcinoma
and
benign trichoblastoma can be distinctively diagnosed.
[0308]
Next example is mammary gland tumors. Mammary gland tumors include
malignant tumors such as mammary adenocarcinoma and mammary gland malignant
mixed tumor, and benign mammary tumors which do not show malignant symptoms.
Canine Patient 4 (Yorkie) underwent extirpation of mammary gland malignant
mixed
tumor and mammary adenocarcinoma on May 17, 2006. In general, the complete
excision of mixed tumors in mammary gland is easy because they are poorly
invasive
to the surrounding tissues even if they are malignant, and thus the
postoperative
course of the patients is usually uneventful. However, Canine Patient 4 had
been
diagnosed as highly malignant tumor, because the pathological diagnosis using
the
extirpated tissue revealed that some components of the specimen from Canine
Patient
4 showed an invasive nature. On the other hand, mammary adenocarcinoma is a
highly invasive tumor which often recurs and metastasizes. Although invasion
of
the tumor cells was not observed in the specimen from Canine Patient 4, it had
been
pointed out that highly malignant components possibly proliferated in other
region
out of the specimen. Thus, the findings in the pathological diagnosis clearly
taught
that Canine Patient 4 was suffering from highly malignant mammary cancer. A
blood sample was collected during the surgery and the serodiagnosis was
carried out
to find that the absorbance at 450 nm was 0.20. Canine Patient 5 (Yorkshire
Terrier) underwent extirpation of mammary tumor on January 28, 2007. According
to the pathological diagnosis using the extirpated tissue, atypism of cells
was low,
and thus Canine Patient 5 was diagnoses as benign mastadenoma without
malignant
findings. A blood sample was collected during the surgery and the
serodiagnosis
CA 02703356 2010-04-22
145
was carried out to find that the absorbance at 450 nm was 0. The results in
the two
cases above revealed that highly malignant tumors show a higher value than low
malignant, benign tumors.
[0309]
(2)-4 Follow-Up of Postoperative Patients
Canine Patient 6 (Shih Tzu) visited the hospital due to an intraoral tumor and
underwent the extirpation on March 22, 2007. The serodiagnosis was carried out
at
that time. As a result, the absorbance at 450 nm was 0.12. In addition, based
on
the pathological diagnosis using the extirpated tissue, Canine Patient 6 was
diagnosed as malignant acanthomatous epulis. This kind of tumor often recurs
if
excision is insufficient, though distant metastasis seldom happens. Thus, it
is
important whether the tumor can be completely excised by surgery or not.
According to the follow up on May 18, 2007, the absorbance at 450 nm was 0.02
and
hence the antibody titer was decreased. Recurrence has not been found till
August
of 2007. Thus, it is considered that the value detected by the serodiagnosis
became
lower than that obtained at the time of surgery because the tumor could be
completely excised from Canine Patient 6.
[0310]
Canine Patient 7 (Yorkie) was diagnosed by the serodiagnosis using a serum
sample collected on May 17, 2006, and the absorbance at 450 rim was 0.20. This
patient visited the hospital on December 16, 2006 for follow-up, and the
serodiagnosis was carried out again. As a result, the absorbance at 450 nm was
0.
No recurrence nor metastasis has been found till August of 2007. Thus, it is
considered that the value detected by the serodiagnosis became lower than that
obtained at the time of surgery because the tumor could be completely excised
from
Canine Patient 7.
[0311]
CA 02703356 2010-04-22
146
(2)-5 Diagnosis of Recurrence
Canine Patient 8 (Husky) underwent an extirpation of mammary
adenocarcinoma on May 8, 2007. The serodiagnosis was carried out at the time
of
the surgery, and the absorbance at 450 nm was 0.04. The pathological diagnosis
using the extirpated tissue revealed that highly atypical epithelial cells
proliferated
and mainly formed ductal structures, and thus this patient was diagnosed as
primary
breast adenocarcinoma. It was said that the patient was at a high risk of
recurrence
or metastasis to lymph nodes or distant organs, as many cancer cells had
already
entered the lymph vessels at that time. On June 28, 2007, about one and a half
months after the surgery, metastasis was found at the same site. The
serodiagnosis
was carried out at that time to find that the value increased to 0.07. Thus,
it was
confirmed that the value detected by the serodiagnosis was higher in the end
of June
than in the beginning of May because the tumor could not have been completely
excised or recurrence would have occurred in Canine Patient 8.
[0312]
(2)-6 Diagnosis of Metastasis
Canine Patient 9 (Scottish Terrier), repeatedly undergoing metastasis and
recurrence, was diagnosed as mammary tumor in February of 2003; intraoral
malignant melanoma in August of 2003; malignant melanoma of the lip in January
of
2005; and as intraoral melanoma on April 13, 2005, all of which were excised
by
surgery. This patient visited the hospital again on December 17, 2006 for
follow-up
after the recurrence of intraoral melanoma in April of 2005, and the
serodiagnosis
was carried out at that time to find that the absorbance at 450 nm was 0. Half
a year
later, on June 20, 2007, the patient again visited the hospital because of
hypertrophy
of cervical and malar lymph nodes. In the case of lymphomas, hypertrophy of
lymph nodes is systemically observed. Because Canine Patient 9 had only two
swollen lymph nodes, this patient was clinically diagnosed as probable
metastatic
CA 02703356 2010-04-22
147
lymphoma. The diagnosis according to the present invention also revealed that
it
was a tumor which had metastasized from the tumor previously existed in this
patient
as the absorbance at 450 nm greatly increased to 0.27.
[0313]
Canine Patient 10 (Shiba mu) underwent extirpation of oral malignant
melanoma of the right lip on March 11, 2006. This patient has a history of
anticancer drug treatment (cyclophosphamide) from June 10 to September 26 in
2006,
and has received BIREMO S, which contains organic germanium as a main
ingredient, since May 23, 2006. On March 20, 2007, this patient underwent
extirpation of a tumor which was considered to be metastasis from the tumor
mentioned above, and the serodiagnosis was carried out. As a result, the
absorbance
at 450 nm was approximately 0, hardly detected. Based on the pathological
diagnosis using the tissue extirpated at that time, Canine Patient 10 was
diagnosed as
metastatic malignant melanoma. On June 27, 2007, three months after the
extirpation of metastatic melanoma, metastasis occurred in this patient again.
The
tumor which was extirpated on March 20, 2007 existed in the right cervical
part, and
the tumor which occurred on June 27, 2007 was on the opposite side. As for the
shape of the tumor, a black mass was formed similarly to the previous tumor.
The
tumor, having the size of 3.1 x 3.2 x 0.8 cm, was also clinically diagnosed as
metastasis. The serodiagnosis was carried out again to find that the
absorbance at
450 nm increased to 0.02, which indicated that it was metastatic tumor from
the
previous one.
[0314]
(2)-7 Therapy Monitoring
Canine Patient 12 (Miniature Dachshund) underwent tumor extirpation on
April 19, 2007. According to the pathological diagnosis using the extirpated
tumor,
the patient was suffering from moderately-malignant combined mammary
CA 02703356 2010-04-22
148
adenocarcinoma with a high probability of invasive and metastatic development.
The serodiagnosis was carried out at that time, and the absorbance at 450 nm
was
0.03. On June 3, 2008, about one year after the extirpation, the serodiagnosis
was
carried out to find that the absorbance at 450 nm was 0, not detected at all.
Although any recurrent tumors were not found with the naked eye, an anticancer
drug
(INTERCAT) was administered once-weekly for 2 months to prevent recurrence.
The serodiagnosis was carried out 2, 4, and 6 weeks after the administration
of the
anticancer drug started. As a result, the absorbance at 450 nm was 0, not
detected at
all, in all trials. These results obtained in Canine Patient 12 confirmed that
the
value becomes lower than that detected in a cancer-bearing state if tumors can
be
completely removed, as well as that the value does not increase if anticancer
drug
treatment successfully prevents cancer metastasis, and thus change in treated
patients
can be followed. In addition, the diagnosis of recurrence can also be carried
out as
shown by Canine Patient 8, which confirms that the therapy monitoring can also
be
made possible.
[0315]
(2)-8 Diagnosis of Malignancy of Recurrent Tumor
Canine Patient 13 (Golden Retriever) underwent tumor extirpation on May 1,
2005. The pathological diagnosis using the extirpated tumor revealed that the
tumor
in this patient was malignant neoplastic lesion originated from mammary ductal
epithelium, i.e., malignant mammary ductal carcinoma and malignant papillary
carcinoma continuously growing through the mammary ducts. On June 28, 2008,
about 3 years thereafter, tumor was found again and thus extirpation was
carried out.
The pathological diagnosis using the extirpated tumor revealed that nothing
but
severe infiltration of inflammatory cells such as neutrophils, macrophages,
plasma
cells and the like could be observed around surgical sutures under the skin
which was
considered to be the previous surgical wound, and thus the patient was
diagnosed as
CA 02703356 2010-04-22
149
having no neoplastic lesions. According to the serodiagnosis carried out at
that time,
the absorbance at 450 nm was 0, not detected at all. The results observed in
Canine
Patients 8 and 13 indicated that the value of the serodiagnosis does not
decrease or is
sustained in cases where the recurrent tumor is malignant, and is not detected
in cases
where the tumor is benign.
[0316]
(3) Diagnosis in Cats
Next, cancer-bearing cats and healthy cats were diagnosed. Using the
above-described partial polypeptide of canine TRIP11 and anti-cat IgG
antibody, the
IgG antibody titer of feline serum which specifically reacts with the
polypeptide was
measured in the same manner as described above. As a secondary antibody, HRP-
conjugated anti-cat IgG antibody (PEROXIDASE-CONJUGATED GOAT IgG
FRACTION TO CAT IgG (WHOLE MOLECULE): manufactured by CAPPEL
RESERCH REAGENTS) 8,000-fold diluted with the blocking solution was used.
[0317]
Feline Patient 1 (Chinchilla) underwent tumor extirpation of mammary
adenocarcinoma on August 17, 2005. The absorbance at 450 nm was 0.05. In
Feline Patient 2 (Himalayan), which underwent extirpation of ductal carcinoma
on
October 17, 2006, the absorbance at 450 nm was 0.34. On the other hand, the
absorbance was not detected in healthy cats at all.
[0318]
Thus, similarly to dogs, the absorbance value was detected in samples from
cats suffering from cancer, while the absorbance value was not detected at all
in
samples from healthy cats. Hence, similarly to dogs, cancers in cats can also
be
detected by this method.
[0319]
(4) Diagnosis in Healthy Human
CA 02703356 2010-04-22
150
Using the above-described partial polypeptide of canine TRIP11 and anti-
human IgG antibody above, the IgG antibody titer of healthy human serum which
specifically reacts with the polypeptide was measured in the same manner as
described above. As a secondary antibody, HRP-conjugated anti-human IgG
antibody (HRP-Goat Anti-Human IgG(H+L) Conjugate: manufactured by Zymed
Laboratories) 10000-fold diluted with the blocking solution was used. As a
positive
control, an immobilized ovalbumin antigen prepared by immobilizing 50 ig/m1
ovalbumin in phosphate buffered saline on a solid phase was used. As a result,
in
Healthy Human 1, the absorbance at 450 nm observed on an ovalbumin antigen was
0.25, while the absorbance at 450 nm observed on the recombinant protein was
0, not
detected at all. Similarly, in Healthy Human 2, the absorbance at 450 nm
observed
on an ovalbumin antigen was 0.18, while the absorbance at 450 nm observed on
the
recombinant protein was 0, not detected at all.
[0320]
Further, the diagnosis was carried out in the same manner as described above
using a full-length canine TRIP11 having the sequence shown in SEQ ID NO:45
prepared in Example D-2. As a result, it was revealed that the diagnosis can
be
similarly attained in humans, dogs and cats.
[0321]
Example D-4: Cancer Diagnosis Using Polypeptide Derived from Human TRIP11
Using the partial polypeptide of human TRIP11 (SEQ ID NO:55; 236th to
1023rd amino acid region of SEQ ID NO:47) prepared in Example D-2, the IgG
antibody titer of human, canine and feline sera which react with the
polypeptide was
measured in the same manner as in Example D-3.
[0322]
The diagnosis was carried out using healthy human serum. In the same
manner as in Example D-3 (4), ovalbumin antigen was used as a positive
control.
CA 02703356 2010-04-22
151
As a result, the absorbance value was detected in the case where ovalbumin was
immobilized on a solid phase, while the absorbance value was hardly detected
in the
case where the partial polypeptide of human TRIP11 was immobilized on a solid
phase.
[0323]
Similarly, in healthy dogs and cats, the absorbance at 450 nm was hardly
detected in the case where the polypeptide was immobilized on a solid phase.
[0324]
On the other hand, Canine Patient 11 (Shih Tzu) underwent extirpation of
mammary adenocarcinoma on June 21, 2007. According to the pathological
diagnosis using the extirpated tissue, the mammary gland tissue contained
highly
atypical, invasive cells, and grew to form adenomatous hyperplasia showing
large
and small massive structures. Hence, this patient was diagnosed as malignant
tumor.
In Canine Patient 11, the absorbance at 450 nm was 0.19. The malignancy
diagnosis was carried out using additional 310 serum samples which had been
diagnosed as malignant by pathological diagnosis. As a result, by diagnosing a
sample showing twice the average value of healthy canine samples as malignant,
74
samples i.e. 23.8% of the malignant cases could be successfully diagnosed as
malignant. Moreover, in Feline Patient 3 (Mixed Breed), which underwent
extirpation of mammary adenocarcinoma on April 3, 2007, the absorbance at 450
nm
was 0.06.
[0325]
The above described results indicated that the diagnosis can also be similarly
attained in humans, dogs and cats by using a polypeptide derived from human
TRIP11.
[0326]
Furthermore, pleural effusion and ascites samples collected from terminal
CA 02703356 2010-04-22
152
cancer dogs were subjected to the diagnosis using the recombinant human
protein in
the same manner as the recombinant canine protein. As a result, values similar
to
those detected in serum samples could be detected, and hence cancer diagnosis
could
be successfully attained.
[0327]
In addition, the diagnosis was carried out in the same manner as described
above using a full-length human TRIP11 having the sequence shown in SEQ ID
NO:47 prepared in Example D-2. As a result, it was revealed that the diagnosis
can
also be similarly attained in humans, dogs and cats.
[0328]
Example D-5: Cancer Diagnosis by Measuring Antigen Polypeptide (1)
Mice and rabbits were immunized with the recombinant canine protein having
the sequence shown in SEQ ID NO:54 prepared in Example D-2 to obtain an
antibody specific to this antigen. Using this polyclonal antibody, detection
of the
antigen polypeptide per se contained in the serum from cancer bearing living
body
was carried out by sandwich ELISA. Using anti-mouse IgG antibody, the amount
of
the protein in the serum which specifically reacts with the prepared
polyclonal
antibody specific to the prepared protein was measured by sandwich ELISA.
[0329]
As for immobilization of a primary antibody on a solid phase, 100 1.1L/well of
the rabbit antiserum 20-fold diluted with phosphate buffered saline was added
to a
96-well Immobilizer Amino plate (manufactured by Nunc), and the plate was
shaken
at room temperature for 2 hours. As for blocking, 100 pL/well of 50 mM sodium
bicarbonate buffer (pH 8.3) containing 0.5% BSA (bovine serum albumin,
manufactured by Sigma Aldrich Japan) (hereinafter referred to as blocking
solution)
was added to the plate, and the plate was shaken at room temperature for 1
hour. To
the plate, 100 RL/well of the serum from cancer-bearing body diluted with the
CA 02703356 2010-04-22
153
blocking solution was added, and the plate was shaken at room temperature for
3
hours to allow the reaction to proceed. As for the diluted serum, a 10-fold
serial
dilution ranging 10 to 1,000-fold was prepared. After washing the wells 3
times
with phosphate buffered saline containing 0.05% Tween20 (manufactured by Wako
Pure Chemicals) (hereinafter referred to as PBS-T), 100 [LL/well of mouse
antiserum
200-fold diluted with the blocking solution was added thereto, and the plate
was
shaken at room temperature for 1 hour to allow the reaction to proceed. After
washing the wells 3 times with PBS-T, 100 pt/well of HRP-conjugated mouse IgG
antibody (Stabilized Goat Anti Mouse HRP conjugated : manufactured by PIERCE)
2000-fold diluted with the blocking solution was added thereto as a tertiary
antibody,
and the plate was shaken at room temperature for 1 hour to allow the reaction
to
proceed. After washing the wells 3 times with PBS-T, 100 111/well of a HRP
substrate, TMB (1-Step Turbo TMB (tetramethylbenzidine), manufactured by
PIERCE), was added thereto, and the enzyme-substrate reaction was allowed to
proceed at room temperature for 30 minutes. Thereafter, the reaction was
stopped
by adding 100 [Ll/well of 0.5 M sulfuric acid solution (manufactured by Sigma
Aldrich Japan), and then the absorbance was measured at 450 nm with a
microplate
reader. As a control, a plate on which the rabbit antiserum was not
immobilized
and a plate with which serum from a cancer-bearing body was not reacted were
measured in the same manner as described above.
[0330]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody which was prepared by using
the
recombinant canine polypeptide as an immunogen.
CA 02703356 2010-04-22
154
[0331]
In addition, the diagnosis was carried out in the same manner as described
above using an antibody which was prepared by using as an immunogen the full-
length canine TRIP11 having the sequence shown in SEQ ID NO:45 prepared in
Example D-2.
[0332]
As a result, cancers could also be diagnosed in dogs and cats by this method
in which the antigen polypeptide was detected with an antibody which was
prepared
by using a full-length canine TRIP11 as an immunogen.
[0333]
Example D-6: Cancer Diagnosis by Measuring Antigen Polypeptide (2)
Mice and rabbits were immunized with the recombinant human protein
having the sequence shown in SEQ ID NO:55 prepared in Example D-2 to obtain an
antibody specific to this antigen. In the same manner as in Example D-5,
detection
of the antigen polypeptide per se contained in the serum from cancer-bearing
body
was carried out by sandwich ELISA using this polyclonal antibody.
[0334]
As a result, the polypeptide was detected in cancer-bearing dogs and cats
suffering from cutaneous leiomyosarcoma, breast cancer, malignant melanoma or
the
like, while the polypeptide was not detected in healthy dogs, healthy cats and
healthy
humans. Hence, cancers could also be diagnosed by this method in which the
antigen polypeptide was detected with an antibody prepared by using the
recombinant
human polypeptide as an immunogen.
[0335]
In addition, the diagnosis was carried out in the same manner as described
above using an antibody which was prepared by using as an immunogen the full-
length human TRIP11 having the sequence shown in SEQ ID NO:47 prepared in
CA 02703356 2010-04-22
155
Example D-2.
[0336]
As a result, cancers could also be diagnosed in dogs and cats by this method
in which the antigen polypeptide was detected with an antibody which was
prepared
by using a full-length human TRIP11 as an immunogen.
[0337]
Example E-1: Combined Diagnosis of Cancer Using Four Antigen Polypeptides (1)
(1) Cancer Diagnosis in Dogs
Using the recombinant canine polypeptide (SEQ ID NO:2) prepared in
Example A-2, the canine calmegin protein (SEQ ID NO:16) prepared in Example B-
2, the full-length (SEQ ID NO:26 or 42) or partial (SEQ ID NO:35; 1514th to
2339th
amino acid region of SEQ ID NO:26) polypeptide of canine CEP prepared in
Example C-2, the full-length (SEQ ID NO:45) or partial (SEQ ID NO:54; 237th to
1023rd amino acid region of SEQ ID NO:45) polypeptide of canine TRIP11
prepared
in Example D-2 and anti-dog IgG antibody, the IgG antibody titer of the serum
which
specifically reacts with any of the proteins or polypeptides mentioned above
was
measured.
[0338]
By diagnosing a sample showing twice the average value of healthy canine
samples as malignant, 272 samples i.e. 87.5% of the malignant cases could be
successfully diagnosed as malignant. The subject living body was diagnosed as
malignant when any one of 4 proteins and polypeptides indicated malignancy
(the
same shall apply hereinafter). The details of these 272 cancer samples are as
follows. It is noted that the following number of each cancer case is a
cumulative
total, as some samples contained multiple primaries.
Malignant melanoma, 10 cases; lymphoma, 13 cases; pheochromocytoma, 1 case;
suppurative inflammation, 1 case; granulosa cell tumor, 1 case; hepatocellular
CA 02703356 2010-04-22
156
carcinoma, 5 cases; angioma, 1 case; malignant testicular tumor, 8 cases;
intraoral
tumor, 4 cases; perianal adenocarcinoma, 14 cases; osteosarcoma, 5 cases;
fibrosarcoma, 9 cases; ductal carcinoma, 10 cases; chondrosarcoma, 2 cases;
4
mammary adenocarcinoma, 56 cases; combined mammary adenocarcinoma, 26
cases; lung cancer, 2 cases; sebaceous carcinoma, 2 cases; nasal
adenocarcinoma, 2
cases; mastocytoma, 37 cases; adrenomedullary tumor, 1 case; leiomyosarcoma, 2
cases; squamous cell carcinoma, 11 cases; chronic lymphocytic leukemia, 1
case;
undifferentiated sarcoma, 2 cases; malignant mixed tumor, 2 cases; tumor in
the
posterior segment of the left lobe of the lung, 1 case; tumor in the right
infra-axillary
region, 1 case; tumor in the elbow of the right forelimb, 1 case; bladder
cancer
(transitional cell carcinoma), 1 case; metastatic malignant melanoma, 3 cases;
amelanotic malignant melanoma, 1 case; adenocarcinoma of the large intestine,
1
case; plasmacytoma, 1 case; histiocytic sarcoma, 1 case; liposarcoma, 1 case;
poorly
differentiated sarcoma, 1 case; synovial sarcoma, 1 case; malignant
hemangiopericytoma, 1 case; apocrine sweat gland carcinoma, 3 cases; bronchial
adenocarcinoma, 1 case; germinoma, 1 case; malignant fibrous histiocytoma, 1
case;
metastatic malignant epithelioma, 1 case; mammary ductal carcinoma, 1 case;
angiosarcoma, 1 case; tubular mammary adenocarcinoma, 1 case; invasive
trichoepithelioma, 1 case; prostate cancer, 1 case; soft part sarcoma (spindle
cell
tumor), 1 case; ceruminous adenocarcinoma, 1 case; multicentric lymphoma, 2
cases;
invasive trichoepithelioma, 1 case; anal sac adenocarcinoma, 1 case; apocrine
carcinoma, 1 case; gastric adenocarcinoma, 1 case; seminoma, 1 case; basal
cell
carcinoma, 1 case; hemangiopericytoma, 4 cases; myxosarcoma, 1 case; sebaceous
epithelioma, 1 case; splenic tumor, 1 case.
[0339]
(2) Cancer Diagnosis in Cats
Next, cancer-bearing cats and healthy cats were diagnosed. Using 4 kinds of
CA 02703356 2010-04-22
157
canine antigen polypeptides described above and anti-cat IgG antibody, the IgG
antibody titer of feline serum which specifically reacts with any of the
polypeptides
was measured in the same manner as described above. As a secondary antibody,
HRP-conjugated anti-cat IgG antibody (PEROXIDASE-CONJUGATED GOAT IgG
FRACTION TO CAT IgG (WHOLE MOLECULE): manufactured by CAPPEL
RESERCH REAGENTS) 8,000-fold diluted with the blocking solution was used.
[0340]
Among a total of 17 samples used in the cancer diagnosis, 11 samples were
definitely diagnosed as malignant by the pathological diagnosis using the
extirpated
tumor tissue. By diagnosing a sample showing twice the average value of
healthy
feline samples as malignant, 9 samples i.e. 81.8% of the malignant cases could
be
successfully diagnosed as malignant.
[0341]
Example E-2: Combined Diagnosis of Cancer Using Four Antigen Polypeptides (2)
(1) Cancer Diagnosis in Dogs
Using the recombinant human polypeptide (SEQ ID NO:4) prepared in
Example A-2, the human calmegin protein (SEQ ID NO:18) prepared in Example B-
2, the full-length (SEQ ID NO:28) or partial (SEQ ID NO:36; 1513rd to 2325th
amino acid region of SEQ ID NO:28) polypeptide of human CEP prepared in
Example C-2, the full-length (SEQ ID NO:47) or partial (SEQ ID NO:55; 236th to
1023rd amino acid region of SEQ ID NO:47) polypeptide of human TRIP11 prepared
in Example D-2 and anti-dog IgG antibody, the IgG antibody titer of the serum
which
specifically reacts with any of the proteins or polypeptides mentioned above
was
measured in the same manner as described above.
[0342]
By diagnosing a sample showing twice the average value of healthy canine
samples as malignant, 268 samples i.e. 86.2% of the malignant cases could be
CA 02703356 2010-04-22
158
successfully diagnosed as malignant.
[0343]
(2) Cancer Diagnosis in Cats
Next, cancer-bearing cats and healthy cats were diagnosed. Using 4 kinds of
canine antigen polypeptides described above and anti-cat IgG antibody, the IgG
antibody titer of feline serum which specifically reacts with any of the
polypeptides
was measured in the same manner as described above. As a secondary antibody,
HRP-conjugated anti-cat IgG antibody (PEROXIDASE-CONJUGATED GOAT IgG
FRACTION TO CAT IgG (WHOLE MOLECULE): manufactured by CAPPEL
RESERCH REAGENTS) 8,000-fold diluted with the blocking solution was used.
[0344]
Among a total of 17 samples used in the cancer diagnosis, 11 samples were
definitely diagnosed as malignant by the pathological diagnosis using the
extirpated
tumor tissue. By diagnosing a sample showing twice the average value of
healthy
feline samples as malignant, 7 samples i.e. 63.6% of the malignant cases could
be
successfully diagnosed as malignant.
[0345]
Example E-3: Combined Diagnosis of Cancer by Measuring Four Antigen
Polypeptides (1)
Mice and rabbits were immunized with the recombinant canine polypeptide
(SEQ ID NO:2) prepared in Example A-2, the canine calmegin protein (SEQ ID
NO:16) prepared in Example B-2, the full-length (SEQ ID NO:26 or 42) or
partial
(SEQ ID NO:35; 1514th to 2339th amino acid region of SEQ ID NO:26) polypeptide
of canine CEP prepared in Example C-2, or the full-length (SEQ ID NO:45) or
partial (SEQ ID NO:54; 237th to 1023rd amino acid region of SEQ ID NO:45)
polypeptide of canine TRIP 11 prepared in Example D-2 to obtain specific
antibodies
against these antigens. In the same manner as in Examples A, B, C, D-5, the
CA 02703356 2010-04-22
159
antigen polypeptides per se contained in serum from cancer-bearing living body
were
detected by sandwich ELISA using the prepared polyclonal antibodies.
,
[0346]
As a result, this method in which antigen polypeptides were detected using
antibodies prepared by using canine antigen polypeptides as an immunogen could
successfully diagnose 252 samples i.e. 81.0% of the malignant cases as
malignant by
diagnosing a sample showing twice the average value of healthy canine samples
as
malignant. Similarly, also in cats, 8 samples i.e. 72.7% of the malignant
cases
could be successfully diagnosed as malignant by diagnosing a sample showing
twice
the average value of healthy feline samples as malignant.
[0347]
Example E-4: Combined Diagnosis of Cancer by Measuring Four Antigen
Polypeptides (2)
Mice and rabbits were immunized with the recombinant human polypeptide
(SEQ ID NO:4) prepared in Example A-2, the human calmegin protein (SEQ ID
NO:18) prepared in Example B-2, the full-length (SEQ ID NO:28) or partial (SEQ
ID
NO:36; 1513rd to 2325th amino acid region of SEQ ID NO:28) polypeptide of
human CEP prepared in Example C-2, or the full-length (SEQ ID NO:47) or
partial
(SEQ ID NO:55; 236th to 1023rd amino acid region of SEQ ID NO:47) polypeptide
of human TRIP11 prepared in Example D-2 to obtain specific antibodies against
these antigens. In the same manner in Examples A, B, C, D-5, the antigen
polypeptides per se contained in serum from cancer-bearing living body were
-
detected by sandwich ELISA using the prepared polyclonal antibodies.
[0348]
As a result, this method in which antigen polypeptides were detected using
antibodies prepared by using human antigen polypeptides as an immunogen could
successfully diagnose 248 samples i.e. 79.7% of the malignant cases as
malignant by
CA 02703356 2010-04-22
160
diagnosing a sample showing twice the average value of healthy canine samples
as
malignant. Similarly, also in cats, 7 samples i.e. 63.6% of the malignant
cases
could be successfully diagnosed as malignant by diagnosing a sample showing
twice
the average value of healthy feline samples as malignant.
CA 02703356 2010-05-31
161
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description
contains a sequence listing in electronic form in ASCII text format
(file: 72643-117 Seq 16-05-10 v1.txt).
A copy of the sequence listing in electronic form is available from the
Canadian Intellectual Property Office.
The sequences in the sequence listing in electronic form are reproduced
in the following table.
SEQUENCE TABLE
<110> TORAY INDUSTRIES, INC.
<120> Method for detecting cancer
<130> PF382-PCT
<160> 59
<170> PatentIn version 3.1
<210> 1
<211> 1508
<212> DNA
<213> Canis familiaris
<220>
<221> CDS
<222> (17)..(937)
<400> 1
gcggcccggg cgggac atg gcg gcg ctc tac gcc tgc acc aag tgc cac cag 52
Met Ala Ala Leu Tyr Ala Cys Thr Lys Cys His Gln
1 5 10
cgc ttc ccc ttc gag gcg ctg tct cag ggg cag cag ctg tgc aag gaa 100
Arg Phe Pro Phe Glu Ala Leu Ser Gln Gly Gln Gln Leu Cys Lys Glu
15 20 25
tgt cgg att gca cac cct gtt gtg aag tgc acc tac tgt aga act gag 148
Cys Arg Ile Ala His Pro Val Val Lys Cys Thr Tyr Cys Arg Thr Glu
30 35 40
tac cag caa gag agt aaa acc aat aca ata tgc aaa aaa tgt gct cag 196
Tyr Gln Gln Glu Ser Lys Thr Asn Thr Ile Cys Lys Lys Cys Ala Gln
45 50 55 60
aat gtg cag tta tat gga acg ccc aaa cct tgt cag tac tgc aac ata 244
Asn Val Gin Leu Tyr Gly Thr Pro Lys Pro Cys Gln Tyr Cys Asn Ile
65 70 75
CA 02703356 2010-05-31
162
att gca gca ttt att ggc aac aaa tgc cag cga tgc acg aat tca gag 292
Ile Ala Ala Phe Ile Gly Asn Lys Cys Gln Arg Cys Thr Asn Ser Glu
80 85 90
aag aag tat gga cca cca tat tca tgt gaa cag tgt aaa caa cag tgt 340
Lys Lys Tyr Gly Pro Pro Tyr Ser Cys Glu Gln Cys Lys Gln Gln Cys
95 100 105
gca ttt gac agg aaa gat gat aga aag aag gta gat ggg aaa ttg ctg 388
Ala Phe Asp Arg Lys Asp Asp Arg Lys Lys Val Asp Gly Lys Leu Leu
110 115 120
tgt tgg ctg tgc aca ctt tca tac aaa cgg gtc ctt caa aag acc aaa 436
Cys Trp Leu Cys Thr Leu Ser Tyr Lys Arg Val Leu Gln Lys Thr Lys
125 130 135 140
gag cag agg aaa cat ctg agc agc tct tcc cgt gcc agc cac cag gag 484
Glu Gln Arg Lys His Leu Ser Ser Ser Ser Arg Ala Ser His Gln Glu
145 150 155
aag gaa cag tat cga ctg agt ggt ggc agc cat tat aac agc cag aaa 532
Lys Glu Gln Tyr Arg Leu Ser Gly Gly Ser His Tyr Asn Ser Gln Lys
160 165 170
aca ctt tct acg tct tca att caa aat gaa ate cca aag aaa aaa tcc 580
Thr Leu Ser Thr Ser Ser Ile Gln Asn Glu Ile Pro Lys Lys Lys Ser
175 180 185
aag ttt gag tca atc aca act aat gga gac agc ttt tcc cca gac ctg 628
Lys Phe Glu Ser Ile Thr Thr Asn Gly Asp Ser Phe Ser Pro Asp Leu
190 195 200
gct ctg gac tca cca ggc act gac cac ttt gtc ate att gcc cag ctg 676
Ala Leu Asp Ser Pro Gly Thr Asp His Phe Val Ile Ile Ala Gln Leu
205 210 215 220
aag gaa gaa gtg gcc act ttg aag aag atg ctg cat caa aag gat caa 724
Lys Glu Glu Val Ala Thr Leu Lys Lys Met Leu His Gln Lys Asp Gln
225 230 235
atg att tta gag aaa gag aag aag ate aca gag ttg aag get gat ttt 772
Met Ile Leu Glu Lys Glu Lys Lys Ile Thr Glu Leu Lys Ala Asp Phe
240 245 250
caa tac caa gaa tct cag atg aga gcc aaa atg aac cag atg gag aaa 820
Gln Tyr Gln Glu Ser Gln Met Arg Ala Lys Met Asn Gln Met Glu Lys
255 260 265
act cac aaa gaa gtc aca gag caa ttg cag gcc aaa aac cga gaa etc 868
Thr His Lys Glu Val Thr Glu Gln Leu Gln Ala Lys Asn Arg Glu Leu
270 275 280
ctg aag cag gca got gcc ttg tcc aag age aag aag tca gag aag tca 916
Leu Lys Gln Ala Ala Ala Leu Ser Lys Ser Lys Lys Ser Glu Lys Ser
285 290 295 300
gga get ata act tct cca tga gagaccataa ggaggcttcc agccacagca 967
Gly Ala Ile Thr Ser Pro
305
CA 02703356 2010-05-31
163
aaggggtttc ctgggttagg gttggtggcc tggctgttat ctgggaattg cccacgctcc 1027
cgggaagggc ctgtcccagt cggctctgcc ctaccgccgc agcgtcccca cctggctgaa 1087
gctgacgtcc gacgacgtga aggagcagat ctacaaactg gccaagaagg gtctgactcc 1147
ctcgcagatc ggtgtgatcc tgagagactc ccatggtgtt gcacaagtac gttttgtgac 1207
aggcaataaa atcttgagaa ttcttaagtc caagggactt gcacctgatc tccctgagga 1267
tctgtaccat ttgattaaga aagctgttgc tgttcgaaag catcttgaga ggaacagaaa 1327
ggataaggat gccaaattcc gactgattct gattgagagc cgtattcacc gattggctcg 1387
atattataag accaaaagag ttctccctcc caattggaaa tacgagtcat ccacagcctc 1447
tgccctggtc gcataaattt ggctatgtac tcaagcaata aaatcattgt ctactagaaa 1507
a 1508
<210> 2
<211> 306
<212> PRT
<213> Canis familiaris
<400> 2
Met Ala Ala Leu Tyr Ala Cys Thr Lys Cys His Gln Arg Phe Pro Phe
1 5 10 15
Glu Ala Leu Ser Gln Gly Gln Gln Leu Cys Lys Glu Cys Arg Ile Ala
20 25 30
His Pro Val Val Lys Cys Thr Tyr Cys Arg Thr Glu Tyr Gln Gln Glu
35 40 45
Ser Lys Thr Asn Thr Ile Cys Lys Lys Cys Ala Gln Asn Val Gln Leu
50 55 60
Tyr Gly Thr Pro Lys Pro Cys Gln Tyr Cys Asn Ile Ile Ala Ala Phe
65 70 75 80
Ile Gly Asn Lys Cys Gln Arg Cys Thr Asn Ser Glu Lys Lys Tyr Gly
85 90 95
Pro Pro Tyr Ser Cys Glu Gln Cys Lys Gln Gln Cys Ala Phe Asp Arg
100 105 110
Lys Asp Asp Arg Lys Lys Val Asp Gly Lys Leu Leu Cys Trp Leu Cys
115 120 125
Thr Leu Ser Tyr Lys Arg Val Leu Gln Lys Thr Lys Glu Gln Arg Lys
130 135 140
His Leu Ser Ser Ser Ser Arg Ala Ser His Gln Glu Lys Glu Gln Tyr
145 150 155 160
Arg Leu Ser Gly Gly Ser His Tyr Asn Ser Gln Lys Thr Leu Ser Thr
165 170 175
Ser Ser Ile Gln Asn Glu Ile Pro Lys Lys Lys Ser Lys Phe Glu Ser
180 185 190
Ile Thr Thr Asn Gly Asp Ser Phe Ser Pro Asp Leu Ala Leu Asp Ser
195 200 205
Pro Gly Thr Asp His Phe Val Ile Ile Ala Gln Leu Lys Glu Glu Val
210 215 220
Ala Thr Leu Lys Lys Met Leu His Gln Lys Asp Gln Met Ile Leu Glu
225 230 235 240
Lys Glu Lys Lys Ile Thr Glu Leu Lys Ala Asp Phe Gln Tyr Gln Glu
245 250 255
Ser Gln Met Arg Ala Lys Met Asn Gln Met Glu Lys Thr His Lys Glu
260 265 270
Val Thr Glu Gln Leu Gln Ala Lys Asn Arg Glu Leu Leu Lys Gln Ala
275 280 285
Ala Ala Leu Ser Lys Ser Lys Lys Ser Glu Lys Ser Gly Ala Ile Thr
290 295 300
Ser Pro
305
CA 02703356 2010-05-31
164
<210> 3
<211> 2161
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (103)..(1026)
<400> 3
gccgcagcca gcagcctgca gccgccgccg ggttgtgcct cagactgtca gataaatcgg 60
cgggccgggc cggcgggtcg gtgagcgcgg cccgggccgg ac atg gcg gcg ctc 114
Met Ala Ala Leu
J.
tac gcc tgc acc aag tgc cac cag cgc ttc ccc ttc gag gcg ctg tct 162
Tyr Ala Cys Thr Lys Cys His Gin Arg Phe Pro Phe Glu Ala Leu Ser
10 15 20
cag ggg cag cag ctg tgc aag gaa tgt cgg att gca cac cot gtt gtg 210
Gin Gly Gin Gin Leu Cys Lys Glu Cys Arg Ile Ala His Pro Val Val
25 30 35
aag tgc acc tac tgc agg act gag tac cag cag gag agt aaa acc aat 258
Lys Cys Thr Tyr Cys Arg Thr Glu Tyr Gin Gin Glu Ser Lys Thr Asn
40 45 50
aca ata tgc aag aaa tgt gct cag aac gtg cag ttg tat gga acg ccc 306
Thr Ile Cys Lys Lys Cys Ala Gin Asn Val Gin Leu Tyr Gly Thr Pro
55 60 65
aaa cct tgt cag tat tgc aac ata att gca gca ttt att ggg aat aaa 354
Lys Pro Cys Gin Tyr Cys Asn Ile Ile Ala Ala Phe Ile Gly Asn Lys
70 75 80
tgc cag cgc tgc aca aat tca gaa aag aag tat gga cca ccc tat tct 402
Cys Gln Arg Cys Thr Asn Ser Glu Lys Lys Tyr Gly Pro Pro Tyr Ser
85 90 95 100
tgt gaa cag tgc aag cag cag tgt gca ttt gac agg aaa gat gat aga 450
Cys Glu Gin Cys Lys Gin Gin Cys Ala Phe Asp Arg Lys Asp Asp Arg
105 110 115
aag aag gta gat ggg aaa ttg ctg tgc tgg ctg tgc aca ctt tca tac 498
Lys Lys Val Asp Gly Lys Leu Leu Cys Trp Leu Cys Thr Leu Ser Tyr
120 125 130
aaa cgg gtc ctt cag aag acc aaa gag cag agg aaa cac ctg agt agc 546
Lys Arg Val Leu Gin Lys Thr Lys Glu Gin Arg Lys His Leu Ser Ser
135 140 145
tct tct cgt gct ggc cac cag gag aag gag cag tat agt cgc ctg agt 594
Ser Ser Arg Ala Gly His Gin Glu Lys Glu Gin Tyr Ser Arg Leu Ser
150 155 160
ggt ggt ggc cat tat aac agc cag aaa aca ctt tct aca tct tca att 642
Gly Gly Gly His Tyr Asn Ser Gin Lys Thr Leu Ser Thr Ser Ser Ile
165 170 175 180
CA 02703356 2010-05-31
165
caa aat gaa atc cca aag aaa aag tcc aag ttt gag tca atc aca act 690
Gin Asn Glu Ile Pro Lys Lys Lys Ser Lys Phe Glu Ser Ile Thr Thr
185 190 195
aat gga gac agc ttc tcc cca gac ctg gct ctg gac tca cca ggc act 738
Asn Gly Asp Ser Phe Ser Pro Asp Leu Ala Leu Asp Ser Pro Gly Thr
200 205 210
gac cac ttt gtc atc att gcc caa ctg aag gaa gaa gtg gct acc ctg 786
Asp His Phe Val Ile Ile Ala Gin Leu Lys Glu Glu Val Ala Thr Leu
215 220 225
aag aag atg ttg cat caa aag gat caa atg att tta gag aaa gag aag 834
Lys Lys Met Leu His Gin Lys Asp Gin Met Ile Leu Glu Lys Glu Lys
230 235 240
aag att aca gag ttg aag gct gat ttt cag tac cag gaa tcg cag atg 882
Lys Ile Thr Glu Leu Lys Ala Asp Phe Gin Tyr Gin Glu Ser Gin Met
245 250 255 260
aga gcc aaa atg aac cag atg gag aaa acc cac aaa gaa gtc aca gaa 930
Arg Ala Lys Met Asn Gin Met Glu Lys Thr His Lys Glu Val Thr Glu
265 270 275
caa ctg cag gcc aaa aac cga gag etc ctg aag cag gca gct gct ttg 978
Gin Leu Gin Ala Lys Asn Arg Glu Leu Leu Lys Gin Ala Ala Ala Leu
280 285 290
tcc aag age aag aag tca gag aag tca gga gct ata acc tct cca tga 1026
Ser Lys Ser Lys Lys Ser Glu Lys Ser Gly Ala Ile Thr Ser Pro
295 300 305
cagacctcaa ggaggctccc tagcaacagc aaatggagtt gtccagggtt agggttggag 1086
acctggctgt tctgtgggaa ttgcaagctt tcttaagaaa tctctatttt attacagtta 1146
tccttctttg tgcgattgca gtgggctgaa tggaaacacc tggtttgtgc tgtgttagac 1206
tgcatgcttg agtgtttggg atttcaagct cgctctcttt ctctcactat taggactttt 1266
ctttttcttc ttcctcttct ctctattttg gttctattct ttttttttct tttttctttt 1326
tttttttttt tttttttttg tggtggtcac tgctcagtgt aatgtgcaga atgatttgtt 1386
ttttgttttt tttttttttt tttggtcctt cattgcatcc tgccataccc atgagcaaac 1446
agtttggcat taattatata tcactgccac cctctgaact ttgaaaactg ccatcttcag 1506
acttggtata atggaagagg ctttctctct ccaataaacc ttttgcttca gggtatactc 1566
ttcggttttt ttccagatgt attatgtatg aactttgtac tatgtatagc cagagtttta 1626
tttatttttt aaaaaagaaa ctttttcttg ataaaggaat aatggtggtc tagctagttc 1686
ttgtaaaagt gatgcctctt gaaaaaaaac agtcctattc actagctttt agtaaaagaa 1746
tcagatcttt tctttcttgt taccttggag tcttaaaaac tgattgctaa ggtgaaacaa 1806
ttcaatgcat aagtatggag ctaagtgcct tttggaggat ttcttggaag agcatttatg 1866
gagatactta agggaggtag caaagatttg aaccgtctgt ctttttaagt aagggcagaa 1926
agcaaggttg tccaggttgt actggacact tctctcccca cccctttcct gattgtttta 1986
tgtgattgat tttaaattct cacactgcca cttctttaaa aaataaaatc ctttatttgc 2046
ttaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2106
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 2161
<210> 4
<211> 307
<212> PRT
<213> Homo sapiens
CA 02703356 2010-05-31
166
<400> 4
Met Ala Ala Leu Tyr Ala Cys Thr Lys Cys His Gin Arg Phe Pro Phe
1 5 10 15
Glu Ala Leu Ser Gin Gly Gin Gin Leu Cys Lys Glu Cys Arg Ile Ala
20 25 30
His Pro Val Val Lys Cys Thr Tyr Cys Arg Thr Glu Tyr Gin Gin Glu
35 40 45
Ser Lys Thr Asn Thr Ile Cys Lys Lys Cys Ala Gin Asn Val Gin Leu
50 55 60
Tyr Gly Thr Pro Lys Pro Cys Gin Tyr Cys Asn Ile Ile Ala Ala Phe
65 70 75 80
Ile Gly Asn Lys Cys Gin Arg Cys Thr Asn Ser Glu Lys Lys Tyr Gly
85 90 95
Pro Pro Tyr Ser Cys Glu Gin Cys Lys Gin Gin Cys Ala Phe Asp Arg
100 105 110
Lys Asp Asp Arg Lys Lys Val Asp Gly Lys Leu Leu Cys Trp Leu Cys
115 120 125
Thr Leu Ser Tyr Lys Arg Val Leu Gin Lys Thr Lys Glu Gin Arg Lys
130 135 140
His Leu Ser Ser Ser Ser Arg Ala Gly His Gin Glu Lys Glu Gin Tyr
145 150 155 160
Ser Arg Leu Ser Gly Gly Gly His Tyr Asn Ser Gin Lys Thr Leu Ser
165 170 175
Thr Ser Ser Ile Gin Asn Glu Ile Pro Lys Lys Lys Ser Lys Phe Glu
180 185 190
Ser Ile Thr Thr Asn Gly Asp Ser Phe Ser Pro Asp Leu Ala Leu Asp
195 200 205
Ser Pro Gly Thr Asp His Phe Val Ile Ile Ala Gin Leu Lys Glu Glu
210 215 220
Val Ala Thr Leu Lys Lys Met Leu His Gin Lys Asp Gin Met Ile Leu
225 230 235 240
Glu Lys Glu Lys Lys Ile Thr Glu Leu Lys Ala Asp Phe Gin Tyr Gin
245 250 255
Glu Ser Gin Met Arg Ala Lys Met Asn Gin Met Glu Lys Thr His Lys
260 265 270
Glu Val Thr Glu Gin Leu Gin Ala Lys Asn Arg Glu Leu Leu Lys Gin
275 280 285
Ala Ala Ala Leu Ser Lys Ser Lys Lys Ser Glu Lys Ser Gly Ala Ile
290 295 300
Thr Ser Pro
305
<210> 5
<211> 20
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 5
aattaaccct cactaaaggg 20
<210> 6
<211> 19
<212> DNA
<213> Artificial
CA 02703356 2010-05-31
167
<220>
<223> primer
<400> 6
taatacgact cactatagg 19
<210> 7
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 7
agctgtgcaa ggaatgtc 18
<210> 8
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 8
ccattagttg tgattgac 18
<210> 9
<211> 18
<212> DNA
<213> Artificial
<220>
<223> GAPDH primer
<400> 9
gggctgcttt taactctg 18
<210> 10
<211> 18
<212> DNA
<213> Artificial
<220>
<223> GAPDH primer
<400> 10
ccaggaaatg agcttgac 18
<210> 11
<211> 22
<212> DNA
<213> Artificial
CA 02703356 2010-05-31
168
<220>
<223> primer
400 11
atcatatggc ggcgctctac gc 22
<210> 12
<211> 25
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 12
cgctcgagtg gagaagttat agctc 25
<210> 13
<211> 23
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 13
gatatcatgg cggcgctcta cgc 23
<210> 14
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 14
gaattctcat ggagaggtta tagc 24
<210> 15
<211> 2326
<212> DNA
<213> Canis familiaris
<220>
<221> CDS
<222> (62)..(1894)
<400> 15
cagcgcctcg gacatcggag ctgccgctgc cgaacacggg cccgcaacac aggtaatcag 60
t atg cat ttc caa agc ttt tgg cta tgt ctg gga ctt ctg ttc atc tca 109
Met His Phe Gin Ser Phe Trp Leu Cys Leu Gly Leu Leu Phe Ile Ser
1 5 10 15
CA 02703356 2010-05-31
169
gtt aat gca gaa ttt atg gat gat gat gtt gag atg gaa gat ttt gat 157
Val Asn Ala Glu Phe Met Asp Asp Asp Val Glu Met Glu Asp Phe Asp
20 25 30
gaa aat tca gaa gag att gat gtt aat gaa ggt gaa ctc ccc tca gag 205
Glu Asn Ser Glu Glu Ile Asp Val Asn Glu Gly Glu Leu Pro Ser Glu
35 40 45
att aat tat aag aca cct cag cct atg gga gaa gta tat ttt aca gaa 253
Ile Asn Tyr Lys Thr Pro Gin Pro Met Gly Glu Val Tyr Phe Thr Glu
50 55 60
act ttt gat agt gga agg ttg gct ggg tgg gtc tta tca aaa gca aag 301
Thr Phe Asp Ser Gly Arg Leu Ala Gly Trp Val Leu Ser Lys Ala Lys
65 70 75 80
aaa gat gat aca gat gca gag att tcc ata tat gat gga aga egg gaa 349
Lys Asp Asp Thr Asp Ala Glu Ile Ser Ile Tyr Asp Gly Arg Trp Glu
85 90 95
ata gaa gaa ttg aaa gaa aac cga gtg cct ggt gac aga ggg ctg gta 397
Ile Glu Glu Leu Lys Glu Asn Arg Val Pro Gly Asp Arg Gly Leu Val
100 105 110
ctg aaa tct aga gca aag cat cat gca ata gct gct gta tta gca aaa 445
Leu Lys Ser Arg Ala Lys His His Ala Ile Ala Ala Val Leu Ala Lys
115 120 125
ccc ttc att ttt gct gac aaa ccc ttg atc gtt caa tat gaa gta aat 493
Pro Phe Ile Phe Ala Asp Lys Pro Leu Ile Val Gin Tyr Glu Val Asn
130 135 140
ttt caa gat ggt att gat tgt gga ggt gca tac att aaa ctc cta gca 541
Phe Gin Asp Gly Ile Asp Cys Gly Gly Ala Tyr Ile Lys Leu Leu Ala
145 150 155 160
gac act gat ggt ttg aat ctg gaa aac ttt tat gat aaa aca tcc tat 589
Asp Thr Asp Gly Leu Asn Leu Glu Asn Phe Tyr Asp Lys Thr Ser Tyr
165 170 175
acc att atg ttt gga cca gat aaa tgt gga gaa gat tat aaa ctt cat 637
Thr Ile Met Phe Gly Pro Asp Lys Cys Gly Glu Asp Tyr Lys Leu His
180 185 190
ttc atc ttc aga cac aaa cat cct aaa act gga gtt ttt gaa gag aaa 685
Phe Ile Phe Arg His Lys His Pro Lys Thr Gly Val Phe Glu Glu Lys
195 200 205
cat gcc aaa cct cca gat gta gac ctt aaa aag ttc ttt aca gac agg 733
His Ala Lys Pro Pro Asp Val Asp Leu Lys Lys Phe Phe Thr Asp Arg
210 215 220
aag act cat ctt tat acc ctt gtg atg aat cca gat gac aca ttt gaa 781
Lys Thr His Leu Tyr Thr Leu Val Met Asn Pro Asp Asp Thr Phe Glu
225 230 235 240
gta cta att gat caa gta gtt gta aac caa gga agc ctc cta gaa gat 829
Val Leu Ile Asp Gin Val Val Val Asn Gin Gly Ser Leu Leu Glu Asp
245 250 255
CA 02703356 2010-05-31
170
gtg gtt cct cct atc aat cct ccc aaa gaa att gaa gac ccc agt gat 877
Val Val Pro Pro Ile Asn Pro Pro Lys Glu Ile Glu Asp Pro Ser Asp
260 265 270
aaa aag cct gat gaa tgg gat gaa aga gca aaa atc cct gat cct tct 925
Lys Lys Pro Asp Glu Trp Asp Glu Arg Ala Lys Ile Pro Asp Pro Ser
275 280 285
gct gtc aaa cca gaa gac tgg gat gaa agt gaa cct gcc caa ata gaa 973
Ala Val Lys Pro Glu Asp Trp Asp Glu Ser Glu Pro Ala Gin Ile Glu
290 295 300
gat tta agt gtt gtt aaa cct gat ggc tgg ctt gat gat gaa cca aaa 1021
Asp Leu Ser Val Val Lys Pro Asp Gly Trp Leu Asp Asp Glu Pro Lys
305 310 315 320
ttt att cca gat cca aat gct gaa aaa cct gat gac tgg aat gaa gac 1069
Phe Ile Pro Asp Pro Asn Ala Glu Lys Pro Asp Asp Trp Asn Glu Asp
325 330 335
atg gat gga gaa tgg gag gca cct cgt att tct aat cca gca tgt cga 1117
Met Asp Gly Glu Trp Glu Ala Pro Arg Ile Ser Asn Pro Ala Cys Arg
340 345 350
att ggg tgt ggt gag tgg tca cct ccc atg ata gat aat ccc aaa tac 1165
Ile Gly Cys Gly Glu Trp Ser Pro Pro Met Ile Asp Asn Pro Lys Tyr
355 360 365
aaa gga gta tgg aga cct cca atg ata gat aat cct aac tac cag gga 1213
Lys Gly Val Trp Arg Pro Pro Met Ile Asp Asn Pro Asn Tyr Gin Gly
370 375 380
atc tgg agt cct cga aaa atc ccg aat cca gat tat ttt gaa gat gat 1261
Ile Trp Ser Pro Arg Lys Ile Pro Asn Pro Asp Tyr Phe Glu Asp Asp
385 390 395 400
cat cca ttt ctt ctg act tct ttc cgt gct ctt ggt tta gag ctt tgg 1309
His Pro Phe Leu Leu Thr Ser Phe Arg Ala Leu Gly Leu Glu Leu Trp
405 410 415
tct atg acc tct aat att tac ttt gat aat ttt att atc tgc tcg gaa 1357
Ser Met Thr Ser Asn Ile Tyr Phe Asp Asn Phe Ile Ile Cys Ser Glu
420 425 430
aag gaa aca gca gat cgc tgg gct gca gat ggg tgg gga gtg aag ata 1405
Lys Glu Thr Ala Asp Arg Trp Ala Ala Asp Gly Trp Gly Val Lys Ile
435 440 445
ctg gta gca aat gct aac gag cct ggt ata ttt aaa cag tta atg gca 1453
Leu Val Ala Asn Ala Asn Glu Pro Gly Ile Phe Lys Gin Leu Met Ala
450 455 460
gct gct gaa gag cgc cca tgg ctt tgg ctc att tat ttt gtg aca gca 1501
Ala Ala Glu Glu Arg Pro Trp Leu Trp Leu Ile Tyr Phe Val Thr Ala
465 470 475 480
ggg ctt cca ata gca tta att gct tea ttt tgt tgg cca aga aaa gtc 1549
Gly Leu Pro Ile Ala Leu Ile Ala Ser Phe Cys Trp Pro Arg Lys Val
485 490 495
=
CA 02703356 2010-05-31
171
aag aaa aaa tat gaa gat tca gag tat aaa aag act gac ata tgc aag 1597
Lys Lys Lys Tyr Glu Asp Ser Glu Tyr Lys Lys Thr Asp Ile Cys Lys
500 505 510
cca caa aca aag gga gca cta gag caa gaa gtg aag gaa aag aaa gct 1645
Pro Gin Thr Lys Gly Ala Leu Glu Gin Glu Val Lys Glu Lys Lys Ala
515 520 525
gcc ctg gag aaa cca gta gac ttg gaa gaa gaa aaa aag caa agt gat 1693
Ala Leu Glu Lys Pro Val Asp Leu Glu Glu Glu Lys Lys Gin Ser Asp
530 535 540
ggt gaa act gtt gaa aaa gaa gag gaa gct gaa cct gag gaa aag agt 1741
Gly Glu Thr Val Glu Lys Glu Glu Glu Ala Glu Pro Glu Glu Lys Ser
545 550 555 560
gaa gaa gaa att gaa atc ata gaa gga caa gaa gaa ggt aat aaa tca 1789
Glu Glu Glu Ile Glu Ile Ile Glu Gly Gin Glu Glu Gly Asn Lys Ser
565 570 575
aat aag tct gga tca gag gat gag atg aag gaa gcg gat gag agc aca 1837
Asn Lys Ser Gly Ser Glu Asp Glu Met Lys Glu Ala Asp Glu Ser Thr
580 585 590
gga tct gga gat ggg cca gtg aag tca gtg cgc aaa aga aga gta cga 1885
Gly Ser Gly Asp Gly Pro Val Lys Ser Val Arg Lys Arg Arg Val Arg
595 600 605
aag gaa taa actatattca agtattttta attcctgagc gagatatttg 1934
Lys Glu
610
gcattctaaa atcagtgtgc cagagctgaa cttgagtcag tctgcacatg tttctaatat 1994
ctagcaatgt tattctttca gacacttatt ttagtctttc ttttcaggaa aaaaaaaact 2054
ttcaagttac ctggtctttg gatttagagt aaaaaagagg ggcatgttac gtatcagatt 2114
taagagacta ataccattag aagttaccaa gttttaatag ttggagaaag ttttggtttg 2174
tacagagaaa aataatatgc agcagctttg ctgctgttgg aaaatcagtt attggaattt 2234
ccccttaaac agctatacaa caatattact ggtagttcta taataaaaat gagagtgtgt 2294
tctgttgtac agagctaact gcaaaaaaaa aa 2326
<210> 16
<211> 610
<212> PRT
<213> Canis familiaris
<400> 16
Met His Phe Gin Ser Phe Trp Leu Cys Leu Gly Leu Leu Phe Ile Ser
1 5 10 15
Val Asn Ala Glu Phe Met Asp Asp Asp Val Glu Met Glu Asp Phe Asp
20 25 30
Glu Asn Ser Glu Glu Ile Asp Val Asn Glu Gly Glu Leu Pro Ser Glu
35 40 45
Ile Asn Tyr Lys Thr Pro Gin Pro Met Gly Glu Val Tyr Phe Thr Glu
50 55 60
Thr Phe Asp Ser Gly Arg Leu Ala Gly Trp Val Leu Ser Lys Ala Lys
65 70 75 60
Lys Asp Asp Thr Asp Ala Glu Ile Ser Ile Tyr Asp Gly Arg Trp Glu
85 90 95
CA 02703356 2010-05-31
172
Ile Glu Glu Leu Lys Glu Asn Arg Val Pro Gly Asp Arg Gly Leu Val
100 105 110
Leu Lys Ser Arg Ala Lys His His Ala Ile Ala Ala Val Leu Ala Lys
115 120 125
Pro Phe Ile Phe Ala Asp Lys Pro Leu Ile Val Gin Tyr Glu Val Asn
130 135 140
Phe Gin Asp Gly Ile Asp Cys Gly Gly Ala Tyr Ile Lys Leu Leu Ala
145 150 155 160
Asp Thr Asp Gly Leu Asn Leu Glu Asn Phe Tyr Asp Lys Thr Ser Tyr
165 170 175
Thr Ile Met Phe Gly Pro Asp Lys Cys Gly Glu Asp Tyr Lys Leu His
180 185 190
Phe Ile Phe Arg His Lys His Pro Lys Thr Gly Val Phe Glu Glu Lys
195 200 205
His Ala Lys Pro Pro Asp Val Asp Leu Lys Lys Phe Phe Thr Asp Arg
210 215 220
Lys Thr His Leu Tyr Thr Leu Val Met Asn Pro Asp Asp Thr Phe Glu
225 230 235 240
Val Leu Ile Asp Gin Val Val Val Asn Gin Gly Ser Leu Leu Glu Asp
245 250 255
Val Val Pro Pro Ile Asn Pro Pro Lys Glu Ile Glu Asp Pro Ser Asp
260 265 270
Lys Lys Pro Asp Glu Trp Asp Glu Arg Ala Lys Ile Pro Asp Pro Ser
275 280 285
Ala Val Lys Pro Glu Asp Trp Asp Glu Ser Glu Pro Ala Gin Ile Glu
290 295 300
Asp Leu Ser Val Val Lys Pro Asp Gly Trp Leu Asp Asp Glu Pro Lys
305 310 315 320
Phe Ile Pro Asp Pro Asn Ala Glu Lys Pro Asp Asp Trp Asn Glu Asp
325 330 335
Met Asp Gly Glu Trp Glu Ala Pro Arg Ile Ser Asn Pro Ala Cys Arg
340 345 350
Ile Gly Cys Gly Glu Trp Ser Pro Pro Met Ile Asp Asn Pro Lys Tyr
355 360 365
Lys Gly Val Trp Arg Pro Pro Met Ile Asp Asn Pro Asn Tyr Gin Gly
370 375 380
Ile Trp Ser Pro Arg Lys Ile Pro Asn Pro Asp Tyr Phe Glu Asp Asp
385 390 395 400
His Pro Phe Leu Leu Thr Ser Phe Arg Ala Leu Gly Leu Glu Leu Trp
405 410 415
Ser Met Thr Ser Asn Ile Tyr Phe Asp Asn Phe Ile Ile Cys Ser Glu
420 425 430
Lys Glu Thr Ala Asp Arg Trp Ala Ala Asp Gly Trp Gly Val Lys Ile
435 440 445
Leu Val Ala Asn Ala Asn Glu Pro Gly Ile Phe Lys Gin Leu Met Ala
450 455 460
Ala Ala Glu Glu Arg Pro Trp Leu Trp Leu Ile Tyr Phe Val Thr Ala
465 470 475 480
Gly Leu Pro Ile Ala Leu Ile Ala Ser Phe Cys Trp Pro Arg Lys Val
485 490 495
Lys Lys Lys Tyr Glu Asp Ser Glu Tyr Lys Lys Thr Asp Ile Cys Lys
500 505 510
Pro Gin Thr Lys Gly Ala Leu Glu Gin Glu Val Lys Glu Lys Lys Ala
515 520 525
Ala Leu Glu Lys Pro Val Asp Leu Glu Glu Glu Lys Lys Gin Ser Asp
530 535 540
Gly Glu Thr Val Glu Lys Glu Glu Glu Ala Glu Pro Glu Glu Lys Ser
545 550 555 560
Glu Glu Glu Ile Glu Ile Ile Glu Gly Gin Glu Glu Gly Asn Lys Ser
565 570 575
CA 02703356 2010-05-31
,
173
Asn Lys Ser Gly Ser Glu Asp Glu Met Lys Glu Ala Asp Glu Ser Thr
580 585 590
Gly Ser Gly Asp Gly Pro Val Lys Ser Val Arg Lys Arg Arg Val Arg
595 600 605
Lys Glu
610
<210> 17
<211> 2710
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (102)..(1934)
<400> 17
cgccggcggg actggtctga agagacgcgg ggacaaagtg gcaacgactt ggacatctga 60
gctgtcactg ccgaaaacag gccgcaagag agataatcaa t atg cat ttc caa gcc 116
Met His Phe Gin Ala
1 5
ttt tgg cta tgt ttg ggt ctt ctg ttc atc tca att aat gca gaa ttt 164
Phe Trp Leu Cys Leu Gly Leu Leu Phe Ile Ser Ile Asn Ala Glu Phe
15 20
atg gat gat gat gtt gag acg gaa gac ttt gaa gaa aat tca gaa gaa 212
Met Asp Asp Asp Val Glu Thr Glu Asp Phe Glu Glu Asn Ser Glu Glu
25 30 35
att gat gtt aat gaa agt gaa ctt tcc tca gag att aaa tat aag aca 260
Ile Asp Val Asn Glu Ser Glu Leu Ser Ser Glu Ile Lys Tyr Lys Thr
40 45 50
cct caa cct ata gga gaa gta tat ttt gca gaa act ttt gat agt gga 308
Pro Gln Pro Ile Gly Glu Val Tyr Phe Ala Glu Thr Phe Asp Ser Gly
55 60 65
agg ttg gct gga tgg gtc tta tca aaa gca aag aaa gat gac atg gat 356
Arg Leu Ala Gly Trp Val Leu Ser Lys Ala Lys Lys Asp Asp Met Asp
70 75 80 85
gag gaa att tca ata tac gat gga aga tgg gaa att gaa gag ttg aaa 404
Glu Glu Ile Ser Ile Tyr Asp Gly Arg Trp Glu Ile Glu Glu Leu Lys
90 95 100
gaa aac cag gta cct ggt gac aga gga ctg gta tta aaa tct aga gca 452
Glu Asn Gin Val Pro Gly Asp Arg Gly Leu Val Leu Lys Ser Arg Ala
105 110 115
aag cat cat gca ata tct gct gta tta gca aaa cca ttc att ttt gct 500
Lys His His Ala Ile Ser Ala Val Leu Ala Lys Pro Phe Ile Phe Ala
120 125 130
gat aaa ccc ttg ata gtt caa tat gaa gta aat ttt caa gat ggt att 548
Asp Lys Pro Leu Ile Val Gin Tyr Glu Val A= Phe Gin Asp Gly Ile
135 140 145
CA 02703356 2010-05-31
174
gat tgt gga ggt gca tac att aaa ctc cta gca gac act gat gat ttg 596
Asp Cys Gly Gly Ala Tyr Ile Lys Leu Leu Ala Asp Thr Asp Asp Leu
150 155 160 165
att ctg gaa aac ttt tat gat aaa aca tcc tat atc att atg ttt gga 644
Ile Leu Glu Asn Phe Tyr Asp Lys Thr Ser Tyr Ile Ile Met Phe Gly
170 175 180
cca gat aaa tgt gga gaa gat tat aaa ctt cat ttt atc ttc aga cat 692
Pro Asp Lys Cys Gly Glu Asp Tyr Lys Leu His Phe Ile Phe Arg His
185 190 195
aaa cat ccc aaa act gga gtt ttc gaa gag aaa cat gcc aaa cct cca 740
Lys His Pro Lys Thr Gly Val Phe Glu Glu Lys His Ala Lys Pro Pro
200 205 210
gat gta gac ctt aaa aag ttc ttt aca gac agg aag act cat ctt tat 788
Asp Val Asp Leu Lys Lys Phe Phe Thr Asp Arg Lys Thr His Leu Tyr
215 220 225
acc ctt gtg atg aat cca gat gac aca ttt gag gtg tta gtt gat caa 836
Thr Leu Val Met Asn Pro Asp Asp Thr Phe Glu Val Leu Val Asp Gin
230 235 240 245
aca gtt gta aac aaa gga agc ctc cta gag gat gtg gtt cct cct atc 884
Thr Val Val Asn Lys Gly Ser Leu Leu Glu Asp Val Val Pro Pro Ile
250 255 260
aaa cct ccc aaa gaa att gaa gat ccc aat gat aaa aaa cct gag gaa 932
Lys Pro Pro Lys Glu Ile Glu Asp Pro Asn Asp Lys Lys Pro Glu Glu
265 270 275
tgg gat gaa aga gca aaa att cct gat cct tct gcc gtc aaa cca gaa 980
Trp Asp Glu Arg Ala Lys Ile Pro Asp Pro Ser Ala Val Lys Pro Glu
280 285 290
gac tgg gat gaa agt gaa cct gcc caa ata gaa gat tca agt gtt gtt 1028
Asp Trp Asp Glu Ser Glu Pro Ala Gin Ile Glu Asp Ser Ser Val Val
295 300 305
aaa cct get ggc tgg ctt gat gat gaa cca aaa ttt atc cct gat cct 1076
Lys Pro Ala Gly Trp Leu Asp Asp Glu Pro Lys Phe Ile Pro Asp Pro
310 315 320 325
aat gct gaa aaa cct gat gac tgg aat gaa gac acg gat gga gaa tgg 1124
Asn Ala Glu Lys Pro Asp Asp Trp Asn Glu Asp Thr Asp Gly Glu Trp
330 335 340
gag gca cct cag att ctt aat cca gca tgt cgg att ggg tgt ggt gag 1172
Glu Ala Pro Gin Ile Leu Asn Pro Ala Cys Arg Ile Gly Cys Gly Glu
345 350 355
tgg aaa cct ccc atg ata gat aac cca aaa tac aaa gga gta tgg aga 1220
Trp Lys Pro Pro Met Ile Asp Asn Pro Lys Tyr Lys Gly Val Trp Arg
360 365 370
cct cca ctg gtc gat aat cct aac tat cag gga atc tgg agt cct cga 1268
Pro Pro Leu Val Asp Asn Pro Asn Tyr Gin Gly Ile Trp Ser Pro Arg
375 380 385
CA 02703356 2010-05-31
175
aaa att cct aat cca gat tat ttc gaa gat gat cat cca ttt ctt ctg 1316
Lys Ile Pro Asn Pro Asp Tyr Phe Glu Asp Asp His Pro Phe Leu Leu
390 395 400 405
act tct ttc agt gct ctt ggt tta gag ctt tgg tct atg acc tct gat 1364
Thr Ser Phe Ser Ala Leu Gly Leu Glu Leu Trp Ser Met Thr Ser Asp
410 415 420
atc tac ttt gat aat ttt att atc tgt tcg gaa aag gaa gta gca gat 1412
Ile Tyr Phe Asp Asn Phe Ile Ile Cys Ser Glu Lys Glu Val Ala Asp
425 430 435
cac tgg gct gca gat ggt tgg aga tgg aaa ata atg ata gca aat gct 1460
His Trp Ala Ala Asp Gly Trp Arg Trp Lys Ile Met Ile Ala Asn Ala
440 445 450
aat aag cct ggt gta tta aaa cag tta atg gca gct gct gaa ggg cac 1508
Asn Lys Pro Gly Val Leu Lys Gin Leu Met Ala Ala Ala Glu Gly His
455 460 465
cca tgg ctt tgg ttg att tat ctt gtg aca gca gga gtg cca ata gca 1556
Pro Trp Leu Trp Leu Ile Tyr Leu Val Thr Ala Gly Val Pro Ile Ala
470 475 480 485
tta att act tca ttt tgt tgg cca aga aaa gta aag aaa aaa cat aaa 1604
Leu Ile Thr Ser Phe Cys Trp Pro Arg Lys Val Lys Lys Lys His Lys
490 495 500
gat aca gag tat aaa aaa acc gac ata tgt ata cca caa aca aaa gga 1652
Asp Thr Glu Tyr Lys Lys Thr Asp Ile Cys Ile Pro Gin Thr Lys Gly
505 510 515
gta cta gag caa gaa gaa aag gaa gag aaa gca gcc ctg gaa aaa cca 1700
Val Leu Glu Gin Glu Glu Lys Glu Glu Lys Ala Ala Leu Glu Lys Pro
520 525 530
atg gac ctg gaa gag gaa aaa aag caa aat gat ggt gaa atg ctt gaa 1748
Met Asp Leu Glu Glu Glu Lys Lys Gin Asn Asp Gly Glu Met Leu Glu
535 540 545
aaa gaa gag gaa agt gaa cct gag gaa aag agt gaa gaa gaa att gaa 1796
Lys Glu Glu Glu Ser Glu Pro Glu Glu Lys Ser Glu Glu Glu Ile Glu
550 555 560 565
atc ata gaa ggg caa gaa gaa agt aat caa tca aat aag tct ggg tca 1844
Ile Ile Glu Gly Gin Glu Glu Ser Asn Gin Ser Asn Lys Ser Gly Ser
570 575 580
gag gat gag atg aaa gaa gca gat gag agc aca gga tct gga gat ggg 1892
Glu Asp Glu Met Lys Glu Ala Asp Glu Ser Thr Gly Ser Gly Asp Gly
585 590 595
ccg ata aag tca gta cgc aaa aga aga gta cga aag gac taa 1934
Pro Ile Lys Ser Val Arg Lys Arg Arg Val Arg Lys Asp
600 605 610
actagattga aatattttta attcccgaga ggatgtttgg cattgtaaaa atcagcatgc 1994
cagacctgaa ctttaatcag tctgcacatc ctgtttctaa tatctagcaa cattatattc 2054
tttcagacat ttattttagt ccttcatttc cgaggaaaaa gaagcaactt tgaagttacc 2114
tcatctttga atttagaata aaagtggcac attacatatc ggatctaaga gattaatacc 2174
CA 02703356 2010-05-31
176
attagaagtt acacagtttt agttgtttgg agatagtttt ggtttgtaca gaacaaaata 2234
atatgtagca gcttcattgc tattggaaaa atcagttatt ggaatttcca cttaaatggc 2294
tatacaacaa tataactggt agttctataa taaaaatgag catatgttct gttgtgaaga 2354
gctaaatgca ataaagtttc tgtatggttg tttgattcta tcaacaattg aaagtgttgt 2414
atatgaccca catttaccta gtttgtgtca aattatagtt acagtgagtt gtttgcttaa 2474
attatagatt cctttaagga catgccttgt tcataaaatc actggattat attgcagcat 2534
attttacatt tgaatacaag gataatgggt tttatcaaaa caaaatgatg tacagatttt 2594
ttttcaagtt tttatagttg ctttatgcca gagtggttta ccccattcac aaaatttctt 2654
atgcatacat tgctattgaa aataaaattt aaatattttt tcatcctgaa aaaaaa 2710
<210> 18
<211> 610
<212> PRT
<213> Homo sapiens
<400> 18
Met His Phe Gin Ala Phe Trp Leu Cys Leu Gly Leu Leu Phe Ile Ser
1 5 10 15
Ile Asn Ala Glu Phe Met Asp Asp Asp Val Glu Thr Glu Asp Phe Glu
20 25 30
Glu Asn Ser Glu Glu Ile Asp Val Asn Glu Ser Glu Leu Ser Ser Glu
35 40 45
Ile Lys Tyr Lys Thr Pro Gin Pro Ile Gly Glu Val Tyr Phe Ala Glu
50 55 60
Thr Phe Asp Ser Gly Arg Leu Ala Gly Trp Val Leu Ser Lys Ala Lys
65 70 75 80
Lys Asp Asp Met Asp Glu Glu Ile Ser Ile Tyr Asp Gly Arg Trp Glu
85 90 95
Ile Glu Glu Leu Lys Glu Asn Gin Val Pro Gly Asp Arg Gly Leu Val
100 105 110
Leu Lys Ser Arg Ala Lys His His Ala Ile Ser Ala Val Leu Ala Lys
115 120 125
Pro Phe Ile Phe Ala Asp Lys Pro Leu Ile Val Gin Tyr Glu Val Asn
130 135 140
Phe Gin Asp Gly Ile Asp Cys Gly Gly Ala Tyr Ile Lys Leu Leu Ala
145 150 155 160
Asp Thr Asp Asp Leu Ile Leu Glu Asn Phe Tyr Asp Lys Thr Ser Tyr
165 170 175
Ile Ile Met Phe Gly Pro Asp Lys Cys Gly Glu Asp Tyr Lys Leu His
180 185 190
Phe Ile Phe Arg His Lys His Pro Lys Thr Gly Val Phe Glu Glu Lys
195 200 205
His Ala Lys Pro Pro Asp Val Asp Leu Lys Lys Phe Phe Thr Asp Arg
210 215 220
Lys Thr His Leu Tyr Thr Leu Val Met Asn Pro Asp Asp Thr Phe Glu
225 230 235 240
Val Leu Val Asp Gin Thr Val Val Asn Lys Gly Ser Leu Leu Glu Asp
245 250 255
Val Val Pro Pro Ile Lys Pro Pro Lys Glu Ile Glu Asp Pro Asn Asp
260 265 270
Lys Lys Pro Glu Glu Trp Asp Glu Arg Ala Lys Ile Pro Asp Pro Ser
275 280 285
Ala Val Lys Pro Glu Asp Trp Asp Glu Ser Glu Pro Ala Gin Ile Glu
290 295 300
Asp Ser Ser Val Val Lys Pro Ala Gly Trp Leu Asp Asp Glu Pro Lys
305 310 315 320
Phe Ile Pro Asp Pro Asn Ala Glu Lys Pro Asp Asp Trp Asn Glu Asp
325 330 335
CA 02703356 2010-05-31
177
Thr Asp Gly Glu Trp Glu Ala Pro Gin Ile Leu Asn Pro Ala Cys Arg
340 345 350
Ile Gly Cys Gly Glu Trp Lys Pro Pro Met Ile Asp Asn Pro Lys Tyr
355 360 365
Lys Gly Val Trp Arg Pro Pro Leu Val Asp Asn Pro Asn Tyr Gin Gly
370 375 380
Ile Trp Ser Pro Arg Lys Ile Pro Asn Pro Asp Tyr Phe Glu Asp Asp
385 390 395 400
His Pro Phe Leu Leu Thr Ser Phe Ser Ala Leu Gly Leu Glu Leu Trp
405 410 415
Ser Met Thr Ser Asp Ile Tyr Phe Asp Asn Phe Ile Ile Cys Ser Glu
420 425 430
Lys Glu Val Ala Asp His Trp Ala Ala Asp Gly Trp Arg Trp Lys Ile
435 440 445
Met Ile Ala Asn Ala Asn Lys Pro Gly Val Leu Lys Gin Leu Met Ala
450 455 460
Ala Ala Glu Gly His Pro Trp Leu Trp Leu Ile Tyr Leu Val Thr Ala
465 470 475 480
Gly Val Pro Ile Ala Leu Ile Thr Ser Phe Cys Trp Pro Arg Lys Val
485 490 495
Lys Lys Lys His Lys Asp Thr Glu Tyr Lys Lys Thr Asp Ile Cys Ile
500 505 510
Pro Gin Thr Lys Gly Val Leu Glu Gin Glu Glu Lys Glu Glu Lys Ala
515 520 525
Ala Leu Glu Lys Pro Met Asp Leu Glu Glu Glu Lys Lys Gin Asn Asp
530 535 540
Gly Glu Met Leu Glu Lys Glu Glu Glu Ser Glu Pro Glu Glu Lys Ser
545 550 555 560
Glu Glu Glu Ile Glu Ile Ile Glu Gly Gin Glu Glu Ser Asn Gin Ser
565 570 575
Asn Lys Ser Gly Ser Glu Asp Glu Met Lys Glu Ala Asp Glu Ser Thr
580 585 590
Gly Ser Gly Asp Gly Pro Ile Lys Ser Val Arg Lys Arg Arg Val Arg
595 600 605
Lys Asp
610
<210> 19
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 19
gtgatgaatc cagatgac 18
<210> 20
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 20
ggtcatagac caaagctc 18
CA 02703356 2010-05-31
178
<210> 21
<211> 23
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 21
aaggatccat gcatttccaa agc 23
<210> 22
<211> 25
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 22
ccgaattctt attcctttcg tactc 25
<210> 23
<211> 26
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 23
gaattcatgc atttccaagc cttttg 26
<210> 24
<211> 23
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 24
ctcgagttag tcctttcgta ctc 23
<210> 25
<211> 7353
<212> DNA
<213> Canis familiaris
<220>
<221> CDS
222 (1)..(7020)
CA 02703356 2010-05-31
179
<400> 25
atg aag aaa ggt tct cag caa aag ttt ttg aaa gca aag atg cca cca 48
Met Lys Lys Gly Ser Gin Gin Lys Phe Leu Lys Ala Lys Met Pro Pro
1 5 10 15
tca tct cac tct cct agt cca cca tcc ctt acg tcc aat atg aga tct 96
Ser Ser His Ser Pro Ser Pro Pro Ser Leu Thr Ser Asn Met Arg Ser
20 25 30
agg tca ctt tcg cct cta agt gga tct gag act ctg cct ttt cat ttt 144
Arg Ser Leu Ser Pro Leu Ser Gly Ser Glu Thr Leu Pro Phe His Phe
35 40 45
gga gga ccg tgg cat gag caa gtt gag att aca gat gaa age aca gtg 192
Gly Gly Pro Trp His Glu Gin Val Glu Ile Thr Asp Glu Ser Thr Val
50 55 60
gtt tta gac tac caa gac cat aaa gaa get gat tca cat gca gga gtc 240
Val Leu Asp Tyr Gin Asp His Lys Glu Ala Asp Ser His Ala Gly Val
65 70 75 80
cga tat att aca gag gcc ctt gtt aga aaa ctt act aaa cag gac aat 288
Arg Tyr Ile Thr Glu Ala Leu Val Arg Lys Leu Thr Lys Gin Asp Asn
85 90 95
ttg gcc ttg gta aaa tct ctg aac ctt tca ctt gct aaa ggt ggt ggc 336
Leu Ala Leu Val Lys Ser Leu Asn Leu Ser Leu Ala Lys Gly Gly Gly
100 105 110
aag aaa ttc agg tgt atc gaa aat ttg gaa aaa tgt gtt aaa ctt gaa 384
Lys Lys Phe Arg Cys Ile Glu Asn Leu Glu Lys Cys Val Lys Leu Glu
115 120 125
gta ctg aat ctc agc tat aat cta ata gga aag att gag aaa gtg gac 432
Val Leu Asn Leu Ser Tyr Asn Leu Ile Gly Lys Ile Glu Lys Val Asp
130 135 140
aaa ctg tta aaa tta cgt gaa etc aac tta tcg tat aac aaa atc cgc 480
Lys Leu Leu Lys Leu Arg Glu Leu Asn Leu Ser Tyr Asn Lys Ile Arg
145 150 155 160
aaa att gaa ggc ata gaa aat tta tat aat ctg caa aag ctg aac ctt 528
Lys Ile Glu Gly Ile Glu Asn Leu Tyr Asn Leu Gin Lys Leu Asn Leu
165 170 175
gca gga aat gaa atc gaa cat atc cca gta tgg tta ggg aag aag tta 576
Ala Gly Asn Glu Ile Glu His Ile Pro Val Trp Leu Gly Lys Lys Leu
180 185 190
aaa tct ttg cga atc ctg aat ctg aaa ggc aac aag ata tca tcg etc 624
Lys Ser Leu Arg Ile Leu Asn Leu Lys Gly Asn Lys Ile Ser Ser Leu
195 200 205
caa gat gta age aag ttg aaa cca ctt caa gat ttg act tct ctg atc 672
Gin Asp Val Ser Lys Leu Lys Pro Leu Gin Asp Leu Thr Ser Leu Ile
210 215 220
cta ctt gaa aat cca gtt gcg ace ctt cct cat tat atc cag ttt ace 720
Leu Leu Glu Asn Pro Val Ala Thr Leu Pro His Tyr Ile Gin Phe Thr
225 230 235 240
CA 02703356 2010-05-31
180
att ttt cac ctt cgc tca ttg gaa agt ttg gaa ggt cag cca gta act 768
Ile Phe His Leu Arg Ser Leu Glu Ser Leu Glu Gly Gin Pro Val Thr
245 250 255
agt cag gac aga caa gaa gct ttt gcg aga ttc agt tta gat gag gta 816
Ser Gin Asp Arg Gin Glu Ala Phe Ala Arg Phe Ser Leu Asp Glu Val
260 265 270
gaa aga ctg gaa aga gac ctg gag aag aag aca atg gaa act gaa gag 864
Glu Arg Leu Glu Arg Asp Leu Glu Lys Lys Thr Met Glu Thr Glu Glu
275 280 285
ctt agg agt gag cag aca agg ttc ctt gag gaa att aaa agt cag gat 912
Leu Arg Ser Glu Gin Thr Arg Phe Leu Glu Glu Ile Lys Ser Gin Asp
290 295 300
aaa ttg aac aaa tca ctg aaa gag gag gcc aga cta caa aaa cag agc 960
Lys Leu Asn Lys Ser Leu Lys Glu Glu Ala Arg Leu Gin Lys Gin Ser
305 310 315 320
tat gag gag ctg gag agt aac cta aac acc aaa aat gaa ttg cta aaa 1008
Tyr Glu Glu Leu Glu Ser Asn Leu Asn Thr Lys Asn Glu Leu Leu Lys
325 330 335
cag aag acc atg gaa cta atg cga gca tgt cag aaa cag tat gag atg 1056
Gin Lys Thr Met Glu Leu Met Arg Ala Cys Gin Lys Gin Tyr Glu Met
340 345 350
gaa cag gag ttg gcc ttt tat aaa att gat gcc aaa ttt gaa cca cta 1104
Glu Gin Glu Leu Ala Phe Tyr Lys Ile Asp Ala Lys Phe Glu Pro Leu
355 360 365
aat tat tac cca tca gag tat gtc gaa att gat aaa acc cca gat gaa 1152
Asn Tyr Tyr Pro Ser Glu Tyr Val Glu Ile Asp Lys Thr Pro Asp Glu
370 375 380
agc cct tac att ggc aaa tcc aga tac aag aga aat atg ttc act aca 1200
Ser Pro Tyr Ile Gly Lys Ser Arg Tyr Lys Arg Asn Met Phe Thr Thr
385 390 395 400
gag agt tat att att gca aat gcc cag aca gta aag atc aag aag atg 1248
Glu Ser Tyr Ile Ile Ala Asn Ala Gin Thr Val Lys Ile Lys Lys Met
405 410 415
gag cta gat gaa ggg gaa caa ctc aga aat gag cac gtg aac ttg gga 1296
Glu Leu Asp Glu Gly Glu Gin Leu Arg Asn Glu His Val Asn Leu Gly
420 425 430
gca tcg cca aca gac ata caa ctg gaa gac aaa gaa aaa aaa ata agt 1344
Ala Ser Pro Thr Asp Ile Gin Leu Glu Asp Lys Glu Lys Lys Ile Ser
435 440 445
gca gca caa act cga cta tca gaa cta cat gat gaa ata gaa aag gca 1392
Ala Ala Gin Thr Arg Leu Ser Glu Leu His Asp Glu Ile Glu Lys Ala
450 455 460
gaa caa caa att tta aga gcc act gaa gaa ttt aaa caa ctg gaa gaa 1440
Glu Gin Gin Ile Leu Arg Ala Thr Glu Glu Phe Lys Gin Leu Glu Glu
465 470 475 480
CA 02703356 2010-05-31
181
get ata caa ctt aaa aaa att tea gaa gcg gag aaa gac ctt ctt ttc 1488
Ala Ile Gin Leu Lys Lys Ile Ser Glu Ala Glu Lys Asp Leu Leu Phe
485 490 495
aag cag ttg agt ggt agg ata cag ctt ctc aat aaa tta cgc caa gaa 1536
Lys Gin Leu Ser Gly Arg Ile Gin Leu Leu Asn Lys Leu Arg Gin Glu
500 505 510
get gtg gat cta gaa aca cag atg gaa aag caa agg caa gaa att ggt 1584
Ala Val Asp Leu Glu Thr Gin Met Glu Lys Gin Arg Gin Glu Ile Gly
515 520 525
gaa aag cag aat gag ate aag gac ctg gaa ata gtc aca gat agc ctg 1632
Glu Lys Gin Asn Glu Ile Lys Asp Leu Glu Ile Val Thr Asp Ser Leu
530 535 540
gat tee aga gac cca aaa cat tgc cat atg aag get cag aaa aga ggt 1680
Asp Ser Arg Asp Pro Lys His Cys His Met Lys Ala Gin Lys Arg Gly
545 550 555 560
aaa gaa caa caa ctt gac att atg aac aag cag tac aaa cag ctt gaa 1728
Lys Glu Gin Gin Leu Asp Ile Met Asn Lys Gin Tyr Lys Gin Leu Glu
565 570 575
age cgt ttg gat gag ata ctt tct aga att gcc aaa gaa act gaa gag 1776
Ser Arg Leu Asp Glu Ile Leu Ser Arg Ile Ala Lys Glu Thr Glu Glu
580 585 590
att aag gac ctt gaa gaa cag ctt act gaa gga caa ata gcc gca aac 1824
Ile Lys Asp Leu Glu Glu Gin Leu Thr Glu Gly Gin Ile Ala Ala Asn
595 600 605
gaa gcc ctg aag aag gac tta gaa agt gtc ate agt ggg ttg caa gaa 1872
Glu Ala Leu Lys Lys Asp Leu Glu Ser Val Ile Ser Gly Leu Gin Glu
610 615 620
tae ctg gag act gtc aaa ggt cag gcc cgt cag gcc cag aat gag tgc 1920
Tyr Leu Glu Thr Val Lys Gly Gin Ala Arg Gin Ala Gin Asn Glu Cys
625 630 635 640
aga aag eta cag gat gag aag gag aca ttg ctg cag aga ttg agt gag 1968
Arg Lys Leu Gin Asp Glu Lys Glu Thr Leu Leu Gin Arg Leu Ser Glu
645 650 655
gtc gag cag gag agg gac caa ctg gaa ata gtg gcc ata gat gca gaa 2016
Val Glu Gin Glu Arg Asp Gin Leu Glu Ile Val Ala Ile Asp Ala Glu
660 665 670
aat atg agg aag gag etc gca gaa ctg gag aat gcc etc cag gag cag 2064
Asn Met Arg Lys Glu Leu Ala Glu Leu Glu Asn Ala Leu Gin Glu Gin
675 680 685
cat gag gtg aat ata tct ctg cag cag ace cag gga gat etc agt gcc 2112
His Glu Val Asn Ile Ser Leu Gin Gin Thr Gin Gly Asp Leu Ser Ala
690 695 700
tat gag get gag eta gag get cag ctg aaa ata egg gat get gaa gcc 2160
Tyr Glu Ala Glu Leu Glu Ala Gin Leu Lys Ile Arg Asp Ala Glu Ala
705 710 715 720
CA 02703356 2010-05-31
182
aac cag ctc aag gag gag ttg gaa aaa ctt aga agg ttg agc cag tta 2208
Asn Gin Leu Lys Glu Glu Leu Glu Lys Leu Arg Arg Leu Ser Gin Leu
725 730 735
gaa caa tcg gcc ctt caa gca gag ctt gag aag gaa aag caa gcc ttc 2256
Glu Gin Ser Ala Leu Gin Ala Glu Leu Glu Lys Glu Lys Gin Ala Phe
740 745 750
aag act gct gtc aaa aaa gcc cag ctc tca gaa gga aag gac caa gaa 2304
Lys Thr Ala Val Lys Lys Ala Gin Leu Ser Glu Gly Lys Asp Gin Glu
755 760 765
aat agt gag ctc cgc aca caa ctc caa cag ctg cag gat gac aat gac 2352
Asn Ser Glu Leu Arg Thr Gin Leu Gin Gin Leu Gin Asp Asp Asn Asp
770 775 780
cta ttg aaa cag caa ctt aaa gat ttc cag agt cac ctt aac cat gtg 2400
Leu Leu Lys Gin Gin Leu Lys Asp Phe Gin Ser His Leu Asn His Val
785 790 795 800
gtt gat ggt ttg att cgt cca gaa gaa gtg gca gct tgt gtg gat gag 2448
Val Asp Gly Leu Ile Arg Pro Glu Glu Val Ala Ala Cys Val Asp Glu
805 810 815
eta agg aaa aaa ctg aag tca gga gct ggg gaa atg aga atc cat act 2496
Leu Arg Lys Lys Leu Lys Ser Gly Ala Gly Glu Met Arg Ile His Thr
820 825 830
cct tca gat gtc tta ggg aaa agt ctt gct gac ttg cag aag caa ttc 2544
Pro Ser Asp Val Leu Gly Lys Ser Leu Ala Asp Leu Gin Lys Gin Phe
835 840 845
agt gag atc ctg gca cgc tcc cag tgg gaa aga cag gaa gca caa gtg 2592
Ser Glu Ile Leu Ala Arg Ser Gin Trp Glu Arg Gin Glu Ala Gin Val
850 855 860
aga gag aga aaa ctc cag gag gaa atg gct ctg caa caa gag aaa ctg 2640
Arg Glu Arg Lys Leu Gin Glu Glu Met Ala Leu Gin Gin Glu Lys Leu
865 870 875 880
gcg agc gga caa gag gag ttc agg cac gcc tgc gag agg gcc ctg gaa 2688
Ala Ser Gly Gin Glu Glu Phe Arg His Ala Cys Glu Arg Ala Leu Glu
885 890 E395
gcc cga att agt ttt gat aag agg cag cac gaa gca aga atc cag cag 2736
Ala Arg Ile Ser Phe Asp Lys Arg Gin His Glu Ala Arg Ile Gin Gin
900 905 910
ttg gag aat gaa att cac tat ttg caa gaa aat eta aaa agt atg gag 2784
Leu Glu Asn Glu Ile His Tyr Leu Gin Glu Asn Leu Lys Ser Met Glu
915 920 925
gaa atc caa ggt ctc aca gac ctc caa ctt cag gaa gct gat gaa gag 2832
Glu Ile Gin Gly Leu Thr Asp Leu Gin Leu Gin Glu Ala Asp Glu Glu
930 935 940
aag gag aga att ctg gcc caa ctc egg gag tta gag aaa aag aag aaa 2880
Lys Glu Arg Ile Leu Ala Gin Leu Arg Glu Leu Glu Lys Lys Lys Lys
945 950 955 960
CA 02703356 2010-05-31
183
ctt gag gat gcc aag teL cag gag cag ttt ctt gga tta gat aga gaa 2928
Leu Glu Asp Ala Lys Ser Gin Glu Gin Phe Leu Gly Leu Amp Arg Glu
965 970 975
ttg aag aag eta aag aaa gct gtg gct gcc tct gat aag ctg gcc aca 2976
Leu Lys Lys Leu Lys Lys Ala Val Ala Ala Ser Asp Lys Leu Ala Thr
980 985 990
gct gag etc ace att gcc aaa gac cag etc aag tcc ctt cat gga act 3024
Ala Glu Leu Thr Ile Ala Lys Asp Gin Leu Lys Ser Leu His Gly Thr
995 1000 1005
gtg atg aaa att aac cag gag cga gca gag gag ctg cag gag acg 3069
Val Met Lys Ile Asn Gin Glu Arg Ala Glu Glu Leu Gin Glu Thr
1010 1015 1020
gag agg ttc agc aga aag gca gca caa gca gct agg gat ctg ate 3114
Glu Arg Phe Ser Arg Lys Ala Ala Gin Ala Ala Arg Asp Leu Ile
1025 1030 1035
cga gca gaa gcg gag att gaa etc ctg cag aag ctt etc aga gat 3159
Arg Ala Glu Ala Glu Ile Glu Leu Leu Gin Lys Leu Leu Arg Asp
1040 1045 1050
aaa gag gag cag ttt cga aat gag att gag aaa gta gat gtc ggc 3204
Lys Glu Glu Gin Phe Arg Asn Glu Ile Glu Lys Val Asp Val Gly
1055 1060 1065
teL gga gga gca aag tea cag atg ctg gag atg gag aaa eta aat 3249
Ser Gly Gly Ala Lys Ser Gin Met Leu Glu Met Glu Lys Leu Asn
1070 1075 1080
gag aca atg gag agg caa aga aca gag att gct agg ctg agg aat 3294
Glu Thr Met Glu Arg Gin Arg Thr Glu Ile Ala Arg Leu Arg Asn
1085 1090 1095
tta eta gac etc ace ggg gct gat aac aaa gga aac ttt gaa aat 3339
Leu Leu Asp Leu Thr Gly Ala Asp Asn Lys Gly Asn Phe Glu Asn
1100 1105 1110
gtt ttg gaa gaa att gct gaa ctt cga cgt gaa gtt tct cat cag 3384
Val Leu Glu Glu Ile Ala Glu Leu Arg Arg Glu Val Ser His Gln
1115 1120 1125
aat gat tac ate age age atg aca gat cct ttc aaa aga cga ggc 3429
Asn Asp Tyr Ile Ser Ser Met Thr Asp Pro Phe Lys Arg Arg Gly
1130 1135 1140
tat tgg tac ttt atg cca cca cca tea tea tea aaa gtt tee age 3474
Tyr Trp Tyr Phe Met Pro Pro Pro Ser Ser Ser Lys Val Ser Ser
1145 1150 1155
cac agt tee cag gcc ace aag gac tct ggt gtt ggc eta aag tac 3519
His Ser Ser Gin Ala Thr Lys Asp Ser Gly Val Gly Leu Lys Tyr
1160 1165 1170
aca gcc tee act ccg gtt aga aaa cca cat cgt gga egg cag gat 3564
Thr Ala Ser Thr Pro Val Arg Lys Pro His Arg Gly Arg Gin Asp
1175 1180 1185
CA 02703356 2010-05-31
184
gga aag gag aac agt ggg cct cca cct gcc tca gga tac tgg gtg 3609
Gly Lys Glu Asn Ser Gly Pro Pro Pro Ala Ser Gly Tyr Trp Val
1190 1195 1200
tat tct cct atc agg agt ggg tta cat aaa tcg ttc tca aat aga 3654
Tyr Ser Pro Ile Arg Ser Gly Leu His Lys Ser Phe Ser Asn Arg
1205 1210 1215
gac gca gac agt gga gga gat agc cag gaa gag agc gag cta gat 3699
Asp Ala Asp Ser Gly Gly Asp Ser Gin Glu Glu Ser Glu Leu Asp
1220 1225 1230
gac caa gaa gac cac cca ttt gta cct cct cct gga tac atg atg 3744
Asp Gin Glu Asp His Pro Phe Val Pro Pro Pro Gly Tyr Met Met
1235 1240 1245
tac act gtg ttt cct gat ggt tct cct gta ccc cag ggc atg gcc 3789
Tyr Thr Val Phe Pro Asp Gly Ser Pro Val Pro Gin Gly Met Ala
1250 1255 1260
ctg tat gca ccc cct cct ccc ttg ccc aac aat agc cag cct ctt 3834
Leu Tyr Ala Pro Pro Pro Pro Leu Pro Asn Asn Ser Gin Pro Leu
1265 1270 1275
gac ctt ggc act gtt gtt tat ggc cca cct cct gtt ggg gct ccc 3879
Asp Leu Gly Thr Val Val Tyr Gly Pro Pro Pro Val Gly Ala Pro
1280 1285 1290
atc gtg tat ggg cct cca cct ccc aac ttc tcc gta ccc ctc atc 3924
Ile Val Tyr Gly Pro Pro Pro Pro Asn Phe Ser Val Pro Leu Ile
1295 1300 1305
ccc gtg ggt gtg ctg cac tgc aat gtc cca gaa cac cat aac ttg 3969
Pro Val Gly Val Leu His Cys Asn Val Pro Glu His His Asn Leu
1310 1315 1320
gag aat gaa gtt tct aga tta gaa gac ata atg cag cat tta aaa 4014
Glu Asn Glu Val Ser Arg Leu Glu Asp Ile Met Gin His Leu Lys
1325 1330 1335
tct ggg aaa cgg gaa cag tgc atg aaa aca ccc aag ctg cag tcg 4059
Ser Gly Lys Arg Glu Gin Cys Met Lys Thr Pro Lys Leu Gin Ser
1340 1345 1350
gag aaa gaa ctc gca gag ctg cag cat aac att gat ggt ctt ttg 4104
Glu Lys Glu Leu Ala Glu Leu Gin His Asn Ile Asp Gly Leu Leu
1355 1360 1365
caa gag aag aaa gac tta gag cat gaa gta gaa gaa tta cat aga 4149
Gin Glu Lys Lys Asp Leu Glu His Glu Val Glu Glu Leu His Arg
1370 1375 1380
acc atc caa aaa cat caa cag cga aaa gat ttc att gat gga aac 4194
Thr Ile Gin Lys His Gin Gin Arg Lys Asp Phe Ile Asp Gly Asn
1385 1390 1395
gtt gag agt ctt gtg aat gat cta gaa ata gag aag tca ctc aaa 4239
Val Glu Ser Leu Val Asn Asp Leu Glu Ile Glu Lys Ser Leu Lys
1400 1405 1410
9E91 0E91 SZ91
nTD ILLI, IPA nID aa5 nID AID Bay viy nip uip
naq day
tT6D EvE gor vgb
er5 aby ryb vbh vgo v5v Ego voE, rvE Buo ogo ovb
0Z9T 9191 0191
PTV skI PTV uTD TPA laN laS nTS uip naq naa 5TH nsa nTO nID
698D gob EVE Dab
bvo Dab bar obv vvb bvo oao pap avo bao bvb rrb
5091 0091 9651
ski ski sTH AID nari nip Bay dsv naa IPA PIV qs14 ni5 uTO uTO
tZ8D BEE BPP Deo
*ebb vaa bvb bbv ovb baa alb pob bav bvb BED bro
0651 9851 OBST
uip Aip ass ivA uip aas ski nali usy nip nat. nip pry ski ski
6LL1' BED v.6.6
vog EgB BED obv PPP bap avv vvb Ego bvb lob EPP Evv
SLST OLST 9991
uip nag atti, nip aas nip ski nail ivA sTH uTD
tELV oob bra bap
ago ODE EvE Boa bvb vvv aao Dab bvo bap ova bvo
0991 SSST OSST
dsy nip usy eTH bay vri atly nip sti dsy ski uip naa sAti uip
68917 oES EvE gvv
ovo E,Bo rob gov EvE aqv ovb bvv BED pap EPP BED
StST OtST SEST
nag nTD AID 271 noa TvA nip eki ski ski usy naq aas TITO 37d
1717917 Ego EvE vbE
vov Ego vgb vvE frev Evv Evu o'er voo obv Eva ogg
OEST SZST OZST
dsy aas dsy Skl PTV PTV TPA irA sArl usy au nTo ern naa aTI
66917 DES vog orb
vvv vob rob ggb gq.6 vvr ouv vgr rvb vry Egg ogv
STST OTST SOST
uID nID TITO TITD 1a1/4 ski sTH uTD nID naa dsy skj it, dsy ply
tSSt vvb EvE vvo
EvE Egv vvv ovo beo EvE Egg orb BEE Bov ovE gob
0051 96171 06VT
uip nari naa Bay nal uip uip dsy viy ski ivA naa us v au vIv
60917 &so oao baa
vbv bap bvo bvo ovb Dab PEP og6 ogo ovv ggv ooE
SEM 08171 SLDT
aqI TITD TITS wry Bay Bay nip naa nID nID PTV dsy sAri TD ia
1791717 gov vv6 Evo
oo.6 ES v &Be. *rub vgg EvE EvE oob avb EPP BEB q0E
OLVT 99171 OW(
uip nag nal usy Bay ski vut dsV 1t1L 914d sAa nTD IPA PTV sTH
6I1717 vro Egg vgg
gvr vbv Evv ooE ,ES gov ogg bvv EvE ggE, goE gra
SSVI OStT Stti
ski ally ski nip sAq 1tJsAD ass naa nTD 139 nIS ETV nTO
DLED ruv vov vvr
Evb vvv bor obq rog ggo vub gEr vvb goE EvE bop
OWL SEtT OEtT
naa par/ Bay dsy viy nip Bay nea nip rill Bay Bay ski naa nari
6ZET7 Ego Ego Bbo
DES oob vES BEE, ogo EvE rob '4E3 obo Err Ego ggo
GUT OZtT STVT
lILLBaV nID aII sAD TITO @II nip dsy IPA aTI dsy TITO sTH sTH
V8Zt oov BEr EvE
ggr gbq vvE olv vrE gv.5 ggb ggv gvE vvb gvo ovo
581
TE-90-0TOZ 99EEOLZO 7/0
CA 02703356 2010-05-31
186
aag tgc aat cac att agg gaa gta aaa tct ctt ctg gaa gaa ctc 4959
Lys Cys Asn His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu
1640 1645 1650
agt ttt cag aaa gga gaa ctg aat gtc cag atc agt gaa aaa aaa 5004
Ser Phe Gin Lys Gly Glu Leu Asn Val Gin Ile Ser Glu Lys Lys
1655 1660 1665
act caa ctt gca ctc ata aag cag gaa att gaa aaa gag gaa gac 5049
Thr Gin Leu Ala Leu Ile Lys Gin Glu Ile Glu Lys Glu Glu Asp
1670 1675 1680
aat ctt cag gta gtt tta ggg caa atg tct aaa cat aaa act gaa 5094
Asn Leu Gin Val Val Leu Gly Gin Met Ser Lys His Lys Thr Glu
1685 1690 1695
cta aag aat att ctg gac atg ttg caa ctt gaa aat aat gag ctg 5139
Leu Lys Asn Ile Leu Asp Met Leu Gin Leu Glu Asn Asn Glu Leu
1700 1705 1710
caa ggt ttg aag ctc caa cat gac caa aag atg tct gaa tta gag 5184
Gin Gly Leu Lys Leu Gin His Asp Gin Lys Met Ser Glu Leu Glu
1715 1720 1725
aag act egg gtt gaa gtg ctg gag gag aaa ctg gag tta gag agt 5229
Lys Thr Arg Val Glu Val Leu Glu Glu Lys Leu Glu Leu Glu Ser
1730 1735 1740
ctg cag cag gca gee ctg cga cag aga ggg gag ata gag tgg cag 5274
Leu Gin Gin Ala Ala Leu Arg Gin Arg Gly Glu Ile Glu Trp Gin
1745 1750 1755
aag cag etc ctc cag agg aac aca cag gaa gta gag egg atg act 5319
Lys Gin Leu Leu Gin Arg Asn Thr Gin Glu Val Glu Arg Met Thr
1760 1765 1770
get gag ace cga gca tta cag tcg tgt gtt gag tct ttg tgc aaa 5364
Ala Glu Thr Arg Ala Leu Gin Ser Cys Val Glu Ser Leu Cys Lys
1775 1780 1785
gaa aag caa gat ctc gaa gaa aaa cag gac age tgg gaa aag aag 5409
Glu Lys Gin Asp Leu Glu Glu Lys Gin Asp Ser Trp Glu Lys Lys
1790 1795 1800
ttg gca cag ace aaa egg gtt eta gca get gca gaa gag gac age 5454
Leu Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asp Ser
1805 1810 1815
gag atg gag egg gca cgc tta gaa aag ttg gaa ctg gac gee agg 5499
Glu Met Glu Arg Ala Arg Leu Glu Lys Leu Glu Leu Asp Ala Arg
1820 1825 1830
aag ctg cag cag gag ttg gac caa cga aac agg gag aag ctc tee 5544
Lys Leu Gin Gin Glu Leu Asp Gin Arg Asn Arg Glu Lys Leu Ser
1835 1840 1845
ctg cat caa gac ctg gca gtg gtg cag cag cag eta caa gaa aaa 5589
Leu His Gin Asp Leu Ala Val Val Gin Gin Gin Leu Gin Glu Lys
1850 1855 1860
S80 Z 080Z SLOZ
naq uip aas bay uTD aTI ski nori vIv nip ski naq aaS PTV IPA
t9Z9 .6go evo afro bbo Evo ogv Bev ggo oob vs6 Bvr Lap obv oob bgb
OLOZ S9OZ 090Z
uip ski nTO ETv ski ski bay nip ally naq aud uip usy bay nari
6IZ9 bro byv Byb oob vvv BEE yby yvb EDE .6q0 OqO byo ovv obo Egg
SSOZ 050Z StOZ
norl aas aud dsy viy bay low aos dsv atiL nip ski uip naq viy
tLI9 ogo obv ogg ovb bob bbv bgy Dog ovb BOP BEB BEE Eva &go Dab
OtOZ SEOZ OEOZ
naq no7 niD cloy aas ski Eiy naq nori uip uTD nID baV nID aaS
6ZT9 bqo bqo bvb ovb vog bry pob bgo vgg BED byo bvb bbo yvb vog
5Z0Z OZOZ STOZ
nri uip bay ski aqi uip aas nari auL ski nip nal ITU niD laS
1809 ggo Eceo ybo bye oov Eva oog ogo bov byv bvb bgo oov byb oby
OTOZ SOOZ 000Z
day bay kip nTD !LID uTO n37 aga, bav TPA baV niD nTO PTV TPA
6E09 bbg bbv rbb bvb brb Eva bgg oor BEY ogb gbo bvb byb gob bgb
5661 0661 S861
naq naq ski viv na7 IvA uip dsy nari ski AID sAri urD nTe qaW
t66S bqg ogo bye gob ogo bgb Evo orb bgo Lee obb yvy bro Brb bgr
0861 SL61 OL6T
naq nip ski nip nor' uip uip uie uTD nip ski naq aqI TEA ski
6t6S blg vvb bee vvb BID byo vvo Eva Eva bvb bee Ego goy .61.6 yvy
S961 0961 SS6T
aas viy nip nor' ski ski nip nip sAD nip Bay nip ski uip nor:
t06S gbv gob vvb vgg Bee veu svb vv6 gbg vrb ybo 5E6 yvy Lea ogo
0S61 St6T 0t6T
Bay uip alTa 4aW 4014 uTO uTD PTV
naq sArl PTV nID usV AID
698S yby BED gqg bgy bgy vvb vvo EVO 3o.6 'ego byy bob byb OEE Ebb
SE6T 0E6T SZ6T
nip ail nip ski uip naq AID uip TITD ulD
LITO ski 'NI nID
tT8S vvb ggv bvb Lee Leo ggo BBB vvo ggo bvo EEO bvo bey voy bvb
0Z61 5161 0161
Aip nip ski tie 5A0 dsy nTD aqd ski ski atiI dij,nTO AID TEA
69L5 bbb vvb vve bra obq orb vrb ggg bee Lee boy bbg vvb gbb bgb
5061 0061 S681
dsy ski nip nori bay LtLtL uip nip aas nan neri viv day ski bay
tZLS ovb bey Lab ogo bbr oov Eva eh obv ogo Ego Yob ovb bee obo
0681 5881 0881
ski atIL aql SAD norT TA nip uip nip viy nari dsy naq sTH nIe
6L9S bry OOP oov obq ago bgb bvb bra vvb Yob 'ego Deb bgg gyp Emb
Stet 0L81 598T
uip IvA citin/ alu nou nip ski uip nor' las usi TvA PTV TITD TrED
tE9S Bra a;B qe.6 qpv ea vvb Eve Eva vgg vog ovr vgb rob evE Eva
L81
1E-SO-OTOZ 9SEE0LZ0 710
OTEZ SO EZ 00EZ
nip PTV naq aas ATP TITO baV aas
nari aas bav xqaaS PTV
6E69 bpb pob, go bog obb bvb OOP obo bog bga ;bp obo oov Dag bob
S6ZZ 06ZZ S8EZ
/as dsv AID aas aqI aas -nu TuA naq ni0 AID uarl PTV dsV TPA
f7689 Dog ovb bb6 aag gav abv OOP agb Bga bub abb bgo aob ovb bgB
08ZZ SL ZZ OLZZ
uip bay Bay nag aas sTH nari aqI AID nTD baV Bald
EaV AID
61'89 BPO bbo Eba bgo obv aro boo OOP BBB bvb bop obo &Bo bbo obb
S9ZZ 09Z SSZZ
nID aas nari IPA uTS PTV uTp ski las law SAD Bay bald narl ulD
P089 brb obr Ego bgb Erb oh Evo bry oog bgr obg obo obo ago bvo
OSZZ ST7ZZ OtZZ
PTV ski nari bav dsv nip Bav sTH bay nari ski nip Bald nal PTV
6SL9 aob bpv ogo bbo opb bvb abo 0E0 obo bgo bvv bpb bba ago EDE,
SEZZ OEZZ SZZZ
nip AID Bay dal uip nip dsld PTV IPA sTH PIV uTs AID aqd usv
FELS BPB vbb &bp bbg bvo Erb, gvb bob bgb ova gob bpo a6.6 qqq. qpu
OZZZ STZZ OTZZ
naq ski nip nip sA0 aas aas oad Bay dsV aaS TPA ata agd oad
6999 bla PPE bvb veb obq gog Pog POO PBP ovb obv bgb OOP gqg boo
SOZZ 00ZZ SGTZ
atd usv nTp ski nari aas nip naq AID AID AID nai usv nTD usv
f7Z99 agg qPP bvb PPP bqg obp bvb bqg abb vbb vbb ;go OPP bvb gvv
06T S8TZ 08TZ
Bay nip nau nari IVnTD nari dsv viv oad naq niS Old naq @Lid
6LS9 Bbv vvb Ego glo oob Bpb boo ovb Bob voo bgo rvB vao ;go gqg
SLTZ OLTZ S9TZ
uip usv naq usv ski nari is aqI Bay aiI nip dsv ski IPA TITS
i7ES9 Eva ovv ago qPP BEE bgo obv oor vbo ogv Pvb gv6 vvv bgb bvb
091Z SSTZ OSTZ
SAD ski nor' viv uip gain' viv dsv aaS aII IDgain' uTp bald bav
68t,9 gbg 'EPP ggo vob EPO &qv bob gvE gbv agp ppb Bqv &ED VBP PEE
StTZ U.-CZ SETZ
nID nari dsv ski uTS usV aUL gaW uip ski bav nai nip ivA aAi
f7T7T79 ppb Bqq qp.6 BPP PPO OPP POP bgv bpa PEP .6.6v ogo EvE. Bgb ovg
OETZ SZTZ OZTZ
nID baV uTO 4aW uTO usv nari nTD bav qapi nari Bay Bav viv bay
66E9 bpb obo Evo bqv bpo ovv ogo bvb Ebv bgv vga obo bbo oab Ebo
STT Z OTT Z SOTZ
nTp sTH usv dsv uTS PTV IPA uT5 TATO aII 1LPTV laW nip bav
f7SE9 Bpb ovo ovv ovb Bp Dab bgb buo vvb ogr oar vob bgv bvb Bbv
OOTZ S6OZ 060Z
1110 gaw SAD aas usv nip uTS ski uiD nID naq nari usid ski niD
60E9 bva bqu obq obv ovv bvb buo &Er PEO beb bgo ggo ovv bvu Erb
881
TE-g0-0TOZ 9gEEOLZO 7/0
CA 02703356 2010-05-31
189
gac gaa ccg ccg ggg ccc agc cag agc tcc cgg cgg ctc ccc cga 6984
Asp Glu Pro Pro Gly Pro Ser Gin Ser Ser Arg Arg Leu Pro Arg
2315 2320 2325
ggc ccg tcg ccg cgg ctg gac gcg cac cga ccc tga ggacccggag 7030
Gly Pro Ser Pro Arg Leu Asp Ala His Arg Pro
2330 2335
gacccggagg cccggcgtcc cctcggaacg cttcctccgc gtccgcggac accaggctca 7090
cgggaaggcg cgtccatgcg ggaagagccg cgagcggaac ccggatgccc gggctggtct 7150
ctgggccttg gaaacgtgtt gccgtaaaag cagcgcccgc ggctgcggac ttgaagcccc 7210
gaactggtaa actcggcggc tgccgggcga actgtactca ggactttttt cacggacacc 7270
gtcagatttt atttttggaa atctattttc atatgaaaat aaaagataaa agcgcctgaa 7330
aaaaaaaaaa aaaaaaaact agt 7353
<210> 26
<211> 2339
<212> PRT
<213> Canis familiaris
<400> 26
Met Lys Lys Gly Ser Gin Gin Lys Phe Leu Lys Ala Lys Met Pro Pro
1 5 10 15
Ser Ser His Ser Pro Ser Pro Pro Ser Leu Thr Ser Asn Met Arg Ser
20 25 30
Arg Ser Leu Ser Pro Leu Ser Gly Ser Glu Thr Leu Pro Phe His Phe
35 40 45
Gly Gly Pro Trp His Glu Gin Val Glu Ile Thr Asp Glu Ser Thr Val
50 55 60
Val Leu Asp Tyr Gin Asp His Lys Glu Ala Asp Ser His Ala Gly Val
65 70 75 80
Arg Tyr Ile Thr Glu Ala Leu Val Arg Lys Leu Thr Lys Gin Asp Asn
85 90 95
Leu Ala Leu Val Lys Ser Leu Asn Leu Ser Leu Ala Lys Gly Gly Gly
100 105 110
Lys Lys Phe Arg Cys Ile Glu Asn Leu Glu Lys Cys Val Lys Leu Glu
115 120 125
Val Leu Asn Leu Ser Tyr Asn Leu Ile Gly Lys Ile Glu Lys Val Asp
130 135 140
Lys Leu Leu Lys Leu Arg Glu Leu Asn Leu Ser Tyr Asn Lys Ile Arg
145 150 155 160
Lys Ile Glu Gly Ile Glu Asn Leu Tyr Asn Leu Gin Lys Leu Asn Leu
165 170 175
Ala Gly Asn Glu Ile Glu His Ile Pro Val Trp Leu Gly Lys Lys Leu
180 185 190
Lys Ser Leu Arg Ile Leu Asn Leu Lys Gly Asn Lys Ile Ser Ser Leu
195 200 205
Gin Asp Val Ser Lys Leu Lys Pro Leu Gin Asp Leu Thr Ser Leu Ile
210 215 220
Leu Leu Glu Asn Pro Val Ala Thr Leu Pro His Tyr Ile Gin Phe Thr
225 230 235 240
Ile Phe His Leu Arg Ser Leu Glu Ser Leu Glu Gly Gin Pro Val Thr
245 250 255
Ser Gin Asp Arg Gin Glu Ala Phe Ala Arg Phe Ser Leu Asp Glu Val
260 265 270
Glu Arg Leu Glu Arg Asp Leu Glu Lys Lys Thr Met Glu Thr Glu Glu
275 280 285
Leu Arg Ser Glu Gin Thr Arg Phe Leu Glu Glu Ile Lys Ser Gin Asp
290 295 300
CA 02703356 2010-05-31
190
Lys Leu Asn Lys Ser Leu Lys Glu Glu Ala Arg Leu Gin Lys Gin Ser
305 310 315 320
Tyr Glu Glu Leu Glu Ser Asn Leu Asn Thr Lys Asn Glu Leu Leu Lys
325 330 335
Gin Lys Thr Met Glu Leu Met Arg Ala Cys Gin Lys Gin Tyr Glu Met
340 345 350
Glu Gin Glu Leu Ala Phe Tyr Lys Ile Asp Ala Lys Phe Glu Pro Leu
355 360 365
Asn Tyr Tyr Pro Ser Glu Tyr Val Glu Ile Asp Lys Thr Pro Asp Glu
370 375 380
Ser Pro Tyr Ile Gly Lys Ser Arg Tyr Lys Arg Asn Met Phe Thr Thr
385 390 395 400
Glu Ser Tyr Ile Ile Ala Asn Ala Gin Thr Val Lys Ile Lys Lys Met
405 410 415
Glu Leu Asp Glu Gly Glu Gin Leu Arg Asn Glu His Val Asn Leu Gly
420 425 430
Ala Ser Pro Thr Asp Ile Gin Leu Glu Asp Lys Glu Lys Lys Ile Ser
435 440 445
Ala Ala Gin Thr Arg Leu Ser Glu Leu His Asp Glu Ile Glu Lys Ala
450 455 460
Glu Gin Gin Ile Leu Arg Ala Thr Glu Glu Phe Lys Gin Leu Glu Glu
465 470 475 480
Ala Ile Gin Leu Lys Lys Ile Ser Glu Ala Glu Lys Asp Leu Leu Phe
485 490 495
Lys Gin Leu Ser Gly Arg Ile Gin Leu Leu Asn Lys Leu Arg Gin Glu
500 505 510
Ala Val Asp Leu Glu Thr Gin Met Glu Lys Gin Arg Gin Glu Ile Gly
515 520 525
Glu Lys Gin Asn Glu Ile Lys Asp Leu Glu Ile Val Thr Asp Ser Leu
530 535 540
Asp Ser Arg Asp Pro Lys His Cys His Met Lys Ala Gin Lys Arg Gly
545 550 555 560
Lys Glu Gin Gin Leu Asp Ile Met Asn Lys Gin Tyr Lys Gin Leu Glu
565 570 575
Ser Arg Leu Asp Glu Ile Leu Ser Arg Ile Ala Lys Glu Thr Glu Glu
580 585 590
Ile Lys Asp Leu Glu Glu Gin Leu Thr Glu Gly Gin Ile Ala Ala Asn
595 600 605
Glu Ala Leu Lys Lys Asp Leu Glu Ser Val Ile Ser Gly Leu Gin Glu
610 615 620
Tyr Leu Glu Thr Val Lys Gly Gin Ala Arg Gin Ala Gin Asn Glu Cys
625 630 635 640
Arg Lys Leu Gin Asp Glu Lys Glu Thr Leu Leu Gin Arg Leu Ser Glu
645 650 655
Val Glu Gin Glu Arg Asp Gin Leu Glu Ile Val Ala Ile Asp Ala Glu
660 665 670
Asn Met Arg Lys Glu Leu Ala Glu Leu Glu Asn Ala Leu Gin Glu Gin
675 680 685
His Glu Val Asn Ile Ser Leu Gin Gin Thr Gin Gly Asp Leu Ser Ala
690 695 700
Tyr Glu Ala Glu Leu Glu Ala Gin Leu Lys Ile Arg Asp Ala Glu Ala
705 710 715 720
Asn Gin Leu Lys Glu Glu Leu Glu Lys Leu Arg Arg Leu Ser Gin Leu
725 730 735
Glu Gin Ser Ala Leu Gin Ala Glu Leu Glu Lys Glu Lys Gin Ala Phe
740 745 750
Lys Thr Ala Val Lys Lys Ala Gin Leu Ser Glu Gly Lys Asp Gin Glu
755 760 765
Asn Ser Glu Leu Arg Thr Gin Leu Gin Gin Leu Gin Asp Asp Asn Asp
770 775 780
CA 02703356 2010-05-31
191
Leu Leu Lys Gin Gin Leu Lys Asp Phe Gin Ser His Leu Asn His Val
785 790 795 800
Val Asp Gly Leu Ile Arg Pro Glu Glu Val Ala Ala Cys Val Asp Glu
805 810 815
Leu Arg Lys Lys Leu Lys Ser Gly Ala Gly Glu Met Arg Ile His Thr
820 825 830
Pro Ser Asp Val Leu Gly Lys Ser Leu Ala Asp Leu Gin Lys Gin Phe
835 840 845
Ser Glu Ile Leu Ala Arg Her Gin Trp Glu Arg Gin Glu Ala Gin Val
850 855 860
Arg Glu Arg Lys Leu Gin Glu Glu Met Ala Leu Gin Gin Glu Lys Leu
865 870 875 880
Ala Ser Gly Gin Glu Glu Phe Arg His Ala Cys Glu Arg Ala Leu Glu
885 890 895
Ala Arg Ile Ser Phe Asp Lys Arg Gin His Glu Ala Arg Ile Gin Gin
900 905 910
Leu Glu Asn Glu Ile His Tyr Leu Gin Glu Asn Leu Lys Ser Met Glu
915 920 925
Glu Ile Gin Gly Leu Thr Asp Leu Gin Leu Gin Glu Ala Asp Glu Glu
930 935 940
Lys Glu Arg Ile Leu Ala Gin Leu Arg. Glu Leu Glu Lys Lys Lys Lys
945 950 955 960
Leu Glu Asp Ala Lys Ser Gin Glu Gin Phe Leu Gly Leu Asp Arg Glu
965 970 975
Leu Lys Lys Leu Lys Lys Ala Val Ala Ala Ser Asp Lys Leu Ala Thr
980 985 990
Ala Glu Leu Thr Ile Ala Lys Asp Gin Leu Lys Ser Leu His Gly Thr
995 1000 1005
Val Met Lys Ile Asn Gin Glu Arg Ala Glu Glu Leu Gin Glu Thr
1010 1015 1020
Glu Arg Phe Ser Arg Lys Ala Ala Gin Ala Ala Arg Asp Leu Ile
1025 1030 1035
Arg Ala Glu Ala Glu Ile Glu Leu Leu Gin Lys Leu Leu Arg Asp
1040 1045 1050
Lys Glu Glu Gin Phe Arg Asn Glu Ile Glu Lys Val Asp Val Gly
1055 1060 1065
Her Gly Gly Ala Lys Ser Gin Met Leu Glu Met Glu Lys Leu Asn
1070 1075 1080
Glu Thr Met Glu Arg Gin Arg Thr Glu Ile Ala Arg Leu Arg Asn,
1085 1090 1095
Leu Leu Asp Leu Thr Gly Ala Asp Asn Lys Gly Asn Phe Glu Asn
1100 1105 1110
Val Leu Glu Glu Ile Ala Glu Leu Arg Arg Glu Val Ser His Gin
1115 1120 1125
Asn Asp Tyr Ile Ser Ser Met Thr Asp Pro Phe Lys Arg Arg Gly
1130 1135 1140
Tyr Trp Tyr Phe Met Pro Pro Pro Ser Ser Her Lys Val Ser Her
1145 1150 1155
His Ser Ser Gin Ala Thr Lys Asp Ser Gly Val Gly Leu Lys Tyr
1160 1165 1170
Thr Ala Ser Thr Pro Val Arg Lys Pro His Arg Gly Arg Gin Asp
1175 1180 1165
Gly Lys Glu Asn Her Gly Pro Pro Pro Ala Ser Gly Tyr Trp Val
1190 1195 1200
Tyr Ser Pro Ile Arg Ser Gly Leu His Lys Ser Phe Ser Asn Arg
1205 1210 1215
Asp Ala Asp Ser Gly Gly Asp Ser Gin Glu Glu Her Glu Leu Asp
1220 1225 1230
Asp Gin Glu Asp His Pro Phe Val Pro Pro Pro Gly Tyr Met Met
1235 1240 1245
CA 02703356 2010-05-31
=
192
Tyr Thr Val Phe Pro Asp Gly Ser Pro Val Pro Gin Gly Met Ala
1250 1255 1260
Leu Tyr Ala Pro Pro Pro Pro Leu Pro Asn Asn Ser Gin Pro Leu
1265 1270 1275
Asp Leu Gly Thr Val Val Tyr Gly Pro Pro Pro Val Gly Ala Pro
1280 1285 1290
Ile Val Tyr Gly Pro Pro Pro Pro Asn Phe Ser Val Pro Leu Ile
1295 1300 1305
Pro Val Gly Val Leu His Cys Asn Val Pro Glu His His Asn Leu
1310 1315 1320
Glu Asn Glu Val Ser Arg Leu Glu Asp Ile Met Gin His Leu Lys
1325 1330 1335
Ser Gly Lys Arg Glu Gin Cys Met Lys Thr Pro Lys Leu Gin Ser
1340 1345 1350
Glu Lys Glu Leu Ala Glu Leu Gin His Asn Ile Asp Gly Leu Leu
1355 1360 1365
Gin Glu Lys Lys Asp Leu Glu His Glu Val Glu Glu Leu His Arg
1370 1375 1380
Thr Ile Gin Lys His Gin Gin Arg Lys Asp Phe Ile Asp Gly Asn
1385 1390 1395
Val Glu Ser Leu Val Asn Asp Leu Glu Ile Glu Lys Ser Leu Lys
1400 1405 1410
His His Glu Asp Ile Val Asp Glu Ile Glu Cys Ile Glu Arg Thr
1415 1420 1425
Leu Leu Lys Arg Arg Ala Glu Leu Arg Glu Ala Asp Arg Leu Leu
1430 1435 1440
Thr Glu Ala Glu Ser Glu Leu Ser Cys Thr Lys Glu Lys Thr Lys
1445 1450 1455
His Ala Val Glu Lys Phe Thr Asp Ala Lys Arg Asn Leu Leu Gin
1460 1465 1470
Thr Glu Lys Asp Ala Glu Glu Leu Glu Arg Arg Ala Gin Glu Thr
1475 1480 1485
Ala Ile Asn Leu Val Lys Ala Asp Gin Gin Leu Arg Leu Leu Gin
1490 1495 1500
Ala Asp Thr Lys Asp Leu Glu Gin His Lys Met Glu Gin Glu Glu
1505 1510 1515
Ile Leu Lys Glu Ile Asn Lys Val Val Ala Ala Lys Asp Ser Asp
1520 1525 1530
Phe Gin Ser Leu Asn Lys Lys Lys Glu Val Leu Thr Gly Glu Leu
1535 1540 1545
Gin Lys Leu Gin Lys Asp Ile Glu Thr Ala Arg His Asn Glu Asp
1550 1555 1560
Gin His Leu Gin Val Leu Lys Glu Ser Glu Thr Leu Leu Gin Ala
1565 1570 1575
Lys Lys Ala Glu Leu Glu Asn Leu Lys Ser Gin Val Ser Gly Gin
1580 1585 1590
Gin Gin Glu Met Ala Val Leu Asp Arg Glu Leu Gly His Lys Lys
1595 1600 1605
Glu Glu Leu His Leu Leu Gin Glu Ser Met Val Gin Ala Lys Ala
1610 1615 1620
Asp Leu Gin Glu Ala Leu Arg Leu Gly Glu Ser Glu Val Thr Glu
1625 1630 1635
Lys Cys Asn His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu
1640 1645 1650
Ser Phe Gin Lys Gly Glu Leu Asn Val Gin Ile Ser Glu Lys Lys
1655 1660 1665
Thr Gin Leu Ala Leu Ile Lys Gin Glu Ile Glu Lys Glu Glu Asp
1670 1675 1680
Asn Leu Gin Val Val Leu Gly Gin Met Ser Lys His Lys Thr Glu
1685 1690 1695
CA 02703356 2010-05-31
193
Leu Lys Asn Ile Leu Asp Met Leu Gin Leu Glu Asn Asn Glu Leu
1700 1705 1710
Gin Gly Leu Lys Leu Gin His Asp Gin Lys Met Ser Glu Leu Glu
1715 1720 1725
Lys Thr Arg Val Glu Val Leu Glu Glu Lys Leu Glu Leu Glu Ser
1730 1735 1740
Leu Gin Gin Ala Ala Leu Arg Gin Arg Gly Glu Ile Glu Trp Gin
1745 1750 1755
Lys Gin Leu Leu Gin Arg Asn Thr Gin Glu Val Glu Arg Met Thr
1760 1765 1770
Ala Glu Thr Arg Ala Leu Gin Ser Cys Val Glu Ser Leu Cys Lys
1775 1780 1785
Glu Lys Gin Asp Leu Glu Glu Lys Gin Asp Ser Trp Glu Lys Lys
1790 1795 1800
Leu Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asp Ser
1805 1810 1815
Glu Met Glu Arg Ala Arg Leu Glu Lys Leu Glu Leu Asp Ala Arg
1820 1825 1830
Lys Leu Gin Gin Glu Leu Asp Gin Arg Asn Arg Glu Lys Leu Ser
1835 1840 1845
Leu His Gin Asp Leu Ala Val Val Gin Gin Gin Leu Gin Glu Lys
1850 1855 1860
Gin Glu Ala Val Asn Ser Leu Gin Lys Glu Leu Thr Asp Val Gin
1865 1870 1875
Glu His Leu Asp Leu Ala Glu Gin Glu Val Leu Cys Thr Thr Lys
1880 1885 1890
Arg Lys Asp Ala Leu Leu Ser Glu Gin Thr Arg Leu Glu Lys Asp
1895 1900 1905
Val Gly Glu Trp Thr Lys Lys Phe Glu Asp Cys Gin Lys Glu Gly
1910 1915 1920
Glu Thr Lys Gin Gin Gin Leu Gin Gly Leu Gin Lys Glu Ile Glu
1925 1930 1935
Gly Asn Glu Ala Lys Leu Ala Gin Gin Glu Met Met Phe Gin Arg
1940 1945 1950
Leu Gln Lys Glu Arg Glu Cys Glu Glu Lys Lys Leu Glu Ala Ser
1955 1960 1965
Lys Val Thr Leu Lys Glu Gin Gin Gin Gin Leu Glu Lys Glu Leu
1970 1975 1980
Met Glu Gin Lys Gly Lys Leu Asp Gin Val Leu Ala Lys Leu Leu
1985 1990 1995
Val Ala Glu Glu Arg Val Arg Thr Leu Gin Glu Glu Gly Arg Trp
2000 2005 2010
Ser Glu Thr Leu Glu Lys Thr Leu Ser Gin Thr Lys Arg Gin Leu
2015 2020 2025
Ser Glu Arg Glu Gin Gin Leu Leu Ala Lys Ser Asp Glu Leu Leu
2030 2035 2040
Ala Leu Gin Lys Glu Thr Asp Ser Met Arg Ala Asp Phe Ser Leu
2045 2050 2055
Leu Arg Asn Gin Phe Leu Thr Glu Arg Lys Lys Ala Glu Lys Gin
2060 2065 2070
Val Ala Ser Leu Lys Glu Ala Leu Lys Ile Gin Arg Ser Gin Leu
2075 2080 2085
Glu Lys Asn Leu Leu Glu Gin Lys Gin Glu Asn Ser Cys Met Gin
2090 2095 2100
Arg Glu Met Ala Thr Ile Glu Gin Val Ala Gin Asp Asn His Glu
2105 2110 2115
Arg Ala Arg Arg Leu Met Arg Glu Leu Asn Gin Met Gin Arg Glu
2120 2125 2130
Tyr Val Glu Leu Arg Lys Gin Met Thr Asn Gin Lys Asp Leu Glu
2135 2140 2145
CA 02703356 2010-05-31
194
Arg Arg Gin Met Glu Ile Ser Asp Ala Met Gin Ala Leu Lys Cys
2150 2155 2160
Glu Val Lys Asp Glu Ile Arg Thr Ser Leu Lys Asn Leu Asn Gin
2165 2170 2175
Phe Leu Pro Glu Leu Pro Ala Asp Leu Glu Ala Leu Leu Glu Arg
2180 2185 2190
Asn Glu Asn Leu Gly Gly Gly Leu Glu Ser Leu Lys Glu Asn Phe
2195 2200 2205
Pro Phe Thr Val Ser Asp Arg Pro Ser Ser Cys Glu Glu Lys Leu
2210 2215 2220
Asn Phe Gly Gin Ala His Val Ala Asp Glu Gin Trp Arg Gly Glu
2225 2230 2235
Ala Leu Arg Glu Lys Leu Arg His Arg Glu Asp Arg Leu Lys Ala
2240 2245 2250
Gin Leu Arg Arg Cys Met Ser Lys Gin Ala Glu Val Leu Ser Glu
2255 2260 2265
Gly Arg Arg Arg Thr Glu Gly Thr Leu His Ser Leu Arg Arg Gin
2270 2275 2280
Val Asp Ala Leu Gly Glu Leu Val Thr Ser Thr Ser Gly Asp Ser
2265 2290 2295
Ala Ser Thr Arg Ser Leu Ser Arg Thr Glu Gly Ser Leu Ala Glu
2300 2305 2310
Asp Glu Pro Pro Gly Pro Ser Gin Ser Ser Arg Arg Leu Pro Arg
2315 2320 2325
Gly Pro Ser Pro Arg Leu Asp Ala His Arg Pro
2330 2335
<210> 27
<211> 7431
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (32)..(7009)
<400> 27
gttttgatga acacctggct ttattcttgc a atg aag aaa ggt tct caa caa 52
Met Lys Lys Gly Ser Gln Gin
1 5
aaa ata ttc tcc aaa gca aag ata cca tca tca tct cac tct cct atc 100
Lys Ile Phe Ser Lys Ala Lys Ile Pro Ser Ser Ser His Ser Pro Ile
15 20
cca tca tct atg tcc aat atg aga tct agg tca ctt tca cct ttg att 148
Pro Ser Ser Met Ser Asn Met Arg Ser Arg Ser Leu Ser Pro Leu Ile
25 30 35
gga tca gag act cta cct ttt cat tct gga gga cag tgg tgt gag caa 196
Gly Ser Glu Thr Leu Pro Phe His Ser Gly Gly Gin Trp Cys Glu Gin
40 45 50 55
gtt gag att gca gat gaa aac aat atg ctt ttg gac tat caa gac cat 244
Val Glu Ile Ala Asp Glu Asn Asn Met Leu Leu Asp Tyr Gin Asp His
60 65 70
CA 02703356 2010-05-31
195
aaa gga gct gat tca cat gca gga gtt aga tat att aca gag gcc ctc 292
Lys Gly Ala Asp Ser His Ala Gly Val Arg Tyr Ile Thr Glu Ala Leu
75 80 85
att aaa aaa ctt act aaa cag gat aat ttg gct ttg ata aaa tct ctg 340
Ile Lys Lys Leu Thr Lys Gin Asp Asn Leu Ala Leu Ile Lys Ser Leu
90 95 100
aac ctt tca ctt tct aaa gac ggt ggc aag aaa ttt aag tat att gag 388
Asn Leu Ser Leu Ser Lys Asp Gly Gly Lys Lys Phe Lys Tyr Ile Glu
105 110 115
aat ttg gaa aaa tgt gtt aaa ctt gaa gta ctg aat ctc age tat aat 436
Asn Leu Glu Lys Cys Val Lys Leu Glu Val Leu Asn Leu Ser Tyr Asn
120 125 130 135
cta ata ggg aag att gaa aag ttg gac aag ctg tta aaa tta cgt gaa 484
Leu Ile Gly Lys Ile Glu Lys Leu Asp Lys Leu Leu Lys Leu Arg Glu
140 145 150
ctc aac tta tca tat aac aaa atc agc aaa att gaa ggc ata gaa aat 532
Leu Asn Leu Ser Tyr Asn Lys Ile Ser Lys Ile Glu Gly Ile Glu Asn
155 160 165
atg tgt aat ctg caa aag ctt aac ctt gca gga aat gaa att gag cat 580
Met Cys Asn Leu Gin Lys Leu Asn Leu Ala Gly Asn Glu Ile Glu His
170 175 180
att cca gta tgg tta ggg aag aag tta aaa tct ttg cga gtc ctc aat 628
Ile Pro Val Trp Leu Gly Lys Lys Leu Lys Ser Leu Arg Val Leu Asn
185 190 195
ttg aaa ggc aac aag ata tca tcg ctc caa gat ata agc aag ttg aaa 676
Leu Lys Gly Asn Lys Ile Ser Ser Leu Gin Asp Ile Ser Lys Leu Lys
200 205 210 215
ccg ctt caa gat ttg att tct ctg atc cta gtt gaa aat cca gtt gtg 724
Pro Leu Gin Asp Leu Ile Ser Leu Ile Leu Val Glu Asn Pro Val Val
220 225 230
acc ctt cct cat tac ctc cag ttt acc att ttc cac ctc cgt tca ttg 772
Thr Leu Pro His Tyr Leu Gin Phe Thr Ile Phe His Leu Arg Ser Leu
235 240 245
gaa agt ttg gaa ggt cag cca gta acc act cag gat aga cag gag gct 820
Glu Ser Leu Glu Gly Gin Pro Val Thr Thr Gin Asp Arg Gin Glu Ala
250 255 260
ttt gag aga ttc agt tta gaa gag gta gaa aga ctg gaa aga gac cta 868
Phe Glu Arg Phe Ser Leu Glu Glu Val Glu Arg Leu Glu Arg Asp Leu
265 270 275
gaa aaa aag atg ata gaa act gaa gag ctt aag agc aaa caa aca agg 916
Glu Lys Lys Met Ile Glu Thr Glu Glu Leu Lys Ser Lys Gin Thr Arg
280 285 290 295
ttc ctt gag gaa att aaa aat caa gat aaa ttg aat aaa tca tta aaa 964
Phe Leu Glu Glu Ile Lys Asn Gin Asp Lys Leu Asn Lys Ser Leu Lys
300 305 310
CA 02703356 2010-05-31
196
gag gag gcc atg tta cag aaa cag agc tgt gag gaa ctc aag agt gac 1012
Glu Glu Ala Met Leu Gin Lys Gin Ser Cys Glu Glu Leu Lys Ser Asp
315 320 325
tta aac aca aaa aat gaa ttg cta aaa cag aag acc ata gaa tta aca 1060
Leu Asn Thr Lys Asn Glu Leu Leu Lys Gin Lys Thr Ile Glu Leu Thr
330 335 340
cga gca tgt cag aag caa tat gag ctg gaa cag gaa ttg gcc ttt tat 1108
Arg Ala Cys Gin Lys Gin Tyr Glu Leu Glu Gin Glu Leu Ala Phe Tyr
345 350 355
aaa att gat get aaa ttt gag cca cta aat tat tat cca tea gag tat 1156
Lys Ile Asp Ala Lys Phe Glu Pro Leu Asn Tyr Tyr Pro Ser Glu Tyr
360 365 370 375
gct gaa att gat aaa gcc cca gat gaa agc cct tac att ggc aaa tcc 1204
Ala Glu Ile Asp Lys Ala Pro Asp Glu Ser Pro Tyr Ile Gly Lys Ser
380 385 390
aga tac aag aga aat atg ttt gcc aca gag agt tat att att gac agt 1252
Arg Tyr Lys Arg Asn Met Phe Ala Thr Glu Ser Tyr Ile Ile Asp Ser
395 400 405
gct cag gca gta cag atc aag aag atg gag cca gat gaa caa ctt aga 1300
Ala Gin Ala Val Gin Ile Lys Lys Met Glu Pro Asp Glu Gin Leu Arg
410 415 420
aat gat cac atg aac ttg aga ggc cac aca cca ctg gac acg caa ctg 1348
Asn Asp His Met Asn Leu Arg Gly His Thr Pro Leu Asp Thr Gin Leu
425 430 435
gaa gac aaa gaa aaa aaa ata agt gca gca caa act cga cta tca gaa 1396
Glu Asp Lys Glu Lys Lys Ile Ser Ala Ala Gin Thr Arg Leu Ser Glu
440 445 450 455
ctg cat gat gaa ata gaa aag gca gaa caa caa att ttg aga gct act 1444
Leu His Asp Glu Ile Glu Lys Ala Glu Gin Gin Ile Leu Arg Ala Thr
460 465 470
gaa gaa ttt aaa caa ctg gaa gaa gct ata caa cta aaa aag att tea 1492
Glu Glu Phe Lys Gin Leu Glu Glu Ala Ile Gin Leu Lys Lys Ile Ser
475 480 485
gaa gca ggg aaa gac ctt ctt tac aag cag ttg agt ggt aga cta caa 1540
Glu Ala Gly Lys Asp Leu Leu Tyr Lys Gin Leu Ser Gly Arg Leu Gin
490 495 500
ctt gta aat aaa tta cgc cag gaa gct ctg gat cta gaa ctg cag atg 1588
Leu Val Asn Lys Leu Arg Gin Glu Ala Leu Asp Leu Glu Leu Gin Met
505 510 515
gaa aag caa aag cag gaa att gcc gga aag cag aag gag att aag gac 1636
Glu Lys Gin Lys Gin Glu Ile Ala Gly Lys Gin Lys Glu Ile Lys Asp
520 525 530 535
ctg caa ata gcc ata gat agc ctg gat tcc aaa gac cca aaa cat tcc 1684
Leu Gin Ile Ala Ile Asp Ser Leu Asp Ser Lys Asp Pro Lys His Ser
540 545 550
CA 02703356 2010-05-31
197
cat atg aag gct caa aag agc ggt aaa gaa caa cag ctt gac att atg 1732
His Met Lys Ala Gin Lys Ser Gly Lys Glu Gin Gin Leu Asp Ile Met
555 560 565
aac aag cag tac caa caa ctt gaa agt cgt ttg gat gag ata ctt tct 1780
Asn Lys Gin Tyr Gin Gin Leu Glu Ser Arg Leu Asp Glu Ile Leu Ser
570 575 580
aga att gct aag gaa acg gaa gag att aag gac ctt gaa gaa cag ctt 1828
Arg Ile Ala Lys Glu Thr Glu Glu Ile Lys Asp Leu Glu Glu Gin Leu
585 590 595
act gaa ggc cag ata gca gca aat gaa gcc ctg aag aag gat tta gaa 1876
Thr Glu Gly Gin Ile Ala Ala Asn Glu Ala Leu Lys Lys Asp Leu Glu
600 605 610 615
ggt gtt atc agt ggg ttg caa gaa tac ctg ggg acc att aaa ggc cag 1924
Gly Val Ile Ser Gly Leu Gin Glu Tyr Leu Gly Thr Ile Lys Gly Gin
620 625 630
gca act cag gcc cag aat gag tgc agg aag ctg cgg gat gag aaa gag 1972
Ala Thr Gin Ala Gin Asn Glu Cys Arg Lys Leu Arg Asp Glu Lys Glu
635 640 645
aca ttg ttg cag aga ttg aca gaa gtc gag cag gag aga gac cag ctg 2020
Thr Leu Leu Gin Arg Leu Thr Glu Val Glu Gin Glu Arg Asp Gin Leu
650 655 660
gaa ata gtt gcc atg gat gca gaa aat atg agg aag gag ctt gca gag 2068
Glu Ile Val Ala Met Asp Ala Glu Asn Met Arg Lys Glu Leu Ala Glu
665 670 675
cta gaa agt gcc ctc caa gag cag cat gag gtg aat gca tct ttg cag 2116
Leu Glu Ser Ala Leu Gin Glu Gin His Glu Val Asn Ala Ser Leu Gin
680 685 690 695
cag acc cag gga gat ctc agt gcc tat gaa gct gag cta gag gct cgg 2164
Gin Thr Gin Gly Asp Leu Ser Ala Tyr Glu Ala Glu Leu Glu Ala Arg
700 705 710
cta aac cta agg gat gct gaa gcc aac cag ctc aag gaa gag ttg gaa 2212
Leu Asn Leu Arg Asp Ala Glu Ala Asn Gin Leu Lys Glu Glu Leu Glu
715 720 725
aaa gta aca aga ctt acc cag tta gaa caa tca gcc ctt caa gca gaa 2260
Lys Val Thr Arg Leu Thr Gin Leu Glu Gin Ser Ala Leu Gin Ala Glu
730 735 740
ctt gag aag gaa agg caa gcc ctc aag aat gcc ctt gga aaa gcc cag 2308
Leu Glu Lys Glu Arg Gin Ala Leu Lys Asn Ala Leu Gly Lys Ala Gin
745 750 755
ttc tca gaa gaa aag gag caa gag aac agt gag ctc cat gca aaa ctt 2356
Phe Ser Glu Glu Lys Glu Gin Glu Asn Ser Glu Leu His Ala Lys Leu
760 765 770 775
aaa cac ttg cag gat gac aat aat ctg tta aaa cag caa ctt aaa gat 2404
Lys His Leu Gin Asp Asp Asn Asn Leu Leu Lys Gin Gin Leu Lys Asp
780 785 790
CA 02703356 2010-05-31
=
198
ttc cag aat cac ctt aac cat gtg gtt gat ggt ttg gtt cgt cca gaa 2452
Phe Gin Asn His Leu Asn His Val Val Asp Gly Leu Val Arg Pro Glu
795 800 805
gaa gtg gca gct cgt gtg gat gag cta aga aga aaa ctg aaa tta gga 2500
Glu Val Ala Ala Arg Val Asp Glu Leu Arg Arg Lys Leu Lys Leu Gly
810 815 820
act ggg gaa atg aac atc cat agt cct tca gat gtc tta ggg aaa agt 2548
Thr Gly Glu Met Asn Ile His Ser Pro Ser Asp Val Leu Gly Lys Ser
825 830 835
ctt gct gat tta cag aaa caa ttc agt gaa att ctt gca cgc tcc aag 2596
Leu Ala Asp Leu Gin Lys Gin Phe Ser Glu Ile Leu Ala Arg Ser Lys
840 845 850 855
tgg gaa aga gat gaa gca caa gtt aga gag aga aaa ctc caa gaa gaa 2644
Trp Glu Arg Asp Glu Ala Gin Val Arg Glu Arg Lys Leu Gin Glu Glu
860 865 870
atg gct ctg cag caa gag aaa ctg gca act gga caa gaa gag ttc agg 2692
Met Ala Leu Gin Gin Glu Lys Leu Ala Thr Gly Gin Glu Glu Phe Arg
875 880 885
cag gcc tgt gag aga gcc ctg gaa gca aga atg aat ttt gat aag agg 2740
Gin Ala Cys Glu Arg Ala Leu Glu Ala Arg Met Asn Phe Asp Lys Arg
890 895 900
caa cat gaa gca aga atc cag caa atg gag aat gaa att cac tat ttg 2788
Gin His Glu Ala Arg Ile Gin Gin Met Glu Asn Glu Ile His Tyr Leu
905 910 915
caa gaa aat cta aaa agt atg gag gaa atc caa ggc ctt aca gat ctc 2836
Gin Glu Asn Leu Lys Ser Met Glu Glu Ile Gin Gly Leu Thr Asp Leu
920 925 930 935
caa ctt cag gaa gct gat gaa gag aag gag aga att ctg gcc caa ctc 2884
Gin Leu Gin Glu Ala Asp Glu Glu Lys Glu Arg Ile Leu Ala Gin Leu
940 945 950
cga gag tta gag aaa aag aag aaa ctt gaa gat gcc aaa tct cag gag 2932
Arg Glu Leu Glu Lys Lys Lys Lys Leu Glu Asp Ala Lys Ser Gin Glu
955 960 965
caa gtt ttt ggt tta gat aaa gaa ctg aag aaa cta aag aaa gcc gtg 2980
Gin Val Phe Gly Leu Asp Lys Glu Leu Lys Lys Leu Lys Lys Ala Val
970 975 980
gcc acc tct gat aag cta gcc aca gct gag ctc acc att gcc aaa gac 3028
Ala Thr Ser Asp Lys Leu Ala Thr Ala Glu Leu Thr Ile Ala Lys Asp
985 990 995
cag ctg aag tcc ctt cat gga act gtt atg aaa att aac cag gag 3073
Gin Leu Lys Ser Leu His Gly Thr Val Met Lys Ile Asn Gln Glu
1000 1005 1010
cga gca gag gag ttg cag gaa gca gag agg ttc agc aga aag gca 3118
Arg Ala Glu Glu Leu Gin Glu Ala Glu Arg Phe Ser Arg Lys Ala
1015 1020 1025
CA 02703356 2010-05-31
199
gca caa gca gcc aga gat ctc acc cga gca gaa gct gag atc gaa 3163
Ala Gin Ala Ala Arg Asp Leu Thr Arg Ala Glu Ala Glu Ile Glu
1030 1035 1040
ctc ctg cag aat ctc ctc agg cag aag ggg gag cag ttt cga ctt 3208
Leu Leu Gin Asn Leu Leu Arg Gin Lys Gly Glu Gin Phe Arg Leu
1045 1050 1055
gag atg gag aaa aca ggt gta ggt act gga gca aac tca cag gtc 3253
Glu Met Glu Lys Thr Gly Val Gly Thr Gly Ala Asn Ser Gin Val
1060 1065 1070
cta gaa att gag aaa ctg aat gag aca atg gaa cga caa agg aca 3298
Leu Glu Ile Glu Lys Leu Asn Glu Thr Met Glu Arg Gin Arg Thr
1075 1080 1085
gag att gca agg ctg cag aat gta cta gac ctc act gga agt gac 3343
Glu Ile Ala Arg Leu Gin Asn Val Leu Asp Leu Thr Gly Ser Asp
1090 1095 1100
aac aaa gga ggc ttt gaa aat gtt tta gaa gaa att gct gaa ctt 3388
Asn Lys Gly Gly Phe Glu Asn Val Leu Glu Glu Ile Ala Glu Leu
1105 1110 1115
cga cgt gaa gtt tct tat cag aat gat tac ata agc agc atg gca 3433
Arg Arg Glu Val Ser Tyr Gin Asn Asp Tyr Ile Ser Ser Met Ala
1120 1125 1130
gat cct ttc aaa aga cga ggc tat tgg tac ttt atg cca cca cca 3478
Asp Pro Phe Lys Arg Arg Gly Tyr Trp Tyr Phe Met Pro Pro Pro
1135 1140 1145
cca tca tca aaa gtt tcc agc cat agt tcc cag gcc acc aag gac 3523
Pro Ser Ser Lys Val Ser Ser His Ser Ser Gin Ala Thr Lys Asp
1150 1155 1160
tct ggt gtt ggc ctt aag tac tca gcc tca act cct gtt aga aaa 3568
Ser Gly Val Gly Leu Lys Tyr Ser Ala Ser Thr Pro Val Arg Lys
1165 1170 1175
cca cgc cct ggg cag cag gat ggg aag gaa ggc agt caa cct ccc 3613
Pro Arg Pro Gly Gin Gin Asp Gly Lys Glu Gly Ser Gin Pro Pro
1180 1185 1190
cct gcc tca gga tac tgg gtt tat tct ccc atc agg agt ggg tta 3658
Pro Ala Ser Gly Tyr Trp Val Tyr Ser Pro Ile Arg Ser Gly Leu
1195 1200 1205
cat aaa ctg ttt cca agt aga gat gca gac agt gga gga gat agt 3703
His Lys Leu Phe Pro Ser Arg Asp Ala Asp Ser Gly Gly Asp Ser
1210 1215 1220
cag gaa gag agt gag ctg gat gac caa gaa gaa ccc cca ttt gtg 3748
Gin Glu Glu Ser Glu Leu Asp Asp Gin Glu Glu Pro Pro Phe Val
1225 1230 1235
cct cct cct gga tac atg atg tat act gtg ctt cct gat ggt tct 3793
Pro Pro Pro Gly Tyr Met Met Tyr Thr Val Leu Pro Asp Gly Ser
1240 1245 1250
CA 02703356 2010-05-31
200
cct gta ccc cag ggc atg gcc ctg tat gca cca cct cct ccc ttg 3838
Pro Val Pro Gln Gly Met Ala Leu Tyr Ala Pro Pro Pro Pro Leu
1255 1260 1265
cca aac aat agc cga cct ctc acc cct ggc act gtt gtt tat ggc 3883
Pro Asn Asn Ser Arg Pro Leu Thr Pro Gly Thr Val Val Tyr Gly
1270 1275 1280
cca cct cct gct ggg gcc ccc atg gtg tat ggg cct cca ccc ccc 3928
Pro Pro Pro Ala Gly Ala Pro Met Val Tyr Gly Pro Pro Pro Pro
1285 1290 1295
aac ttc tcc atc ccc ttc atc cct atg ggt gtg ctg cat tgc aac 3973
Asn Phe Ser Ile Pro Phe Ile Pro Met Gly Val Leu His Cys Asn
1300 1305 1310
gtc cct gaa cac cat aac tta gag aat gaa gtt tct aga tta gaa 4018
Val Pro Glu His His Asn Leu Glu Asn Glu Val Ser Arg Leu Glu
1315 1320 1325
gac ata atg cag cat tta aaa tca aag aag cgg gaa gaa agg tgg 4063
Asp Ile Met Gln His Leu Lys Ser Lys Lys Arg Glu Glu Arg Trp
1330 1335 1340
atg aga gca tcc aag cgg cag tcg gag aaa gaa atg gaa gaa ctg 4108
Met Arg Ala Ser Lys Arg Gln Ser Glu Lys Glu Met Glu Glu Leu
1345 1350 1355
cat cat aat att gat gat ctt ttg caa gag aag aaa agc tta gag 4153
His His Asn Ile Asp Asp Leu Leu Gln Glu Lys Lys Ser Leu Glu
1360 1365 1370
tgt gaa gta gaa gaa tta cat aga act gtc cag aaa cgt caa cag 4198
Cys Glu Val Glu Glu Leu His Arg Thr Val Gln Lys Arg Gln Gln
1375 1380 1385
caa aag gac ttc att gat gga aat gtt gag agt ctt atg act gaa 4243
Gln Lys Asp Phe Ile Asp Gly Asn Val Glu Ser Leu Met Thr Glu
1390 1395 1400
cta gaa ata gaa aaa tca ctc aaa cat cat gaa gat att gta gat 4288
Leu Glu Ile Glu Lys Ser Leu Lys His His Glu Asp Ile Val Asp
1405 1410 1415
gaa att gag tgc att gag aag act ctt ctg aaa cgt cgc tca gag 4333
Glu Ile Glu Cys Ile Glu Lys Thr Leu Leu Lys Arg Arg Ser Glu
1420 1425 1430
ctc agg gaa gct gac cga ctc ctg gca gag gct gag agt gaa ctt 4378
Leu Arg Glu Ala Asp Arg Leu Leu Ala Glu Ala Glu Ser Glu Leu
1435 1440 1445
tca tgc act aaa gaa aag aca aaa aat gct gtt gaa aag ttc act 4423
Ser Cys Thr Lys Glu Lys Thr Lys Asn Ala Val Glu Lys Phe Thr
1450 1455 1460
gat gcc aag aga agt tta ttg caa act gag tca gat gct gag gaa 4468
Asp Ala Lys Arg Ser Leu Leu Gln Thr Glu Ser Asp Ala Glu Glu
1465 1470 1475
CA 02703356 2010-05-31
201
tta gaa agg aga gct cag gaa act gct gtt aac ctc gtc aaa gct 4513
Leu Glu Arg Arg Ala Gin Glu Thr Ala Val Asn Leu Val Lys Ala
1480 1485 1490
gat cag cag cta aga tcg ctc cag gct gat gca aag gat ttg gag 4558
Asp Gin Gin Leu Arg Ser Leu Gin Ala Asp Ala Lys Asp Leu Glu
1495 1500 1505
cag cac aaa atc aag caa gaa gaa atc ttg aaa gaa ata aac aaa 4603
Gin His Lys Ile Lys Gin Glu Glu Ile Leu Lys Glu Ile Asn Lys
1510 1515 1520
att gta gca gca aaa gac tca gac ttc caa tgt tta agc aag aag 4648
Ile Val Ala Ala Lys Asp Ser Asp Phe Gin Cys Leu Ser Lys Lys
1525 1530 1535
aag gaa aaa ctg aca gaa gag ctt cag aaa cta cag aaa gac ata 4693
Lys Glu Lys Leu Thr Glu Glu Leu Gin Lys Leu Gin Lys Asp Ile
1540 1545 1550
gag atg gca gaa cgc aat gag gat cac cac ctg cag gtc ctt aaa 4738
Glu Met Ala Glu Arg Asn Glu Asp His His Leu Gin Val Leu Lys
1555 1560 1565
gaa tct gag gtg ctt ctt cag gcc aaa aga gcc gag ctg gaa aag 4783
Glu Ser Glu Val Leu Leu Gin Ala Lys Arg Ala Glu Leu Glu Lys
1570 1575 1580
ctg aaa agc cag gtg aca agt cag cag cag gag atg gct gtc ttg 4828
Leu Lys Ser Gin Val Thr Ser Gin Gin Gin Glu Met Ala Val Leu
1585 1590 1595
gac agg cag tta ggg cat aaa aag gag gag ctg cat cta ctc caa 4873
Asp Arg Gin Leu Gly His Lys Lys Glu Glu Leu His Leu Leu Gin
1600 1605 1610
gga agc atg gtc cag gca aaa gct gac ctc cag gaa gct ctg aga 4918
Gly Ser Met Val Gin Ala Lys Ala Asp Leu Gin Glu Ala Leu Arg
1615 1620 1625
ctg gga gag act gaa gta act gag aag tgc aat cac att agg gaa 4963
Leu Gly Glu Thr Glu Val Thr Glu Lys Cys Asn His Ile Arg Glu
1630 1635 1640
gta aaa tct ctt ctg gaa gaa ctg agt ttt cag aaa gga gaa cta 5008
Val Lys Ser Leu Leu Glu Glu Leu Ser Phe Gin Lys Gly Glu Leu
1645 1650 1655
aat gtt cag att agt gaa aga aaa act caa ctt aca ctt ata aag 5053
Asn Val Gin Ile Ser Glu Arg Lys Thr Gin Leu Thr Leu Ile Lys
1660 1665 1670
cag gaa att gaa aaa gag gaa gaa aat ctt cag gtt gtt tta agg 5098
Gin Glu Ile Glu Lys Glu Glu Glu Asn Leu Gin Val Val Leu Arg
1675 1680 1685
cag atg tct aaa cat aaa acc gaa cta aag aat att ctg gac atg 5143
Gin Met Ser Lys His Lys Thr Glu Leu Lys Asn Ile Leu Asp Met
1690 1695 1700
CA 02703356 2010-05-31
202
ttg caa ctt gaa aac cat gag cta caa ggt ttg aag cta caa cat 5188
Leu Gin Leu Glu Asn His Glu Leu Gin Gly Leu Lys Leu Gin His
1705 1710 1715
gac caa agg gta tat gaa tta gag aag act cag gtg gca gtg cta 5233
Asp Gin Arg Val Ser Glu Leu Glu Lys Thr Gin Val Ala Val Leu
1720 1725 1730
gag gag aaa ctg gag tta gag aat ttg cag cag ata tcc cag cag 5278
Glu Glu Lys Leu Glu Leu Glu Asn Leu Gin Gin Ile Ser Gin Gin
1735 1740 1745
cag aaa ggg gaa ata gag tgg cag aag cag ctc ctt gag agg gat 5323
Gin Lys Gly Glu Ile Glu Trp Gin Lys Gin Leu Leu Glu Arg Asp
1750 1755 1760
aaa cga gaa ata gaa cga atg act gct gag tcc cga gct tta caa 5368
Lys Arg Glu Ile Glu Arg Met Thr Ala Glu Ser Arg Ala Leu Gin
1765 1770 1775
tcg tgt gtt gag tgt ttg agc aaa gaa aag gaa gat ctc caa gag 5413
Ser Cys Val Glu Cys Leu Ser Lys Glu Lys Glu Asp Leu Gin Glu
1780 1785 1790
aaa tgt gac att tgg gaa aaa aag ttg gca caa acc aaa agg gtt 5458
Lys Cys Asp Ile Trp Glu Lys Lys Leu Ala Gin Thr Lys Arg Val
1795 1800 1805
tta gca gca gca gaa gaa aat agc aaa atg gag caa tca aac tta 5503
Leu Ala Ala Ala Glu Glu Asn Ser Lys Met Glu Gin Ser Asn Leu
1810 1815 1820
gaa aag ttg gaa ttg aat gtc aga aaa ctg cag cag gaa cta gac 5548
Glu Lys Leu Glu Leu Asn Val Arg Lys Leu Gin Gin Glu Leu Asp
1825 1830 1835
caa cta aac aga gac aag ttg tca ctg cat aac gac att tca gca 5593
Gin Leu Asn Arg Asp Lys Leu Ser Leu His Asn Asp Ile Ser Ala
1840 1E345 1850
atg caa cag cag ctc caa gaa aaa cga gaa gca gta aac tca ctg 5638
Met Gin Gin Gin Leu Gin Glu Lys Arg Glu Ala Val Asn Ser Leu
1855 1860 1865
cag gag gaa cta gct aat gtc caa gac cat ttg aac cta gca aaa 5683
Gin Glu Glu Leu Ala Asn Val Gin Asp His Leu Asn Leu Ala Lys
1870 1875 1860
cag gac ctg ctt cac acc acc aag cat cag gat gtg ttg ctc agt 5728
Gin Asp Leu Leu His Thr Thr Lys His Gin Asp Val Leu Leu Ser
1885 1890 1895
gag cag acc cga etc cag aag gac atc agt gaa tgg gca aat agg 5773
Glu Gin Thr Arg Leu Gin Lys Asp Ile Ser Glu Trp Ala Asn Arg
1900 1905 1910
ttt gaa gac tgt cag aaa gaa gag gag aca aaa caa caa caa ctt 5818
Phe Glu Asp Cys Gin Lys Glu Glu Glu Thr Lys Gin Gin Gin Leu
1915 1920 1925
OSTZ StTZ OtTZ
ass 911 nTD 4s14 uTe bav bav nip naq dsv ski uiD usV vTV qati
E69 qbv Dqv ppb
bqv vvo vbv vbv bvb bql qvb vvv vvo ovv vob blv
SCTZ OETZ SZTZ
uie ski ski nali nie auy a/cy nie aAy uie qaw uie usv nari nie
89 BED PPP BPP
Dqo bvb EDE. pvl bvb qeq BED bqv bvp OPP DqD bvb
OZTZ STTZ OTTZ
ski qaw nari bay bay viv bay nip sTH usv dsy uie viv ivA nari
0V9 BPP bqv bqo
obo bbp Dab bbp bvb quo DPP OPB BPD Dab pqb bqD
SOTZ OOTZ 560Z
IIID all -TETI PTV qsW nTS ski uID aTI GAD aas usv nie uie ski
85E9 vpb qq*E
POP POB bqv Ppb EPP PPO pqv obq obv OPP bpb &SO PPP
060Z S80Z 080Z
uie nie nai nai usv ski nie narl uID 1@S 6.1V TITO ail ski nag
ETE9 PUO bpb Tao
qqo DPP PPP bpb bqo BPD obv bbo BPD DTP. ESP qqD
SLOZ OLOZ 590Z
PTV uTD ski nari /as PTV IPA uiD skl nTD PTV ski ski Bay nID
999 vob vpb BPV
bqD obp oob Eqb bpo BPP bvb qob vvv bvv vbv ppb
090Z SSOZ OSOZ
agy naq aud uie usv bav nari nag ass slid dsV PTV &TV qa14 aaS
EZZ9 rov .6.44
ol; bvo ovr bbo bqD qqa obv Dqq Dub rob bbr bqv qp;
5t0Z OtOZ SEOZ
dsv viv nip ski uie naq viv nari nari nie AID ass ski niD IPA
8L19 qvb rob bvb
vvr bro oqo oob bqq boo bvb lbb voq 'err bvb bqb
OEOZ SZOZ OZOZ
nor' uie uie nie bav nie aas nari uie Bay ski ally TITD aas nari
ET9 bll rvo bvo
bvb bbv vv6 vol 1.qo bvo BED EPP lop PPO Doo DID
STOZ OTOZ SOOZ
au ski nie nali aas nie sAD day bay nip ni0 nID uTO narl aqI
8809 POP EPP bvb
bqo Das bpb obq BEI bbv bvb bvb ppb BP0 bqo qop
000Z 5661 0661
bav TA bav nip nip viv viv nari ivA ski aas nari ivA uie dsv
E09 bbv qqb qbo
bvb vvb qob gob bqo bqb Bev vol oqo bqb vvo Dvb
5861 0861 SL61
naa ski aas ski uie dsV aUI narl nTO skl nTO nerl uID sTH uID
8665 bqo vvr obv
PPP bvp Dvb rov v;q vvb BPP vvb bqo bpo ovo bpo
0L61 S961 0961
uie nip ski nai auy ivA ski aas aqi, nie naa ski is nie nIe
ES6S pro bvb bvp
bqo pot, bqb Pee qbv oor pvb 'eq.; see obv vpb vvb
5561 056T St6T
aas nie bay nip ski uTe nari bav uie aqd qaw aaw nie uie uie
8065 lbv vvb vbv
bpb PPP BP olo vbv bvo qqq blp boy vvb vvo PPO
0t6T SE6T 0E6T
IPA Tiara ski naq ski usv nie nie aii nie usv uie nari ivA uie
E985 Dlb vqo vvr
oqo bry ovv Erb vvb qqv Erb qvp &so qqo bqb PPO
EOZ .
TE-50-0TOZ 96EEOLZO v0
CA 02703356 2010-05-31
204
gat gca atg agg aca ctt aaa tct gag gtg aag gat gaa atc aga 6538
Asp Ala Met Arg Thr Leu Lys Ser Glu Val Lys Asp Glu Ile Arg
2155 2160 2165
acc agc ttg aag aat ctt aat cag ttt ctt cca gaa cta cca gca 6583
Thr Ser Leu Lys Asn Leu Asn Gin Phe Leu Pro Glu Leu Pro Ala
2170 2175 2180
gat cta gaa gct att ttg gaa aga aac gaa aac cta gaa gga gaa 6628
Asp Leu Glu Ala Ile Leu Glu Arg Asn Glu Asn Leu Glu Gly Glu
2185 2190 2195
ttg gaa agc ttg aaa gag aac ctt cca ttt acc atg aat gag gga 6673
Leu Glu Ser Leu Lys Glu Asn Leu Pro Phe Thr Met Asn Glu Gly
2200 2205 2210
cot ttt gaa gaa.aaa ctg aac ttt tcc caa gtt cac ata atg gat 6718
Pro Phe Glu Glu Lys Leu Asn Phe Ser Gin Val His Ile Met Asp
2215 2220 2225
gaa cac tgg cgt gga gaa gca etc cgg gag aaa ctg cgt cac cgg 6763
Glu His Trp Arg Gly Glu Ala Leu Arg Glu Lys Leu Arg His Arg
2230 2235 2240
gaa gac cga ctc aag gcc caa ctc cga cac tgt atg tcc aag caa 6808
Glu Asp Arg Leu Lys Ala Gin Leu Arg His Cys Met Ser Lys Gin
2245 2250 2255
gca gaa gta tta att aaa gga aag cgg cag aca gag ggc act tta 6853
Ala Glu Val Leu Ile Lys Gly Lys Arg Gin Thr Glu Gly Thr Leu
2260 2265 2270
cac agt ttg agg aga caa gta gat gct tta ggg gaa ttg gtc acc 6898
His Ser Leu Arg Arg Gin Val Asp Ala Leu Gly Glu Leu Val Thr
2275 2280 2285
agc acc tct gca gat tca gcg tca tca ccc agt ctg tct cag ctg 6943
Ser Thr Ser Ala Asp Ser Ala Ser Ser Pro Ser Leu Ser Gln Leu
2290 2295 2300
gag tct tcc ctc aca gag gac tct caa ctt gga caa aat cag gaa 6988
Glu Ser Ser Leu Thr Glu Asp Ser Gin Leu Gly Gin Asn Gin Glu
2305 2310 2315
aag aat gcc tca gcc aga tga ggaatactgt cttgtgtaaa tatattcaag 7039
Lys Asn Ala Ser Ala Arg
2320 2325
gaaaacacct ccactacctc actgacttca taattggaat gtcacatggt ttttttaatc 7099
aagatgcagt gaactgagat tctgaaactc cactgtagtt tactttgcct gtaccattaa 7159
tgccaatgtt tttataaatc acttgtacat agtacatatg ggaatagttg catatgggaa 7219
tttaaaccaa catgtggctg agcctttttt tttttaatct tcgtaacatg tttaaaaaaa 7279
aacagtgatt ttaactgcat atttgaacct acaaactggt aaatcttatt aacaaaaaga 7339
atgtacttaa ggccctcttt atttatagtg tcgagttatt tttgaatttt gcttaaaatc 7399
tatttttcat atgaaaataa aagataacaa to 7431
<210> 28
<211> 2325
CA 02703356 2010-05-31
=
205
<212> PRT
<213> Homo sapiens
<400> 28
Met Lys Lys Gly Ser Gin Gin Lys Ile Phe Ser Lys Ala Lys Ile Pro
1 5 10 15
Ser Ser Ser His Ser Pro Ile Pro Ser Ser Met Ser Asn Met Arg Ser
20 25 30
Arg Ser Leu Ser Pro Leu Ile Gly Ser Glu Thr Leu Pro Phe His Ser
35 40 45
Gly Gly Gin Trp Cys Glu Gin Val Glu Ile Ala Asp Glu Asn Asn Met
50 55 60
Leu Leu Asp Tyr Gin Asp His Lys Gly Ala Asp Ser His Ala Gly Val
65 70 75 80
Arg Tyr Ile Thr Glu Ala Leu Ile Lys Lys Leu Thr Lys Gin Asp Asn
85 90 95
Leu Ala Leu Ile Lys Ser Leu Asn Leu Ser Leu Ser Lys Asp Gly Gly
100 105 110
Lys Lys Phe Lys Tyr Ile Glu Asn Leu Glu Lys Cys Val Lys Leu Glu
115 120 125
Val Leu Asn Leu Ser Tyr Asn Leu Ile Gly Lys Ile Glu Lys Leu Asp
130 135 140
Lys Leu Leu Lys Leu Arg Glu Leu Asn Leu Ser Tyr Asn Lys Ile Ser
145 150 155 160
Lys Ile Glu Gly Ile Glu Asn Met Cys Asn Leu Gin Lys Leu Asn Leu
165 170 175
Ala Gly Asn Glu Ile Glu His Ile Pro Val Trp Leu Gly Lys Lys Leu
180 185 190
Lys Ser Leu Arg Val Leu Asn Leu Lys Gly Asn Lys Ile Ser Ser Leu
195 200 205
Gin Asp Ile Ser Lys Leu Lys Pro Leu Gin Asp Leu Ile Ser Leu Ile
210 215 220
Leu Val Glu Asn Pro Val Val Thr Leu Pro His Tyr Leu Gin Phe Thr
225 230 235 240
Ile Phe His Leu Arg Ser Leu Glu Ser Leu Glu Gly Gin Pro Val Thr
245 250 255
Thr Gin Asp Arg Gin Glu Ala Phe Glu Arg Phe Ser Leu Glu Glu Val
260 265 270
Glu Arg Leu Glu Arg Asp Leu Glu Lys Lys Met Ile Glu Thr Glu Glu
275 280 285
Leu Lys Ser Lys Gin Thr Arg Phe Leu Glu Glu Ile Lys Asn Gin Asp
290 295 300
Lys Leu Asn Lys Ser Leu Lys Glu Glu Ala Met Leu Gin Lys Gin Ser
305 310 315 320
Cys Glu Glu Leu Lys Ser Asp Leu Asn Thr Lys Asn Glu Leu Leu Lys
325 330 335
Gin Lys Thr Ile Glu Leu Thr Arg Ala Cys Gin Lys Gin Tyr Glu Leu
340 345 350
Glu Gin Glu Leu Ala Phe Tyr Lys Ile Asp Ala Lys Phe Glu Pro Leu
355 360 365
Asn Tyr Tyr Pro Ser Glu Tyr Ala Glu Ile Asp Lys Ala Pro Asp Glu
370 375 380
Ser Pro Tyr Ile Gly Lys Ser Arg Tyr Lys Arg Asn Met Phe Ala Thr
385 390 395 400
Glu Ser Tyr Ile Ile Asp Ser Ala Gin Ala Val Gin Ile Lys Lys Met
405 410 415
Glu Pro Asp Glu Gin Leu Arg Asn Asp His Met Asn Leu Arg Gly His
420 425 430
Thr Pro Leu Asp Thr Gin Leu Glu Asp Lys Glu Lys Lys Ile Ser Ala
435 440 445
CA 02703356 2010-05-31
206
Ala Gin Thr Arg Leu Ser Glu Leu His Asp Glu Ile Glu Lys Ala Glu
450 455 460
Gin Gin Ile Leu Arg Ala Thr Glu Glu Phe Lys Gin Leu Glu Glu Ala
465 470 475 480
Ile Gin Leu Lys Lys Ile Ser Glu Ala Gly Lys Asp Leu Leu Tyr Lys
485 490 495
Gin Leu Ser Gly Arg Leu Gin Leu Val Asn Lys Leu Arg Gin Glu Ala
500 505 510
Leu Asp Leu Glu Leu Gin Met Glu Lys Gin Lys Gin Glu Ile Ala Gly
515 520 525
Lys Gin Lys Glu Ile Lys Asp Leu Gin Ile Ala Ile Asp Ser Leu Asp
530 535 540
Ser Lys Asp Pro Lys His Ser His Met Lys Ala Gin Lys Ser Gly Lys
545 550 555 560
Glu Gin Gin Leu Asp Ile Met Asn Lys Gin Tyr Gin Gin Leu Glu Ser
565 570 575
Arg Leu Asp Glu Ile Leu Ser Arg Ile Ala Lys Glu Thr Glu Glu Ile
580 585 590
Lys Asp Leu Glu Glu Gin Leu Thr Glu Gly Gin Ile Ala Ala Asn Glu
595 600 605
Ala Leu Lys Lys Asp Leu Glu Gly Val Ile Ser Gly Leu Gin Glu Tyr
610 615 620
Leu Gly Thr Ile Lys Gly Gin Ala Thr Gin Ala Gin Asn Glu Cys Arg
625 630 635 640
Lys Leu Arg Asp Glu Lys Glu Thr Leu Leu Gin Arg Leu Thr Glu Val
645 650 655
Glu Gin Glu Arg Asp Gin Leu Glu Ile Val Ala Met Asp Ala Glu Asn
660 665 670
Met Arg Lys Glu Leu Ala Glu Leu Glu Ser Ala Leu Gin Glu Gin His
675 680 685
Glu Val Asn Ala Ser Leu Gin Gin Thr Gin Gly Asp Leu Ser Ala Tyr
690 695 700
Glu Ala Glu Leu Glu Ala Arg Leu Asn Leu Arg Asp Ala Glu Ala Asn
705 710 715 720
Gin Leu Lys Glu Glu Leu Glu Lys Val Thr Arg Leu Thr Gin Leu Glu
725 730 735
Gin Ser Ala Leu Gin Ala Glu Leu Glu Lys Glu Arg Gin Ala Leu Lys
740 745 750
Asn Ala Leu Gly Lys Ala Gin Phe Ser Glu Glu Lys Glu Gin Glu Asn
755 760 765
Ser Glu Leu His Ala Lys Leu Lys His Leu Gin Asp Asp Asn Asn Leu
770 775 780
Leu Lys Gin Gin Leu Lys Asp Phe Gin Asn His Leu Asn His Val Val
785 790 795 800
Asp Gly Leu Val Arg Pro Glu Glu Val Ala Ala Arg Val Asp Glu Leu
805 810 815
Arg Arg Lys Leu Lys Leu Gly Thr Gly Glu Met Asn Ile His Ser Pro
820 825 830
Ser Asp Val Leu Gly Lys Ser Leu Ala Asp Leu Gin Lys Gin Phe Ser
835 840 845
Glu Ile Leu Ala Arg Ser Lys Trp Glu Arg Asp Glu Ala Gin Val Arg
850 855 860
Glu Arg Lys Leu Gin Glu Glu Met Ala Leu Gin Gin Glu Lys Leu Ala
865 870 875 880
Thr Gly Gin Glu Glu Phe Arg Gin Ala Cys Glu Arg Ala Leu Glu Ala
885 890 895
Arg Met Asn Phe Asp Lys Arg Gin His Glu Ala Arg Ile Gin Gin Met
900 905 910
Glu Asn Glu Ile His Tyr Leu Gin Glu Asn Leu Lys Ser Met Glu Glu
915 920 925
CA 02703356 2010-05-31
207
Ile Gin Gly Leu Thr Asp Leu Gin Leu Gin Glu Ala Asp Glu Glu Lys
930 935 940
Glu Arg Ile Leu Ala Gin Leu Arg Glu Leu Glu Lys Lys Lys Lys Leu
945 950 955 960
Glu Asp Ala Lys Ser Gin Glu Gin Val Phe Gly Leu Asp Lys Glu Leu
965 970 975
Lys Lys Leu Lys Lys Ala Val Ala Thr Ser Asp Lys Leu Ala Thr Ala
980 985 990
Glu Leu Thr Ile Ala Lys Asp Gin Leu Lys Ser Leu His Gly Thr Val
995 1000 1005
Met Lys Ile Asn Gin Glu Arg Ala Glu Glu Leu Gin Glu Ala Glu
1010 1015 1020
Arg Phe Ser Arg Lys Ala Ala Gin Ala Ala Arg Asp Leu Thr Arg
1025 1030 1035
Ala Glu Ala Glu Ile Glu Leu Leu Gln Asn Leu Leu Arg Gin Lys
1040 1045 1050
Gly Glu Gin Phe Arg Leu Glu Met Glu Lys Thr Gly Val Gly Thr
1055 1060 1065
Gly Ala Asn Ser Gin Val Leu Glu Ile Glu Lys Leu Asn Glu Thr
1070 1075 1080
Met Glu Arg Gin Arg Thr Glu Ile Ala Arg Leu Gin Asn Val Leu
1085 1090 1095
Asp Leu Thr Gly Ser Asp Asn Lys Gly Gly Phe Glu Asn Val Leu
1100 1105 1110
Glu Glu Ile Ala Glu Leu Arg Arg Glu Val Ser Tyr Gin Asn Asp
1115 1120 1125
Tyr Ile Ser Ser Met Ala Asp Pro Phe Lys Arg Arg Gly Tyr Trp
1130 1135 1140
Tyr Phe Met Pro Pro Pro Pro Ser Ser Lys Val Ser Ser His Ser
1145 1150 1155
Ser Gin Ala Thr Lys Asp Ser Gly Val Gly Leu Lys Tyr Ser Ala
1160 1165 1170
Ser Thr Pro Val Arg Lys Pro Arg Pro Gly Gin Gin Asp Gly Lys
1175 1180 1185
Glu Gly Ser Gin Pro Pro Pro Ala Ser Gly Tyr Trp Val Tyr Ser
1190 1195 1200
Pro Ile Arg Ser Gly Leu His Lys Leu Phe Pro Ser Arg Asp Ala
1205 1210 1215
Asp Ser Gly Gly Asp Ser Gin Glu Glu Ser Glu Leu Asp Asp Gin
1220 1225 1230
Glu Glu Pro Pro Phe Val Pro Pro Pro Gly Tyr Met Met Tyr Thr
1235 1240 1245
Val Leu Pro Asp Gly Ser Pro Val Pro Gin Gly Met Ala Leu Tyr
1250 1255 1260
Ala Pro Pro Pro Pro Leu Pro Asn Asn Ser Arg Pro Leu Thr Pro
1265 1270 1275
Gly Thr Val Val Tyr Gly Pro Pro Pro Ala Gly Ala Pro Met Val
1280 1285 1290
Tyr Gly Pro Pro Pro Pro Asn Phe Ser Ile Pro Phe Ile Pro Met
1295 1300 1305
Gly Val Leu His Cys Asn Val Pro Glu His His Asn Leu Glu Asn
1310 1315 1320
Glu Val Ser Arg Leu Glu Asp Ile Met Gin His Leu Lys Ser Lys
1325 1330 1335
Lys Arg Glu Glu Arg Trp Met Arg Ala Ser Lys Arg Gin Ser Glu
1340 1345 1350
Lys Glu Met Glu Glu Leu His His Asn Ile Asp Asp Leu Leu Gin
1355 1360 1365
Glu Lys Lys Ser Leu Glu Cys Glu Val Glu Glu Leu His Arg Thr
1370 1375 1380
CA 02703356 2010-05-31
208
Val Gin Lys Arg Gin Gin Gin Lys Asp Phe Ile Asp Gly Asn Val
1385 1390 1395
Glu Ser Leu Met Thr Glu Leu Glu Ile Glu Lys Ser Leu Lys His
1400 1405 1410
His Glu Asp Ile Val Asp Glu Ile Glu Cys Ile Glu Lys Thr Leu
1415 1420 1425
Leu Lys Arg Arg Ser Glu Leu Arg Glu Ala Asp Arg Leu Leu Ala
1430 1435 1440
Glu Ala Glu Ser Glu Leu Ser Cys Thr Lys Glu Lys Thr Lys Asn
1445 1450 1455
Ala Val Glu Lys Phe Thr Asp Ala Lys Arg Ser Leu Leu Gin Thr
1460 1465 1470
Glu Ser Asp Ala Glu Glu Leu Glu Arg Arg Ala Gin Glu Thr Ala
1475 1480 1485
Val Asn Leu Val Lys Ala Asp Gin Gin Leu Arg Ser Leu Gin Ala
1490 1495 1500
Asp Ala Lys Asp Leu Glu Gin His Lys Ile Lys Gin Glu Glu Ile
1505 1510 1515
Leu Lys Glu Ile Asn Lys Ile Val Ala Ala Lys Asp Ser Asp Phe
1520 1525 1530
Gin Cys Leu Ser Lys Lys Lys Glu Lys Leu Thr Glu Glu Leu Gin
1535 1540 1545
Lys Leu Gin Lys Asp Ile Glu Met Ala Glu Arg Asn Glu Asp His
1550 1555 1560
= His Leu Gin Val Leu Lys Glu Ser Glu Val Leu Leu Gin Ala Lys
1565 1570 1575
Arg Ala Glu Leu Glu Lys Leu Lys Ser Gin Val Thr Ser Gin Gin
1580 1585 1590
Gin Glu Met Ala Val Leu Asp Arg Gin Leu Gly His Lys Lys Glu
1595 1600 1605
Glu Leu His Leu Leu Gin Gly Ser Met Val Gin Ala Lys Ala Asp
1610 1615 1620
Leu Gin Glu Ala Leu Arg Leu Gly Glu Thr Glu Val Thr Glu Lys
1625 1630 1635
Cys Asn His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu Ser
1640 1645 1650
Phe Gin Lys Gly Glu Leu Asn Val Gin Ile Ser Glu Arg Lys Thr
1655 1660 1665
Gin Leu Thr Leu Ile Lys Gin Glu Ile Glu Lys Glu Glu Glu Asn
1670 1675 1680
Leu Gin Val Val Leu Arg Gin Met Ser Lys His Lys Thr Glu Leu
1685 1690 1695
Lys Asn Ile Leu Asp Met Leu Gin Leu Glu Asn His Glu Leu Gin
1700 1705 1710
Gly Leu Lys Leu Gin His Asp Gin Axg Val Ser Glu Leu Glu Lys
1715 1720 1725
Thr Gin Val Ala Val Leu Glu Glu Lys Leu Glu Leu Glu Asn Leu
1730 1735 1740
Gin Gin Ile Ser Gin Gin Gin Lys Gly Glu Ile Glu Trp Gin Lys
1745 1750 1755
Gin Leu Leu Glu Arg Asp Lys Arg Glu Ile Glu Arg Met Thr Ala
1760 1765 1770
Glu Ser Arg Ala Leu Gin Ser Cys Val Glu Cys Leu Ser Lys Glu
1775 1780 1785
Lys Glu Asp Leu Gin Glu Lys Cys Asp Ile Trp Glu Lys Lys Leu
1790 1795 1800
Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asn Ser Lys
1805 1810 1815
Met Glu Gin Ser Asn Leu Glu Lys Leu Glu Leu Asn Val Arg Lys
1820 1825 1830
CA 02703356 2010-05-31
=
209
Leu Gin Gin Glu Leu Asp Gin Leu Asn Arg Asp Lys Leu Ser Leu
1835 1840 1845
His Asn Asp Ile Ser Ala Met Gin Gin Gin Leu Gin Glu Lys Arg
1850 1855 1860
Glu Ala Val Asn Ser Leu Gin Glu Glu Leu Ala Asn Val Gin Asp
1865 1870 1875
His Leu An Leu Ala Lys Gin Asp Leu Leu His Thr Thr Lys His
1880 1885 1890
Gin Asp Val Leu Leu Ser Glu Gin Thr Arg Leu Gin Lys Asp Ile
1895 1900 1905
Ser Glu Trp Ala Asn Arg Phe Glu Asp Cys Gin Lys Glu Glu Glu
1910 1915 1920
Thr Lys Gin Gin Gin Leu Gin Val Leu Gin Asn Glu Ile Glu Glu
1925 1930 1935
Asn Lys Leu Lys Leu Val Gln Gin Glu Met Met Phe Gin Arg Leu
1940 1945 1950
Gin Lys Glu Arg Glu Ser Glu Glu Ser Lys Leu Glu Thr Ser Lys
1955 1960 1965
Val Thr Leu Lys Glu Gin Gin His Gin Leu Glu Lys Glu Leu Thr
1970 1975 1980
Asp Gin Lys Ser Lys Leu Asp Gin Val Leu Ser Lys Val Leu Ala
1985 1990 1995
Ala Glu Glu Arg Val Arg Thr Leu Gin Glu Glu Glu Arg Trp Cys
2000 2005 2010
Glu Ser Leu Glu Lys Thr Leu Ser Gin Thr Lys Arg Gin Leu Ser
2015 2020 2025
Glu Arg Glu Gin Gin Leu Val Glu Lys Ser Gly Glu Leu Leu Ala
2030 2035 2040
Leu Gin Lys Glu Ala Asp Ser Met Arg Ala Asp he Ser Leu Leu
2045 2050 2055
Arg Asn Gin Phe Leu Thr Glu Arg Lys Lys Ala Glu Lys Gin Val
2060 2065 2070
Ala Ser Leu Lys Glu Ala Leu Lys Ile Gin Arg Ser Gin Leu Glu
2075 2080 2085
Lys Asn Leu Leu Glu Gin Lys Gin Glu Asn Ser Cys Ile Gin Lys
2090 2095 2100
Glu Met Ala Thr Ile Glu Leu Val Ala Gin Asp Asn His Glu Arg
2105 2110 2115
Ala Arg Arg Leu Met Lys Glu Leu Asn Gin Met Gin Tyr Glu Tyr
2120 2125 2130
Thr Glu Leu Lys Lys Gin Met Ala Asn Gin Lys Asp Leu Glu Arg
2135 2140 2145
Arg Gin Met Glu Ile Ser Asp Ala Met Arg Thr Leu Lys Ser Glu
2150 2155 2160
Val Lys Asp Glu Ile Arg Thr Ser Leu Lys Asn Leu Asn Gin Phe
2165 2170 2175
Leu Pro Glu Leu Pro Ala Asp. Leu Glu Ala Ile Leu Glu Arg Asn
2180 2185 2190
Glu Asn Leu Glu Gly Glu Leu Glu Ser Leu Lys Glu Asn Leu Pro
2195 = 2200 2205
Phe Thr Met Asn Glu Gly Pro Phe Glu Glu Lys Leu Asn Phe Ser
2210 2215 2220
Gin Val His Ile Met Asp Glu His Trp Arg Gly Glu Ala Leu Arg
2225 2230 2235
Glu Lys Leu Arg His Arg Glu Asp Arg Leu Lys Ala Gin Leu Arg
2240 2245 2250
His Cys Met Ser Lys Gin Ala Glu Val Leu Ile Lys Gly Lys Arg
2255 2260 2265
Gin Thr Glu Gly Thr Leu His Ser Leu Arg Arg Gin Val Asp Ala
2270 2275 2280
CA 02703356 2010-05-31
210
Leu Gly Glu Leu Val Thr Ser Thr Ser Ala Asp Ser Ala Ser Ser
2285 2290 2295
Pro Ser Leu Ser Gin Leu Glu Ser Ser Leu Thr Glu Asp Ser Gin
2300 2305 2310
Leu Gly Gin Asn Gin Glu Lys Asn Ala Ser Ala Arg
2315 2320 2325
<210> 29
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 29
gcagcaaaag actcagac 18
<210> 30
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 30
aagttgcaac atgtccag 18
<210> 31
<211> 28
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 31
catatggagc aagaggaaat cttgaaag 28
<210> 32
<211> 21
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 32
ggtaccgggt cggtgcgcgt c 21
<210> 33
<211> 24
<212> DNA
<213> Artificial
CA 02703356 2010-05-31
211
<220>
<223> primer
<400> 33
ggatccatca agcaagaaga aatc 24
<210> 34
<211> 25
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 34
gtcgactcat ctggctgagg cattc 25
<210> 35
<211> 826
<212> PRT
<213> Canis familiaris
<400> 35
Met Glu Gln Glu Glu Ile Leu Lys Glu Ile Asn Lys Val Val Ala Ala
1 5 10 15
Lys Asp Ser Asp Phe Gin Ser Leu Asn Lys Lys Lys Glu Val Leu Thr
20 25 30
Gly Glu Leu Gin Lys Leu Gin Lys Asp Ile Glu Thr Ala Arg His Asn
35 40 45
Glu Asp Gin His Leu Gin Val Leu Lys Glu Ser Glu Thr Leu Leu Gin
50 55 60
Ala Lys Lys Ala Glu Leu Glu Asn Leu Lys Ser Gin Val Ser Gly Gin
65 70 75 80
Gin Gin Glu Met Ala Val Leu Asp Arg Glu Leu Gly His Lys Lys Glu
85 90 95
Glu Leu His Leu Leu Gin Glu Ser Met Val Gin Ala Lys Ala Asp Leu
100 105 110
Gin Glu Ala Leu Arg Leu Gly Glu Ser Glu Val Thr Glu Lys Cys Asn
115 120 125
His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu Ser Phe Gin Lys
130 135 140
Gly Glu Leu Asn Val Gin Ile Ser Glu Lys Lys Thr Gin Leu Ala Leu
145 150 155 160
Ile Lys Gin Glu Ile Glu Lys Glu Glu Asp Asn Leu Gin Val Val Leu
165 170 175
Gly Gin Met Ser Lys His Lys Thr Glu Leu Lys Asn Ile Leu Asp Met
180 185 190
Leu Gin Leu Glu Asn Asn Glu Leu Gin Gly Leu Lys Leu Gin His Asp
195 200 205
Gin Lys Met Ser Glu Leu Glu Lys Thr Arg Val Glu Val Leu Glu Glu
210 215 220
Lys Leu Glu Leu Glu Ser Leu Gin Gin Ala Ala Leu Arg Gin Arg Gly
225 230 235 240
Glu Ile Glu Trp Gin Lys Gin Leu Leu Gin Arg Asn Thr Gin Glu Val
245 250 255
Glu Arg Met Thr Ala Glu Thr Arg Ala Leu Gin Ser Cys Val Glu Ser
260 265 270
CA 02703356 2010-05-31
=
212
Leu Cys Lys Glu Lys Gin Asp Leu Glu Glu Lys Gin Asp Ser Trp Glu
275 280 285
Lys Lys Leu Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asp
290 295 300
Ser Glu Met Glu Arg Ala Arg Leu Glu Lys Leu Glu Leu Asp Ala Arg
305 310 315 320
Lys Leu Gin Gin Glu Leu Asp Gin Arg Asn Arg Glu Lys Leu Ser Leu
325 330 335
His Gin Asp Leu Ala Val Val Gin Gin Gin Leu Gin Glu Lys Gin Glu
340 345 350
Ala Val Asn Ser Leu Gin Lys Glu Leu Thr Asp Val Gin Glu His Leu
355 360 365
Asp Leu Ala Glu Gin Glu Val Leu Cys Thr Thr Lys Arg Lys Asp Ala
370 375 380
Leu Leu Ser Glu Gin Thr Arg Leu Glu Lys Asp Val Gly Glu Trp Thr
385 390 395 400
Lys Lys Phe Glu Asp Cys Gin Lys Glu Gly Glu Thr Lys Gin Gin Gin
405 410 415
Leu Gin Gly Leu Gin Lys Glu Ile Glu Gly Asn Glu Ala Lys Leu Ala
420 425 430
Gin Gin Glu Met Met Phe Gin Arg Leu Gin Lys Glu Arg Glu Cys Glu
435 440 445
Glu Lys Lys Leu Glu Ala Ser Lys Val Thr Leu Lys Glu Gin Gin Gin
450 455 460
Gin Leu Glu Lys Glu Leu Met Glu Gin Lys Gly Lys Leu Asp Gin Val
465 470 475 480
Leu Ala Lys Leu Leu Val Ala Glu Glu Arg Val Arg Thr Leu Gin Glu
485 490 495
Glu Gly Arg Trp Ser Glu Thr Leu Glu Lys Thr Leu Ser Gin Thr Lys
500 505 510
Arg Gin Leu Ser Glu Arg Glu Gin Gin Leu Leu Ala Lys Ser Asp Glu
515 520 525
Leu Leu Ala Leu Gin Lys Glu Thr Asp Ser Met Arg Ala Asp Phe Ser
530 535 540
Leu Leu Arg Asn Gin Phe Leu Thr Glu Arg Lys Lys Ala Glu Lys Gin
545 550 555 560
Val Ala Ser Leu Lys Glu Ala Leu Lys Ile Gin Arg Ser Gin Leu Glu
565 570 575
Lys Asn Leu Leu Glu Gin Lys Gin Glu Asn Ser Cys Met Gin Arg Glu
580 585 590
Met Ala Thr Ile Glu Gin Val Ala Gin Asp Asn His Glu Arg Ala Arg
595 600 605
Arg Leu Met Arg Glu Leu Asn Gin Met Gin Axg Glu Tyr Val Glu Leu
610 615 620
Arg Lys Gin Met Thr Asn Gin Lys Asp Leu Glu Arg Arg Gin Met Glu
625 630 635 640
Ile Ser Asp Ala Met Gin Ala Leu Lys Cys Glu Val Lys Asp Glu Ile
645 650 655
Arg Thr Ser Leu Lys Asn Leu Asn Gin Phe Leu Pro Glu Leu Pro Ala
660 665 670
Asp Leu Glu Ala Leu Leu Glu Arg Asn Glu Asn Leu Gly Gly Gly Leu
675 680 685
Glu Ser Leu Lys Glu Asn Phe Pro Phe Thr Val Ser Asp Arg Pro Ser
690 695 700
Ser Cys Glu Glu Lys Leu Asn Phe Gly Gin Ala His Val Ala Asp Glu
705 710 715 720
Gin Trp Arg Gly Glu Ala Leu Arg Glu Lys Leu Arg His Arg Glu Asp
725 730 735
Arg Leu Lys Ala Gin Leu Arg Arg Cys Met Ser Lys Gin Ala Glu Val
740 745 750
CA 02703356 2010-05-31
213
Leu Ser Glu Gly Arg Arg Arg Thr Glu Gly Thr Leu His Ser Leu Arg
755 760 765
Arg Gin Val Asp Ala Leu Gly Glu Leu Val Thr Ser Thr Ser Gly Asp
770 775 780
Ser Ala Ser Thr Arg Ser Leu Ser Arg Thr Glu Gly Ser Leu Ala Glu
785 790 795 800
Asp Glu Pro Pro Gly Pro Ser Gin Ser Ser Arg Arg Leu Pro Arg Gly
805 810 815
Pro Ser Pro Arg Leu Asp Ala His Arg Pro
820 825
<210> 36
<211> 813
<212> PRT
<213> Homo sapiens
<400> 36
Ile Lys Gin Glu Glu Ile Leu Lys Glu Ile Asn Lys Ile Val Ala Ala
1 5 10 15
Lys Asp Ser Asp Phe Gin Cys Leu Ser Lys Lys Lys Glu Lys Leu Thr
20 25 30
Glu Glu Leu Gin Lys Leu Gin Lys Asp Ile Glu Met Ala Glu Arg Asn
35 40 45
Glu Asp His His Leu Gin Val Leu Lys Glu Ser Glu Val Leu Leu Gin
50 55 60
Ala Lys Avg. Ala Glu Leu Glu Lys Leu Lys Ser Gin Val Thr Ser Gin
65 70 75 80
Gin Gin Glu Met Ala Val Leu Asp Arg Gin Leu Gly His Lys Lys Glu
85 90 95
Glu Leu His Leu Leu Gin Gly Ser Met Val Gin Ala Lys Ala Asp Leu
100 105 110
Gin Glu Ala Leu Avg Leu Gly Glu Thr Glu Val Thr Glu Lys Cys Asn
115 120 125
His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu Ser Phe Gin Lys
130 135 140
Gly Glu Leu Asn Val Gin Ile Ser Glu Arg Lys Thr Gin Leu Thr Leu
145 150 155 160
Ile Lys Gin Glu Ile Glu Lys Glu Glu Glu Asn Leu Gin Val Val Leu
165 170 175
Arg Gin Met Ser Lys His Lys Thr Glu Leu Lys Asn Ile Leu Asp Met
180 185 190
Leu Gin Leu Glu Asn His Glu Leu Gin Gly Leu Lys Leu Gin His Asp
195 200 205
Gin Arg Val Ser Glu Leu Glu Lys Thr Gin Val Ala Val Leu Glu Glu
210 215 220
Lys Leu Glu Leu Glu Asn Leu Gin Gin Ile Ser Gin Gin Gin Lys Gly
225 230 235 240
Glu Ile Glu Trp Gin Lys Gin Leu Leu Glu Arg Asp Lys Arg Glu Ile
245 250 255
Glu Arg Met Thr Ala Glu Ser Arg Ala Leu Gin Ser Cys Val Glu Cys
260 265 270
Leu Ser Lys Glu Lys Glu Asp Leu Gin Glu Lys Cys Asp Ile Trp Glu
275 280 285
Lys Lys Leu Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asn
290 295 300
Ser Lys Met Glu Gin Ser Asn Leu Glu Lys Leu Glu Leu Asn Val Avg
305 310 315 320
Lys Leu Gin Gin Glu Leu Asp Gin Leu Asn Arg Asp Lys Leu Ser Leu
325 330 335
CA 02703356 2010-05-31
214
His Asn Asp Ile Ser Ala Met Gin Gin Gin Leu Gin Glu Lys Arg Glu
340 345 350
Ala Val Asn Ser Leu Gin Glu Glu Leu Ala Asn Val Gin Asp His Leu
355 360 365
Asn Leu Ala Lys Gin Asp Leu Leu His Thr Thr Lys His Gin Asp Val
370 375 380
Leu Leu Ser Glu Gin Thr Arg Leu Gin Lys Asp Ile Ser Glu Trp Ala
385 390 395 400
Asn Arg Phe Glu Asp Cys Gin Lys Glu Glu Glu Thr Lys Gin Gin Gin
405 410 415
Leu Gin Val Leu Gin Asn Glu Ile Glu Glu Asn Lys Leu Lys Leu Val
420 425 430
Gin Gin Glu Met Met Phe Gin Arg Leu Gin Lys Glu Arg Glu Ser Glu
435 440 445
Glu Ser Lys Leu Glu Thr Ser Lys Val Thr Leu Lys Glu Gin Gin His
450 455 460
Gin Leu Glu Lys Glu Leu Thr Asp Gin Lys Ser Lys Leu Asp Gin Val
465 470 475 480
Leu Ser Lys Val Leu Ala Ala Glu Glu Arg Val Arg Thr Leu Gin Glu
485 490 495
Glu Glu Arg Trp Cys Glu Ser Leu Glu Lys Thr Leu Ser Gin Thr Lys
500 505 510
Arg Gin Leu Ser Glu Arg Glu Gin Gin Leu Val Glu Lys Ser Gly Glu
515 520 525
Leu Leu Ala Leu Gin Lys Glu Ala Asp Ser Met Arg Ala Asp Phe Ser
530 535 540
Leu Leu Arg Asn Gin Phe Leu Thr Glu Arg Lys Lys Ala Glu Lys Gin
545 550 555 560
Val Ala Ser Leu Lys Glu Ala Leu Lys Ile Gin Arg Ser Gin Leu Glu
565 570 575
Lys Asn Leu Leu Glu Gin Lys Gin Glu Asn Ser Cys Ile Gin Lys Glu
580 585 590
Met Ala Thr Ile Glu Leu Val Ala Gin Asp Asn His Glu Arg Ala Arg
595 600 605
Arg Leu Met Lys Glu Leu Asn Gin Met Gin Tyr Glu Tyr Thr Glu Leu
610 615 620
Lys Lys Gin Met Ala Asn Gin Lys Asp Leu Glu Arg Arg Gin Met Glu
625 630 635 640
Ile Ser Asp Ala Met Arg Thr Leu Lys Ser Glu Val Lys Asp Glu Ile
645 650 655
Arg Thr Ser Leu Lys Asn Leu Asn Gin Phe Leu Pro Glu Leu Pro Ala
660 665 670
Asp Leu Glu Ala Ile Leu Glu Arg Asn Glu Asn Leu Glu Gly Glu Leu
675 680 685
Glu Ser Leu Lys Glu Asn Leu Pro Phe Thr Met Asn Glu Gly Pro Phe
690 695 700
Glu Glu Lys Leu Asn Phe Ser Gin Val His Ile Met Asp Glu His Trp
705 710 715 720
Arg Gly Glu Ala Leu Arg Glu Lys Leu Arg His Arg Glu Asp Arg Leu
725 730 735
Lys Ala Gin Leu Arg His Cys Met Ser Lys Gin Ala Glu Val Leu Ile
740 745 750
Lys Gly Lys Arg Gin Thr Glu Gly Thr Leu His Ser Leu Arg Arg Gin
755 760 765
Val Asp Ala Leu Gly Glu Leu Val Thr Ser Thr Ser Ala Asp Ser Ala
770 775 780
Ser Ser Pro Ser Leu Ser Gin Leu Glu Ser Ser Leu Thr Glu Asp Ser
785 790 795 800
Gin Leu Gly Gin Asn Gin Glu Lys Asn Ala Ser Ala Arg
805 810
CA 02703356 2010-05-31
215
<210> 37
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 37
ggatccatga agaaaggttc tcag 24
<210> 38
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 38
gtcgactcag ggtcggtgcg cgtc 24
<210> 39
<211> 25
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 39
ggatccatga agaaaggttc tcaac 25
<210> 40
<211> 25
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 40
gtcgactcat ctggctgagg cattc 25
<210> 41
<211> 7770
<212> DNA
<213> Canis familiaris
<220>
<221> CDS
<222> (1)..(7770)
CA 02703356 2010-05-31
216
<400> 41
atg aag aaa ggt tct cag caa aag ttt ttg aaa gca aag atg cca cca 48
Met Lys Lys Gly Ser Gin Gin Lys Phe Leu Lys Ala Lys Met Pro Pro
1 5 10 15
tca tct cac tct cct agt cca cca tee ctt acg tcc aat atg aga tct 96
Ser Ser His Ser Pro Ser Pro Pro Ser Leu Thr Ser Asn Met Arg Ser
20 25 30
agg tca ctt tcg cct eta agt gga tct gag act ctg cct ttt cat ttt 144
Arg Ser Leu Ser Pro Leu Ser Gly Ser Glu Thr Leu Pro Phe His Phe
35 40 45
gga gga ccg tgg cat gag caa gtt gag att aca gat gaa agc aca gtg 192
Gly Gly Pro Trp His Glu Gin Val Glu Ile Thr Asp Glu Ser Thr Val
50 55 60
gtt tta gac tac caa gac cat aaa gaa get gat tca cat gca gga gtc 240
Val Leu Asp Tyr Gin Asp His Lys Glu Ala Asp Ser His Ala Gly Val
65 70 75 80
cga tat att aca gag gcc ctt gtt aga aaa ctt act aaa cag gac aat 288
Arg Tyr Ile Thr Glu Ala Leu Val Arg Lys Leu Thr Lys Gin Asp Asn
85 90 95
ttg gee ttg gta aaa tct ctg aac ctt tca ctt get aaa ggt ggt ggc 336
Leu Ala Leu Val Lys Ser Leu Asn Leu Ser Leu Ala Lys Gly Gly Gly
100 105 110
aag aaa ttc agg tgt atc gaa aat ttg gaa aaa tgt gtt aaa ctt gaa 384
Lys Lys Phe Arg Cys Ile Glu Asn Leu Glu Lys Cys Val Lys Leu Glu
115 120 125
gta ctg aat etc age tat aat eta ata gga aag att gag aaa gtg gac 432
Val Leu Asn Leu Ser Tyr Asn Leu Ile Gly Lys Ile Glu Lys Val Asp
130 135 140
aaa ctg tta aaa tta cgt gaa etc aac tta tcg tat aac aaa atc cgc 480
Lys Leu Leu Lys Leu Arg Glu Leu Asn Leu Ser Tyr Asn Lys Ile Arg
145 150 155 160
aaa att gaa ggc ata gaa aat tta tat aat ctg caa aag ctg aac ctt 528
Lys Ile Glu Gly Ile Glu Asn Leu Tyr Asn Leu Gin Lys Leu Asn Leu
165 170 175
gca gga aat gaa atc gaa cat atc cca gta tgg tta ggg aag aag tta 576
Ala Gly Asn Glu Ile Glu His Ile Pro Val Trp Leu Gly Lys Lys Leu
180 185 190
aaa tct ttg cga atc ctg aat ctg aaa ggc aac aag ata tca tcg etc 624
Lys Ser Leu Arg Ile Leu Asn Leu Lys Gly Asn Lys Ile Ser Ser Leu
195 200 205
caa gat gta age aag ttg aaa cca ctt caa gat ttg act tct ctg atc 672
Gin Asp Val Ser Lys Leu Lys Pro Leu Gin Asp Leu Thr Ser Leu Ile
210 215 220
eta ctt gaa aat cca gtt gcg ace ctt cct cat tat atc cag ttt ace 720
Leu Leu Glu Asn Pro Val Ala Thr Leu Pro His Tyr Ile Gin Phe Thr
225 230 235 240
CA 02703356 2010-05-31
217
att ttt cac ctt cgc tca ttg gaa agt ttg gaa ggt cag cca gta act 768
Ile Phe His Leu Arg Ser Leu Glu Ser Leu Glu Gly Gin Pro Val Thr
245 250 255
agt cag gac aga caa gaa gct ttt gcg aga ttc agt tta gat gag gta 816
Ser Gin Asp Arg Gin Glu Ala Phe Ala Arg Phe Ser Leu Asp Glu Val
260 265 270
gaa aga ctg gaa aga gac ctg gag aag aag aca atg gaa act gaa gag 864
Glu Arg Leu Glu Arg Asp Leu Glu Lys Lys Thr Met Glu Thr Glu Glu
275 280 285
ctt agg agt gag cag aca agg ttc ctt gag gaa att aaa agt cag gat 912
Leu Arg Ser Glu Gin Thr Arg Phe Leu Glu Glu Ile Lys Ser Gin Asp
290 295 300
aaa ttg aac aaa tca ctg aaa gag gag gcc aga cta caa aaa cag agc 960
Lys Leu Asn Lys Ser Leu Lys Glu Glu Ala Arg Leu Gin Lys Gin Ser
305 310 315 320
tat gag gag ctg gag agt aac cta aac ace aaa aat gaa ttg cta aaa 1008
Tyr Glu Glu Leu Glu Ser Asn Leu Asn Thr Lys Asn Glu Leu Leu Lys
325 330 335
cag aag acc atg gaa cta atg cga gca tgt cag aaa cag tat gag atg 1056
Gin Lys Thr Met Glu Leu Met Arg Ala Cys Gin Lys Gin Tyr Glu Met
340 345 350
gaa cag gag ttg gcc ttt tat aaa att gat gcc aaa ttt gaa cca cta 1104
Glu Gin Glu Leu Ala Phe Tyr Lys Ile Asp Ala Lys Phe Gam Pro Leu
355 360 365
aat tat tac cca tca gag tat gtc gaa att gat aaa ace cca gat gaa 1152
Asn Tyr Tyr Pro Ser Glu Tyr Val Glu Ile Asp Lys Thr Pro Asp Glu
370 375 380
agc cct tac att ggc aaa tcc aga tac aag aga aat atg ttc act aca 1200
Ser Pro Tyr Ile Gly Lys Ser Arg Tyr Lys Arg Asn Met Phe Thr Thr
385 390 395 400
gag agt tat att att gca aat gcc cag aca gta aag atc aag aag atg 1248
Glu Ser Tyr Ile Ile Ala Asn Ala Gin Thr Val Lys Ile Lys Lys Met
405 410 415
gag cta gat gaa ggg gaa caa ctc aga aat gag cac gtg aac ttg gga 1296
Glu Leu Asp Glu Gly Glu Gin Leu Arg Asn Glu His Val Asn Leu Gly
420 425 430
gca tcg cca aca gac ata caa ctg gaa gac aaa gaa aaa aaa ata agt 1344
Ala Ser Pro Thr Asp Ile Gin Leu Glu Asp Lys Glu Lys Lys Ile Ser
435 440 445
gca gca caa act cga cta tca gaa cta cat gat gaa ata gaa aag gca 1392
Ala Ala Gin Thr Arg Leu Ser Glu Leu His Asp Glu Ile Glu Lys Ala
450 455 460
gaa caa caa att tta aga gcc act gaa gaa ttt aaa caa ctg gaa gaa 1440
Glu Gin Gin Ile Leu Arg Ala Thr Glu Glu Phe Lys Gin Leu Glu Glu
465 470 475 480
CA 02703356 2010-05-31
=
218
=
gct ata caa ctt aaa aaa att tca gaa gcg gag aaa gac ctt ctt ttc 1488
Ala Ile Gin Leu Lys Lys Ile Ser Glu Ala Glu Lys Asp Leu Leu Phe
485 490 495
aag cag ttg agt ggt agg ata cag ctt etc aat aaa tta cgc caa gaa 1536
Lys Gin Leu Ser Gly Arg Ile Gin Leu Leu Asn Lys Leu Arg Gin Glu
500 505 510
gct gtg gat cta gaa aca cag atg gaa aag caa agg caa gaa att ggt 1584
Ala Val Asp Leu Glu Thr Gin Met Glu Lys Gin Arg Gin Glu Ile Gly
515 520 525
gaa aag cag aat gag atc aag gac ctg gaa ata gtc aca gat agc ctg 1632
Glu Lys Gin Asn Glu Ile Lys Asp Leu Glu Ile Val Thr Asp Ser Leu
530 535 540
gat tcc aga gac cca aaa cat tgc cat atg aag get cag aaa aga ggt 1680
Asp Ser Arg Asp Pro Lys His Cys His Met Lys Ala Gin Lys Arg Gly
545 550 555 560
aaa gaa caa caa ctt gac att atg aac aag cag tac aaa cag ctt gaa 1728
Lys Glu Gin Gin Leu Asp Ile Met Asn Lys Gin Tyr Lys Gin Leu Glu
565 570 575
age cgt ttg gat gag ata ctt tct aga att gcc aaa gaa act gaa gag 1776
Ser Arg Leu Asp Glu Ile Leu Ser Arg Ile Ala Lys Glu Thr Glu Glu
580 585 590
att aag gac ctt gaa gaa cag ctt act gaa gga caa ata gcc gca aac 1824
Ile Lys Asp Leu Glu Glu Gin Leu Thr Glu Gly Gin Ile Ala Ala Asn
595 600 605
gaa gcc ctg aag aag gac tta gaa agt gtc atc agt ggg ttg caa gaa 1872
Glu Ala Leu Lys Lys Asp Leu Glu Ser Val Ile Ser Gly Leu Gin Glu
610 615 620
tac ctg gag act gtc aaa ggt cag gcc cgt cag gcc cag aat gag tgc 1920
Tyr Leu Glu Thr Val Lys Gly Gin Ala Arg Gin Ala Gin Asn Glu Cys
625 630 635 640
aga aag cta cag gat gag aag gag aca ttg ctg cag aga ttg agt gag 1968
Arg Lys Leu Gin Asp Glu Lys Glu Thr Leu Leu Gin Arg Leu Ser Glu
645 650 655
gtc gag cag gag agg gac caa ctg gaa ata gtg gcc ata gat gca gaa 2016
Val Glu Gin Glu Arg Asp Gin Leu Glu Ile Val Ala Ile Asp Ala Glu
660 665 670
aat atg agg aag gag ctc gca gaa ctg gag aat gcc etc cag gag cag 2064
Asn Met Arg Lys Glu Leu Ala Glu Leu Glu Asn Ala Leu Gin Glu Gin
675 680 685
cat gag gtg aat ata tct ctg cag cag acc cag gga gat etc agt gcc 2112
His Glu Val Asn Ile Ser Leu Gin Gin Thr Gin Gly Asp Leu Ser Ala
690 695 700
tat gag get gag cta gag gct cag ctg aaa ata cgg gat gct gaa gcc 2160
Tyr Glu Ala Glu Leu Glu Ala Gln Leu Lys Ile Arg Asp Ala Glu Ala
705 710 715 720
CA 02703356 2010-05-31
219
aac cag ctc aag gag gag ttg gaa aaa ctt aga agg ttg agc cag tta 2208
Asn Gin Leu Lys Glu Glu Leu Glu Lys Leu Arg Arg Leu Ser Gin Leu
725 730 735
gaa caa tcg gcc ctt caa gca gag ctt gag aag gaa aag caa gcc ttc 2256
Glu Gin Ser Ala Leu Gin Ala Glu Leu Glu Lys Glu Lys Gin Ala Phe
740 745 750
aag act gct gtc aaa aaa gcc cag ctc tca gaa gga aag gac caa gaa 2304
Lys Thr Ala Val Lys Lys Ala Gin Leu Ser Glu Gly Lys Asp Gin Glu
755 760 765
aat agt gag ctc cgc aca caa ctc caa cag ctg cag gat gac aat gac 2352
Asn Ser Glu Leu Arg Thr Gin Leu Gin Gin Leu Gin Asp Asp Asn Asp
770 775 780
cta ttg aaa cag caa ctt aaa gat ttc cag agt cac ctt aac cat gtg 2400
Leu Leu Lys Gin Gin Leu Lys Asp Phe Gin Ser His Leu Asn His Val
785 790 795 800
gtt gat ggt ttg att cgt cca gaa gaa gtg gca gct tgt gtg gat gag 2448
Val Asp Gly Leu Ile Arg Pro Glu Glu Val Ala Ala Cys Val Asp Glu
805 810 815
cta agg aaa aaa ctg aag tca gga gct ggg gaa atg aga atc cat act 2496
Leu Arg Lys Lys Leu Lys Ser Gly Ala Gly Glu Met Arg Ile His Thr
820 825 830
cct tca gat gtc tta ggg aaa agt ctt gct gac ttg cag aag caa ttc 2544
Pro Ser Asp Val Leu Gly Lys Ser Leu Ala Asp Leu Gin Lys Gin Phe
835 840 845
agt gag atc ctg gca cgc tcc cag tgg gaa aga cag gaa gca caa gtg 2592
Ser Glu Ile Leu Ala Arg Ser Gin Trp Glu Arg Gin Glu Ala Gin Val
850 855 860
aga gag aga aaa ctc cag gag gaa atg gct ctg caa caa gag aaa ctg 2640
Arg Glu Arg Lys Leu Gin Glu Glu Met Ala Leu Gin Gin Glu Lys Leu
865 870 875 880
gcg agc gga caa gag gag ttc agg cac gcc tgc gag agg gcc ctg gaa 2688
Ala Ser Gly Gin Glu Glu Phe Arg His Ala Cys Glu Arg Ala Leu Glu
885 890 895
gcc cga att agt ttt gat aag agg cag cac gaa gca aga atc cag cag 2736
Ala Arg Ile Ser Phe Asp Lys Arg Gin His Glu Ala Arg Ile Gin Gin
900 905 910
ttg gag aat gaa att cac tat ttg caa gaa aat cta aaa agt atg gag 2764
Leu Glu Asn Glu Ile His Tyr Leu Gin Glu Asn Leu Lys Ser Met Glu
915 920 925
gaa atc caa ggt ctc aca gac ctc caa ctt cag gaa gct gat gaa gag 2832
Glu Ile Gin Gly Leu Thr Asp Leu Gin Leu Gin Glu Ala Asp Glu Glu
930 935 940
aag gag aga att ctg gcc caa ctc cgg gag tta gag aaa aag aag aaa 2880
Lys Glu Arg Ile Leu Ala Gin Leu Arg Glu Leu Glu Lys Lys Lys Lys
945 950 955 960
CA 02703356 2010-05-31
220
ctt gag gat gcc aag tct cag gag cag ttt ctt gga tta gat aga gaa 2928
Leu Glu Asp Ala Lys Ser Gin Glu Gin Phe Leu Gly Leu Asp Arg Glu
965 970 975
ttg aag aag cta aag aaa get gtg get gcc tct gat aag ctg gcc aca 2976
Leu Lys Lys Leu Lys Lys Ala Val Ala Ala Ser Asp Lys Leu Ala Thr
980 985 990
get gag ctc ace att gcc aaa gac cag etc aag tcc ctt cat gga act 3024
Ala Glu Leu Thr Ile Ala Lys Asp Gin Leu Lys Ser Leu His Gly Thr
995 1000 1005
gtg atg aaa att aac cag gag cga gca gag gag ctg cag gag acg 3069
Val Met Lys Ile Asn Gin Glu Arg Ala Glu Glu Leu Gin Glu Thr
1010 1015 1020
gag agg ttc age aga aag gca gca caa gca get agg gat ctg atc 3114
Glu Arg Phe Ser Arg Lys Ala Ala Gin Ala Ala Arg Asp Leu Ile
1025 1030 1035
cga gca gaa gcg gag att gaa etc ctg cag aag ctt etc aga gat 3159
Arg Ala Glu Ala Glu Ile Glu Leu Leu Gin Lys Leu Leu Arg Asp
1040 1045 1050
aaa gag gag cag ttt cga aat gag att gag aaa gta gat gtc ggc 3204
Lys Glu Glu Gin Phe Arg Asn Glu Ile Glu Lys Val Asp Val Gly
1055 1060 1065
tct gga gga gca aag tea cag atg ctg gag atg gag aaa eta aat 3249
Ser Gly Gly Ala Lys Ser Gin Met Leu Glu Met Glu Lys Leu Asn
1070 1075 1080
gag aca atg gag agg caa aga aca gag att get agg ctg agg aat 3294
Glu Thr Met Glu Arg Gin Arg Thr Glu Ile Ala Arg Leu Arg Asn
1085 1090 1095
tta eta gac etc ace ggg get gat aac aaa gga aac ttt gaa aat 3339
Leu Leu Asp Leu Thr Gly Ala Asp Asn Lys Gly Asn Phe Glu Asn
1100 1105 1110
gtt ttg gaa gaa att get gaa ctt cga cgt gaa gtt tct cat cag 3384
Val Leu Glu Glu Ile Ala Glu Leu Arg Arg Glu Val Ser His Gin
1115 1120 1125
aat gat tac ate age age atg aca gat cct ttc aaa aga cga ggc 3429
Asn Asp Tyr Ile Ser Ser Met Thr Asp Pro Phe Lys Arg Arg Gly
1130 1135 1140
tat tgg tac ttt atg cca cca cca tea tea tea aaa gtt tee ago 3474
Tyr Trp Tyr Phe Met Pro Pro Pro Ser Ser Ser Lys Val Ser Ser
1145 1150 1155
cac agt tee cag gcc ace aag gac tct ggt gtt ggc eta aag tac 3519
His Ser Ser Gin Ala Thr Lys Asp Ser Gly Val Gly Leu Lys Tyr
1160 1165 1170
aca gcc tee act ccg gtt aga aaa cca cat cgt gga egg cag gat 3564
Thr Ala Ser Thr Pro Val Arg Lys Pro His Arg Gly Arg Gin Asp
1175 1180 1185
CA 02703356 2010-05-31
221
gga aag gag aac agt ggg cct cca cct gcc tca gga tac tgg gtg 3609
Gly Lys Glu Asn Ser Gly Pro Pro Pro Ala Ser Gly Tyr Trp Val
1190 1195 1200
tat tct cct atc agg agt ggg tta cat aaa tcg ttc tca aat aga 3654
Tyr Ser Pro Ile Arg Ser Gly Leu His Lys Ser Phe Ser Asn Arg
1205 1210 1215
gac gca gac agt gga gga gat agc cag gaa gag agc gag cta gat 3699
Asp Ala Asp Ser Gly Gly Asp Ser Gin Glu Glu Ser Glu Leu Asp
1220 1225 1230
gac caa gaa gac cac cca ttt gta cct cct cct gga tac atg atg 3744
Asp Gin Glu Asp His Pro Phe Val Pro Pro Pro Gly Tyr Met Met
1235 1240 1245
tac act gtg ttt cct gat ggt tct cct gta ccc cag ggc atg gcc 3789
Tyr Thr Val Phe Pro Asp Gly Ser Pro Val Pro Gin Gly Met Ala
1250 1255 1260
ctg tat gca ccc cct cct ccc ttg ccc aac aat agc cag cct ctt 3834
Leu Tyr Ala Pro Pro Pro Pro Leu Pro Asn Asn Ser Gin Pro Leu
1265 1270 1275
gac ctt ggc act gtt gtt tat ggc cca cct cct gtt ggg got ccc 3879
Asp Leu Gly Thr Val Val Tyr Gly Pro Pro Pro Val Gly Ala Pro
1280 1285 1290
atc gtg tat ggg cct cca cct ccc aac ttc tcc gta ccc ctc atc 3924
Ile Val Tyr Gly Pro Pro Pro Pro Asn Phe Ser Val Pro Leu Ile
1295 1300 1305
ccc gtg ggt gtg ctg cac tgc aat gtc cca gaa cac cat aac ttg 3969
Pro Val Gly Val Leu His Cys Asn Val Pro Glu His His Asn Leu
1310 1315 1320
gag aat gaa gtt tct aga tta gaa gac ata atg cag cat tta aaa 4014
Glu Asn Glu Val Ser Arg Leu Glu Asp Ile Met Gin His Leu Lys
1325 1330 1335
tct ggg aaa cgg gaa cag tgc atg aaa aca ccc aag ctg cag tcg 4059
Ser Gly Lys Arg Glu Gin Cys Met Lys Thr Pro Lys Leu Gin Ser
1340 1345 1350
gag aaa gaa ctc gca gag ctg cag cat aac att gat ggt ctt ttg 4104
Glu Lys Glu Leu Ala Glu Leu Gin His Asn Ile Asp Gly Leu Leu
1355 1360 1365
caa gag aag aaa gac tta gag cat gaa gta gaa gaa tta cat aga 4149
Gin Glu Lys Lys Asp Leu Glu His Glu Val Glu Glu Leu His Arg
1370 1375 1380
acc atc caa aaa cat caa cag cga aaa gat ttc att gat gga aac 4194
Thr Ile Gin Lys His Gin Gin Arg Lys Asp Phe Ile Asp Gly Asn
1385 1390 1395
gtt gag agt ctt gtg aat gat cta gaa ata gag aag tca ctc aaa 4239
Val Glu Ser Leu Val Asn Asp Leu Glu Ile Glu Lys Ser Leu Lys
1400 1405 1410
SE9I 0E9T SZ9T
nip alu, TEA nTO XS TITO Ate nori Bay nari viy nip UT ni dsy
tibt Bub lou uqb uub oby rub 'ebb ulo uby bqo vob vvb Leo oqo oub
OZ9I 5191 0191
sTH nari nip nip
'ETV ski "sTV TITO TA "asS nip uip nari nari
698t qob EVE =E. bra 34.6 bqv obv vrb Leo oqo oqo quo bqo bub uvb
5091 0091 5651
ski ski sTH ATO nsq nip bav dsv nori TEA ETV low nip uip nip
tZ8t Lee Buv 0E0 EBB voq brb bEr ovb bqq oqb oo5 bqu Bub Leo Leo
065I 5851 0851
uis ATO laS TEA uTO aas ski nal usv nip nori nTo viv ski ski
6LLT, bvo ubb poo Bob Leo obv vuu bqo quu uub bqo Bub qob vuu Lee
SLST OLST 595I
ETV uTO narT nag aqI, nie S L1O ski naq TEA uTO nag 5TH uTe
tELV Dab BED bqo oqo DOV Bub bol Bub vrr qqo oqb Leo boo pro Leo
0951 SSGT OSST
dsy nip usv sTH bald 'ETV 1141 nie aTI dsy ski uip nor ski u-
689t ovb Erb qvu OPO Bbo 'sob qou bub lou osb Lee Leo ago EVE Leo
StST OVST SEST
nai nip AID /III nari IPA to ski ski ski us' d- nag ass uTS ot
tt9t bqo bvb ubb POE Lo "sob uvb Buu Bee buu ovu vqo obv Leo oq4
OEST SST OZST
dsv aas del/ sAl vIV viV TEA TEA ski usv ail nip ski nari aTI
66St oub goo ovb PPE PDB vob qq.6 qqb PPP OPP viu vvb PPE bqq. oqu
GIST 01ST SOST
nT0 nip uip nip qaW ski sTH uie nip nari dsy ski attI dsV PTV
tSST7 uub Bub EED bub bqv EPV DVD Leo bvb bin. qub Lee bov oub gab
0051 S6tT 06tT
uip nari nag bay nsi 1110 uTS dSV viVsAni _tvA. non usV ail vTV
60St Eva oqo bqq. ubv bqo Leo Leo orb oob vuu oqb oqo DEE qqr oob
SetT 08tT SLtT
aql nTO uTS ETV bay Bald nip neri nip nie ETV dsv ski to aqi
V9tt oar upb Leo oaf) rbu .6.6r uub eqq Bub Bub qob ovb rug Bub qou
OLtT S9tT 09VT
uip nari non usy bay ski viv dsv aqd ski nip
ivA viy sTH
6Ttt ruo bqo ulo quu vbu buy pob lvb lou oqq. bee Bub q46 qob quo
SSPT OStT SVPI
ski mu ski nip ski /III SAD aas nari nip /as nip siv nip atly
'LET, VEE EDE VET bub vuu bou oE eo o rub 15v
rub oob Bub bov
OT SEti OUT
naq nor/ bay clay viy nip bay non i nip viy bay Bay ski nari nari
6ZEt bqo bqo bbo oub Dab uvb .6.6u pop Bub vob obo obo BEE Bqo 2qo
SZPT OZVI STi7T
-IJIBald nTO aTI sAO nie 01I nTO dsV TEA aTI dsv ni0 sTH sTH
V8Zt DOP bbv Bub qqp qBq spE qqp ps.6 qp.5 qq.6 qqe qpb ps6 gpo DPO
TE-GO-OTOZ 9GEEOLZO 7/0
CA 02703356 2010-05-31
223
aag tgc aat cac att agg gaa gta aaa tct ctt ctg gaa gaa ctc 4959
Lys Cys Asn His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu
1640 1645 1650
agt ttt cag aaa gga gaa ctg aat gtc cag atc agt gaa aaa aaa 5004
Ser Phe Gin Lys Gly Glu Leu Asn Val Gin Ile Ser Glu Lys Lys
1655 1660 1665
act caa ctt gca ctc ata aag cag gaa att gaa aaa gag gaa gac 5049
Thr Gin Leu Ala Leu Ile Lys Gin Glu Ile Glu Lys Glu Glu Asp
1670 1675 1680
aat ctt cag gta gtt tta ggg caa atg tct aaa cat aaa act gaa 5094
Asn Leu Gin Val Val Leu Gly Gin Met Ser Lys His Lys Thr Glu
1685 1690 1695
eta aag aat att ctg gac atg ttg caa ctt gaa aat aat gag ctg 5139
Leu Lys Asn Ile Leu Asp Met Leu Gin Leu Glu Asn Asn Glu Leu
1700 1705 1710
caa ggt ttg aag ctc caa cat gac caa aag atg tct gaa tta gag 5184
Gin Gly Leu Lys Leu Gin His Asp Gin Lys Net Ser Glu Leu Glu
1715 1720 1725
aag act egg gtt gaa gtg ctg gag gag aaa ctg gag tta gag agt 5229
Lys Thr Arg Val Glu Val Leu Glu Glu Lys Leu Glu Leu Glu Ser
1730 1735 1740
ctg cag cag gca gee ctg cga cag aga ggg gag ata gag tgg cag 5274
Leu Gin Gin Ala Ala Leu Arg Gin Arg Gly Glu Ile Glu Trp Gin
1745 1750 1755
aag cag ctc ctc cag agg aac aca cag gaa gta gag egg atg act 5319
Lys Gin Leu Leu Gin Arg Asn Thr Gin Glu Val Glu Arg Met Thr
1760 1765 1770
get gag ace cga gca tta cag tea tgt gtt gag tct ttg tgc aaa 5364
Ala Glu Thr Arg Ala Leu Gin Ser Cys Val Glu Ser Leu Cys Lys
1775 1780 1785
gaa aag caa gat ctc gaa gaa aaa cag gac age tgg gaa aag aag 5409
Glu Lys Gin Asp Leu Glu Glu Lys Gin Asp Ser Trp Glu Lys Lys
1790 1795 1800
ttg gca cag ace aaa egg gtt eta gca get gca gaa gag gac age 5454
Leu Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asp Ser
1805 1810 1815
gag atg gag egg gca cgc tta gaa aag ttg gaa ctg gac gee agg 5499
Glu Met Glu Arg Ala Arg Leu Glu Lys Leu Glu Leu Asp Ala Arg
1820 1825 1830
aag ctg cag cag gag ttg gac caa cga aac agg gag aag ctc tee 5544
Lys Leu Gin Gin Glu Leu Asp Gin Arg Asn Arg Glu Lys Leu Ser
1835 1840 1845
ctg cat caa gac ctg gca gtg gtg cag cag cag eta caa gaa aaa 5589
Leu His Gin Asp Leu Ala Val Val Gin Gin Gin Leu Gin Glu Lys
1850 1855 1860
580E 080Z SLOZ
nari uip ass bay "ID aII ski nor' viv nip ski nor/ ass rIV TPA
V99 bqo vvo obv
&Bo bro olv bvr lqo Dab vvb bvu bqo obv oaf. bqb
OLOZ 590Z 090Z
uip ski nip viv ski ski bav nTD 1LJ. naa aqd nip usv bav nari
6TZ9 bvo frev
Brb Dab PTV bry rbv rvb vor bqo oqq bvo ovv oBD Bql
SSOZ 050Z StOZ
nari aas aqd dsv viv bav qaw aas dsv nTO ski TITO narl vIV
tLI9 oqo Dbv olq
ovB Bob bbv bqv Doq ovb bor brb 5vr bro bqo oob
OtOZ SEOZ OEOZ
nari nari nip dsv ass ski viv nari nari "ID uis nTS BaV nTS as5
6ZT9 bqo bqo Bvb
ovb voq Bee oob bqo vqq bvo bro bvb bbo reb voq
SZOZ OZOZ STOZ
nari uip Bay ski ally uip ass nari mu ski nip nari au nip aas
V809 qqo bvo vbo
bee Dor Leo ooq oqo boy Bev BvB bqo oov bvb obv
OTOZ SOOZ 000Z
day Bak( Au) nip nip uip nari auy bay ivA bav nip nip viv TEA
6E09 bbq bbv ebb
Bvb bvb Leo .6;q oov bbv oqb qbo Bvb BvB lob blb
6661 0661 5861
naq nali ski vivnri irA *nip dsv nari ski Aip ski uTO niD laW
t665 bqq oqo Bev
qob DID blb Leo ovb bqo ETP obb PPP bvo bvb bqv
0861 6L61 0L61
nari nip ski nip naq TITS "ID "ID "ID nip ski nail aqy TEA ski
6V6S bqq vs6 Lee
rvb Bqo Bea evo Leo Leo bvb bee Lo qor bqb PPP
6961 0961 SS6T
X ss viV nTS sAri ski
nip nip sAD niD bav nip ski uip nari
t06S qbv qob vrb
vqq Lee vvv vvb vv.6 qbq rvb vbo bvb vvv Leo oqo
0661 St6T 0t61
bay aqd laW qaW
niD ui0 "ID PTV nari ski eiv ni0 nsit AID
6686 rbr BED qqq
bqr bqr Erb Era vro Dab vqo Bev bob bvb ovr ebb
6E61 0E61 SZ61
'ID aTI nTO sArl nID nag A15 nID narl TITS nTD sArl
JILL 'TD
ti85 evb qqv Bvb
ETV Leo qqo bbb vro qqo Leo vvo Leo ETV TOP Bvb
0Z6T 6161 0161
AID nID ski nip sAp dsv nID a'-Id ski ski auI niD AID TEA
69L6 BBB vub evr
EEO obq DEB vrb qqq bee ETP bov bbq rvb qbb bqb
6061 0061 6681
dsv ski nip nor' bav aqy uip nip aas nau viv dsv ski bay
tZLS ovb bry BEE
oqo bbv ODP Leo vvb obv oqo bqo rob ovb BET obo
0681 6881 0881
ski atTI sAp TEA niD "TO
nip riv nari dsv naq sTH niD
6L9S _Eve oov
00P obq oqo bqb bvb BED EEL vob rqo ovb bql Teo breb
6L8I OL8T 6981
"ID TEA dsv riv naq nip ski uis n37 aas usit TPA PTV nTS TITO
tE9S Leo oqb qvb
qob vqo vvb bee Leo vqq voq ovv rqb 'rob vvb Leo
T7ZZ
TE-SO-OTOZ 96EEOLZO v0
OTEZ SOEZ 00EZ
nTs PTV nog aas AID nTs atly bald aas nog aos bay aTIL aaS PTV
6E69 bvb oob olo boq obb bob Doe obo boq blo qbv obo ope ooq bob
S6ZZ 06ZZ 58ZZ
aes dsy AID aas aLTI aaS agI TPA nag TITO AID nag vilf dsld TPA
V689 opq orb bbb 304 qov obv oor oqb bqo bvb obb bqo oob ovb bqb
08Z SL ZZ OLZZ
uTO Bald BaV nag aaS sTH nag agI AID TITO aqI Bald BaV Bald AID
6T789 freo Bbo bbo bqo obv ova bqo oov BBB bvb bar obo bbo bbo obb
59ZZ 09ZZ SSZZ
nTs aas nag TPA TITO PTV uTs ski aas qaw sAD bay bay nag uTs
T7089 if e6 obv blo bqb bvb oob beo bvv ooq bqv obq obo obo blo bvo
OSZZ ST7ZZ OT7ZZ
vpi. ski neri bav day nTs bay sTH bay nag sAg nTS Bal/ nag PTV
65L9 =5 Bev oqo bbo orb bvb obo pro obo So bor brb bbo oqo voB
SEZZ OEZZ 5ZZZ
nID AID Bay dal UTS uTD dsV PIV IPA sTH PTV uTS AiD oqd usy
tqL9 bob ebb Up bbq bvo vvb lvb bob bqb ovo qob Ero obb qqq Teo
OZZZ SIZZ OTZZ
nag sAg nTs nTs sA0 aas aas oad bay dsy aos IA aqa, aqd Old
6999 bqo EVE bvb vvb obq qoq voq POD vbv ovb obe Si OOP qqg boo
SOZZ 00ZZ S6TZ
aqd usy nTs ski nag aos nTs nag AID AID AID nag usy nTs usy
T7Z99 31.4 qvv bvb EVE 511 obv bvb bql obb -ebb vbb qqo OPP bob Ter
06T 08TZ
bay nTs nog nog rill. /yrs nog dsy sTy oad nog nip oad nag aqd
6LS9 bbv vv5 bqo qqo oo5 bvb So ovb bob voo bqo bvb voo qqo qq;
SUEZ OLTZ 59TZ
uTs asy nag usy ski nag aas aqI BaV aTI TITO dsld sAg TPA uT5
tES9 5vo o'er oqo lvv bvv bqo obv oov vbo oqv vvb ;vb vve bqb bvb
091Z SST OSIZ
sAD ski nag viV uI0 laW PTV dsy aas aII nTs qaw TITs bay bay
689 qbq vvv ;lo vob VED &qv bob qvb oqv vvb &Ts
bvo vbv vbe
St-CZ ()VIZ SCIZ
nTs nag dsy sAg uTs usy atu qaw uTs sAg bay nag nTs TPA IAI
vvb bqq lvb bvv vvo ove POE blv Boo vvv bay oqo bvb bqb ov;
OEIZ SZTZ OZTZ
nip bay uTs qaw uTs usy nag nTs bay qaw nag bay bay 'sty bay
66E9 bob obo boo bqv beo ove oqo bvb bbv bqv bqo obo bbo oob bbo
STIZ OTTZ SOIZ
nip sTH usy d9Y uTD IY IA uTO uTO aTI 214,1, PTV laW uID baV
f7SE9 bob ovo ovu DE6 BED oob bqb bvo esb oqv ODE vob &qv bvb bbv
00IZ 560Z 060Z
uTs law sAD aas usy nTs uTs sAg uTO Tits nog nag usy sAg uTD
60E9 BED bqv obq DBE DEE bob BED BEE vvo bvb bqo qqo OPP frev bvb
SZZ
TE-SO-OTOZ 9SEEOLZO vo
SESZ OESZ SZSZ
IA BaV bay Old old IV aqI nip atu six PiV PTV "III TPA BIV
tI9L bqb obo ODD qoo
pob pov bvb qov ovo Dab EDB DOV 115 obo
OZSZ SISZ OTSZ
AT oad Old bay nTD uTD eTH uip oad sTH uTD Bay bay ivA old
69SL bbb voo op
55v rvb bvo ova 5vo 000 qvo bvb bbo vbo bqb boo
SOSZ 009Z S6tZ
bay Oi ttt.L 241 SaV att.'. AID bay aas uip nau bay AID day oad
tZSL bbo poo oov
oov bbo bov 555 vbo ooq &ea bqo obo obb 5E3 boo
06tZ S8tZ 08tZ
'E'en vIV AID BaV AID BaV AID bay
Old IA naq oad aAy
6LtL oar bgb 335
bbb rbo vbb gov bbo 3E6 55o qoo 5.45 ago qoo ovg
SLVZ OLtZ S9tZ
BaV TPA aeS PTV AID sAD Bay PTV BaV Bald sAD usV old PTV uID
tEtL bbo bqb obv
bob ebb obq bbo pob qSo obo obq ovv boo oob veb
09tZ SStZ OSVZ =
naq Aip SAD AID bay viy 29S aas sAri bay sA0 SAD aqy nIp
68EL ggo vbb obq
obb obo oob obr obv vrr qbo 354 qbq has vvb 544
SttZ OttZ SEtZ
vTy di' naq AiD Iy bay viy dsy oad usy bay nip bay aas ski
ttEL oob oqo qbb ;oh
Sbo pob qvb Soo as bbo bvb obo obv brr
OT7, SZtZ OZVZ
AID 62c3 old bay vIv ski AID sTH vIV uiD sTH AID BaV IvA BaV
66ZL BBB o.B;
voo qbo bob bvv 55 ovo qob bvo ovo vbb obo oqb obo
STtZ OTtZ SOtZ
flIarqd bay nip aas old TPA AID Old bay bay ii bay bay aq1
DSZL olo oqq.
obo VP.6 bog opo 335 obb opo bbv bbo Doe &be bbo oov
00VZ SSEZ 06EZ
bay nari it old 'sty
bay AID ply vIV viV TPA oad bay old Old
60ZL bbv bqo oov
boo 'sob obo ubb qob bob pob oqb poo bbv Boo poo
S8EZ 08EZ SLEZ
PIV PTV Old naq ni0 vIV Old bay aas SAD in IA nsrl PTV Si
D9IL gob bob boo
olo Erb v35 goo obo ooq obq poq olb 544 oaf, vbo
OLEZ S9EZ 09EZ
atd vIV vTV Ai SaV AID vTV AID nTD bay old old bay bay old
6TTL ogg =6 bob
obb bbo bbb rob Ebb 6v5 5bo POO 000 bbv bbo boo
SSEZ OSEZ StEZ
AID uvrI BaV PTV uID AID sTH usy day bay bay bay bay las nal
tLOL obb ago obo
bob vvb vbb ovo ovv bbq obo obo obo rbo 33.4 3.43
OE Z SEE Z OEEZ
Ale ski BaV AID AID AID Bali AID AID AID Sly dsV aaS AID AID
6ZOL obb Bev bbv
obb BBB 355 bbo vbb vbb qbb vbo ovb obv obb obb
SZEZ OZEZ STEZ
/as AID nari TvA sTH nari nID uTD aas Old AID old Old Trip day
t869 bog bbb bqo
535 pep 530 bvb 5v3 obv poo BBB boo boo vvb ovb
9ZZ
IE-SO-OTOZ 9SEEOLZO VO
CA 02703356 2010-05-31
227
ttc cac gcg cga gta gca gtc ggg gag gte agc etc ggg ccc ggc 7659
Phe His Ala Arg Val Ala Val Gly Glu Val Ser Leu Gly Pro Gly
2540 2545 2550
cgc ggt ctc gag cga aca cgg ggc ggg ggc ggg ggg gcg ggg gcg 7704
Arg Gly Leu Glu Arg Thr Arg Gly Gly Gly Gly Gly Ala Gly Ala
2555 2560 2565
gga ctc ctc gca gag gcc gcg gcc acg gcc cgg tgc gca gac ccc 7749
Gly Leu Leu Ala Glu Ala Ala Ala Thr Ala Arg Cys Ala Asp Pro
2570 2575 2580
tcc aca gac ccc tcc gca tag 7770
Ser Thr Asp Pro Ser Ala
2585
<210> 42
<211> 2589
<212> PRT
<213> Canis familiaris
<400> 42
Met Lys Lys Gly Ser Gin Gin Lys Phe Leu Lys Ala Lys Met Pro Pro
1 5 10 15
Ser Ser His Ser Pro Ser Pro Pro Ser Leu Thr Ser Asn Met Arg Ser
20 25 30
Arg Ser Leu Ser Pro Leu Ser Gly Ser Glu Thr Leu Pro Phe His Phe
35 40 45
Gly Gly Pro Trp His Glu Gin Val Glu Ile Thr Asp Glu Ser Thr Val
50 55 60
Val Leu Asp Tyr Gin Asp His Lys Glu Ala Asp Ser His Ala Gly Val
65 70 75 80
Arg Tyr Ile Thr Glu Ala Leu Val Arg Lys Leu Thr Lys Gin Asp Asn
85 90 95
Leu Ala Leu Val Lys Ser Leu Asn Leu Ser Leu Ala Lys Gly Gly Gly
100 105 110
Lys Lys Phe Arg Cys Ile Glu Asn Leu Glu Lys Cys Val Lys Leu Glu
115 120 125
Val Leu Asn Leu Ser Tyr Asn Leu Ile Gly Lys Ile Glu Lys Val Asp
130 135 140
Lys Leu Leu Lys Leu Arg Glu Leu Asn Leu Ser Tyr Asn Lys Ile Arg
145 150 155 160
Lys Ile Glu Gly Ile Glu Asn Leu Tyr Asn Leu Gin Lys Leu Asn Leu
165 170 175
Ala Gly Asn Glu Ile Glu His Ile Pro Val Trp Leu Gly Lys Lys Leu
180 185 190
Lys Ser Leu Arg Ile Leu Asn Leu Lys Gly Asn Lys Ile Ser Ser Leu
195 200 205
Gin Asp Val Ser Lys Leu Lys Pro Leu Gin Asp Leu Thr Ser Leu Ile
210 215 220
Leu Leu Glu Asn Pro Val Ala Thr Leu Pro His Tyr Ile Gin Phe Thr
225 230 235 240
Ile Phe His Leu Arg Ser Leu Glu Ser Leu Glu Gly Gin Pro Val Thr
245 250 255
Ser Gin Asp Arg Gln Glu Ala Phe Ala Arg Phe Ser Leu Asp Glu Val
260 265 270
Glu Arg Leu Glu Arg Asp Leu Glu Lys Lys Thr Met Glu Thr Glu Glu
275 280 285
CA 02703356 2010-05-31
228
Leu Arg Ser Glu Gin Thr Arg Phe Leu Glu Glu Ile Lys Ser Gin Asp
290 295 300
Lys Leu Asn Lys Ser Leu Lys Glu Glu Ala Arg Leu Gin Lys Gin Ser
305 310 315 320
Tyr Glu Glu Leu Glu Ser Asn Leu Asn Thr Lys Asn Glu Leu Leu Lys
325 330 335
Gin Lys Thr Met Glu Leu Met Arg Ala Cys Gin Lys Gin Tyr Glu Met
340 345 350
Glu Gin Glu Leu Ala Phe Tyr Lys Ile Asp Ala Lys Phe Glu Pro Leu
355 360 365
Asn Tyr Tyr Pro Ser Glu Tyr Val Glu Ile Asp Lys Thr Pro Asp Glu
370 375 380
Ser Pro Tyr Ile Gly Lys Ser Arg Tyr Lys Arg Asn Met Phe Thr Thr
385 390 395 400
Glu Ser Tyr Ile Ile Ala Asn Ala Gin Thr Val Lys Ile Lys Lys Met
405 410 415
Glu Leu Asp Glu Gly Glu Gin Leu Arg Asn Glu His Val Asn Leu Gly
420 425 430
Ala Ser Pro Thr Asp Ile Gin Leu Glu Asp Lys Glu Lys Lys Ile Ser
435 440 445
Ala Ala Gin Thr Arg Leu Ser Glu Leu His Asp Glu Ile Glu Lys Ala
450 455 460
Glu Gin Gin Ile Leu Arg Ala Thr Glu Glu Phe Lys Gin Leu Glu Glu
465 470 475 480
Ala Ile Gin Leu Lys Lys Ile Ser Glu Ala Glu Lys Asp Leu Leu Phe
485 490 495
Lys Gin Leu Ser Gly Arg Ile Gin Leu Leu Asn Lys Leu Arg Gin Glu
500 505 510
Ala Val Asp Leu Glu Thr Gin Met Glu Lys Gin Arg Gin Glu Ile Gly
515 520 525
Glu Lys Gin Asn Glu Ile Lys Asp Leu Glu Ile Val Thr Asp Ser Leu
530 535 540
Asp Ser Arg Asp Pro Lys His Cys His Met Lys Ala Gin Lys Arg Gly
545 550 555 560
Lys Glu Gin Gin Leu Asp Ile Met Asn Lys Gin Tyr Lys Gin Leu Glu
565 570 575
Ser Arg Leu Asp Glu Ile Leu Ser Arg Ile Ala Lys Glu Thr Glu Glu
580 585 590
Ile Lys Asp Leu Glu Glu Gin Leu Thr Glu Gly Gin Ile Ala Ala Asn
595 600 605
Glu Ala Leu Lys Lys Asp Leu Glu Ser Val Ile Ser Gly Leu Gin Glu
610 615 620
Tyr Leu Glu Thr Val Lys Gly Gin Ala Arg Gin Ala Gin Asn Glu Cys
625 630 635 640
Arg Lys Leu Gin Asp Glu Lys Glu Thr Leu Leu Gin Arg Leu Ser Glu
645 650 655
Val Glu Gin Glu Arg Asp Gin Leu Glu Ile Val Ala Ile Asp Ala Glu
660 665 670
Asn Met Arg Lys Glu Leu Ala Glu Leu Glu Asn Ala Leu Gin Glu Gin
675 680 685
His Glu Val Asn Ile Ser Leu Gin Gin Thr Gin Gly Asp Leu Ser Ala
690 695 700
Tyr Glu Ala Glu Leu Glu Ala Gin Leu Lys Ile Arg Asp Ala Glu Ala
705 710 715 720
Asn Gin Leu Lys Glu Glu Leu Glu Lys Leu Arg Arg Leu Ser Gin Leu
725 730 735
Glu Gin Ser Ala Leu Gin Ala Glu Leu Glu Lys Glu Lys Gin Ala Phe
740 745 750
Lys Thr Ala Val Lys Lys Ala Gin Leu Ser Glu Gly Lys Asp Gin Glu
755 760 765
CA 02703356 2010-05-31
229
Asn Ser Glu Leu Arg Thr Gin Leu Gin Gin Leu Gin Asp Asp Asn Asp
770 775 780
Leu Leu Lys Gin Gin Leu Lys Asp Phe Gin Ser His Leu Asn His Val
785 790 795 800
Val Asp Gly Leu Ile Arg Pro Glu Glu Val Ala Ala Cys Val Asp Glu
805 810 815
Leu Arg Lys Lys Leu Lys Ser Gly Ala Gly Glu Met Arg Ile His Thr
820 825 830
Pro Ser Asp Val Leu Gly Lys Ser Leu Ala Asp Leu Gin Lys Gin Phe
835 840 845
Ser Glu Ile Leu Ala Arg Ser Gin Trp Glu Arg Gin Glu Ala Gin Val
850 855 860
Arg Glu Arg Lys Leu Gin Glu Glu Met Ala Leu Gin Gin Glu Lys Leu
865 870 875 880
Ala Ser Gly Gin Glu Glu Phe Arg His Ala Cys Glu Arg Ala Leu Glu
885 890 895
Ala Arg Ile Ser Phe Asp Lys Arg Gin His Glu Ala Arg Ile Gin Gin
900 905 910
Leu Glu Asn Glu Ile His Tyr Leu Gin Glu Asn Leu Lys Ser Met Glu
915 920 925
Glu Ile Gin Gly Leu Thr Asp Leu Gin Leu Gin Glu Ala Asp Glu Glu
930 935 940
Lys Glu Arg Ile Leu Ala Gin Leu Arg Glu Leu Glu Lys Lys Lys Lys
945 950 955 960
Leu Glu Asp Ala Lys Ser Gin Glu Gin Phe Leu Gly Leu Asp Arg Glu
965 970 975
Leu Lys Lys Leu Lys Lys Ala Val Ala Ala Ser Asp Lys Leu Ala Thr
980 985 990
Ala Glu Leu Thr Ile Ala Lys Asp Gin Leu Lys Ser Leu His Gly Thr
995 1000 1005
Val Met Lys Ile Asn Gin Glu Arg Ala Glu Glu Leu Gin Glu Thr
1010 1015 1020
Glu Arg Phe Ser Arg Lys Ala Ala Gin Ala Ala Arg Asp Leu Ile
1025 1030 1035
Arg Ala Glu Ala Glu Ile Glu Leu Leu Gin Lys Leu Leu Arg Asp
1040 1045 1050
Lys Glu Glu Gin Phe Arg Asn Glu Ile Glu Lys Val Asp Val Gly
1055 1060 1065
Ser Gly Gly Ala Lys Ser Gin Met Leu Glu Met Glu Lys Leu Asn
1070 1075 1080
Glu Thr Net Glu Arg Gin Arg Thr Glu Ile Ala Arg Leu Arg Asn
1085 1090 1095
Leu Leu Asp Leu Thr Gly Ala Asp Asn Lys Gly Asn Phe Glu Asn
1100 1105 1110
Val Leu Glu Glu Ile Ala Glu Leu Arg Arg Glu Val Ser His Gin
1115 1120 1125
Asn Asp Tyr Ile Ser Ser Met Thr Asp Pro Phe Lys Arg Arg Gly
1130 1135 1140
Tyr Trp Tyr Phe Met Pro Pro Pro Ser Ser Ser Lys Val Ser Ser
1145 1150 1155
His Ser Ser Gin Ala Thr Lys Asp Ser Gly Val Gly Leu Lys Tyr
1160 1165 1170
Thr Ala Ser Thr Pro Val Arg Lys Pro His Arg Gly Arg Gin Asp
1175 1180 1185
Gly Lys Glu Asn Ser Gly Pro Pro Pro Ala Ser Gly Tyr Trp Val
1190 1195 1200
Tyr Ser Pro Ile Arg Ser Gly Leu His Lys Ser Phe Ser Asn Arg
1205 1210 1215
Asp Ala Asp Ser Gly Gly Asp Ser Gin Glu Glu Ser Glu Leu Asp
1220 1225 1230
CA 02703356 2010-05-31
230
Asp Gin Glu Asp His Pro Phe Val Pro Pro Pro Gly Tyr Met Met
1235 1240 1245
Tyr Thr Val Phe Pro Asp Gly Ser Pro Val Pro Gin Gly Met Ala
1250 1255 1260
Leu Tyr Ala Pro Pro Pro Pro Leu Pro Asn Asn Ser Gin Pro Leu
1265 1270 1275
Asp Leu Gly Thr Val Val Tyr Gly Pro Pro Pro Val Gly Ala Pro
1280 1285 1290
Ile Val Tyr Gly Pro Pro Pro Pro Asn Phe Ser Val Pro Leu Ile
1295 1300 1305
Pro Val Gly Val Leu His Cys Asn Val Pro Glu His His Asn Leu
1310 1315 1320
Glu Asn Glu Val Ser Arg Leu Glu Asp Ile Met Gin His Leu Lys
1325 1330 1335
Ser Gly Lys Arg Glu Gin Cys Met Lys Thr Pro Lys Leu Gin Ser
1340 1345 1350
Glu Lys Glu Leu Ala Glu Leu Gin His Asn Ile Asp Gly Leu Leu
1355 1360 1365
Gin Glu Lys Lys Asp Leu Glu His Glu Val Glu Glu Leu His Arg
1370 1375 1380
Thr Ile Gin Lys His Gin Gin Arg Lys Asp Phe Ile Asp Gly Asn
1385 1390 1395
Val Glu Ser Leu Val Asn Asp Leu Glu Ile Glu Lys Ser Leu Lys
1400 1405 1410
His His Glu Asp Ile Val Asp Glu Ile Glu Cys Ile Glu Arg Thr
1415 1420 1425
Leu Leu Lys Arg Arg Ala Glu Leu Arg Glu Ala Asp Arg Leu Leu
1430 1435 1440
Thr Glu Ala Glu Ser Glu Leu Ser Cys Thr Lys Glu Lys Thr Lys
1445 1450 1455
His Ala Val Glu Lys Phe Thr Asp Ala Lys Arg Asn Leu Leu Gin
1460 1465 1470
Thr Glu Lys Asp Ala Glu Glu Leu Glu Arg Arg Ala Gin Glu Thr
1475 1480 1485
Ala Ile Asn Leu Val Lys Ala Asp Gin Gin Leu Arg Leu Leu Gin
1490 1495 1500
Ala Asp Thr Lys Asp Leu Glu Gin His Lys Met Glu Gin Glu Glu
1505 1510 1515
Ile Leu Lys Glu Ile Asn Lys Val Val Ala Ala Lys Asp Ser Asp
1520 1525 1530
Phe Gin Ser Leu Asn Lys Lys Lys Glu Val Leu Thr Gly Glu Leu
1535 1540 1545
Gin Lys Leu Gin Lys Asp Ile Glu Thr Ala Arg His Asn Glu Asp
1550 1555 1560
Gin His Leu Gin Val Leu Lys Glu Ser Glu Thr Leu Leu Gin Ala
1565 1570 1575
Lys Lys Ala Glu Leu Glu Asn Leu Lys Ser Gin Val Ser Gly Gin
1580 1585 1590
Gin Gin Glu Met Ala Val Leu Asp Arg Glu Leu Gly His Lys Lys
1595 1600 1605
Glu Glu Leu His Leu Leu Gin Glu Ser Met Val Gin Ala Lys Ala
1610 1615 1620
Asp Leu Gin Glu Ala Leu Arg Leu Gly Glu Ser Glu Val Thr Glu
1625 1630 1635
Lys Cys Asn His Ile Arg Glu Val Lys Ser Leu Leu Glu Glu Leu
1640 1645 1650
Ser Phe Gin Lys Gly Glu Leu Asn Val Gin Ile Ser Glu Lys Lys
1655 1660 1665
Thr Gin Leu Ala Leu Ile Lys Gin Glu Ile Glu Lys Glu Glu Asp
1670 1675 1680
CA 02703356 2010-05-31
=
231
Asn Leu Gin Val Val Leu Gly Gin Met Ser Lys His Lys Thr Glu
1685 1690 1695
Leu Lys Asn Ile Leu Asp Met Leu Gin Leu Glu Asn Asn Glu Leu
1700 1705 1710
Gin Gly Leu Lys Leu Gin His Asp Gin Lys Met Ser Glu Leu Glu
1715 1720 1725
Lys Thr Arg Val Glu Val Leu Glu Glu Lys Leu Glu Leu Glu Ser
1730 1735 1740
Leu Gin Gin Ala Ala Leu Arg Gin Arg Gly Glu Ile Glu Trp Gin
1745 1750 1755
Lys Gin Leu Leu Gin Arg Asn Thr Gin Glu Val Glu Arg Met Thr
1760 1765 1770
Ala Glu Thr Arg Ala Leu Gin Ser Cys Val Glu Ser Leu Cys Lys
1775 1780 1785
Glu Lys Gin Asp Leu Glu Glu Lys Gin Asp Ser Trp Glu Lys Lys
1790 1795 1800
Leu Ala Gin Thr Lys Arg Val Leu Ala Ala Ala Glu Glu Asp Ser
1805 1810 1815
Glu Met Glu Arg Ala Arg Leu Glu Lys Leu Glu Leu Asp Ala Arg
1820 1825 1830
Lys Leu Gin Gin Glu Leu Asp Gin Arg Asn Arg Glu Lys Leu Ser
1835 1840 1845
Leu His Gin Asp Leu Ala Val Val Gin Gin Gin Leu Gin Glu Lys
1850 1855 1860
Gin Glu Ala Val Asn Ser Leu Gin Lys Glu Leu Ala Asp Val Gin
1865 1870 1875
Glu His Leu Asp Leu Ala Glu Gin Glu Val Leu Cys Thr Thr Lys
1880 1885 1890
Arg Lys Asp Ala Leu Leu Ser Glu Gin Thr Arg Leu Glu Lys Asp
1895 1900 1905
Val Gly Glu Trp Thr Lys Lys Phe Glu Asp Cys Gin Lys Glu Gly
1910 1915 1920
Glu Thr Lys Gin Gin Gin Leu Gin Gly Leu Gin Lys Glu Ile Glu
1925 1930 1935
Gly Asn Glu Ala Lys Leu Ala Gin Gin Glu Met Met Phe Gin Arg
1940 1945 1950
Leu Gin Lys Glu Arg Glu Cys Glu Glu Lys Lys Leu Glu Ala Ser
1955 1960 1965
Lys Val Thr Leu Lys Glu Gin Gin Gin Gin Leu Glu Lys Glu Leu
1970 1975 1980
Met Glu Gin Lys Gly Lys Leu Asp Gin Val Leu Ala Lys Leu Leu
1985 1990 1995
Val Ala Glu Glu Arg Val Arg Thr Leu Gin Glu Glu Gly Arg Trp
2000 2005 2010
Ser Glu Thr Leu Glu Lys Thr Leu Ser Gin Thr Lys Arg Gin Leu
2015 2020 2025
Ser Glu Arg Glu Gin Gin Leu Leu Ala Lys Ser Asp Glu Leu Leu
2030 2035 2040
Ala Leu Gin Lys Glu Thr Asp Ser Met Arg Ala Asp Phe Ser Leu
2045 2050 2055
Leu Arg Asn Gin Phe Leu Thr Glu Arg Lys Lys Ala Glu Lys Gin
2060 2065 2070
Val Ala Ser Leu Lys Glu Ala Leu Lys Ile Gin Arg Ser Gin Leu
2075 2080 2085
Glu Lys Asn Leu Leu Glu Gin Lys Gin Glu Asn Ser Cys Met Gin
2090 2095 2100
Arg Glu Net Ala Thr Ile Glu Gin Val Ala Gin Asp Asn His Glu
2105 2110 2115
Arg Ala Arg Arg Leu Met Arg Glu Leu Asn Gin Met Gin Arg Glu
2120 2125 2130
CA 02703356 2010-05-31
232
Tyr Val Glu Leu Arg Lys Gin Met Thr Asn Gin Lys Asp Leu Glu
2135 2140 2145
Arg Arg Gin Met Glu Ile Ser Asp Ala Met Gin Ala Leu Lys Cys
2150 2155 2160
Glu Val Lys Asp Glu Ile Arg Thr Ser Leu Lys Asn Leu Asn Gin
2165 2170 2175
Phe Leu Pro Glu Leu Pro Ala Asp Leu Glu Ala Leu Leu Glu Arg
2180 2185 2190
Asn Glu Asn Leu Gly Gly Gly Leu Glu Ser Leu Lys Glu Asn Phe
2195 2200 2205
Pro Phe Thr Val Ser Asp Arg Pro Ser Ser Cys Glu Glu Lys Leu
2210 2215 2220
Asn Phe Gly Gin Ala His Val Ala Asp Glu Gin Trp Arg Gly Glu
2225 2230 2235
Ala Leu Arg Glu Lys Leu Arg His Arg Glu Asp Arg Leu Lys Ala
2240 2245 2250
Gin Leu Arg Arg Cys Met Ser Lys Gin Ala Glu Val Leu Ser Glu
2255 2260 2265
Gly Arg Arg Arg Thr Glu Gly Thr Leu His Ser Leu Arg Arg Gin
2270 2275 2280
Val Asp Ala Leu Gly Glu Leu Val Thr Ser Thr Ser Gly Asp Ser
2285 2290 2295
Ala Ser Thr Arg Ser Leu Ser Arg Thr Glu Gly Ser Leu Ala Glu
2300 2305 2310
Asp Glu Pro Pro Gly Pro Ser Gin Glu Leu His Val Leu Gly Ser
2315 2320 2325
Gly Gly Ser Asp Arg Gly Gly Gly Arg Gly Gly Gly Arg Lys Gly
2330 2335 2340
Leu Ser Arg Arg Arg Arg Trp Asn His Gly Glu Ala Arg Leu Gly
2345 2350 2355
Pro Arg Arg Pro Pro Arg Glu Gly Ala Gly Arg Gly Ala Ala Phe
2360 2365 2370
Arg Ala Leu Val Ser Cys Ser Arg Pro Ala Glu Leu Pro Ala Ala
2375 2380 2385
Pro Pro Arg Pro Val Ala Ala Ala Gly Arg Ala Pro Thr Leu Arg
2390 2395 2400
Thr Arg Arg Thr Arg Arg Pro Gly Val Pro Ser Glu Arg Phe Leu
2405 2410 2415
Arg Val Arg Gly His Gin Ala His Gly Lys Ala Arg Pro Cys Gly
2420 2425 2430
Lys Ser Arg Glu Arg Asn Pro Asp Ala Arg Ala Gly Leu Trp Ala
2435 2440 2445
Leu Glu Thr Cys Cys Arg Lys Ser Ser Ala Arg Gly Cys Gly Leu
2450 2455 2460
Glu Ala Pro Asn Cys Arg Arg Ala Arg Cys Gly Ala Ser Val Arg
2465 2470 2475
Tyr Pro Leu Val Pro Arg Gly Arg Thr Gly Arg Gly Ala Val Thr
2480 2485 2490
Pro Trp Gly Arg Leu Gin Ser Arg Gly Thr Arg Thr Thr Pro Arg
2495 2500 2505
Pro Val Arg Arg Glu His Pro Gin His Gin Glu Arg Pro Pro Gly
2510 2515 2520
Arg Val Thr Ala Ala His Thr Glu Thr Ala Pro Pro Arg Arg Val
2525 2530 2535
Phe His Ala Arg Val Ala Val Gly Glu Val Ser Leu Gly Pro Gly
2540 2545 2550
Arg Gly Leu Glu Arg Thr Arg Gly Gly Gly Gly Gly Ala Gly Ala
2555 2560 2565
CA 02703356 2010-05-31
233
Gly Leu Leu Ala Glu Ala Ala Ala Thr Ala Arg Cys Ala Asp Pro
2570 2575 2580
Ser Thr Asp Pro Ser Ala
2585
<210> 43
<211> 23
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 43
gtcgacctat gcggaggggt ctg 23
<210> 44
<211> 6046
<212> DNA
<213> Canis familiaris
<220>
<221> CDS
<222> (1)..(5934)
<400> 44
atg tcg tcc tgg ctc ggg ggc ctg ggc tcc ggc ctg ggc cag tcg ctg 48
Met Ser Ser Trp Leu Gly Gly Leu Gly Ser Gly Leu Gly Gln Ser Leu
1 5 10 15
ggg caa gtc gga ggc agc ctg gcc tcc ctc act ggc cag att tca aac 96
Gly Gln Val Gly Gly Ser Leu Ala Ser Leu Thr Gly Gln Ile Ser Asn
20 25 30
ttt acg aag gac atg ctg atg gag ggc acg gag gag gtg gaa gca gaa 144
Phe Thr Lys Asp Met Leu Met Glu Gly Thr Glu Glu Val Glu Ala Glu
35 40 45
tta cct aat tct agg aga aag gaa gtt gaa gcc att cat gca atc tta 192
Leu Pro Asn Ser Arg Arg Lys Glu Val Glu Ala Ile His Ala Ile Leu
50 55 60
aga tca gag aat gag aga ctc aaa gaa ctt tgt act gat tta gaa gag 240
Arg Ser Glu Asn Glu Arg Leu Lys Glu Leu Cys Thr Asp Leu Glu Glu
65 70 75 80
aag cat gaa gca tca gag ctt caa ata aag caa caa tct sea aat tac 288
Lys His Glu Ala Ser Glu Leu Gln Ile Lys Gln Gln Ser Thr Asn Tyr
85 90 95
cga aat caa cta caa cag aaa gag gta gaa ate agc cat ctt aaa gca 336
Arg Asn Gln Leu Gln Gln Lys Glu Val Glu Ile Ser His Leu Lys Ala
100 105 110
aga cag att gca ctg cag gat cag ttg ctg aag ctg cag tca gct gct 384
Arg Gln Ile Ala Leu Gln Asp Gln Leu Leu Lys Leu Gln Ser Ala Ala
115 120 125
CA 02703356 2010-05-31
234
cag tct gca cat tca gga gct agc agc gta cca gca gcc ctg gca tca 432
Gin Ser Ala His Ser Gly Ala Ser Ser Val Pro Ala Ala Leu Ala Ser
130 135 140
tct ccg ttc agc tat tct gtc agt cat cat gct tca gct ttc cat gac 480
Ser Pro Phe Ser Tyr Ser Val Ser His His Ala Ser Ala Phe His Asp
145 150 155 160
gat gac atg gac ttc agt gac ata att tca tca caa caa gaa ata aac 528
Asp Asp Met Asp Phe Ser Asp Ile Ile Ser Ser Gin Gin Glu Ile Asn
165 170 175
aga tta tca aat gaa gtt tca aga ctt gag tct gag gtt ggc cat tgg 576
Arg Leu Ser Asn Glu Val Ser Arg Leu Glu Ser Glu Val Gly His Trp
180 185 190
agg cat att gct cag act tct aaa gca caa gga tca aat agc tct gat 624
Arg His Ile Ala Gin Thr Ser Lys Ala Gin Gly Ser Asn Ser Ser Asp
195 200 205
caa agt gaa atc tgt aaa cta caa agt atc att aag gaa ctc aaa cag 672
Gin Ser Glu Ile Cys Lys Leu Gin Ser Ile Ile Lys Glu Leu Lys Gin
210 215 220
att cga agt cag gaa atc gat gac cat caa cat gaa atg tca gtg ttg 720
Ile Arg Ser Gin Glu Ile Asp Asp His Gin His Glu Met Ser Val Leu
225 230 235 240
cag aat gca cat caa cag aag ttg aca gat ata agt cgt cgg cat cga 768
Gin Asn Ala His Gin Gin Lys Leu Thr Asp Ile Ser Arg Arg His Arg
245 250 255
gaa gaa tta cgt gac tat gaa gaa cga att gaa gaa ctg gaa aat ctg 816
Glu Glu Leu Arg Asp Tyr Glu Glu Arg Ile Glu Glu Leu Glu Asn Leu
260 265 270
tta gaa caa ggt ggc tca gga att gta ata cct gat cac tca aaa atc 864
Leu Glu Gin Gly Gly Ser Gly Ile Val Ile Pro Asp His Ser Lys Ile
275 280 285
cat gag atg caa aaa act att cag aat cta caa act gaa aaa gta gca 912
His Glu Met Gin Lys Thr Ile Gin Asn Leu Gin Thr Glu Lys Val Ala
290 295 300
tct ata aaa aaa att gaa gaa ctt gag gat aaa ata aaa gac ata gat 960
Ser Ile Lys Lys Ile Glu Glu Leu Glu Asp Lys Ile Lys Asp Ile Asp
305 310 315 320
aaa aaa ttg tct tct gca gaa aat gac aga gat gtt ttg agg aag gag 1008
Lys Lys Leu Ser Ser Ala Glu Asn Asp Arg Asp Val Leu Arg Lys Glu
325 330 335
aaa gaa tgc cta aat gtt gaa aac aga caa ata aca gaa caa tgt gaa 1056
Lys Glu Cys Leu Asn Val Glu Asn Arg Gin Ile Thr Glu Gin Cys Glu
340 345 350
agc ttg aaa ctg gaa tgt aaa ttg cag cat gat gct gag aag caa ggt 1104
Ser Leu Lys Leu Glu Cys Lys Leu Gln His Asp Ala Glu Lys Gin Gly
355 360 365
CA 02703356 2010-05-31
235
gat act gtg aca gaa aaa gaa aga atc ctt cca cag agt aca tca gtg 1152
Asp Thr Val Thr Glu Lys Glu Arg Ile Leu Pro Gin Ser Thr Ser Val
370 375 380
gaa gag gaa gtg ctc aaa ctg cag caa gca ctg tct gat gcg gaa aat 1200
Glu Glu Glu Val Leu Lys Leu Gin Gin Ala Leu Ser Asp Ala Glu Asn
385 390 395 400
gaa att atg aga ctg agt aat tta tac cag gat aac agt ctc act gaa 1248
Glu Ile Met Arg Leu Ser Asn Leu Tyr Gin Asp Asn Ser Leu Thr Glu
405 410 415
gat aat ttg aaa ctt aaa atg cat gtc gaa ttt tta gaa aaa cag aag 1296
Asp Asn Leu Lys Leu Lys Met His Val Glu Phe Leu Glu Lys Gin Lys
420 425 430
tcc tta ttg agt caa gaa aag gaa gag ctt caa cta tca ctt tta aag 1344
Ser Leu Leu Ser Gin Glu Lys Glu Glu Leu Gin Leu Ser Leu Leu Lys
435 440 445
ttg aac aat gaa tat gaa gtg att aaa agt aca gct gtg aga gac atg 1392
Leu Asn Asn Glu Tyr Glu Val Ile Lys Ser Thr Ala Val Arg Asp Met
450 455 460
gat atg gat tca aca tta tgt gat tta aga ctg acc ttg gag gca aag 1440
Asp Met Asp Ser Thr Leu Cys Asp Leu Arg Leu Thr Leu Glu Ala Lys
465 470 475 480
gac cag gaa ctc aat cag agt ctc act gag aag gaa ata ttg gtt gct 1488
Asp Gin Glu Leu Asn Gin Ser Leu Thr Glu Lys Glu Ile Leu Val Ala
485 490 495
gag tta gag gaa ttg gac aga caa aac caa gaa gct aca aag cac atg 1536
Glu Leu Glu Glu Leu Asp Arg Gin Asn Gin Glu Ala Thr Lys His Met
500 505 510
att ctg ata aaa gat cag cta tca aaa caa caa agt gag gga gaa act 1584
Ile Leu Ile Lys Asp Gin Leu Ser Lys Gin Gin Ser Glu Gly Glu Thr
515 520 525
atc att agt aaa ctg aga aaa gat cta aat gat gaa aac aag aga gtc 1632
Ile Ile Ser Lys Leu Arg Lys Asp Leu Asn Asp Glu Asn Lys Arg Val
530 535 540
cat caa ctt gaa gat gat aaa aag aat atg act aaa gaa cta aat gtg 1680
His Gin Leu Glu Asp Asp Lys Lys Asn Met Thr Lys Glu Leu Asn Val
545 550 555 560
cag aaa gag aag tta gtt caa agt goo ctc gtc cta aat ggc ttg cat 1728
Gin Lys Glu Lys Leu Val Gin Ser Glu Leu Val Leu Asn Gly Leu His
565 570 575
tta gcc aag cag aag ctt gag gag aaa gta gaa gat tta gtg gat cag 1776
Leu Ala Lys Gin Lys Leu Glu Glu Lys Val Glu Asp Leu Val Asp Gin
580 585 590
cta aat aaa tca caa aaa agt aat tta aac atg cag aag gag aac ttt 1824
Leu Asn Lys Ser Gin Lys Ser Asn Leu Asn Met Gin Lys Glu Asn Phe
595 600 605
CA 02703356 2010-05-31
236
gga ctt aag gaa cat att aaa caa aat gag gaa gag ctt tct aga gtc 1872
Gly Leu Lys Glu His Ile Lys Gln Asn Glu Glu Glu Leu Ser Arg Val
610 615 620
agg gat gag tta act cag tct cta agt cga gac tct ggc agt gat ttt 1920
Arg Asp Glu Leu Thr Gln Ser Leu Ser Arg Asp Ser Gly Ser Asp Phe
625 630 635 640
aag gat gac tta ctt aaa gaa agg gaa gct gaa gtc aga aac tta aaa 1968
Lys Asp Asp Leu Leu Lys Glu Arg Glu Ala Glu Val Arg Asn Leu Lys
645 650 655
caa aat ctt tca gaa ata gaa cag ctc aat gac agt tta aac aaa gtt 2016
Gln Asn Leu Ser Glu Ile Glu Gln Leu Asn Asp Ser Leu Asn Lys Val
660 665 670
gcc ttt gat ctc aaa atg gaa aat gaa aag ttg gtc tta gcg tgt gaa 2064
Ala Phe Asp Leu Lys Met Glu Asn Glu Lys Leu Val Leu Ala Cys Glu
675 680 685
gat ata aga cat cag ttg gaa gaa tca att gtt ggc agc aat cag atg 2112
Asp Ile Arg His Gln Leu Glu Glu Ser Ile Val Gly Ser Asn Gln Met
690 695 700
tct ctg gaa aga aac act att gtg gag gct cta aaa atg gaa aaa gga 2160
Ser Leu Glu Arg Asn Thr Ile Val Glu Ala Leu Lys Met Glu Lys Gly
705 710 715 720
cag tta gaa gca gaa ttg agt cga gct gac caa agg ctg ttg gaa gaa 2208
Gln Leu Glu Ala Glu Leu Ser Arg Ala Asp Gln Arg Leu Leu Glu Glu
725 730 735
gcc agt aag tat gaa cag acg att caa gag cta tca aag gca cgt gat 2256
Ala Ser Lys Tyr Glu Gln Thr Ile Gln Glu Leu Ser Lys Ala Arg Asp
740 745 750
ttg agg acc tct gct tta cag ctg gag cag cag cat tta atg aaa ctc 2304
Leu Arg Thr Ser Ala Leu Gln Leu Glu Gln Gln His Leu Met Lys Leu
755 760 765
agt caa gag aag gac ttc gaa ata gca gaa ctt aaa aag aac att gaa 2352
Ser Gln Glu Lys Asp Phe Glu Ile Ala Glu Leu Lys Lys Asn Ile Glu
770 775 780
cag atg gat act gat cat aaa gaa act aag gca att ttg tca tct att 2400
Gln Met Asp Thr Asp His Lys Glu Thr Lys Ala Ile Leu Ser Ser Ile
785 790 795 800
tta gaa gag cag aag caa ttg acg caa ctt ata agt gag aag gaa att 2448
Leu Glu Glu Gln Lys Gln Leu Thr Gln Leu Ile Ser Glu Lys Glu Ile
805 810 815
ttt att gag aaa ctt aaa gaa aga agt tca gag ctt cag gag gaa tta 2496
Phe Ile Glu Lys Leu Lys Glu Arg Ser Ser Glu Leu Gln Glu Glu Leu
820 825 830
gag aaa tct act cag gcc tca agg aaa att gaa att tta aag caa acc 2544
Glu Lys Ser Thr Gln Ala Ser Arg Lys Ile Glu Ile Leu Lys Gln Thr
835 840 845
CA 02703356 2010-05-31
=
237
att gag gag aaa gac aga agt ctt ggg tcc atg aaa gaa gaa aac aat 2592
Ile Glu Glu Lys Asp Arg Ser Leu Gly Ser Met Lys Glu Glu Asn Asn
850 855 860
cat ctg aaa gaa gaa ctg gaa egg etc cgt gaa cag cag agt cga gcc 2640
His Leu Lys Glu Glu Leu Glu Arg Leu Arg Glu Gin Gin Ser Arg Ala
865 870 875 880
gtg cct gtg gtg gag cct aaa ccc ctg gat agt gtt aca gag eta gaa 2688
Val Pro Val Val Glu Pro Lys Pro Leu Asp Ser Val Thr Glu Leu Glu
885 890 895
tct gag gtg ttg cag eta aat ata gta aag egg aat ctt gag gag gaa 2736
Ser Glu Val Leu Gin Leu Asn Ile Val Lys Arg Asn Leu Glu Glu Glu
900 905 910
ata aaa cgt cat cag aag att ata gaa gat caa aac cag agt aaa atg 2784
Ile Lys Arg His Gin Lys Ile Ile Glu Asp Gin Asn Gin Ser Lys Met
915 920 925
cag ctg ctt cag tct eta gag gag cag aag aag gaa atg gat gaa ttt 2832
Gin Leu Leu Gin Ser Leu Glu Glu Gin Lys Lys Glu Met Asp Glu Phe
930 935 940
aag tgc cag cat gag caa atg aac gtc aca cac ace caa etc ttc tta 2880
Lys Cys Gin His Glu Gin Met Asn Val Thr His Thr Gin Leu Phe Leu
945 950 955 960
gag aaa gat gag gag att aag aat ttg caa aaa aca att gaa caa atc 2928
Glu Lys Asp Glu Glu Ile Lys Asn Leu Gin Lys Thr Ile Glu Gin Ile
965 970 975
aaa ace caa tgg cat gaa gaa aga cag gac gtt caa atg gag aat tct 2976
Lys Thr Gin Trp His Glu Glu Arg Gin Asp Val Gin Met Glu Asn Ser
980 985 990
gag ttc ttt caa gaa aca aaa gtg cag age ctt aat eta gaa aat ggc 3024
Glu Phe Phe Gin Glu Thr Lys Val Gin Ser Leu Asn Leu Glu Asn Gly
995 1000 1005
agt gaa aag cat gat tta tcg aaa gcc gaa act gag agg tta gta 3069
Ser Glu Lys His Asp Leu Ser Lys Ala Glu Thr Glu Arg Leu Val
1010 1015 1020
aaa gga ata aaa gaa cga qag ctg gag att aaa ctt eta aat gaa 3114
Lys Gly Ile Lys Glu Arg Glu Leu Glu Ile Lys Leu Leu Asn Glu
1025 1030 1035
aag aat ata tct tta aca aaa caa att gat cag ctg tcc aaa gat 3159
Lys Asn Ile Ser Leu Thr Lys Gin Ile Asp Gin Leu Ser Lys Asp
1040 1045 1050
gag gtt ggt aaa etc act cag ate ate cag cag aaa gac tta gag 3204
Glu Val Gly Lys Leu Thr Gin Ile Ile Gin Gin Lys Asp Leu Glu
1055 1060 1065
ata caa get ctt cat get egg att tct tea get tee tac ace cag 3249
Ile Gin Ala Leu His Ala Arg Ile Ser Ser Ala Ser Tyr Thr Gin
1070 1075 1080
CA 02703356 2010-05-31
238
gat gtt gtc tac ctt cag cag cag ctg cag gee tat gct atg gag 3294
Asp Val Val Tyr Leu Gln Gln Gln Leu Gln Ala Tyr Ala Met Glu
1085 1090 1095
aga gaa caa gta tta gct gtt ttg agt gag aag ace agg gaa aat 3339
Arg Glu Gln Val Leu Ala Val Leu Ser Glu Lys Thr Arg Glu Asn
1100 1105 1110
agc cat ctg aaa aca gaa tac cac aaa atg atg gat ate gtt gct 3384
Ser His Leu Lys Thr Glu Tyr His Lys Met Met Asp Ile Val Ala
1115 1120 1125
gct aaa gaa gca gct ctc att aag ctg caa gat gaa aat aaa aaa 3429
Ala Lys Glu Ala Ala Leu Ile Lys Leu Gln Asp Glu Asn Lys Lys
1130 1135 1140
ttg tct gct aga tee gaa ggt ggt ggc cag gat atg ttt aga gag 3474
Leu Ser Ala Arg Ser Glu Gly Gly Gly Gln Asp Met Phe Arg Glu
1145 1150 1155
act gtc cag aat tta tea cgt ate att cga gaa aaa gac att gag 3519
Thr Val Gln Asn Leu Ser Arg Ile Ile Arg Glu Lys Asp Ile Glu
1160 1165 1170
ata gat gcg tta agt cag aag tgc cag ace tta ttg aca gtt tta 3564
Ile Asp Ala Leu Ser Gln Lys Cys Gln Thr Leu Leu Thr Val Leu
1175 1180 1185
caa aca tcg agc act ggg aat gag gtt gga ggc gtt aat agc aat 3609
Gln Thr Ser Ser Thr Gly Asn Glu Val Gly Gly Val Asn Ser Asn
1190 1195 1200
cag ttt gag gag ctt cta cag gaa cgc gac aaa tta aaa caa caa 3654
Gln Phe Glu Glu Leu Leu Gln Glu Arg Asp Lys Leu Lys Gln Gln
1205 1210 1215
gta aag aag atg gaa gag tgg aaa cag cag gtg atg ace aca gtt 3699
Val Lys Lys Met Glu Glu Trp Lys Gln Gln Val Met Thr Thr Val
1220 1225 1230
cag aat atg cag cat gag tca gee cag ctt caa gaa gaa ctt cat 3744
Gln Asn Met Gln His Glu Ser Ala Gln Leu Gln Glu Glu Leu His
1235 1240 1245
cag ctt cag gca caa gtt ttg gtt gac agt gat aat aat tct aaa 3789
Gln Leu Gln Ala Gln Val Leu Val Asp Ser Asp Asn Asn Ser Lys
1250 1255 1260
tta caa gtg gat tat act ggc ctg ate caa agt tat gag cag aat 3834
Leu Gln Val Asp Tyr Thr Gly Leu Ile Gln Ser Tyr Glu Gln Asn
1265 1270 1275
gaa act aaa etc aaa aat ttt ggg cag gag eta gca caa gtt cag 3879
Glu Thr Lys Leu Lys Asn Phe Gly Gln Glu Leu Ala Gln Val Gln
1280 1285 1290
cac agc ata ggg cag ctg tac agt ace aaa gac ctt etc tta gga 3924
His Ser Ile Gly Gln Leu Tyr Ser Thr Lys Asp Leu Leu Leu Gly
1295 1300 1305
CA 02703356 2010-05-31
=
239
aaa ctt gat att att tct cct caa ctc ccc tcc gga tca tcg cct 3969
Lys Leu Asp Ile Ile Ser Pro Gin Leu Pro Ser Gly Ser Ser Pro
1310 1315 1320
cct tcc cag tca gca gag tct ctt gga atg gat aag cgt gat aca 4014
Pro Ser Gin Ser Ala Glu Ser Leu Gly Met Asp Lys Arg Asp Thr
1325 1330 1335
tca agt gag tct tca aaa cag gag cta gaa gag cta aga aag tca 4059
Ser Ser Glu Ser Ser Lys Gin Glu Leu Glu Glu Leu Arg Lys Ser
1340 1345 1350
ctg cag gaa aaa gat gca acg att aaa aca ctc cag gaa aat aac 4104
Leu Gin Glu Lys Asp Ala Thr Ile Lys Thr Leu Gin Glu Asn Asn
1355 1360 1365
cac aga ttg tcc gat tca att gct gcc acc tca gag cta gaa aga 4149
His Arg Leu Ser Asp Ser Ile Ala Ala Thr Ser Glu Leu Glu Arg
1370 1375 1380
aaa gaa cac gaa cag act gat tca gaa att aag cag cta aag gag 4194
Lys Glu His Glu Gin Thr Asp Ser Glu Ile Lys Gin Leu Lys Glu
1385 1390 1395
aaa caa gat gtt tta caa aag tca ctt aag gag aaa gac ctc tta 4239
Lys Gin Asp Val Leu Gin Lys Ser Leu Lys Glu Lys Asp Leu Leu
1400 1405 1410
atc aaa gcc aaa agt gat cag tta ctt tct tta aat gaa aat ttc 4284
Ile Lys Ala Lys Ser Asp Gin Leu Leu Ser Leu Asn Glu Asn Phe
1415 1420 1425
acc aac aaa gtg aat gaa aat gaa ctc ttg agg cag gca gta acc 4329
Thr Asn Lys Val Asn Glu Asn Glu Leu Leu Arg Gin Ala Val Thr
1430 1435 1440
aac ctg aag gag cgg gta tta att tta gaa atg gac att ggt aaa 4374
Asn Leu Lys Glu Arg Val Leu Ile Leu Glu Met Asp Ile Gly Lys
1445 1450 1455
cta aaa gaa gaa aat gaa aaa ata gtt gaa aga acc agg gaa aag 4419
Leu Lys Glu Glu Asn Glu Lys Ile Val Glu Arg Thr Arg Glu Lys
1460 1465 1470
gaa acg gag tat caa gca tta cag gag act aat atg aag ttt tcc 4464
Glu Thr Glu Tyr Gin Ala Leu Gin Glu Thr Asn Met Lys Phe Ser
1475 1480 1485
atg atg ctt cga gaa aaa gag ttt gag tgc cat tca atg aag gaa 4509
Met Met Leu Arg Glu Lys Glu Phe Glu Cys His Ser Met Lys Glu
1490 1495 1500
aaa tct ctt gca ttt gag cag cta ctg aaa gaa aaa gag cag ggc 4554
Lys Ser Leu Ala Phe Glu Gin Leu Leu Lys Glu Lys Glu Gin Gly
1505 1510 1515
aag act ggg gag tta aat caa ctt tta aat gca gtt aag tca atg 4599
Lys Thr Gly Glu Leu Asn Gin Leu Leu Asn Ala Val Lys Ser Met
1520 1525 1530
CA 02703356 2010-05-31
= 240
cag gag aag aca gtt aag ttt caa caa gag aga gac cag gtc atg 4644
Gin Glu Lys Thr Val Lys Phe Gin Gin Glu Arg Asp Gin Val Met
1535 1540 1545
ttg gcc ctg aaa cag aaa caa atg gaa aac agt gct tta cag aat 4689
Leu Ala Leu Lys Gin Lys Gin Met Glu Asn Ser Ala Leu Gin Asn
1550 1555 1560
gag gtt caa cat tta cgc gac aaa gaa tta cgc tta aac cag gag 4734
Glu Val Gin His Leu Arg Asp Lys Glu Leu Arg Leu Asn Gin Glu
1565 1570 1575
cta gag aga ttg cgt aac cat ctt tta gaa tca gag gat tct tac 4779
Leu Glu Arg Leu Arg Asn His Leu Leu Glu Ser Glu Asp Ser Tyr
1580 1585 1590
acc cgt gaa gct ttg gct gca gaa gag aga gag gcc aaa ctg aga 4824
Thr Arg Glu Ala Leu Ala Ala Glu Glu Arg Glu Ala Lys Leu Arg
1595 1600 1605
agg aaa gtc aca gta ttg gag gaa aag cta gtt tca tct tct aat 4869
Arg Lys Val Thr Val Leu Glu Glu Lys Leu Val Ser Ser Ser Asn
1610 1615 1620
gca atg gaa aat gca agc cat cag gcc agt ttg cag gta gag tca 4914
Ala Met Glu Asn Ala Ser His Gin Ala Ser Leu Gin Val Glu Ser
1625 1630 1635
ctg cag gag cag ctg aat gtg gtc tct aag cag agg gat gaa acc 4959
Leu Gin Glu Gin Leu Asn Val Val Ser Lys Gin Arg Asp Glu Thr
1640 1645 1650
gcc ctg cag ctc tct gtg tct cgg gaa caa gta aag cag tat gct 5004
Ala Leu Gin Leu Ser Val Ser Arg Glu Gin Val Lys Gin Tyr Ala
1655 1660 1665
ctc tca ctc tcc aac ctg cag atg gta cta gag cat ttc cag caa 5049
Leu Ser Leu Ser Asn Leu Gin Met Val Leu Glu His Phe Gin Gin
1670 1675 1680
gag gaa aaa gct gtg tat tct gct gaa cta gaa aag cac aaa cag 5094
Glu Glu Lys Ala Val Tyr Ser Ala Glu Leu Glu Lys His Lys Gin
1685 1690 1695
ctt gta gct gaa tgg aag aaa aag gca gaa aat ctg gaa gga aaa 5139
Leu Val Ala Glu Trp Lys Lys Lys Ala Glu Asn Leu Glu Gly Lys
1700 1705 1710
ctg atg tca tta cag gag cgt ttt gat gaa gca aat gct gcg ttg 5184
Leu Met Ser Leu Gin Glu Arg Phe Asp Glu Ala Asn Ala Ala Leu
1715 1720 1725
gat tca gca tca aga ctt aca gag cag tta gat tta aag gaa gaa 5229
Asp Ser Ala Ser Arg Leu Thr Glu Gin Leu Asp Leu Lys Glu Glu
1730 1735 1740
caa att gaa gaa ctt aaa aaa caa aat gaa etc cga caa gaa atg 5274
Gin Ile Glu Glu Leu Lys Lys Gin Asn Glu Leu Arg Gin Glu Met
1745 1750 1755
CA 02703356 2010-05-31
241
ctg gat gat gta caa aag aaa ttg atg aac tta gta aac agc aca 5319
Leu Asp Asp Val Gin Lys Lys Leu Met Asn Leu Val Asn Ser Thr
1760 1765 1770
gaa gga aaa gtg gac aaa gtc cta atg aga aac ctc ttc att gga 5364
Glu Gly Lys Val Asp Lys Val Leu Met Arg Asn Leu Phe Ile Gly
1775 1780 1785
cat ttc cac aca cca aag cat cag cgc cac gag gtg tta cga tta 5409
His Phe His Thr Pro Lys His Gin Arg His Glu Val Leu Arg Leu
1790 1795 1800
atg gga agc atc ctt ggt atc aag agg gag gaa atg gaa cag ttg 5454
Met Gly Ser Ile Leu Gly Ile Lys Arg Glu Glu Met Glu Gin Leu
1805 1810 1815
ctt cat gaa gat cag ggt ggt gtt acc agg tgg atg act gga tgg 5499
Leu His Glu Asp Gin Gly Gly Val Thr Arg Trp Met Thr Gly Trp
1820 1825 1830
ctt gga gga gga tca aaa agt gtc ccc aac aca cct ctg aga cca 5544
Leu Gly Gly Gly Ser Lys Ser Val Pro Asn Thr Pro Leu Arg Pro
1835 1840 1845
aat caa caa tct gtg ctt aat agc tct ttt tca gaa ctt ttt gtt 5589
Asn Gin Gin Ser Val Leu Asn Ser Ser Phe Ser Glu Leu Phe Val
1850 1855 1860
aaa ttt cta gaa aca gaa tct cat cca tct gtt cca cca cca aag 5634
Lys Phe Leu Glu Thr Glu Ser His Pro Ser Val Pro Pro Pro Lys
1865 1870 1875
ctt tct gtt cat gat atg aaa cct ctg gat tca cca gga agg aga 5679
Leu Ser Val His Asp Met Lys Pro Leu Asp Ser Pro Gly Arg Arg
1880 1885 1890
aaa gta gtc ata cat gta tca gaa agt ttt aaa gaa acc aca gag 5724
Lys Val Val Ile His Val Ser Glu Ser Phe Lys Glu Thr Thr Glu
1895 1900 1905
tcc aga tgt gga agg aga aca gat gtg aat cca ttc ttg gct ccc 5769
Ser Arg Cys Gly Arg Arg Thr Asp Val Asn Pro Phe Leu Ala Pro
1910 1915 1920
cgc tct gca gct gtg cct ctc att aac cca gct gga ctt gga cct 5814
Arg Ser Ala Ala Val Pro Leu Ile Asn Pro Ala Gly Leu Gly Pro
1925 1930 1935
ggt ggg cct ggg cat ctt ctt ttg aag ccc atc tca gac gtg ttg 5859
Gly Gly Pro Gly His Leu Leu Leu Lys Pro Ile Ser Asp Val Leu
1940 1945 1950
ccc aca ttt aca cct ttg ccg gtg tca cct gac aac agt gct gga 5904
Pro Thr Phe Thr Pro Leu Pro Val Ser Pro Asp Asn Ser Ala Gly
1955 1960 1965
gtt gtg ttg aaa gac ctt tta aag caa tag atgattctca agccagagac 5954
Val Val Leu Lys Asp Leu Leu Lys Gin
1970 1975
CA 02703356 2010-05-31
242
aacatatgta gcactttaaa gaaaccatga acactatgtg tatgtacttt atcacaaagt 6014
ggcctttcag aaaaagtcat gtgtttgttt go 6046
<210> 45
<211> 1977
<212> PRT
<213> Canis familiaris
<400> 45
Met Ser Ser Trp Leu Gly Gly Leu Gly Ser Gly Leu Gly Gin Ser Leu
1 5 10 15
Gly Gin Val Gly Gly Ser Leu Ala Ser Leu Thr Gly Gin Ile Ser Asn
20 25 30
Phe Thr Lys Asp Met Leu Met Glu Gly Thr Glu Glu Val Glu Ala Glu
35 40 45
Leu Pro Asn Ser Arg Arg Lys Glu Val Glu Ala Ile His Ala Ile Leu
50 55 60
Arg Ser Glu Asn Glu Arg Leu Lys Glu Leu Cys Thr Asp Leu Glu Glu
65 70 75 80
Lys His Glu Ala Ser Glu Leu Gin Ile Lys Gin Gin Ser Thr Asn Tyr
85 90 95
Arg Asn Gin Leu Gin Gin Lys Glu Val Glu Ile Ser His Leu Lys Ala
100 105 110
Arg Gin Ile Ala Leu Gin Asp Gin Leu Leu Lys Leu Gin Ser Ala Ala
115 120 125
Gin Ser Ala His Ser Gly Ala Ser Ser Val Pro Ala Ala Leu Ala Ser
130 135 140
Ser Pro Phe Ser Tyr Ser Val Ser His His Ala Ser Ala Phe His Asp
145 150 155 160
Asp Asp Met Asp Phe Ser Asp Ile Ile Ser Ser Gin Gin Glu Ile Asn
165 170 175
Arg Leu Ser Asn Glu Val Ser Arg Leu Glu Ser Glu Val Gly His Trp
180 185 190
Arg His Ile Ala Gin Thr Ser Lys Ala Gin Gly Ser Asn Ser Ser Asp
195 200 205
Gin Ser Glu Ile Cys Lys Leu Gin Ser Ile Ile Lys Glu Leu Lys Gin
210 215 220
Ile Arg Ser Gin Glu Ile Asp Asp His Gin His Glu Met Ser Val Leu
225 230 235 240
Gin Asn Ala His Gin Gin Lys Leu Thr Asp Ile Ser Arg Arg His Arg
245 250 255
Glu Glu Leu Arg Asp Tyr Glu Glu Arg Ile Glu Glu Leu Glu Asn Leu
260 265 270
Leu Glu Gin Gly Gly Ser Gly Ile Val Ile Pro Amp His Ser Lys Ile
275 280 285
His Glu Met Gin Lys Thr Ile Gin Asn Leu Gin Thr Glu Lys Val Ala
290 295 300
Ser Ile Lys Lys Ile Glu Glu Leu Glu Asp Lys Ile Lys Asp Ile Asp
305 310 315 320
Lys Lys Leu Ser Ser Ala Glu Asn Asp Arg Asp Val Leu Arg Lys Glu
325 330 335
Lys Glu Cys Leu Asn Val Glu An Arg Gin Ile Thr Glu Gin Cys Glu
340 345 350
Ser Leu Lys Leu Glu Cys Lys Leu Gin His Asp Ala Glu Lys Gin Gly
355 360 365
Asp Thr Val Thr Glu Lys Glu Arg Ile Leu Pro Gin Ser Thr Ser Val
370 375 380
Glu Glu Glu Val Leu Lys Leu Gin Gin Ala Leu Ser Asp Ala Glu Asn
385 390 395 400
CA 02703356 2010-05-31
243
Glu Ile Met Arg Leu Ser Asn Leu Tyr Gin Asp Asn Ser Leu Thr Glu
405 410 415
Asp Asn Leu Lys Leu Lys Met His Val Glu Phe Leu Glu Lys Gin Lys
420 425 430
Ser Leu Leu Ser Gin Glu Lys Glu Glu Leu Gin Leu Ser Leu Leu Lys
435 440 445
Leu Asn Asn Glu Tyr Glu Val Ile Lys Set Thr Ala Val Arg Asp Met
450 455 460
Asp Met Asp Ser Thr Leu Cys Asp Leu Arg Leu Thr Leu Glu Ala Lys
465 470 475 480
Asp Gin Glu Leu Asn Gin Ser Leu Thr Glu Lys Glu Ile Leu Val Ala
485 490 495
Glu Leu Glu Glu Leu Asp Arg Gin Asn Gin Glu Ala Thr Lys His Met
500 505 510
Ile Leu Ile Lys Asp Gin Leu Ser Lys Gin Gin Ser Glu Gly Glu Thr
515 520 525
Ile Ile Ser Lys Leu Arg Lys Asp Leu Asn Asp Glu Asn Lys Arg Val
530 535 540
His Gin Leu Glu Asp Asp Lys Lys Asn Met Thr Lys Glu Leu Asn Val
545 550 555 560
Gin Lys Glu Lys Leu Val Gin Ser Glu Leu Val Leu Asn Gly Leu His
565 570 575
Leu Ala Lys Gin Lys Leu Glu Glu Lys Val Glu Asp Leu Val Asp Gin
580 585 590
Leu Asn Lys Ser Gin Lys Ser Asn Leu Asn Met Gin Lys Glu Asn Phe
595 600 605
Gly Leu Lys Glu His Ile Lys Gin Asn Glu Glu Glu Leu Ser Arg Val
610 615 620
Arg Asp Glu Leu Thr Gin Ser Leu Ser Arg Asp Ser Gly Ser Asp Phe
625 630 635 640
Lys Asp Asp Leu Leu Lys Glu Arg Glu Ala Glu Val Arg Asn Leu Lys
645 650 655
Gin Asn Leu Ser Glu Ile Glu Gin Leu Asn Asp Ser Leu Asn Lys Val
660 665 670
Ala Phe Asp Leu Lys Met Glu Asn Glu Lys Leu Val Leu Ala Cys Glu
675 680 685
Asp Ile Arg His Gin Leu Glu Glu Ser Ile Val Gly Ser Asn Gin Met
690 695 700
Ser Leu Glu Arg Asn Thr Ile Val Glu Ala Leu Lys Met Glu Lys Gly
705 710 715 720
Gin Leu Glu Ala Glu Leu Ser Arg Ala Asp Gin Arg Leu Leu Glu Glu
725 730 735
Ala Ser Lys Tyr Glu Gin Thr Ile Gin Glu Leu Ser Lys Ala Arg Asp
740 745 750
Leu Arg Thr Ser Ala Leu Gin Leu Glu Gin Gin His Leu Met Lys Leu
755 760 765
Ser Gin Glu Lys Asp Phe Glu Ile Ala Glu Leu Lys Lys Asn Ile Glu
770 775 780
Gin Met Asp Thr Asp His Lys Glu Thr Lys Ala Ile Leu Ser Ser Ile
785 790 795 800
Leu Glu Glu Gin Lys Gin Leu Thr Gin Leu Ile Ser Glu Lys Glu Ile
805 810 815
Phe Ile Glu Lys Leu Lys Glu Arg Ser Ser Glu Leu Gin Glu Glu Leu
820 825 830
Glu Lys Ser Thr Gin Ala Ser Arg Lys Ile Glu Ile Leu Lys Gin Thr
835 840 845
Ile Glu Glu Lys Asp Arg Ser Leu Gly Ser Met Lys Glu Glu Asn Asn
850 855 860
His Leu Lys Glu Glu Leu Glu Arg Leu Arg Glu Gin Gin Ser Arg Ala
865 870 875 880
CA 02703356 2010-05-31
=
244
Val Pro Val Val Glu Pro Lys Pro Leu Asp Ser Val Thr Glu Leu Glu
885 890 895
Ser Glu Val Lou Gin Leu Asn Ile Val Lys Arg Asn Lou Glu Glu Glu
900 905 910
Ile Lys Arg His Gin Lys Ile Ile Glu Asp Gin Asn Gin Ser Lys Met
915 920 925
Gin Leu Leu Gin Ser Leu Glu Glu Gin Lys Lys Glu Met Asp Glu Phe
930 935 940
Lys Cys Gin His Glu Gin Met Asn Val Thr His Thr Gin Leu Phe Leu
945 950 955 960
Glu Lys Asp Glu Glu Ile Lys Asn Leu Gin Lys Thr Ile Glu Gin Ile
965 970 975
Lys Thr Gin Trp His Glu Glu Arg Gin Asp Val Gin Met Glu Asn Ser
980 985 990
Glu Phe Phe Gin Glu Thr Lys Val Gin Ser Leu Asn Leu Glu Asn Gly
995 1000 1005
Ser Glu Lys His Asp Leu Ser Lys Ala Glu Thr Glu Arg Leu Val
1010 1015 1020
Lys Gly Ile Lys Glu Arg Glu Leu Glu Ile Lys Leu Leu Asn Glu
1025 1030 1035
Lys Asn Ile Ser Leu Thr Lys Gin Ile Asp Gin Leu Ser Lys Asp
1040 1045 1050
Glu Val Gly Lys Lou Thr Gin Ile Ile Gin Gin Lys Asp Lou Glu
1055 1060 1065
Ile Gin Ala Lou His Ala Arg Ile Ser Ser Ala Ser Tyr Thr Gin
1070 1075 1080
Asp Val Val Tyr Leu Gin Gin Gin Leu Gin Ala Tyr Ala Met Glu
1085 1090 1095
Arg Glu Gin Val Leu Ala Val Leu Ser Glu Lys Thr Arg Glu Asn
1100 1105 1110
Ser His Leu Lys Thr Glu Tyr His Lys Met Met Asp Ile Val Ala
1115 1120 1125
Ala Lys Glu Ala Ala Lou Ile Lys Lou Gin Asp Glu Asn Lys Lys
1130 1135 1140
Lou Ser Ala Arg Ser Glu Gly Gly Gly Gin Asp Met Phe Arg Glu
1145 1150 1155
Thr Val Gin Asn Lou Ser Arg Ile Ile Arg Glu Lys Asp Ile Glu
1160 1165 1170
Ile Asp Ala Leu Ser Gin Lys Cys Gin Thr Leu Leu Thr Val Leu
1175 1180 1185
Gin Thr Ser Ser Thr Gly Asn Glu Val Gly Gly Val Asn Ser Asn
1190 1195 1200
Gin Phe Glu Glu Leu Leu Gin Glu Arg Asp Lys Leu Lys Gin Gin
1205 1210 1215
Val Lys Lys Met Glu Glu Trp Lys Gin Gin Val Met Thr Thr Val
1220 1225 1230
Gin Asn Met Gin His Glu Ser Ala Gin Lou Gin Glu Glu Leu His
1235 1240 1245
Gin Lou Gin Ala Gin Val Lou Val Asp Ser Asp Asn Asn Ser Lys
1250 1255 1260
Lou Gin Val Asp Tyr Thr Gly Lou Ile Gin Ser Tyr Glu Gin Asn
1265 1270 1275
Glu Thr Lys Leu Lys Asn Phe Gly Gin Glu Leu Ala Gin Val Gin
1280 1285 1290
His Ser Ile Gly Gin Lou Tyr Ser Thr Lys Asp Lou Leu Leu Gly
1295 1300 1305
Lys Leu Asp Ile Ile Ser Pro Gin Leu Pro Ser Gly Ser Ser Pro
1310 1315 1320
Pro Ser Gin Ser Ala Glu Ser Leu Gly Met Asp Lys Arg Asp Thr
1325 1330 1335
CA 02703356 2010-05-31
245
Ser Ser Glu Ser Ser Lys Gin Glu Leu Glu Glu Leu Arg Lys Ser
1340 1345 1350
Leu Gin Glu Lys Asp Ala Thr Ile Lys Thr Leu Gin Glu Asn Asn
1355 1360 1365
His Arg Leu Ser Asp Ser Ile Ala Ala Thr Ser Glu Leu Glu Arg
1370 1375 1380
Lys Glu His Glu Gin Thr Asp Ser Glu Ile Lys Gin Leu Lys Glu
1385 1390 1395
Lys Gin Asp Val Leu Gin Lys Ser Leu Lys Glu Lys Asp Leu Leu
1400 1405 1410
Ile Lys Ala Lys Ser Asp Gin Leu Leu Ser Leu Asn Glu Asn Phe
1415 1420 1425
Thr Asn Lys Val Asn Glu Asn Glu Leu Leu Arg Gin Ala Val Thr
1430 1435 1440
Asn Leu Lys Glu Arg Val Leu Ile Leu Glu Met Asp Ile Gly Lys
1445 1450 1455
Leu Lys Glu Glu Asn Glu Lys Ile Val Glu Arg Thr Arg Glu Lys
1460 1465 1470
Glu Thr Glu Tyr Gin Ala Leu Gin Glu Thr Asn Met Lys Phe Ser
1475 1480 1485
Met Met Leu Arg Glu Lys Glu Phe Glu Cys His Ser Met Lys Glu
1490 1495 1500
Lys Ser Leu Ala Phe Glu Gin Leu Leu Lys Glu Lys Glu Gin Gly
1505 1510 1515
Lys Thr Gly Glu Leu Asn Gin Leu Leu Asn Ala Val Lys Ser Met
1520 1525 1530
Gin Glu Lys Thr Val Lys Phe Gin Gin Glu Arg Asp Gin Val Met
1535 1540 1545
Leu Ala Leu Lys Gin Lys Gin Met Glu Asn Ser Ala Leu Gin Asn
1550 1555 1560
Glu Val Gin His Leu Arg Asp Lys Glu Leu Arg Leu Asn Gin Glu
1565 1570 1575
Leu Glu Arg Leu Arg Asn His Leu Leu Glu Ser Glu Asp Ser Tyr
1580 1585 1590
Thr Arg Glu Ala Leu Ala Ala Glu Glu Arg Glu Ala Lys Leu Arg
1595 1600 1605
Arg Lys Val Thr Val Leu Glu Glu Lys Leu Val Ser Ser Ser Asn
1610 1615 1620
Ala Met Glu Asn Ala Ser His Gin Ala Ser Leu Gin Val Glu Ser
1625 1630 1635
Leu Gin Glu Gin Leu Asn Val Val Ser Lys Gin Arg Asp Glu Thr
1640 1645 1650
Ala Leu Gin Leu Ser Val Ser Arg Glu Gin Val Lys Gin Tyr Ala
1655 1660 1665
Leu Ser Leu Ser Asn Leu Gin Met Val Leu Glu His Phe Gin Gin
1670 1675 1680
Glu Glu Lys Ala Val Tyr Ser Ala Glu Leu Glu Lys His Lys Gin
1685 1690 1695
Leu Val Ala Glu Trp Lys Lys Lys Ala Glu Asn Leu Glu Gly Lys
1700 1705 1710
Leu Met Ser Leu Gin Glu Arg Phe Asp Glu Ala Asn Ala Ala Leu
1715 1720 1725
Asp Ser Ala Ser Arg Leu Thr Glu Gin Leu Asp Leu Lys Glu Glu
1730 1735 1740
Gin Ile Glu Glu Leu Lys Lys Gin Asn Glu Leu Arg Gin Glu Met
1745 1750 1755
Leu Asp Asp Val Gin Lys Lys Leu Met Asn Leu Val Asn Ser Thr
1760 1765 1770
Glu Gly Lys Val Asp Lys Val Leu Met Arg Asn Leu Phe Ile Gly
1775 1780 1785
CA 02703356 2010-05-31
246
His Phe His Thr Pro Lys His Gin Arg His Glu Val Leu Arg Leu
1790 1795 1800
Met Gly Ser Ile Leu Gly Ile Lys Arg Glu Glu Met Glu Gin Leu
1805 1810 1815
Leu His Glu Asp Gin Gly Gly Val Thr Arg Trp Met Thr Gly Trp
1820 1825 1830
Leu Gly Gly Gly Ser Lys Ser Val Pro Asn Thr Pro Leu Arg Pro
1835 1840 1845
Asn Gin Gin Ser Val Leu Asn Ser Ser Phe Ser Glu Leu Phe Val
1850 1855 1860
Lys Phe Leu Glu Thr Glu Ser His Pro Ser Val Pro Pro Pro Lys
1865 1870 1875
Leu Ser Val His Asp Met Lys Pro Leu Asp Ser Pro Gly Arg Arg
1880 1885 1890
Lys Val Val Ile His Val Ser Glu Ser Phe Lys Glu Thr Thr Glu
1895 1900 1905
Ser Arg Cys Gly Arg Arg Thr Asp Val Asn Pro Phe Leu Ala Pro
1910 1915 1920
Arg Ser Ala Ala Val Pro Leu Ile Asn Pro Ala Gly Leu Gly Pro
1925 1930 1935
Gly Gly Pro Gly His Leu Leu Leu Lys Pro Ile Ser Asp Val Leu
1940 1945 1950
Pro Thr Phe Thr Pro Leu Pro Val Ser Pro Asp Asn Ser Ala Gly
1955 1960 1965
Val Val Leu Lys Asp Leu Leu Lys Gin
1970 1975
<210> 46
<211> 6452
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (357)..(6296)
<400> 46
cgagcgagtg tcatggcggc cggcgtcgag ttggcaggag taacccacgg aactgaggaa 60
agtcattaga gctgagaaag aagtggccca atctggacgg tgggaattcg tgggaatgag 120
cagaaggccc tccgtagtga ctgtgtcact agaggcgggc ccctggtaaa attccaggcc 180
aggcctctgc gtttctaggc agaacctgga gtcggccttg cctgagaacc cagctttgtg 240
ttatcgtatc ctgtctcgcg aaggcaggcg ttcaaggata tttggtcgga tcgcccggcg 300
gcgctaaacg ttttcttttt tccgagegga ccgggtcgtt ctctaaactc gccgcg atg 359
Met
1
tog tcc tgg ctt ggg ggc ctc ggc tcc gga ttg ggc cag tct ctg ggt 407
Ser Ser Trp Leu Gly Gly Leu Gly Ser Gly Leu Gly Gin Ser Leu Gly
10 15
caa gtc ggg ggc age ctg gct tcc etc act ggc cag ata tca aac ttt 455
Gin Val Gly Gly Ser Leu Ala Ser Leu Thr Gly Gin Ile Ser Asn Phe
20 25 30
aca aag gat atg ctg atg gag ggc acg gag gaa gtg gaa gca gaa tta 503
Thr Lys Asp Met Leu Met Glu Gly Thr Glu Glu Val Glu Ala Glu Leu
35 40 45
CA 02703356 2010-05-31
247
cct gat tct agg aca aag gaa att gaa gcc att cat gca atc ttg aga 551
Pro Asp Ser Arg Thr Lys Glu Ile Glu Ala Ile His Ala Ile Leu Arg
50 55 60 65
tca gag aat gaa agg ctt aag aaa ctt tgt act gat cta gaa gag aaa 599
Ser Glu Asn Glu Arg Leu Lys Lys Leu Cys Thr Asp Leu Glu Glu Lys
70 75 80
cat gaa gca tca gag att caa ata aag cag caa tct aca agt tac cga 647
His Glu Ala Ser Glu Ile Gin Ile Lys Gin Gin Ser Thr Ser Tyr Arg
85 90 95
aat caa ctt caa caa aaa gag gta gaa atc agc cat ctt aaa gcc aga 695
Asn Gin Leu Gin Gin Lys Glu Val Glu Ile Ser His Leu Lys Ala Arg
100 105 110
cag att gca ctc cag gat cag ttg ctg aaa ctg cag tca gct gct cag 743
Gin Ile Ala Leu Gin Asp Gin Leu Leu Lys Leu Gin Ser Ala Ala Gin
115 120 125
tca gta cct tca gga gct ggt gta cca gca acc act gca tca tct tca 791
Ser Val Pro Ser Gly Ala Gly Val Pro Ala Thr Thr Ala Ser Ser Ser
130 135 140 145
ttc gct tat ggg att agt cat cat cct tca gct ttc cat gac gat gac 839
Phe Ala Tyr Gly Ile Ser His His Pro Ser Ala Phe His Asp Asp Asp
150 155 160
atg gac ttt ggt gat ata att tca tcc caa caa gaa ata aac cga ctc 887
Met Asp Phe Gly Asp Ile Ile Ser Ser Gin Gin Glu Ile Asn Arg Leu
165 170 175
tca aat gaa gtt tca aga ctt gag tct gaa gtt ggc cat tgg agg cat 935
Ser Asn Glu Val Ser Arg Leu Glu Ser Glu Val Gly His Trp Arg His
180 185 190
att gct cag act tcc aaa gca caa gga aca gat aac tct gat caa agt 983
Ile Ala Gin Thr Ser Lys Ala Gin Gly Thr Asp Asn Ser Asp Gin Ser
195 200 205
gaa ata tgt aaa cta caa aat atc att aag gaa cta aaa cag aac cga 1031
Glu Ile Cys Lys Leu Gin Asn Ile Ile Lys Glu Leu Lys Gin Asn Arg
210 215 220 225
agt cag gaa att gat gac cat caa cat gaa atg tca gta ctg cag aat 1079
Ser Gin Glu Ile Asp Asp His Gin His Glu Met Ser Val Leu Gin Asn
230 235 240
gca cac caa cag aaa ttg aca gaa ata agt cga cga cat cga gaa gaa 1127
Ala His Gin Gin Lys Leu Thr Glu Ile Ser Arg Arg His Arg Glu Glu
245 250 255
tta agt gac tat gaa gaa cga att gaa gaa ctt gaa aat ctg tta caa 1175
Leu Ser Asp Tyr Glu Glu Arg Ile Glu Glu Leu Glu Asn Leu Leu Gin
260 265 270
caa ggt ggc tct gga gtt ata gaa act gat ctc tct aaa atc tat gag 1223
Gin Gly Gly Ser Gly Val Ile Glu Thr Asp Leu Ser Lys Ile Tyr Glu
275 280 285
CA 02703356 2010-05-31
248
atg caa aaa act att caa gtt cta caa ata gaa aaa gtg gag tct acc 1271
Met Gin Lys Thr Ile Gin Val Leu Gin Ile Glu Lys Val Glu Ser Thr
290 295 300 305
aaa aaa atg gaa caa ctt gag gat aaa ata aaa gat ata aat aaa aaa 1319
Lys Lys Met Glu Gin Leu Glu Asp Lys Ile Lys Asp Ile Asn Lys Lys
310 315 320
tta tct tct gca gaa aat gac aga gat att ttg agg agg gaa caa gaa 1367
Leu Ser Ser Ala Glu Asn Asp Arg Asp Ile Leu Arg Arg Glu Gin Glu
325 330 335
cag cta aat gtg gaa aag aga caa ata atg gaa gaa tgt gaa aac ttg 1415
Gin Leu Asn Val Glu Lys Arg Gin Ile Met Glu Glu Cys Glu Asn Leu
340 345 350
aaa ttg gaa tgt agt aaa ttg cag cct tct gct gtg aag caa agt gat 1463
Lys Leu Glu Cys Ser Lys Leu Gin Pro Ser Ala Val Lys Gin Ser Asp
355 360 365
act atg aca gaa aag gaa aga att ctt gcc cag agt gca tca gtg gaa 1511
Thr Met Thr Glu Lys Glu Arg Ile Leu Ala Gin Ser Ala Ser Val Glu
370 375 380 385
gaa gtg ttc aga cta caa caa gca ctg tct gat gcc gaa aat gaa ata 1559
Glu Val Phe Arg Leu Gin Gin Ala Leu Ser Asp Ala Glu Asn Glu Ile
390 395 400
atg aga ttg agt agt tta aac cag gat aac agt ctt gct gaa gac aat 1607
Met Arg Leu Ser Ser Leu Asn Gin Asp Asn Ser Leu Ala Glu Asp Asn
405 410 415
ctg aaa ctt aaa atg cgt atc gaa gtt tta gaa aaa gag aag tca tta 1655
Leu Lys Leu Lys Met Arg Ile Glu Val Leu Glu Lys Glu Lys Ser Leu
420 425 430
ctg agt caa gaa aag gaa gaa ctt cag atg tca ctt tta aaa ttg aac 1703
Leu Ser Gin Glu Lys Glu Glu Leu Gin Met Ser Leu Leu Lys Leu Asn
435 440 445
aat gaa tat gaa gta att aaa agt aca gct aca aga gac ata agt ttg 1751
Asn Glu Tyr Glu Val Ile Lys Ser Thr Ala Thr Arg Asp Ile Ser Leu
450 455 460 465
gat tca gaa tta cat gac tta aga ctt aat ttg gag gca aag gaa caa 1799
Asp Ser Glu Leu His Asp Leu Arg Leu Asn Leu Glu Ala Lys Glu Gin
470 475 480
gaa ctc aat cag agt att agt gaa aag gaa aca ctg ata gct gag ata 1847
Glu Leu Asn Gin Ser Ile Ser Glu Lys Glu Thr Leu Ile Ala Glu Ile
485 490 495
gaa gaa ttg gac aga cag aat caa gaa gct aca aag cac atg att ttg 1895
Glu Glu Leu Asp Arg Gin Asn Gin Glu Ala Thr Lys His Met Ile Leu
500 505 510
ata aaa gat cag cta tca aaa caa caa aat gaa gga gat agc atc atc 1943
Ile Lys Asp Gin Leu Ser Lys Gin Gin Asn Glu Gly Asp Ser Ile Ile
515 520 525
CA 02703356 2010-05-31
249
agt aaa ctg aaa caa gat cta aat gat gaa aaa aag aga gtt cat caa 1991
Ser Lys Leu Lys Gln Asp Leu Asn Asp Glu Lys Lys Arg Val His Gin
530 535 540 545
ctt gaa gat gat aaa atg gac att act aaa gag tta gat gta cag aaa 2039
Leu Glu Asp Asp Lys Met Asp Ile Thr Lys Glu Leu Asp Val Gin Lys
550 555 560
gaa aag cta att caa agt gaa gtg gcc cta aat gat tta cat tta acc 2087
Glu Lys Leu Ile Gin Ser Glu Val Ala Leu Asn Asp Leu His Leu Thr
565 570 575
aag cag aaa ctt gag gac aaa gta gaa aat tta gta gat cag cta aat 2135
Lys Gin Lys Leu Glu Asp Lys Val Glu Asn Leu Val Asp Gin Leu Asn
580 585 590
aaa tea caa gaa agt aat gta age ate cag aag gag aat tta gaa ctt 2183
Lys Ser Gin Glu Ser Asn Val Ser Ile Gln Lys Glu Asn Leu Glu Leu
595 600 605
aag gag cat att aga caa aat gag gag gag ctt tct aga ata agg aat 2231
Lys Glu His Ile Arg Gin Asn Glu Glu Glu Leu Ser Arg Ile Arg Asn
610 615 620 625
gag tta atg cag tct cta aat caa gac teL aat agt aat ttt aag gat 2279
Glu Leu Met Gin Ser Leu Asn Gin Asp Ser Asn Ser Asn Phe Lys Asp
630 635 640
ace tta ctt aaa gaa aga gaa get gaa gtt aga aac tta aag caa aat 2327
Thr Leu Leu Lys Glu Arg Glu Ala Glu Val Arg Asn Leu Lys Gin Asn
645 650 655
ctt tea gaa tta gaa cag etc aat gaa aat tta aag aaa gtt get ttt 2375
Leu Ser Glu Leu Glu Gin Leu Asn Glu Asn Leu Lys Lys Val Ala Phe
660 665 670
gat gtc aaa atg gaa aat gaa aag tta gtt tta gca tgt gaa gat gtg 2423
Asp Val Lys Met Glu Asn Glu Lys Leu Val Leu Ala Cys Glu Asp Val
675 680 685
agg cat cag tta gaa gaa tgt ctt get ggt aac aat cag ctt tct ctg 2471
Arg His Gin Leu Glu Glu Cys Leu Ala Gly Asn Asn Gin Leu Ser Leu
690 695 700 705
gaa aaa aac act att gtg gag act cta aaa atg gaa aaa gga gag ata 2519
Glu Lys Asn Thr Ile Val Glu Thr Leu Lys Met Glu Lys Gly Glu Ile
710 715 720
gag gca gaa ttg tgt tgg get aaa aag agg ctg ttg gaa gaa gca aac 2567
Glu Ala Glu Leu Cys Trp Ala Lys Lys Arg Leu Leu Glu Glu Ala Asn
725 730 735
aag tat gag aaa ace att gaa gaa ctg tea aat gca cgt aat ttg aat 2615
Lys Tyr Glu Lys Thr Ile Glu Glu Leu Ser Asn Ala Arg Asn Leu Asn
740 745 750
ace tct gee tta cag ctg gaa cat gag cat tta att aaa etc aat caa 2663
Thr Ser Ala Leu Gin Leu Glu His Glu His Leu Ile Lys Leu Asn Gin
755 760 765
CA 02703356 2010-05-31
=
250
aag aaa gac atg gaa ata gca gaa ctc aaa aag aat att gaa caa atg 2711
Lys Lys Asp Met Glu Ile Ala Glu Leu Lys Lys Asn Ile Glu Gin Met
. 770 775 780 785
gat act gac cat aaa gaa act aag gac gtt ttg tca tct agt tta gaa 2759
Asp Thr Asp His Lys Glu Thr Lys Asp Val Leu Ser Ser Ser Leu Glu
790 795 800
gag cag aag cag ttg aca caa ctt ata aac aag aaa gaa att ttt att 2807
Glu Gin Lys Gin Leu Thr Gin Leu Ile Asn Lys Lys Glu Ile Phe Ile
805 810 815
gaa aag ctt aaa gaa aga agt tca aag ctg cag gag gaa ttg gat aaa 2855
Glu Lys Leu Lys Glu Arg Ser Ser Lys Leu Gin Glu Glu Leu Asp Lys
820 825 830
tat tct cag gcc tta aga aaa aat gaa att tta aga cag acc ata gag 2903
Tyr Ser Gin Ala Leu Arg Lys Asn Glu Ile Leu Arg Gin Thr Ile Glu
835 840 845
gaa aaa gac cga agt ctt gga tcc atg aaa gag gaa aat aat cat ctg 2951
Glu Lys Asp Arg Ser Leu Gly Ser Met Lys Glu Glu Asn Asn His Leu
850 855 860 865
caa gaa gaa ttg gaa cga ctc agg gaa gag cag agt cga acc gca cct 2999
Gin Glu Glu Leu Glu Arg Leu Arg Glu Glu Gin Ser Arg Thr Ala Pro
870 875 880
gtg gct gac cct aaa acc ctt gat agt gtt act gaa cta gca tct gag 3047
Val Ala Asp Pro Lys Thr Leu Asp Ser Val Thr Glu Leu Ala Ser Glu
885 890 895
gta tct caa ctg aac acg atc aag gaa cat ctt gaa gag gaa att aaa 3095
Val Ser Gin Leu Asn Thr Ile Lys Glu His Leu Glu Glu Glu Ile Lys
900 905 910
cat cat caa aag ata att gaa gat caa aac cag agt aag atg caa cta 3143
His His Gin Lys Ile Ile Glu Asp Gin Asn Gin Ser Lys Met Gin Leu
915 920 925
ctt cag tct tta caa gag caa aag aag gaa atg gat gag ttt aga tac 3191
Leu Gin Ser Leu Gin Glu Gin Lys Lys Glu Met Asp Glu Phe Arg Tyr
930 935 940 945
cag cat gag caa atg aac gcc aca cac acc cag ctc ttt tta gag aag 3239
Gin His Glu Gin Met Asn Ala Thr His Thr Gin Leu Phe Leu Glu Lys
950 955 960
gat gag gaa att aag agt ttg caa aaa aca att gaa caa atc aaa acc 3287
Asp Glu Glu Ile Lys Ser Leu Gin Lys Thr Ile Glu Gin Ile Lys Thr
965 970 975
cag ttg cat gaa gaa aga cag gac att caa aca gat aac tct gat att 3335
Gin Leu His Glu Glu Arg Gin Asp Ile Gin Thr Asp Asn Ser Asp Ile
980 985 990
ttt caa gaa aca aaa gtt cag agc ctt aat ata gaa aat gga agt gaa 3383
Phe Gin Glu Thr Lys Val Gin Ser Leu Asn Ile Glu Asn Gly Ser Glu
995 1000 1005
CA 02703356 2010-05-31
251
aag cat gat tta tct aaa gct gaa acg gaa aga tta gtg aaa gga 3428
Lys His Asp Leu Ser Lys Ala Glu Thr Glu Arg Leu Val Lys Gly
1010 1015 1020
ata aaa gag cga gaa ctg gag att aaa ctt cta aat gaa aag aat 3473
Ile Lys Glu Arg Glu Leu Glu Ile Lys Leu Leu Asn Glu Lys Asn
1025 1030 1035
ata tct tta act aaa cag att gat cag ttg tcc aaa gat gaa gtt 3518
Ile Ser Leu Thr Lys Gln Ile Asp Gln Leu Ser Lys Asp Glu Val
1040 1045 1050
ggt aaa cta act cag att att cag cag aaa gat ttg gag ata caa 3563
Gly Lys Leu Thr Gln Ile Ile Gln Gln Lys Asp Leu Glu Ile Gln
1055 1060 1065
gct ctt cat gct aga att tct tca act tcc cat act caa gat gtt 3608
Ala Leu His Ala Arg Ile Ser Ser Thr Ser His Thr Gln Asp Val
1070 1075 1080
gtt tac ctt caa cag caa ctg cag gct tat gct atg gaa aga gaa 3653
Val Tyr Leu Gln Gln Gln Leu Gln Ala Tyr Ala Met Glu Arg Glu
1085 1090 1095
aag gta ttt gct gtt ttg aat gag aag act agg gaa aat agc cat 3698
Lys Val Phe Ala Val Leu Asn Glu Lys Thr Arg Glu Asn Ser His
1100 1105 1110
cta aaa aca gaa tat cac aaa atg atg gat att gtt gct gcc aag 3743
Leu Lys Thr Glu Tyr His Lys Met Met Asp Ile Val Ala Ala Lys
1115 1120 1125
gaa gca gct ctt atc aaa ctg caa gat gaa aat aaa aaa ttg tcc 3788
Glu Ala Ala Leu Ile Lys Leu Gln Asp Glu Asn Lys Lys Leu Ser
1130 1135 1140
act aga ttt gaa agt agt ggc caa gat atg ttt aga gaa act att 3833
Thr Arg Phe Glu Ser Ser Gly Gln Asp Met Phe Arg Glu Thr Ile
1145 1150 1155
cag aat tta tca cgt atc att cga gaa aaa gac atc gaa ata gat 3878
Gln Asn Leu Ser Arg Ile Ile Arg Glu Lys Asp Ile Glu Ile Asp
1160 1165 1170
gca cta agt cag aaa tgt cag act tta ttg gca gtt tta caa aca 3923
Ala Leu Ser Gln Lys Cys Gln Thr Leu Leu Ala Val Leu Gln Thr
1175 1180 1185
tcc age act ggt aat gag gct gga ggt gtt aat agt cat caa ttt 3968
Ser Ser Thr Gly Asn Glu Ala Gly Gly Val Asn Ser His Gln Phe
1190 1195 1200
gag gag ctt cta cag gaa cgt gac aag tta aaa cag caa gta aag 4013
Glu Glu Leu Leu Gln Glu Arg Asp Lys Leu Lys Gln Gln Val Lys
1205 1210 1215
aaa atg gaa gag tgg aag cag cag gtg atg acc aca gta caa aat 4058
Lys Met Glu Glu Trp Lys Gln Gln Val Met Thr Thr Val Gln Asn
1220 1225 1230
CA 02703356 2010-05-31
252
atg caa cac gag tca gcc cag ctt cag gaa gag ctt cac caa ctt 4103
Met Gin His Glu Ser Ala Gin Leu Gin Glu Glu Leu His Gin Leu
1235 1240 1245
caa gca cag gtt ttg gtt gac agt gat aat aat tct aaa tta caa 4148
Gin Ala Gin Val Leu Val Asp Ser Asp Asn Asn Ser Lys Leu Gin
1250 1255 1260
gtg gac tat act ggc ctg ate caa agt tat gag cag aat gaa acc 4193
Val Asp Tyr Thr Gly Leu Ile Gin Ser Tyr Glu Gin Asn Glu Thr
1265 1270 1275
aaa ctc aaa aat ttt ggg cag gaa tta gca caa gtt cag cac agc 4238
Lys Leu Lys Asn Phe Gly Gin Glu Leu Ala Gin Val Gin His Ser
1280 1285 1290
att ggg cag ctt tgc aat acc aag gat ctt ctt tta gga aaa ctt 4283
Ile Gly Gin Leu Cys Asn Thr Lys Asp Leu Leu Leu Gly Lys Leu
1295 1300 1305
gat att att tca ccc cag ctg tct tct gca tca ttg ctt act ccc 4328
Asp Ile Ile Ser Pro Gin Leu Ser Ser Ala Ser Leu Leu Thr Pro
1310 1315 1320
cag tct gca gag tgt ctt aga gca agt aag tct gaa gta ttg agt 4373
Gin Ser Ala Glu Cys Leu Arg Ala Ser Lys Ser Glu Val Leu Ser
1325 1330 1335
gaa tct tct gaa ttg ctt cag caa gag tta gaa gag cta aga aaa 4416
Glu Ser Ser Glu Leu Leu Gin Gin Glu Leu Glu Glu Leu Arg Lys
1340 1345 1350
tca cta cag gaa aaa gat gca aca att aga act etc cag gaa aat 4463
Ser Leu Gin Glu Lys Asp Ala Thr Ile Arg Thr Leu Gin Glu Asn
1355 1360 1365
aac cac aga ttg tct gat tcg att get gcc acc tca gag cta gaa 4508
Asn His Arg Leu Ser Asp Ser Ile Ala Ala Thr Ser Glu Leu Glu
1370 1375 1380
aga aaa gaa cac gaa caa acc gat tca gaa ate aag cag cta aag 4553
Arg Lys Glu His Glu Gin Thr Asp Ser Glu Ile Lys Gin Leu Lys
1385 1390 1395
gag aaa caa gat gtt ttg caa aag tta ctt aag gaa aaa gac etc 4598
Glu Lys Gin Asp Val Leu Gin Lys Leu Leu Lys Glu Lys Asp Leu
1400 1405 1410
tta ate aaa gcc aaa agt gat caa cta ctt tct tee aat gaa aat 4643
Leu Ile Lys Ala Lys Ser Asp Gin Leu Leu Ser Ser Asn Glu Asn
1415 1420 1425
ttc act aac aaa gta aat gaa aac gaa ctt ttg agg cag gca gta 4688
Phe Thr Asn Lys Val Asn Glu Asn Glu Leu Leu Arg Gin Ala Val
1430 1435 1440
aca aac ctg aag gag aga ata tta att cta gag atg gac att ggc 4733
Thr Asn Leu Lys Glu Arg Ile Leu Ile Leu Glu Met Asp Ile Gly
1445 1450 1455
CA 02703356 2010-05-31
253
aaa cta aaa gga gaa aat gaa aaa ata gtg gaa aca tac agg gga 4778
Lys Leu Lys Gly Glu Asn Glu Lys Ile Val Glu Thr Tyr Arg Gly
1460 1465 1470
aag gaa aca gaa tat caa gcg tta caa gag act aac atg aag ttt 4823
Lys Glu Thr Glu Tyr Gin Ala Leu Gin Glu Thr Asn Met Lys Phe
1475 1480 1485
tct atg atg ctg cga gaa aaa gag ttt gag tgc cac tca atg aag 4868
Ser Met Met Leu Arg Glu Lys Glu Phe Glu Cys His Ser Met Lys
1490 1495 1500
gag aag gct ctt gct ttt gaa cag cta ttg aaa gag aaa gaa cag 4913
Glu Lys Ala Leu Ala Phe Glu Gin Leu Leu Lys Glu Lys Glu Gin
1505 1510 1515
ggc aag act gga gag tta aat cag ctt tta aat gca gtt aaa tca 4958
Gly Lys Thr Gly Glu Leu Asn Gin Leu Leu Asn Ala Val Lys Ser
1520 1525 1530
atg cag gag aag aca gtt gtg ttt caa cag gag aga gac caa gtc 5003
Met Gin Glu Lys Thr Val Val Phe Gin Gin Glu Arg Asp Gin Val
1535 1540 1545
atg ttg gcc ctg aaa caa aaa caa atg gaa aat act gcc cta cag 5048
Met Leu Ala Leu Lys Gin Lys Gin Met Glu Asn Thr Ala Leu Gin
1550 1555 1560
aat gag gtt caa cgt tta cgt gac aaa gaa ttt cgt tca aac caa 5093
Asn Glu Val Gin Arg Leu Arg Asp Lys Glu Phe Arg Ser Asn Gin
1565 1570 1575
gag eta gag aga ttg cgt aat cat ctt tta gaa tca gaa gat tct 5138
Glu Leu Glu Arg Leu Arg Asn His Leu Leu Glu Ser Glu Asp Ser
1580 1585 1590
tat acc cgt gaa gct ttg get gca gaa gat aga gag gct aaa cta 5183
Tyr Thr Arg Glu Ala Leu Ala Ala Glu Asp Arg Glu Ala Lys Leu
1595 1600 1605
aga aag aaa gtc aca gta ttg gag gaa aag cta gtt tca tcc tct 5228
Arg Lys Lys Val Thr Val Leu Glu Glu Lys Leu Val Ser Ser Ser
1610 1615 1620
aat gca atg gaa aat gca agc cat caa gcc agt gtg cag gta gag 5273
Asn Ala Met Glu Asn Ala Ser His Gin Ala Ser Val Gin Val Glu
1625 1630 1635
tca ttg caa gaa cag ttg aat gta gtt tcc aag caa agg gat gaa 5318
Ser Leu Gin Glu Gin Leu Asn Val Val Ser Lys Gin Arg Asp Glu
1640 1645 1650
act gcg ctg cag ctt tct gtc tct cag gaa caa gta aag cag tat 5363
Thr Ala Leu Gin Leu Ser Val Ser Gin Glu Gin Val Lys Gin Tyr
1655 1660 1665
gct ctg tca ctg gcc aac ctg cag atg gta eta gag cat ttc caa 5408
Ala Leu Ser Leu Ala Asn Leu Gin Met Val Leu Glu His Phe Gin
1670 1675 1680
CA 02703356 2010-05-31
= 254
caa gag gaa aaa get atg tat tot gct gaa ctc gaa aag caa aaa 5453
Gin Glu Glu Lys Ala Met Tyr Ser Ala Glu Leu Glu Lys Gin Lys
1685 1690 1695
cag ctt ata get gaa tgg aag aaa aac gca gaa aat ctg gaa gga 5498
Gin Leu Ile Ala Glu Trp Lys Lys Asn Ala Glu Asn Leu Glu Gly
1700 1705 1710
aaa gtg ata tea tta cag gaa tgt ttg gat gaa gca aat get gca 5543
Lys Val Ile Ser Leu Gin Glu Cys Leu Asp Glu Ala Asn Ala Ala
1715 1720 1725
ttg gat tea gca tea aga ctt aca gaa cag tta gat gta aaa gaa 5588
Leu Asp Ser Ala Ser Arg Leu Thr Glu Gin Leu Asp Val Lys Glu
1730 1735 1740
gaa caa att gaa gaa ctt aaa aga caa aat gag etc cga caa gaa 5633
Glu Gin Ile Glu Glu Leu Lys Arg Gin Asn Glu Leu Arg Gin Glu
1745 1750 1755
atg ctg gat gat gta caa aag aaa ttg atg age tta gca aac age 5678
Met Leu Asp Asp Val Gin Lys Lys Leu Met Ser Leu Ala Asn Ser
1760 1765 1770
tea gaa gga aaa gta gac aaa gtc eta atg aga aac etc ttc att 5723
Ser Glu Gly Lys Val Asp Lys Val Leu Met Arg Asn Leu Phe Ile
1775 1780 1785
ggt cat ttc cac aca ccg aaa aat cag cgt cat gaa gtg tta egg 5768
Gly His Phe His Thr Pro Lys Asn Gln Arg His Glu Val Leu Arg
1790 1795 1800
tta atg ggg age ate ctg ggc gtc aga agg gag gag atg gag cag 5813
Leu Met Gly Ser Ile Leu Gly Val Arg Arg Glu Glu Met Glu Gin
1805 1810 1815
ttg ttt cat gac gat cag ggc agt gtt ace agg tgg atg act ggg 5858
Leu Phe His Asp Asp Gln Gly Ser Val Thr Arg Trp Met Thr Gly
1820 1825 1830
tgg ctt gga gga gga tea aaa agt gtt ccc aac aca Oct ttg aga 5903
Trp Leu Gly Gly Gly Ser Lys Ser Val Pro Asn Thr Pro Leu Arg
1835 1840 1845
cca aat cag caa tct gtg gtt aat agt tct ttt tea gaa ctt ttt 5948
Pro Asn Gin Gin Ser Val Val Asn Ser Ser Phe Ser Glu Leu Phe
1850 1855 1860
gtt aaa ttt eta gaa aca gaa tct cat cca tee att cca cca cca 5993
Val Lys Phe Leu Glu Thr Glu Ser His Pro Ser Ile Pro Pro Pro
1865 1870 1875
aag ctt tct gtt cat gat atg aaa cct ctg gat tea cca gga aga 6038
Lys Leu Ser Val His Asp Met Lys Pro Leu Asp Ser Pro Gly Arg
1880 1885 1890
aga aaa aga gat aca aat gca cca gaa agt ttt aaa gat aca gca 6083
Arg Lys Arg Asp Thr Asn Ala Pro Glu Ser Phe Lys Asp Thr Ala
1895 1900 1905
CA 02703356 2010-05-31
255
gaa tcc agg tct ggt aga aga aca gat gta aat ccg ttt ttg gct 6128
Glu Ser Arg Ser Gly Arg Arg Thr Asp Val Asn Pro Phe Leu Ala
1910 1915 1920
cct cgc tcg gca gct gta cct ctt att aac cca gct gga ctt gga 6173
Pro Arg Ser Ala Ala Val Pro Leu Ile Asn Pro Ala Gly Leu Gly
1925 1930 1935
cct ggt ggg ccc ggg cat ctt ctt ctg aaa ccc atc tca gat gtt 6218
Pro Gly Gly Pro Gly His Leu Leu Leu Lys Pro Ile Ser Asp Val
1940 1945 1950
ttg ccc aca ttt aca cct ttg cca gcg tta cct gac aac agt gct 6263
Leu Pro Thr Phe Thr Pro Leu Pro Ala Leu Pro Asp Asn Ser Ala
1955 1960 1965
ggg gtt gtg ctg aaa gac ctt tta aag caa tag atgattctca 6306
Gly Val Val Leu Lys Asp Leu Leu Lys Gin
1970 1975
agccagagac aatctagcac tttaaagaaa ccatgaacac tatatgtatg tactttatca 6366
caaagtggcc tttggggaga aagtcatgta tttgttcgca attatgcttt ctctgaattt 6426
aataaaaata ttcctaatgc ttttag 6452
<210> 47
<211> 1979
<212> PRT
<213> Homo sapiens
<400> 47
Met Ser Ser Trp Leu Gly Gly Leu Gly Ser Gly Leu Gly Gin Ser Leu
1 5 10 15
Gly Gin Val Gly Gly Ser Leu Ala Ser Leu Thr Gly Gin Ile Ser Asn
20 25 30
Phe Thr Lys Asp Met Leu Met Glu Gly Thr Glu Glu Val Glu Ala Glu
35 40 45
Leu Pro Asp Ser Arg Thr Lys Glu Ile Glu Ala Ile His Ala Ile Leu
50 55 60
Arg Ser Glu Asn Glu Arg Leu Lys Lys Leu Cys Thr Asp Leu Glu Glu
65 70 75 80
Lys His Glu Ala Ser Glu Ile Gin Ile Lys Gin Gin Ser Thr Ser Tyr
85 90 95
Arg Asn Gin Leu Gin Gin Lys Glu Val Glu Ile Ser His Leu Lys Ala
100 105 110
Arg Gin Ile Ala Leu Gin Asp Gin Leu Leu Lys Leu Gin Ser Ala Ala
115 120 125
Gin Ser Val Pro Ser Gly Ala Gly Val Pro Ala Thr Thr Ala Ser Ser
130 135 140
Ser Phe Ala Tyr Gly Ile Ser His His Pro Ser Ala Phe His Asp Asp
145 150 155 160
Asp Met Asp Phe Gly Asp Ile Ile Ser Ser Gin Gin Glu Ile Asn Arg
165 170 175
Leu Ser Asn Glu Val Ser Arg Leu Glu Ser Glu Val Gly His Trp Arg
180 185 190
His Ile Ala Gin Thr Ser Lys Ala Gin Gly Thr Asp Asn Ser Asp Gin
195 200 205
Ser Glu Ile Cys Lys Leu Gin Asn Ile Ile Lys Glu Leu Lys Gin Asn
210 215 220
CA 02703356 2010-05-31
256
Arg Ser Gin Glu Ile Asp Asp His Gin His Glu Met Ser Val Leu Gin
225 230 235 240
Asn Ala His Gin Gin Lys Leu Thr Glu Ile Ser Arg Arg His Arg Glu
245 250 255
Glu Leu Ser Asp Tyr Glu Glu Arg Ile Glu Glu Leu Glu Asn Leu Leu
260 265 270
Gin Gin Gly Gly Ser Gly Val Ile Glu Thr Asp Leu Ser Lys Ile Tyr
275 280 285
Glu Met Gin Lys Thr Ile Gin Val Leu Gin Ile Glu Lys Val Glu Ser
290 295 300
Thr Lys Lys Met Glu Gin Leu Glu Asp Lys Ile Lys Asp Ile Asn Lys
305 310 315 320
Lys Leu Ser Ser Ala Glu Asn Asp Arg Asp Ile Leu Arg Arg Glu Gin
325 330 335
Glu Gin Leu Asn Val Glu Lys Arg Gin Ile Met Glu Glu Cys Glu Asn
340 345 350
Leu Lys Leu Glu Cys Ser Lys Leu Gin Pro Ser Ala Val Lys Gin Ser
355 360 365
Asp Thr Met Thr Glu Lys Glu Arg Ile Leu Ala Gin Ser Ala Ser Val
370 375 380
Glu Glu Val Phe Arg Leu Gin Gin Ala Leu Ser Asp Ala Glu Asn Glu
385 390 395 400
Ile Met Arg Leu Ser Ser Leu Asn Gin Asp Asn Ser Leu Ala Glu Asp
405 410 415
Asn Leu Lys Leu Lys Met Arg Ile Glu Val Leu Glu Lys Glu Lys Ser
420 425 430
Leu Leu Ser Gin Glu Lys Glu Glu Leu Gin Met Ser Leu Leu Lys Leu
435 440 445
Asn Asn Glu Tyr Glu Val Ile Lys Ser Thr Ala Thr Arg Asp Ile Ser
450 455 460
Leu Asp Ser Glu Leu His Asp Leu Arg Leu Asn Leu Glu Ala Lys Glu
465 470 475 480
Gin Glu Leu Asn Gin Ser Ile Ser Glu Lys Glu Thr Leu Ile Ala Glu
485 490 495
Ile Glu Glu Leu Asp Arg Gin Asn Gin Glu Ala Thr Lys His Met Ile
500 505 510
Leu Ile Lys Asp Gin Leu Ser Lys Gin Gin Asn Glu Gly Asp Ser Ile
515 520 525
Ile Ser Lys Leu Lys Gin Asp Leu Asn Asp Glu Lys Lys Arg Val His
530 535 540
Gin Leu Glu Asp Asp Lys Met Asp Ile Thr Lys Glu Leu Asp Val Gin
545 550 555 560
Lys Glu Lys Leu Ile Gin Ser Glu Val Ala Leu Asn Asp Leu His Leu
565 570 575
Thr Lys Gin Lys Leu Glu Asp Lys Val Glu Asn Leu Val Asp Gin Leu
580 585 590
Asn Lys Ser Gin Glu Ser Asn Val Ser Ile Gin Lys Glu Asn Leu Glu
595 600 605
Leu Lys Glu His Ile Arg Gin Asn Glu Glu Glu Leu Ser Arg Ile Arg
610 615 620
Asn Glu Leu Met Gin Ser Leu Asn Gin Asp Ser Asn Ser Asn Phe Lys
625 630 635 640
Asp Thr Leu Leu Lys Glu Arg Glu Ala Glu Val Arg Asn Leu Lys Gin
645 650 655
Asn Leu Ser Glu Leu Glu Gin Leu Asn Glu Asn Leu Lys Lys Val Ala
660 665 670
Phe Asp Val Lys Met Glu Asn Glu Lys Leu Val Leu Ala Cys Glu Asp
675 680 685
Val Arg His Gin Leu Glu Glu Cys Leu Ala Gly Asn Asn Gin Leu Ser
690 695 700
CA 02703356 2010-05-31
= 257
Leu Glu Lys Asn Thr Ile Val Glu Thr Leu Lys Met Glu Lys Gly Glu
705 710 715 720
Ile Glu Ala Glu Leu Cys Trp Ala Lys Lys Arg Leu Leu Glu Glu Ala
725 730 735
Asn Lys Tyr Glu Lys Thr Ile Glu Glu Leu Ser Asn Ala Arg Asn Leu
740 745 750
Asn Thr Ser Ala Leu Gin Leu Glu His Glu His Leu Ile Lys Leu Asn
755 760 765
Gin Lys Lys Asp Met Glu Ile Ala Glu Leu Lys Lys Asn Ile Glu Gin
770 775 780
Met Asp Thr Asp His Lys Glu Thr Lys Asp Val Leu Ser Ser Ser Leu
785 790 795 800
Glu Glu Gin Lys Gin Leu Thr Gin Leu Ile Asn Lys Lys Glu Ile Phe
805 810 815
Ile Glu Lys Leu Lys Glu Arg Ser Ser Lys Leu Gin Glu Glu Leu Asp
820 825 830
Lys Tyr Ser Gin Ala Leu Arg Lys Asn Glu Ile Leu Arg Gin Thr Ile
835 840 845
Glu Glu Lys Asp Arg Ser Leu Gly Ser Met Lys Glu Glu Asn Asn His
850 855 860
Leu Gin Glu Glu Leu Glu Arg Leu Arg Glu Glu Gin Ser Arg Thr Ala
865 870 875 880
Pro Val Ala Asp Pro Lys Thr Leu Asp Ser Val Thr Glu Leu Ala Ser
885 890 895
Glu Val Ser Gin Leu Asn Thr Ile Lys Glu His Leu Glu Glu Glu Ile
900 905 910
Lys His His Gin Lys Ile Ile Glu Asp Gin Asn Gin Ser Lys Met Gin
915 920 925
Leu Leu Gin Ser Leu Gin Glu Gin Lys Lys Glu Met Asp Glu Phe Arg
930 935 940
Tyr Gin His Glu Gin Met Asn Ala Thr His Thr Gin Leu Phe Leu Glu
945 950 955 960
Lys Asp Glu Glu Ile Lys Ser Leu Gin Lys Thr Ile Glu Gin Ile Lys
965 970 975
Thr Gin Leu His Glu Glu Arg Gin Asp Ile Gin Thr Asp Asn Ser Asp
980 985 990
Ile Phe Gin Glu Thr Lys Val Gin Ser Leu Asn Ile Glu Asn Gly Ser
995 1000 1005
Glu Lys His Asp Leu Ser Lys Ala Glu Thr Glu Arg Leu Val Lys
1010 1015 1020
Gly Ile Lys Glu Arg Glu Leu Glu Ile Lys Leu Leu Asn Glu Lys
1025 1030 1035
Asn Ile Ser Leu Thr Lys Gin Ile Asp Gin Leu Ser Lys Asp Glu
1040 1045 1050
Val Gly Lys Leu Thr Gin Ile Ile Gin Gin Lys Asp Leu Glu Ile
1055 1060 1065
Gin Ala Leu His Ala Arg Ile Ser Ser Thr Ser His Thr Gin Asp
1070 1075 1080
Val Val Tyr Leu Gin Gin Gin Leu Gin Ala Tyr Ala Met Glu Arg
1085 1090 1095
Glu Lys Val Phe Ala Val Leu Asn Glu Lys Thr Arg Glu Asn Ser
1100 1105 1110
His Leu Lys Thr Glu Tyr His Lys Met Met Asp Ile Val Ala Ala
1115 1120 1125
Lys Glu Ala Ala Leu Ile Lys Leu Gin Asp Glu Asn Lys Lys Leu
1130 1135 1140
Ser Thr Arg Phe Glu Ser Ser Gly Gin Asp Met Phe Arg Glu Thr
1145 1150 1155
Ile Gin An Leu Ser Arg Ile Ile Arg Glu Lys Asp Ile Glu Ile
1160 1165 1170
CA 02703356 2010-05-31
258
Asp Ala Leu Ser Gin Lys Cys Gin Thr Leu Leu Ala Val Leu Gin
1175 1180 1185
Thr Ser Ser Thr Gly Asn Glu Ala Gly Gly Val Asn Ser His Gin
1190 1195 1200
Phe Glu Glu Leu Leu Gin Glu Arg Asp Lys Leu Lys Gin Gin Val
1205 1210 1215
Lys Lys Met Glu Glu Trp Lys Gin Gin Val Met Thr Thr Val Gin
1220 1225 1230
Asn Met Gin His Glu Ser Ala Gin Leu Gin Glu Glu Leu His Gin
1235 1240 1245
Leu Gin Ala Gin Val Leu Val Asp Ser Asp Asn Asn Ser Lys Leu
1250 1255 1260
Gin Val Asp Tyr Thr Gly Leu Ile Gin Ser Tyr Glu Gin Asn Glu
1265 1270 1275
Thr Lys Leu Lys Asn Phe Gly Gin Glu Leu Ala Gin Val Gin His
1280 1285 1290
Ser Ile Gly Gin Leu Cys Asn Thr Lys Asp Leu Leu Leu Gly Lys
1295 1300 1305
Leu Asp Ile Ile Ser Pro Gin Leu Ser Ser Ala Ser Leu Leu Thr
1310 1315 1320
Pro Gin Ser Ala Glu Cys Leu Arg Ala Ser Lys Ser Glu Val Leu
1325 1330 1335
Ser Glu Ser Ser Glu Leu Leu Gin Gin Glu Leu Glu Glu Leu Arg
1340 1345 1350
Lys Ser Leu Gin Glu Lys Asp Ala Thr Ile Arg Thr Leu Gin Glu
1355 1360 1365
Asn Asn His Arg Leu Ser Asp Ser Ile Ala Ala Thr Ser Glu Leu
1370 1375 1380
Glu Arg Lys Glu His Glu Gin Thr Asp Ser Glu Ile Lys Gln Leu
1385 1390 1395
Lys Glu Lys Gin Asp Val Leu Gin Lys Leu Leu Lys Glu Lys Asp
1400 1405 1410
Leu Leu Ile Lys Ala Lys Ser Asp Gin Leu Leu Ser Ser Asn Glu
1415 1420 1425
Asn Phe Thr Asn Lys Val Asn Glu Asn Glu Leu Leu Arg Gin Ala
1430 1435 1440
Val Thr Asn Leu Lys Glu Arg Ile Leu Ile Leu Glu Met Asp Ile
1445 1450 1455
Gly Lys Leu Lys Gly Glu Asn Glu Lys Ile Val Glu Thr Tyr Arg
1460 1465 1470
Gly Lys Glu Thr Glu Tyr Gin Ala Leu Gin Glu Thr Asn Met Lys
1475 1480 1485
Phe Ser Met Met Leu Arg Glu Lys Glu Phe Glu Cys His Ser Met
1490 1495 1500
Lys Glu Lys Ala Leu Ala Phe Glu Gin Leu Leu Lys Glu Lys Glu
1505 1510 1515
Gin Gly Lys Thr Gly Glu Leu Asn Gin Leu Leu Asn Ala Val Lys
1520 1525 1530
Ser Met Gin Glu Lys Thr Val Val Phe Gin Gin Glu Arg Asp Gin
1535 1540 1545
Val Met Leu Ala Leu Lys Gin Lys Gin Met Glu Asn Thr Ala Leu
1550 1555 1560
Gin Asn Glu Val Gin Arg Leu Arg Asp Lys Glu Phe Arg Ser Asn
1565 1570 1575
Gin Glu Leu Glu Arg Leu Arg Asn His Leu Leu Glu Ser Glu Asp
1580 1585 1590
Ser Tyr Thr Arg Glu Ala Leu Ala Ala Glu Asp Arg Glu Ala Lys
1595 1600 1605
Leu Arg Lys Lys Val Thr Val Leu Glu Glu Lys Leu Val Ser Ser
1610 1615 1620
CA 02703356 2010-05-31
259
Ser Asn Ala Met Glu Asn Ala Ser His Gin Ala Ser Val Gin Val
1625 1630 1635
Glu Ser Leu Gin Glu Gin Leu Asn Val Val Ser Lys Gin Arg Asp
1640 1645 1650
Glu Thr Ala Leu Gin Leu Ser Val Ser Gin Glu Gin Val Lys Gin
1655 1660 1665
Tyr Ala Leu Ser Leu Ala Asn Leu Gin Met Val Leu Glu His Phe
1670 1675 1680
Gin Gin Glu Glu Lys Ala Met Tyr Ser Ala Glu Leu Glu Lys Gin
1685 1690 1695
Lys Gin Leu Ile Ala Glu Trp Lys Lys Asn Ala Glu Asn Leu Glu
1700 1705 1710
Gly Lys Val Ile Ser Leu Gin Glu Cys Leu Asp Glu Ala Asn Ala
1715 1720 1725
Ala Leu Asp Ser Ala Ser Arg Leu Thr Glu Gin Leu Asp Val Lys
1730 1735 1740
Glu Glu Gin Ile Glu Glu Leu Lys Arg Gin Asn Glu Leu Arg Gin
1745 1750 1755
Glu Met Leu Asp Asp Val Gin Lys Lys Leu Met Ser Leu Ala Asn
1760 1765 1770
Ser Ser Glu Gly Lys Val Asp Lys Val Leu Met Arg Asn Leu Phe
1775 1780 1785
Ile Gly His Phe His Thr Pro Lys Asn Gin Arg His Glu Val Leu
1790 1795 1800
Arg Leu Met Gly Ser Ile Leu Gly Val Arg Arg Glu Glu Met Glu
1805 1810 1815
Gin Leu Phe His Asp Asp Gin Gly Ser Val Thr Arg Trp Met Thr
1820 1825 1830
Gly Trp Leu Gly Gly Gly Ser Lys Ser Val Pro Asn Thr Pro Leu
1835 1840 1845
Arg Pro Asn Gin Gin Ser Val Val Asn Ser Ser Phe Ser Glu Leu
1850 1855 1860
Phe Val Lys Phe Leu Glu Thr Glu Ser His Pro Ser Ile Pro Pro
1865 1870 1875
Pro Lys Leu Ser Val His Asp Met Lys Pro Leu Asp Ser Pro Gly
1880 1885 1890
Arg Arg Lys Arg Asp Thr Asn Ala Pro Glu Ser Phe Lys Asp Thr
1895 1900 1905
Ala Glu Ser Arg Ser Gly Arg Arg Thr Asp Val Asn Pro Phe Leu
1910 1915 1920
Ala Pro Arg Ser Ala Ala Val Pro Leu Ile Asn Pro Ala Gly Leu
1925 1930 1935
Gly Pro Gly Gly Pro Gly His Leu Leu Leu Lys Pro Ile Ser Asp
1940 1945 1950
Val Leu Pro Thr Phe Thr Pro Leu Pro Ala Leu Pro Asp Asn Ser
1955 1960 1965
Ala Gly Val Val Leu Lys Asp Leu Leu Lys Gin
1970 1975
<210> 48
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 48
gaagctacaa agcacatg 18
CA 02703356 2010-05-31
260
<210> 49
<211> 18
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 49
tcctgtcttt cttcatgc 18
<210> 50
<211> 23
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 50
catatgtcag tgttgcagaa tgc 23
<210> 51
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 51
ggtacctact aacctctcag tttc 24
<210> 52
<211> 23
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 52
catatgtcag tactgcagaa tgc 23
<210> 53
<211> 26
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 53
ggtacctttt attcctttca ctaatc 26
CA 02703356 2010-05-31
261
<210> 54
<211> 787
<212> PRT
<213> Canis familiaris
<400> 54
Met Ser Val Leu Gin Asn Ala His Gin Gin Lys Leu Thr Asp Ile Ser
1 5 10 15
Arg Arg His Arg Glu Glu Leu Arg Asp Tyr Glu Glu Arg Ile Glu Glu
20 25 30
Leu Glu Asn Leu Leu Glu Gin Gly Gly Ser Gly Ile Val Ile Pro Asp
35 40 45
His Ser Lys Ile His Glu Met Gin Lys Thr Ile Gin Asn Leu Gin Thr
50 55 60
Glu Lys Val Ala Ser Ile Lys Lys Ile Glu Glu Leu Glu Asp Lys Ile
65 70 75 80
Lys Asp Ile Asp Lys Lys Leu Ser Ser Ala Glu Asn Asp Arg Asp Val
85 90 95
Leu Arg Lys Glu Lys Glu Cys Leu Asn Val Glu Asn Arg Gin Ile Thr
100 105 110
Glu Gin Cys Glu Ser Leu Lys Leu Glu Cys Lys Leu Gin His Asp Ala
115 120 125
Glu Lys Gin Gly Asp Thr Val Thr Glu Lys Glu Arg Ile Leu Pro Gin
130 135 140
Ser Thr Ser Val Glu Glu Glu Val Leu Lys Leu Gin Gin Ala Leu Ser
145 150 155 160
Asp Ala Glu Asn Glu Ile Met Arg Leu Ser Asn Leu Tyr Gin Asp Asn
165 170 175
Ser Leu Thr Glu Asp Asn Leu Lys Leu Lys Met His Val Glu Phe Leu
180 185 190
Glu Lys Gin Lys Ser Leu Leu Ser Gin Glu Lys Glu Glu Leu Gin Leu
195 200 205
Ser Leu Leu Lys Leu Asn Asn Glu Tyr Glu Val Ile Lys Ser Thr Ala
210 215 220
Val Arg Asp Met Asp Met Asp Ser Thr Leu Cys Asp Leu Arg Leu Thr
225 230 235 240
Leu Glu Ala Lys Asp Gin Glu Leu Asn Gin Ser Leu Thr Glu Lys Glu
245 250 255
Ile Leu Val Ala Glu Leu Glu Glu Leu Asp Arg Gin Asn Gin Glu Ala
260 265 270
Thr Lys His Met Ile Leu Ile Lys Asp Gin Leu Ser Lys Gin Gin Ser
275 280 285
Glu Gly Glu Thr Ile Ile Ser Lys Leu Arg Lys Asp Leu Asn Asp Glu
290 295 300
Asn Lys Arg Val His Gin Leu Glu Asp Asp Lys Lys Asn Met Thr Lys
305 310 315 320
Glu Leu Asn Val Gin Lys Glu Lys Leu Val Gin Ser Glu Leu Val Leu
325 330 335
Asn Gly Leu His Leu Ala Lys Gin Lys Leu Glu Glu Lys Val Glu Asp
340 345 350
Leu Val Asp Gin Leu Asn Lys Ser Gin Lys Ser Asn Leu Asn Met Gin
355 360 365
Lys Glu Asn Phe Gly Leu Lys Glu His Ile Lys Gin Asn Glu Glu Glu
370 375 380
Leu Ser Arg Val Arg Asp Glu Leu Thr Gin Ser Leu Ser Arg Asp Ser
385 390 395 400
Gly Ser Asp Phe Lys Asp Asp Leu Leu Lys Glu Arg Glu Ala Glu Val
405 410 415
Arg Asn Leu Lys Gin Asn Leu Ser Glu Ile Glu Gin Leu Asn Asp Ser
420 425 430
CA 02703356 2010-05-31
262
Leu Asn Lys Val Ala Phe Asp Leu Lys Met Glu Asn Glu Lys Leu Val
435 440 445
Leu Ala Cys Glu Asp Ile Arg His Gin Leu Glu Glu Ser Ile Val Gly
450 455 460
Ser Asn Gin Met Ser Leu Glu Arg Asn Thr Ile Val Glu Ala Leu Lys
465 470 475 480
Met Glu Lys Gly Gin Leu Glu Ala Glu Leu Ser Arg Ala Asp Gin Arg
485 490 495
Leu Leu Glu Glu Ala Ser Lys Tyr Glu Gin Thr Ile Gin Glu Leu Ser
500 505 510
Lys Ala Arg Asp Leu Arg Thr Ser Ala Leu Gin Leu Glu Gin Gin His
515 520 525
Leu Met Lys Leu Ser Gin Glu Lys Asp Phe Glu Ile Ala Glu Leu Lys
530 535 540
Lys Asn Ile Glu Gin Met Asp Thr Asp His Lys Glu Thr Lys Ala Ile
545 550 555 560
Leu Ser Ser Ile Leu Glu Glu Gin Lys Gin Leu Thr Gin Leu Ile Ser
565 570 575
Glu Lys Glu Ile Phe Ile Glu Lys Leu Lys Glu Arg Ser Ser Glu Leu
580 585 590
Gin Glu Glu Leu Glu Lys Ser Thr Gin Ala Ser Arg Lys Ile Glu Ile
595 600 605
Leu Lys Gin Thr Ile Glu Glu Lys Asp Arg Ser Leu Gly Ser Met Lys
610 615 . 620
Glu Glu Asn Asn His Leu Lys Glu Glu Leu Glu Arg Leu Arg Glu Gin
625 630 635 640
Gin Ser Arg Ala Val Pro Val Val Glu Pro Lys Pro Leu Asp Ser Val
645 650 655
Thr Glu Leu Glu Ser Glu Val Leu Gin Leu Asn Ile Val Lys Arg Asn
660 665 670
Leu Glu Glu Glu Ile Lys Arg His Gin Lys Ile Ile Glu Asp Gin Asn
675 680 685
Gin Ser Lys Met Gin Leu Leu Gin Ser Leu Glu Glu Gin Lys Lys Glu
690 695 700
Met Asp Glu Phe Lys Cys Gin His Glu Gin Met Asn Val Thr His Thr
705 710 715 720
Gin Leu Phe Leu Glu Lys Asp Glu Glu Ile Lys Asn Leu Gin Lys Thr
725 730 735
Ile Glu Gin Ile Lys Thr Gin Trp His Glu Glu Arg Gin Asp Val Gin
740 745 750
Met Glu Asn Ser Glu Phe Phe Gin Glu Thr Lys Val Gin Ser Leu Asn
755 760 765
Leu Glu Asn Gly Ser Glu Lys His Asp Leu Ser Lys Ala Glu Thr Glu
770 775 780
Arg Leu Val
785
<210> 55
<211> 788
<212> PRT
<213> Homo sapiens
<400> 55
Met Ser Val Leu Gin Asn Ala His Gin Gin Lys Leu Thr Glu Ile Ser
1 5 10 15
Arg Arg His Arg Glu Glu Leu Ser Asp Tyr Glu Glu Arg Ile Glu Glu
20 25 30
Leu Glu Asn Leu Leu Gin Gin Gly Gly Ser Gly Val Ile Glu Thr Asp
35 40 45
CA 02703356 2010-05-31
0
263
Leu Ser Lys Ile Tyr Glu Met Gin Lys Thr Ile Gin Val Leu Gin Ile
50 55 60
Glu Lys Val Glu Ser Thr Lys Lys Met Glu Gin Leu Glu Asp Lys Ile
65 70 75 80
Lys Asp Ile Asn Lys Lys Leu Ser Ser Ala Glu Asn Asp Arg Asp Ile
85 90 95
Leu Arg Arg Glu Gin Glu Gin Leu Asn Val Glu Lys Arg Gin Ile Met
100 105 110
Glu Glu Cys Glu Asn Leu Lys Leu Glu Cys Ser Lys Leu Gin Pro Ser
115 120 125
Ala Val Lys Gin Ser Asp Thr Met Thr Glu Lys Glu Arg Ile Leu Ala
130 135 140
Gin Ser Ala Ser Val Glu Glu Val Phe Arg Leu Gin Gin Ala Leu Ser
145 150 155 160
Asp Ala Glu Asn Glu Ile Met Arg Leu Ser Ser Leu Asn Gin Asp Asn
165 170 175
Ser Leu Ala Glu Asp Asn Leu Lys Leu Lys Met Arg Ile Glu Val Leu
180 185 190
Glu Lys Glu Lys Ser Leu Leu Ser Gin Glu Lys Glu Glu Leu Gin Met
195 200 205
Ser Leu Leu Lys Leu Asn Asn Glu Tyr Glu Val Ile Lys Ser Thr Ala
210 215 220
Thr Arg Asp Ile Ser Leu Asp Ser Glu Leu His Asp Leu Arg Leu Asn
225 230 235 240
Leu Glu Ala Lys Glu Gin Glu Leu Asn Gin Ser Ile Ser Glu Lys Glu
245 250 255
Thr Leu Ile Ala Glu Ile Glu Glu Leu Asp Arg Gin Asn Gin Glu Ala
260 265 270
Thr Lys His Met Ile Leu Ile Lys Asp Gin Leu Ser Lys Gin Gin Asn
275 280 285
Glu Gly Asp Ser Ile Ile Ser Lys Leu Lys Gin Asp Leu Asn Asp Glu
290 295 300
Lys Lys Arg Val His Gin Leu Glu Asp Asp Lys Met Asp Ile Thr Lys
305 310 315 320
Glu Leu Asp Val Gin Lys Glu Lys Leu Ile Gin Ser Glu Val Ala Leu
325 330 335
Asn Asp Leu His Leu Thr Lys Gin Lys Leu Glu Asp Lys Val Glu Asn
340 345 350
Leu Val Asp Gin Leu Asn Lys Ser Gin Glu Ser Asn Val Ser Ile Gin
355 360 365
Lys Glu Asn Leu Glu Leu Lys Glu His Ile Arg Gin Asn Glu Glu Glu
370 375 380
Leu Ser Arg Ile Arg Asn Glu Leu Met Gin Ser Leu Asn Gin Asp Ser
385 390 395 400
Asn Ser Asn Phe Lys Asp Thr Leu Leu Lys Glu Arg Glu Ala Glu Val
405 410 415
Arg Asn Leu Lys Gin Asn Leu Ser Glu Leu Glu Gin Leu Asn Glu Asn
420 425 430
Leu Lys Lys Val Ala Phe Asp Val Lys Met Glu Asn Glu Lys Leu Val
435 440 445
Leu Ala Cys Glu Asp Val Arg His Gin Leu Glu Glu Cys Leu Ala Gly
450 455 460
Asn Asn Gin Leu Ser Leu Glu Lys Asn Thr Ile Val Glu Thr Leu Lys
465 470 475 460
Met Glu Lys Gly Glu Ile Glu Ala Glu Leu Cys Trp Ala Lys Lys Arg
485 490 495
Leu Leu Glu Glu Ala Asn Lys Tyr Glu Lys Thr Ile Glu Glu Leu Ser
500 505 510
Asn Ala Arg Asn Leu Asn Thr Ser Ala Leu Gin Leu Glu His Glu His
515 520 525
CA 02703356 2010-05-31
264
Leu Ile Lys Leu Asn Gin Lys Lys Asp Met Glu Ile Ala Glu Leu Lys
530 535 540
Lys Asn Ile Glu Gin Met Asp Thr Asp His Lys Glu Thr Lys Asp Val
545 550 555 560
Leu Ser Ser Ser Leu Glu Glu Gin Lys Gin Leu Thr Gin Leu Ile Asn
565 570 575
Lys Lys Glu Ile Phe Ile Glu Lys Leu Lys Glu Arg Ser Ser Lys Leu
580 585 590
Gin Glu Glu Leu Asp Lys Tyr Ser Gin Ala Leu Arg Lys Asn Glu Ile
595 600 605
Leu Arg Gin Thr Ile Glu Glu Lys Asp Arg Ser Leu Gly Ser Met Lys
610 615 620
Glu Glu Asn Asn His Leu Gin Glu Glu Leu Glu Arg Leu Arg Glu Glu
625 630 635 640
Gin Ser Arg Thr Ala Pro Val Ala Asp Pro Lys Thr Leu Asp Ser Val
645 650 655
Thr Glu Leu Ala Ser Glu Val Ser Gin Leu Asn Thr Ile Lys Glu His
660 665 670
Leu Glu Glu Glu Ile Lys His His Gin Lys Ile Ile Glu Asp Gin Asn
675 680 685
Gin Ser Lys Met Gin Leu Leu Gin Ser Leu Gin Glu Gin Lys Lys Glu
690 695 700
Met Asp Glu Phe Arg Tyr Gin His Glu Gin Met Asn Ala Thr His Thr
705 710 715 720
Gin Leu Phe Leu Glu Lys Asp Glu Glu Ile Lys Ser Leu Gin Lys Thr
725 730 735
Ile Glu Gin Ile Lys Thr Gin Leu His Glu Glu Arg Gin Asp Ile Gin
740 745 750
Thr Asp Asn Ser Asp Ile Phe Gin Glu Thr Lys Val Gin Ser Leu Asn
755 760 765
Ile Glu Asn Gly Ser Glu Lys His Asp Leu Ser Lys Ala Glu Thr Glu
770 775 780
Arg Leu Val Lys
785
<210> 56
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 56
gtcgacatgt cgtcctggct cggg 24
<210> 57
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 57
ctcgagctat tgctttaaaa ggtc 24
CA 02703356 2010-05-31
=
265
<210> 58
<211> 24
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 58
catatgtcgt cctggcttgg gggc 24
<210> 59
<211> 25
<212> DNA
<213> Artificial
<220>
<223> primer
<400> 59
ggtaccttgc tttaaaaggt ctttc 25
